id	sid	tid	token	lemma	pos
dpc-5749	1	1	dermatology	dermatology	NOUN
dpc-5749	1	2	:	:	PUNCT
dpc-5749	1	3	practical	practical	ADJ
dpc-5749	1	4	and	and	CCONJ
dpc-5749	1	5	conceptual	conceptual	ADJ
dpc-5749	1	6	review	review	NOUN
dpc-5749	1	7	|	|	ADV
dpc-5749	1	8	dermatol	dermatol	ADJ
dpc-5749	1	9	pract	pract	NOUN
dpc-5749	1	10	concept	concept	NOUN
dpc-5749	1	11	.	.	PUNCT
dpc-5749	2	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	2	2	1	1	NUM
dpc-5749	2	3	targeted	target	VERB
dpc-5749	2	4	therapies	therapy	NOUN
dpc-5749	2	5	and	and	CCONJ
dpc-5749	2	6	pharmacologic	pharmacologic	ADJ
dpc-5749	2	7	advances	advance	NOUN
dpc-5749	2	8	in	in	ADP
dpc-5749	2	9	mucous	mucous	ADJ
dpc-5749	2	10	membrane	membrane	NOUN
dpc-5749	2	11	pemphigoid	pemphigoid	NOUN
dpc-5749	2	12	:	:	PUNCT
dpc-5749	2	13	a	a	DET
dpc-5749	2	14	comprehensive	comprehensive	ADJ
dpc-5749	2	15	review	review	NOUN
dpc-5749	2	16	vera	vera	NOUN
dpc-5749	2	17	nikolaevna	nikolaevna	PROPN
dpc-5749	2	18	busol1	busol1	PROPN
dpc-5749	2	19	,	,	PUNCT
dpc-5749	2	20	nikita	nikita	PROPN
dpc-5749	2	21	victorovich	victorovich	PROPN
dpc-5749	2	22	kudryashov2	kudryashov2	NOUN
dpc-5749	2	23	1	1	NUM
dpc-5749	2	24	n.v	n.v	PROPN
dpc-5749	2	25	.	.	PROPN
dpc-5749	2	26	sklifosovsky	sklifosovsky	PROPN
dpc-5749	2	27	institute	institute	PROPN
dpc-5749	2	28	of	of	ADP
dpc-5749	2	29	clinical	clinical	ADJ
dpc-5749	2	30	medicine	medicine	NOUN
dpc-5749	2	31	,	,	PUNCT
dpc-5749	2	32	federal	federal	ADJ
dpc-5749	2	33	state	state	PROPN
dpc-5749	2	34	autonomous	autonomous	ADJ
dpc-5749	2	35	educational	educational	ADJ
dpc-5749	2	36	institution	institution	NOUN
dpc-5749	2	37	of	of	ADP
dpc-5749	2	38	higher	high	ADJ
dpc-5749	2	39	education	education	PROPN
dpc-5749	2	40	i.m	i.m	PROPN
dpc-5749	3	1	.	.	PUNCT
dpc-5749	3	2	sechenov	sechenov	PROPN
dpc-5749	3	3	first	first	PROPN
dpc-5749	3	4	moscow	moscow	PROPN
dpc-5749	3	5	state	state	PROPN
dpc-5749	3	6	medical	medical	PROPN
dpc-5749	3	7	university	university	PROPN
dpc-5749	3	8	of	of	ADP
dpc-5749	3	9	the	the	DET
dpc-5749	3	10	ministry	ministry	PROPN
dpc-5749	3	11	of	of	ADP
dpc-5749	3	12	health	health	PROPN
dpc-5749	3	13	of	of	ADP
dpc-5749	3	14	the	the	DET
dpc-5749	3	15	russian	russian	PROPN
dpc-5749	3	16	federation	federation	PROPN
dpc-5749	3	17	(	(	PUNCT
dpc-5749	3	18	sechenov	sechenov	PROPN
dpc-5749	3	19	university	university	PROPN
dpc-5749	3	20	)	)	PUNCT
dpc-5749	3	21	,	,	PUNCT
dpc-5749	3	22	moscow	moscow	PROPN
dpc-5749	3	23	,	,	PUNCT
dpc-5749	3	24	russia	russia	PROPN
dpc-5749	3	25	2	2	NUM
dpc-5749	3	26	department	department	NOUN
dpc-5749	3	27	of	of	ADP
dpc-5749	3	28	pharmacology	pharmacology	NOUN
dpc-5749	3	29	,	,	PUNCT
dpc-5749	3	30	institute	institute	NOUN
dpc-5749	3	31	of	of	ADP
dpc-5749	3	32	digital	digital	ADJ
dpc-5749	3	33	biodesign	biodesign	NOUN
dpc-5749	3	34	and	and	CCONJ
dpc-5749	3	35	modelling	modelling	NOUN
dpc-5749	3	36	of	of	ADP
dpc-5749	3	37	living	living	NOUN
dpc-5749	3	38	systems	system	NOUN
dpc-5749	3	39	,	,	PUNCT
dpc-5749	3	40	federal	federal	ADJ
dpc-5749	3	41	state	state	PROPN
dpc-5749	3	42	autonomous	autonomous	ADJ
dpc-5749	3	43	educational	educational	ADJ
dpc-5749	3	44	institution	institution	NOUN
dpc-5749	3	45	of	of	ADP
dpc-5749	3	46	higher	high	ADJ
dpc-5749	3	47	education	education	PROPN
dpc-5749	3	48	i.m	i.m	PROPN
dpc-5749	3	49	.	.	PUNCT
dpc-5749	4	1	sechenov	sechenov	PROPN
dpc-5749	4	2	first	first	PROPN
dpc-5749	4	3	moscow	moscow	PROPN
dpc-5749	4	4	state	state	PROPN
dpc-5749	4	5	medical	medical	PROPN
dpc-5749	4	6	university	university	PROPN
dpc-5749	4	7	of	of	ADP
dpc-5749	4	8	the	the	DET
dpc-5749	4	9	ministry	ministry	PROPN
dpc-5749	4	10	of	of	ADP
dpc-5749	4	11	health	health	PROPN
dpc-5749	4	12	of	of	ADP
dpc-5749	4	13	the	the	DET
dpc-5749	4	14	russian	russian	PROPN
dpc-5749	4	15	federation	federation	PROPN
dpc-5749	4	16	(	(	PUNCT
dpc-5749	4	17	sechenov	sechenov	PROPN
dpc-5749	4	18	university	university	PROPN
dpc-5749	4	19	)	)	PUNCT
dpc-5749	4	20	,	,	PUNCT
dpc-5749	4	21	moscow	moscow	PROPN
dpc-5749	4	22	,	,	PUNCT
dpc-5749	4	23	russia	russia	PROPN
dpc-5749	4	24	key	key	ADJ
dpc-5749	4	25	words	word	NOUN
dpc-5749	4	26	:	:	PUNCT
dpc-5749	4	27	autoimmune	autoimmune	ADJ
dpc-5749	4	28	bullous	bullous	ADJ
dpc-5749	4	29	dermatoses	dermatosis	NOUN
dpc-5749	4	30	,	,	PUNCT
dpc-5749	4	31	mucous	mucous	ADJ
dpc-5749	4	32	membrane	membrane	NOUN
dpc-5749	4	33	pemphigoid	pemphigoid	NOUN
dpc-5749	4	34	,	,	PUNCT
dpc-5749	4	35	cicatricial	cicatricial	ADJ
dpc-5749	4	36	pemphigoid	pemphigoid	NOUN
dpc-5749	4	37	,	,	PUNCT
dpc-5749	4	38	pemphigoid	pemphigoid	ADJ
dpc-5749	4	39	antibodies	antibody	NOUN
dpc-5749	4	40	,	,	PUNCT
dpc-5749	4	41	novel	novel	ADJ
dpc-5749	4	42	therapies	therapy	NOUN
dpc-5749	4	43	citation	citation	NOUN
dpc-5749	4	44	:	:	PUNCT
dpc-5749	4	45	busol	busol	PROPN
dpc-5749	4	46	vn	vn	PROPN
dpc-5749	4	47	,	,	PUNCT
dpc-5749	4	48	kudryashov	kudryashov	PROPN
dpc-5749	4	49	nv	nv	PROPN
dpc-5749	4	50	.	.	PROPN
dpc-5749	4	51	targeted	target	VERB
dpc-5749	4	52	therapies	therapy	NOUN
dpc-5749	4	53	and	and	CCONJ
dpc-5749	4	54	pharmacologic	pharmacologic	ADJ
dpc-5749	4	55	advances	advance	NOUN
dpc-5749	4	56	in	in	ADP
dpc-5749	4	57	mucous	mucous	ADJ
dpc-5749	4	58	membrane	membrane	NOUN
dpc-5749	4	59	pemphigoid	pemphigoid	NOUN
dpc-5749	4	60	:	:	PUNCT
dpc-5749	4	61	a	a	DET
dpc-5749	4	62	comprehensive	comprehensive	ADJ
dpc-5749	4	63	review	review	NOUN
dpc-5749	4	64	.	.	PUNCT
dpc-5749	5	1	dermatol	dermatol	NOUN
dpc-5749	5	2	pract	pract	PROPN
dpc-5749	5	3	concept	concept	NOUN
dpc-5749	5	4	.	.	PUNCT
dpc-5749	6	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	6	2	.	.	PUNCT
dpc-5749	7	1	doi	doi	PROPN
dpc-5749	7	2	:	:	PUNCT
dpc-5749	7	3	https://doi.org/10.5826/dpc.1504a5749	https://doi.org/10.5826/dpc.1504a5749	PROPN
dpc-5749	7	4	accepted	accept	VERB
dpc-5749	7	5	:	:	PUNCT
dpc-5749	7	6	july	july	PROPN
dpc-5749	7	7	20	20	NUM
dpc-5749	7	8	,	,	PUNCT
dpc-5749	7	9	2025	2025	NUM
dpc-5749	7	10	;	;	PUNCT
dpc-5749	7	11	published	publish	VERB
dpc-5749	7	12	:	:	PUNCT
dpc-5749	8	1	october	october	PROPN
dpc-5749	8	2	2025	2025	NUM
dpc-5749	8	3	copyright	copyright	NOUN
dpc-5749	8	4	:	:	PUNCT
dpc-5749	8	5	©	©	PROPN
dpc-5749	8	6	2025	2025	NUM
dpc-5749	8	7	busol	busol	NOUN
dpc-5749	8	8	et	et	PROPN
dpc-5749	8	9	al	al	PROPN
dpc-5749	8	10	.	.	PUNCT
dpc-5749	9	1	this	this	PRON
dpc-5749	9	2	is	be	AUX
dpc-5749	9	3	an	an	DET
dpc-5749	9	4	open	open	ADJ
dpc-5749	9	5	-	-	PUNCT
dpc-5749	9	6	access	access	NOUN
dpc-5749	9	7	article	article	NOUN
dpc-5749	9	8	distributed	distribute	VERB
dpc-5749	9	9	under	under	ADP
dpc-5749	9	10	the	the	DET
dpc-5749	9	11	terms	term	NOUN
dpc-5749	9	12	of	of	ADP
dpc-5749	9	13	the	the	DET
dpc-5749	9	14	creative	creative	ADJ
dpc-5749	9	15	commons	common	NOUN
dpc-5749	9	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-5749	9	17	license	license	NOUN
dpc-5749	9	18	(	(	PUNCT
dpc-5749	9	19	by	by	ADP
dpc-5749	9	20	-	-	PUNCT
dpc-5749	9	21	nc-4.0	nc-4.0	NOUN
dpc-5749	9	22	)	)	PUNCT
dpc-5749	9	23	,	,	PUNCT
dpc-5749	9	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-5749	9	25	,	,	PUNCT
dpc-5749	9	26	which	which	PRON
dpc-5749	9	27	permits	permit	VERB
dpc-5749	9	28	unrestricted	unrestricted	ADJ
dpc-5749	9	29	noncommercial	noncommercial	ADJ
dpc-5749	9	30	use	use	NOUN
dpc-5749	9	31	,	,	PUNCT
dpc-5749	9	32	distribution	distribution	NOUN
dpc-5749	9	33	,	,	PUNCT
dpc-5749	9	34	and	and	CCONJ
dpc-5749	9	35	reproduction	reproduction	NOUN
dpc-5749	9	36	in	in	ADP
dpc-5749	9	37	any	any	DET
dpc-5749	9	38	medium	medium	NOUN
dpc-5749	9	39	,	,	PUNCT
dpc-5749	9	40	provided	provide	VERB
dpc-5749	9	41	the	the	DET
dpc-5749	9	42	original	original	ADJ
dpc-5749	9	43	authors	author	NOUN
dpc-5749	9	44	and	and	CCONJ
dpc-5749	9	45	source	source	NOUN
dpc-5749	9	46	are	be	AUX
dpc-5749	9	47	credited	credit	VERB
dpc-5749	9	48	.	.	PUNCT
dpc-5749	10	1	funding	funding	NOUN
dpc-5749	10	2	:	:	PUNCT
dpc-5749	10	3	none	none	NOUN
dpc-5749	10	4	.	.	PUNCT
dpc-5749	11	1	competing	compete	VERB
dpc-5749	11	2	interests	interest	NOUN
dpc-5749	11	3	:	:	PUNCT
dpc-5749	11	4	none	none	NOUN
dpc-5749	11	5	.	.	PUNCT
dpc-5749	12	1	authorship	authorship	NOUN
dpc-5749	12	2	:	:	PUNCT
dpc-5749	12	3	all	all	DET
dpc-5749	12	4	authors	author	NOUN
dpc-5749	12	5	have	have	AUX
dpc-5749	12	6	contributed	contribute	VERB
dpc-5749	12	7	significantly	significantly	ADV
dpc-5749	12	8	to	to	ADP
dpc-5749	12	9	this	this	DET
dpc-5749	12	10	publication	publication	NOUN
dpc-5749	12	11	.	.	PUNCT
dpc-5749	13	1	corresponding	correspond	VERB
dpc-5749	13	2	author	author	NOUN
dpc-5749	13	3	:	:	PUNCT
dpc-5749	13	4	vera	vera	NOUN
dpc-5749	13	5	nikolaevna	nikolaevna	PROPN
dpc-5749	13	6	busol	busol	PROPN
dpc-5749	13	7	,	,	PUNCT
dpc-5749	13	8	the	the	DET
dpc-5749	13	9	federal	federal	ADJ
dpc-5749	13	10	state	state	PROPN
dpc-5749	13	11	autonomous	autonomous	ADJ
dpc-5749	13	12	,	,	PUNCT
dpc-5749	13	13	educational	educational	ADJ
dpc-5749	13	14	institution	institution	NOUN
dpc-5749	13	15	of	of	ADP
dpc-5749	13	16	higher	high	ADJ
dpc-5749	13	17	education	education	PROPN
dpc-5749	13	18	i.m	i.m	PROPN
dpc-5749	13	19	.	.	PUNCT
dpc-5749	14	1	sechenov	sechenov	PROPN
dpc-5749	14	2	first	first	PROPN
dpc-5749	14	3	moscow	moscow	PROPN
dpc-5749	14	4	state	state	PROPN
dpc-5749	14	5	medical	medical	PROPN
dpc-5749	14	6	university	university	PROPN
dpc-5749	14	7	of	of	ADP
dpc-5749	14	8	the	the	DET
dpc-5749	14	9	ministry	ministry	PROPN
dpc-5749	14	10	of	of	ADP
dpc-5749	14	11	health	health	PROPN
dpc-5749	14	12	of	of	ADP
dpc-5749	14	13	russia	russia	PROPN
dpc-5749	14	14	,	,	PUNCT
dpc-5749	14	15	sechenov	sechenov	PROPN
dpc-5749	14	16	university	university	PROPN
dpc-5749	14	17	.	.	PUNCT
dpc-5749	15	1	8	8	NUM
dpc-5749	15	2	-	-	SYM
dpc-5749	15	3	2	2	NUM
dpc-5749	15	4	trubetskaya	trubetskaya	NOUN
dpc-5749	15	5	str	str	NOUN
dpc-5749	15	6	.	.	PUNCT
dpc-5749	15	7	,	,	PUNCT
dpc-5749	15	8	moscow	moscow	PROPN
dpc-5749	15	9	,	,	PUNCT
dpc-5749	15	10	russia	russia	PROPN
dpc-5749	15	11	,	,	PUNCT
dpc-5749	15	12	119991	119991	NUM
dpc-5749	15	13	.	.	PUNCT
dpc-5749	16	1	e	e	X
dpc-5749	16	2	-	-	NOUN
dpc-5749	16	3	mail	mail	NOUN
dpc-5749	16	4	:	:	PUNCT
dpc-5749	16	5	verafbmusik@yandex.ru	verafbmusik@yandex.ru	PROPN
dpc-5749	16	6	.	.	PUNCT
dpc-5749	17	1	introduction	introduction	NOUN
dpc-5749	17	2	:	:	PUNCT
dpc-5749	17	3	mucous	mucous	ADJ
dpc-5749	17	4	membrane	membrane	NOUN
dpc-5749	17	5	pemphigoid	pemphigoid	NOUN
dpc-5749	17	6	(	(	PUNCT
dpc-5749	17	7	mmp	mmp	PROPN
dpc-5749	17	8	)	)	PUNCT
dpc-5749	17	9	is	be	AUX
dpc-5749	17	10	a	a	DET
dpc-5749	17	11	rare	rare	ADJ
dpc-5749	17	12	autoimmune	autoimmune	ADJ
dpc-5749	17	13	bullous	bullous	ADJ
dpc-5749	17	14	dermatosis	dermatosis	NOUN
dpc-5749	17	15	which	which	PRON
dpc-5749	17	16	predominantly	predominantly	ADV
dpc-5749	17	17	affects	affect	VERB
dpc-5749	17	18	the	the	DET
dpc-5749	17	19	mucous	mucous	ADJ
dpc-5749	17	20	membranes	membrane	NOUN
dpc-5749	17	21	and	and	CCONJ
dpc-5749	17	22	,	,	PUNCT
dpc-5749	17	23	occasionally	occasionally	ADV
dpc-5749	17	24	,	,	PUNCT
dpc-5749	17	25	the	the	DET
dpc-5749	17	26	skin	skin	NOUN
dpc-5749	17	27	.	.	PUNCT
dpc-5749	18	1	the	the	DET
dpc-5749	18	2	exact	exact	ADJ
dpc-5749	18	3	pathogenesis	pathogenesis	NOUN
dpc-5749	18	4	of	of	ADP
dpc-5749	18	5	mmp	mmp	PROPN
dpc-5749	18	6	remains	remain	VERB
dpc-5749	18	7	unclear	unclear	ADJ
dpc-5749	18	8	and	and	CCONJ
dpc-5749	18	9	should	should	AUX
dpc-5749	18	10	be	be	AUX
dpc-5749	18	11	considered	consider	VERB
dpc-5749	18	12	as	as	ADP
dpc-5749	18	13	a	a	DET
dpc-5749	18	14	unique	unique	ADJ
dpc-5749	18	15	phenomenon	phenomenon	NOUN
dpc-5749	18	16	,	,	PUNCT
dpc-5749	18	17	which	which	PRON
dpc-5749	18	18	involves	involve	VERB
dpc-5749	18	19	the	the	DET
dpc-5749	18	20	formation	formation	NOUN
dpc-5749	18	21	of	of	ADP
dpc-5749	18	22	subepithelial	subepithelial	ADJ
dpc-5749	18	23	blisters	blister	NOUN
dpc-5749	18	24	and	and	CCONJ
dpc-5749	18	25	fibrosis	fibrosis	NOUN
dpc-5749	18	26	.	.	PUNCT
dpc-5749	19	1	objectives	objective	NOUN
dpc-5749	19	2	:	:	PUNCT
dpc-5749	19	3	this	this	DET
dpc-5749	19	4	narrative	narrative	NOUN
dpc-5749	19	5	review	review	NOUN
dpc-5749	19	6	aimed	aim	VERB
dpc-5749	19	7	to	to	PART
dpc-5749	19	8	summarize	summarize	VERB
dpc-5749	19	9	the	the	DET
dpc-5749	19	10	pharmacological	pharmacological	ADJ
dpc-5749	19	11	agents	agent	NOUN
dpc-5749	19	12	which	which	PRON
dpc-5749	19	13	showed	show	VERB
dpc-5749	19	14	efficacy	efficacy	NOUN
dpc-5749	19	15	in	in	ADP
dpc-5749	19	16	the	the	DET
dpc-5749	19	17	management	management	NOUN
dpc-5749	19	18	of	of	ADP
dpc-5749	19	19	mmp	mmp	PROPN
dpc-5749	19	20	but	but	CCONJ
dpc-5749	19	21	that	that	PRON
dpc-5749	19	22	are	be	AUX
dpc-5749	19	23	not	not	PART
dpc-5749	19	24	included	include	VERB
dpc-5749	19	25	in	in	ADP
dpc-5749	19	26	the	the	DET
dpc-5749	19	27	guidelines	guideline	NOUN
dpc-5749	19	28	.	.	PUNCT
dpc-5749	20	1	methods	method	NOUN
dpc-5749	20	2	:	:	PUNCT
dpc-5749	20	3	we	we	PRON
dpc-5749	20	4	conducted	conduct	VERB
dpc-5749	20	5	a	a	DET
dpc-5749	20	6	search	search	NOUN
dpc-5749	20	7	on	on	ADP
dpc-5749	20	8	google	google	PROPN
dpc-5749	20	9	scholar	scholar	NOUN
dpc-5749	20	10	,	,	PUNCT
dpc-5749	20	11	pubmed	pubmed	PROPN
dpc-5749	20	12	,	,	PUNCT
dpc-5749	20	13	and	and	CCONJ
dpc-5749	20	14	the	the	DET
dpc-5749	20	15	web	web	NOUN
dpc-5749	20	16	of	of	ADP
dpc-5749	20	17	science	science	NOUN
dpc-5749	20	18	databases	database	NOUN
dpc-5749	20	19	concerning	concern	VERB
dpc-5749	20	20	articles	article	NOUN
dpc-5749	20	21	published	publish	VERB
dpc-5749	20	22	in	in	ADP
dpc-5749	20	23	english	english	PROPN
dpc-5749	20	24	on	on	ADP
dpc-5749	20	25	the	the	DET
dpc-5749	20	26	management	management	NOUN
dpc-5749	20	27	of	of	ADP
dpc-5749	20	28	mmp	mmp	PROPN
dpc-5749	20	29	between	between	ADP
dpc-5749	20	30	january	january	PROPN
dpc-5749	20	31	2000	2000	NUM
dpc-5749	20	32	and	and	CCONJ
dpc-5749	20	33	february	february	PROPN
dpc-5749	20	34	2025	2025	NUM
dpc-5749	20	35	;	;	PUNCT
dpc-5749	20	36	all	all	DET
dpc-5749	20	37	the	the	DET
dpc-5749	20	38	sourced	source	VERB
dpc-5749	20	39	articles	article	NOUN
dpc-5749	20	40	were	be	AUX
dpc-5749	20	41	full	full	ADJ
dpc-5749	20	42	-	-	PUNCT
dpc-5749	20	43	text	text	NOUN
dpc-5749	20	44	reviewed	review	VERB
dpc-5749	20	45	.	.	PUNCT
dpc-5749	21	1	results	result	NOUN
dpc-5749	21	2	:	:	PUNCT
dpc-5749	21	3	we	we	PRON
dpc-5749	21	4	included	include	VERB
dpc-5749	21	5	13	13	NUM
dpc-5749	21	6	articles	article	NOUN
dpc-5749	21	7	.	.	PUNCT
dpc-5749	22	1	the	the	DET
dpc-5749	22	2	studied	study	VERB
dpc-5749	22	3	pharmacological	pharmacological	ADJ
dpc-5749	22	4	agents	agent	NOUN
dpc-5749	22	5	are	be	AUX
dpc-5749	22	6	classified	classify	VERB
dpc-5749	22	7	as	as	ADP
dpc-5749	22	8	immunosuppressive	immunosuppressive	ADJ
dpc-5749	22	9	agents	agent	NOUN
dpc-5749	22	10	(	(	PUNCT
dpc-5749	22	11	leflunomide	leflunomide	ADJ
dpc-5749	22	12	,	,	PUNCT
dpc-5749	22	13	sirolimus	sirolimus	NOUN
dpc-5749	22	14	,	,	PUNCT
dpc-5749	22	15	daclizumab	daclizumab	NOUN
dpc-5749	22	16	)	)	PUNCT
dpc-5749	22	17	and	and	CCONJ
dpc-5749	22	18	biologics	biologic	NOUN
dpc-5749	22	19	(	(	PUNCT
dpc-5749	22	20	daclizumab	daclizumab	NOUN
dpc-5749	22	21	,	,	PUNCT
dpc-5749	22	22	dupilumab	dupilumab	NOUN
dpc-5749	22	23	,	,	PUNCT
dpc-5749	22	24	omalizumab	omalizumab	NOUN
dpc-5749	22	25	,	,	PUNCT
dpc-5749	22	26	bevacizumab	bevacizumab	NOUN
dpc-5749	22	27	,	,	PUNCT
dpc-5749	22	28	aflibercept	aflibercept	ADJ
dpc-5749	22	29	,	,	PUNCT
dpc-5749	22	30	cenegermin	cenegermin	NOUN
dpc-5749	22	31	)	)	PUNCT
dpc-5749	22	32	;	;	PUNCT
dpc-5749	22	33	the	the	DET
dpc-5749	22	34	immunosuppressant	immunosuppressant	PROPN
dpc-5749	22	35	leflunomide	leflunomide	NOUN
dpc-5749	22	36	and	and	CCONJ
dpc-5749	22	37	the	the	DET
dpc-5749	22	38	antimalarial	antimalarial	ADJ
dpc-5749	22	39	agent	agent	NOUN
dpc-5749	22	40	hydroxychloroquine	hydroxychloroquine	PROPN
dpc-5749	22	41	are	be	AUX
dpc-5749	22	42	also	also	ADV
dpc-5749	22	43	classified	classify	VERB
dpc-5749	22	44	as	as	ADP
dpc-5749	22	45	disease	disease	NOUN
dpc-5749	22	46	-	-	PUNCT
dpc-5749	22	47	modifying	modify	VERB
dpc-5749	22	48	antirheumatic	antirheumatic	ADJ
dpc-5749	22	49	drugs	drug	NOUN
dpc-5749	22	50	.	.	PUNCT
dpc-5749	23	1	other	other	ADJ
dpc-5749	23	2	pharmacological	pharmacological	ADJ
dpc-5749	23	3	agents	agent	NOUN
dpc-5749	23	4	(	(	PUNCT
dpc-5749	23	5	colchicine	colchicine	PROPN
dpc-5749	23	6	,	,	PUNCT
dpc-5749	23	7	corticotropin	corticotropin	NOUN
dpc-5749	23	8	,	,	PUNCT
dpc-5749	23	9	varenicline	varenicline	NOUN
dpc-5749	23	10	,	,	PUNCT
dpc-5749	23	11	lifitegrast	lifitegrast	NOUN
dpc-5749	23	12	)	)	PUNCT
dpc-5749	23	13	exert	exert	VERB
dpc-5749	23	14	miscellaneous	miscellaneous	ADJ
dpc-5749	23	15	mechanisms	mechanism	NOUN
dpc-5749	23	16	.	.	PUNCT
dpc-5749	24	1	abstract	abstract	ADJ
dpc-5749	24	2	2	2	NUM
dpc-5749	24	3	review	review	NOUN
dpc-5749	24	4	|	|	ADV
dpc-5749	24	5	dermatol	dermatol	ADJ
dpc-5749	24	6	pract	pract	NOUN
dpc-5749	24	7	concept	concept	NOUN
dpc-5749	24	8	.	.	PUNCT
dpc-5749	25	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	25	2	introduction	introduction	NOUN
dpc-5749	25	3	mucous	mucous	ADJ
dpc-5749	25	4	membrane	membrane	NOUN
dpc-5749	25	5	pemphigoid	pemphigoid	NOUN
dpc-5749	25	6	(	(	PUNCT
dpc-5749	25	7	mmp	mmp	PROPN
dpc-5749	25	8	)	)	PUNCT
dpc-5749	25	9	is	be	AUX
dpc-5749	25	10	a	a	DET
dpc-5749	25	11	rare	rare	ADJ
dpc-5749	25	12	autoimmune	autoimmune	ADJ
dpc-5749	25	13	bullous	bullous	ADJ
dpc-5749	25	14	dermatosis	dermatosis	NOUN
dpc-5749	25	15	(	(	PUNCT
dpc-5749	25	16	aibd	aibd	NOUN
dpc-5749	25	17	)	)	PUNCT
dpc-5749	25	18	which	which	PRON
dpc-5749	25	19	predominantly	predominantly	ADV
dpc-5749	25	20	affects	affect	VERB
dpc-5749	25	21	mucous	mucous	ADJ
dpc-5749	25	22	membranes	membrane	NOUN
dpc-5749	25	23	and	and	CCONJ
dpc-5749	25	24	the	the	DET
dpc-5749	25	25	skin	skin	NOUN
dpc-5749	25	26	.	.	PUNCT
dpc-5749	26	1	generally	generally	ADV
dpc-5749	26	2	,	,	PUNCT
dpc-5749	26	3	mmp	mmp	PROPN
dpc-5749	26	4	has	have	VERB
dpc-5749	26	5	a	a	DET
dpc-5749	26	6	late	late	ADJ
dpc-5749	26	7	onset	onset	NOUN
dpc-5749	26	8	,	,	PUNCT
dpc-5749	26	9	and	and	CCONJ
dpc-5749	26	10	the	the	DET
dpc-5749	26	11	mean	mean	ADJ
dpc-5749	26	12	age	age	NOUN
dpc-5749	26	13	of	of	ADP
dpc-5749	26	14	patients	patient	NOUN
dpc-5749	26	15	ranges	range	VERB
dpc-5749	26	16	from	from	ADP
dpc-5749	26	17	60	60	NUM
dpc-5749	26	18	to	to	PART
dpc-5749	26	19	80	80	NUM
dpc-5749	26	20	years	year	NOUN
dpc-5749	26	21	;	;	PUNCT
dpc-5749	26	22	the	the	DET
dpc-5749	26	23	association	association	NOUN
dpc-5749	26	24	between	between	ADP
dpc-5749	26	25	the	the	DET
dpc-5749	26	26	condition	condition	NOUN
dpc-5749	26	27	and	and	CCONJ
dpc-5749	26	28	hladqb1	hladqb1	NOUN
dpc-5749	26	29	*	*	NOUN
dpc-5749	26	30	0301	0301	NUM
dpc-5749	26	31	,	,	PUNCT
dpc-5749	26	32	hla	hla	PROPN
dpc-5749	26	33	-	-	PUNCT
dpc-5749	26	34	drb1	drb1	PROPN
dpc-5749	26	35	*	*	NOUN
dpc-5749	26	36	1101	1101	NUM
dpc-5749	26	37	,	,	PUNCT
dpc-5749	26	38	hla	hla	PROPN
dpc-5749	26	39	-	-	PUNCT
dpc-5749	26	40	dqa1	dqa1	PROPN
dpc-5749	26	41	*	*	NOUN
dpc-5749	26	42	0505	0505	NUM
dpc-5749	26	43	alleles	allele	NOUN
dpc-5749	26	44	has	have	AUX
dpc-5749	26	45	been	be	AUX
dpc-5749	26	46	notes	note	NOUN
dpc-5749	26	47	noted	note	VERB
dpc-5749	26	48	.	.	PUNCT
dpc-5749	27	1	the	the	DET
dpc-5749	27	2	pathogenesis	pathogenesis	NOUN
dpc-5749	27	3	of	of	ADP
dpc-5749	27	4	mmp	mmp	PROPN
dpc-5749	27	5	remains	remain	VERB
dpc-5749	27	6	unclear	unclear	ADJ
dpc-5749	27	7	and	and	CCONJ
dpc-5749	27	8	involves	involve	VERB
dpc-5749	27	9	the	the	DET
dpc-5749	27	10	formation	formation	NOUN
dpc-5749	27	11	of	of	ADP
dpc-5749	27	12	subepithelial	subepithelial	ADJ
dpc-5749	27	13	blisters	blister	NOUN
dpc-5749	27	14	and	and	CCONJ
dpc-5749	27	15	fibrosis	fibrosis	NOUN
dpc-5749	27	16	.	.	PUNCT
dpc-5749	28	1	the	the	DET
dpc-5749	28	2	formation	formation	NOUN
dpc-5749	28	3	of	of	ADP
dpc-5749	28	4	blisters	blister	NOUN
dpc-5749	28	5	is	be	AUX
dpc-5749	28	6	linked	link	VERB
dpc-5749	28	7	to	to	ADP
dpc-5749	28	8	the	the	DET
dpc-5749	28	9	production	production	NOUN
dpc-5749	28	10	of	of	ADP
dpc-5749	28	11	antibodies	antibody	NOUN
dpc-5749	28	12	(	(	PUNCT
dpc-5749	28	13	igg	igg	PROPN
dpc-5749	28	14	and/or	and/or	CCONJ
dpc-5749	28	15	iga	iga	PROPN
dpc-5749	28	16	)	)	PUNCT
dpc-5749	28	17	against	against	ADP
dpc-5749	28	18	the	the	DET
dpc-5749	28	19	basement	basement	NOUN
dpc-5749	28	20	membrane	membrane	NOUN
dpc-5749	28	21	proteins	protein	NOUN
dpc-5749	28	22	bp230	bp230	VERB
dpc-5749	28	23	and	and	CCONJ
dpc-5749	28	24	bp180	bp180	PROPN
dpc-5749	28	25	,	,	PUNCT
dpc-5749	28	26	α6	α6	PROPN
dpc-5749	28	27	and	and	CCONJ
dpc-5749	28	28	β4	β4	PROPN
dpc-5749	28	29	integrin	integrin	NOUN
dpc-5749	28	30	subunits	subunit	NOUN
dpc-5749	28	31	,	,	PUNCT
dpc-5749	28	32	laminin-332	laminin-332	NOUN
dpc-5749	28	33	,	,	PUNCT
dpc-5749	28	34	laminin-6	laminin-6	PROPN
dpc-5749	28	35	,	,	PUNCT
dpc-5749	28	36	type	type	NOUN
dpc-5749	28	37	vii	vii	PROPN
dpc-5749	28	38	collagen	collagen	PROPN
dpc-5749	28	39	.	.	PUNCT
dpc-5749	29	1	the	the	DET
dpc-5749	29	2	activation	activation	NOUN
dpc-5749	29	3	of	of	ADP
dpc-5749	29	4	fibroblasts	fibroblast	NOUN
dpc-5749	29	5	and	and	CCONJ
dpc-5749	29	6	hyperproduction	hyperproduction	NOUN
dpc-5749	29	7	of	of	ADP
dpc-5749	29	8	collagen	collagen	NOUN
dpc-5749	29	9	may	may	AUX
dpc-5749	29	10	be	be	AUX
dpc-5749	29	11	associated	associate	VERB
dpc-5749	29	12	with	with	ADP
dpc-5749	29	13	the	the	DET
dpc-5749	29	14	dysregulation	dysregulation	NOUN
dpc-5749	29	15	of	of	ADP
dpc-5749	29	16	immunity	immunity	NOUN
dpc-5749	29	17	,	,	PUNCT
dpc-5749	29	18	excessive	excessive	ADJ
dpc-5749	29	19	release	release	NOUN
dpc-5749	29	20	of	of	ADP
dpc-5749	29	21	proinflammatory	proinflammatory	ADJ
dpc-5749	29	22	molecules	molecule	NOUN
dpc-5749	29	23	,	,	PUNCT
dpc-5749	29	24	and	and	CCONJ
dpc-5749	29	25	proteolytic	proteolytic	ADJ
dpc-5749	29	26	enzymes	enzyme	NOUN
dpc-5749	29	27	[	[	X
dpc-5749	29	28	1	1	NUM
dpc-5749	29	29	]	]	PUNCT
dpc-5749	29	30	.	.	PUNCT
dpc-5749	30	1	transforming	transform	VERB
dpc-5749	30	2	growth	growth	NOUN
dpc-5749	30	3	factor	factor	NOUN
dpc-5749	30	4	beta	beta	NOUN
dpc-5749	30	5	(	(	PUNCT
dpc-5749	30	6	tgf	tgf	PROPN
dpc-5749	30	7	-	-	PUNCT
dpc-5749	30	8	β	β	NOUN
dpc-5749	30	9	)	)	PUNCT
dpc-5749	30	10	plays	play	VERB
dpc-5749	30	11	a	a	DET
dpc-5749	30	12	major	major	ADJ
dpc-5749	30	13	role	role	NOUN
dpc-5749	30	14	in	in	ADP
dpc-5749	30	15	fibrosis	fibrosis	NOUN
dpc-5749	30	16	,	,	PUNCT
dpc-5749	30	17	and	and	CCONJ
dpc-5749	30	18	an	an	DET
dpc-5749	30	19	increased	increase	VERB
dpc-5749	30	20	expression	expression	NOUN
dpc-5749	30	21	of	of	ADP
dpc-5749	30	22	tgf	tgf	PROPN
dpc-5749	30	23	-	-	PUNCT
dpc-5749	30	24	β	β	PROPN
dpc-5749	30	25	and	and	CCONJ
dpc-5749	30	26	alpha	alpha	NOUN
dpc-5749	30	27	-	-	PUNCT
dpc-5749	30	28	smooth	smooth	ADJ
dpc-5749	30	29	muscle	muscle	NOUN
dpc-5749	30	30	actin	actin	NOUN
dpc-5749	30	31	were	be	AUX
dpc-5749	30	32	observed	observe	VERB
dpc-5749	30	33	in	in	ADP
dpc-5749	30	34	conjunctiva	conjunctiva	NOUN
dpc-5749	30	35	samples	sample	NOUN
dpc-5749	30	36	taken	take	VERB
dpc-5749	30	37	from	from	ADP
dpc-5749	30	38	patients	patient	NOUN
dpc-5749	30	39	with	with	ADP
dpc-5749	30	40	mmp	mmp	PROPN
dpc-5749	31	1	[	[	X
dpc-5749	31	2	2	2	NUM
dpc-5749	31	3	]	]	PUNCT
dpc-5749	31	4	.	.	PUNCT
dpc-5749	32	1	mmp	mmp	PROPN
dpc-5749	32	2	develops	develop	VERB
dpc-5749	32	3	through	through	ADP
dpc-5749	32	4	three	three	NUM
dpc-5749	32	5	distinct	distinct	ADJ
dpc-5749	32	6	phases	phase	NOUN
dpc-5749	32	7	:	:	PUNCT
dpc-5749	32	8	injury	injury	NOUN
dpc-5749	32	9	,	,	PUNCT
dpc-5749	32	10	acute	acute	ADJ
dpc-5749	32	11	inflammation	inflammation	NOUN
dpc-5749	32	12	and	and	CCONJ
dpc-5749	32	13	proliferation	proliferation	NOUN
dpc-5749	32	14	,	,	PUNCT
dpc-5749	32	15	and	and	CCONJ
dpc-5749	32	16	fibrosis	fibrosis	NOUN
dpc-5749	32	17	.	.	PUNCT
dpc-5749	33	1	subepithelial	subepithelial	ADJ
dpc-5749	33	2	tense	tense	ADJ
dpc-5749	33	3	blisters	blister	NOUN
dpc-5749	33	4	precede	precede	VERB
dpc-5749	33	5	erosions	erosion	NOUN
dpc-5749	33	6	and	and	CCONJ
dpc-5749	33	7	scarring	scarring	NOUN
dpc-5749	33	8	.	.	PUNCT
dpc-5749	34	1	histologically	histologically	ADV
dpc-5749	34	2	,	,	PUNCT
dpc-5749	34	3	the	the	DET
dpc-5749	34	4	separation	separation	NOUN
dpc-5749	34	5	of	of	ADP
dpc-5749	34	6	the	the	DET
dpc-5749	34	7	epithelium	epithelium	NOUN
dpc-5749	34	8	from	from	ADP
dpc-5749	34	9	the	the	DET
dpc-5749	34	10	underlying	underlie	VERB
dpc-5749	34	11	connective	connective	ADJ
dpc-5749	34	12	tissue	tissue	NOUN
dpc-5749	34	13	,	,	PUNCT
dpc-5749	34	14	leukocyte	leukocyte	NOUN
dpc-5749	34	15	infiltrates	infiltrate	NOUN
dpc-5749	34	16	,	,	PUNCT
dpc-5749	34	17	granulation	granulation	ADJ
dpc-5749	34	18	tissue	tissue	NOUN
dpc-5749	34	19	,	,	PUNCT
dpc-5749	34	20	and	and	CCONJ
dpc-5749	34	21	fibrosis	fibrosis	NOUN
dpc-5749	34	22	may	may	AUX
dpc-5749	34	23	be	be	AUX
dpc-5749	34	24	seen	see	VERB
dpc-5749	34	25	.	.	PUNCT
dpc-5749	35	1	direct	direct	ADJ
dpc-5749	35	2	immunofluorescence	immunofluorescence	NOUN
dpc-5749	35	3	demonstrates	demonstrate	VERB
dpc-5749	35	4	peculiar	peculiar	ADJ
dpc-5749	35	5	linear	linear	ADJ
dpc-5749	35	6	depositions	deposition	NOUN
dpc-5749	35	7	of	of	ADP
dpc-5749	35	8	immunoglobulins	immunoglobulin	NOUN
dpc-5749	35	9	(	(	PUNCT
dpc-5749	35	10	igg	igg	PROPN
dpc-5749	35	11	and/or	and/or	CCONJ
dpc-5749	35	12	iga	iga	PROPN
dpc-5749	35	13	)	)	PUNCT
dpc-5749	35	14	and/or	and/or	CCONJ
dpc-5749	35	15	complement	complement	VERB
dpc-5749	35	16	c3	c3	NOUN
dpc-5749	35	17	along	along	ADP
dpc-5749	35	18	the	the	DET
dpc-5749	35	19	basal	basal	ADJ
dpc-5749	35	20	membrane	membrane	NOUN
dpc-5749	35	21	;	;	PUNCT
dpc-5749	35	22	indirect	indirect	ADJ
dpc-5749	35	23	immunofluorescence	immunofluorescence	NOUN
dpc-5749	35	24	(	(	PUNCT
dpc-5749	35	25	salt	salt	NOUN
dpc-5749	35	26	-	-	PUNCT
dpc-5749	35	27	split	split	NOUN
dpc-5749	35	28	)	)	PUNCT
dpc-5749	35	29	and	and	CCONJ
dpc-5749	35	30	immunoserological	immunoserological	ADJ
dpc-5749	35	31	tests	test	NOUN
dpc-5749	35	32	detect	detect	VERB
dpc-5749	35	33	pathogenic	pathogenic	ADJ
dpc-5749	35	34	autoantibodies	autoantibody	NOUN
dpc-5749	35	35	[	[	X
dpc-5749	35	36	1	1	NUM
dpc-5749	35	37	]	]	PUNCT
dpc-5749	35	38	.	.	PUNCT
dpc-5749	36	1	since	since	SCONJ
dpc-5749	36	2	2002	2002	NUM
dpc-5749	36	3	,	,	PUNCT
dpc-5749	36	4	several	several	ADJ
dpc-5749	36	5	guidelines	guideline	NOUN
dpc-5749	36	6	have	have	AUX
dpc-5749	36	7	evolved	evolve	VERB
dpc-5749	36	8	on	on	ADP
dpc-5749	36	9	the	the	DET
dpc-5749	36	10	management	management	NOUN
dpc-5749	36	11	of	of	ADP
dpc-5749	36	12	mmp	mmp	PROPN
dpc-5749	36	13	.	.	PUNCT
dpc-5749	37	1	the	the	DET
dpc-5749	37	2	first	first	ADJ
dpc-5749	37	3	international	international	ADJ
dpc-5749	37	4	consensus	consensus	NOUN
dpc-5749	37	5	on	on	ADP
dpc-5749	37	6	mmp	mmp	PROPN
dpc-5749	37	7	[	[	X
dpc-5749	37	8	3	3	NUM
dpc-5749	37	9	]	]	PUNCT
dpc-5749	37	10	and	and	CCONJ
dpc-5749	37	11	the	the	DET
dpc-5749	37	12	guidelines	guideline	NOUN
dpc-5749	37	13	of	of	ADP
dpc-5749	37	14	the	the	DET
dpc-5749	37	15	brazilian	brazilian	ADJ
dpc-5749	37	16	society	society	NOUN
dpc-5749	37	17	of	of	ADP
dpc-5749	37	18	dermatology	dermatology	NOUN
dpc-5749	37	19	[	[	X
dpc-5749	37	20	4	4	NUM
dpc-5749	37	21	]	]	PUNCT
dpc-5749	37	22	and	and	CCONJ
dpc-5749	37	23	the	the	DET
dpc-5749	37	24	japanese	japanese	ADJ
dpc-5749	37	25	dermatological	dermatological	ADJ
dpc-5749	37	26	association	association	NOUN
dpc-5749	38	1	[	[	X
dpc-5749	38	2	5	5	NUM
dpc-5749	38	3	]	]	PUNCT
dpc-5749	38	4	classify	classify	VERB
dpc-5749	38	5	patients	patient	NOUN
dpc-5749	38	6	as	as	ADP
dpc-5749	38	7	low	low	ADJ
dpc-5749	38	8	risk	risk	NOUN
dpc-5749	38	9	(	(	PUNCT
dpc-5749	38	10	oral	oral	ADJ
dpc-5749	38	11	and/or	and/or	CCONJ
dpc-5749	38	12	cutaneous	cutaneous	ADJ
dpc-5749	38	13	lesions	lesion	NOUN
dpc-5749	38	14	)	)	PUNCT
dpc-5749	38	15	or	or	CCONJ
dpc-5749	38	16	high	high	ADJ
dpc-5749	38	17	risk	risk	NOUN
dpc-5749	38	18	(	(	PUNCT
dpc-5749	38	19	ocular	ocular	ADJ
dpc-5749	38	20	,	,	PUNCT
dpc-5749	38	21	pharyngeal	pharyngeal	ADJ
dpc-5749	38	22	,	,	PUNCT
dpc-5749	38	23	laryngeal	laryngeal	ADJ
dpc-5749	38	24	,	,	PUNCT
dpc-5749	38	25	esophageal	esophageal	ADJ
dpc-5749	38	26	,	,	PUNCT
dpc-5749	38	27	and/or	and/or	CCONJ
dpc-5749	38	28	genital	genital	ADJ
dpc-5749	38	29	involvement	involvement	NOUN
dpc-5749	38	30	)	)	PUNCT
dpc-5749	38	31	,	,	PUNCT
dpc-5749	38	32	with	with	ADP
dpc-5749	38	33	adapted	adapt	VERB
dpc-5749	38	34	treatment	treatment	NOUN
dpc-5749	38	35	options	option	NOUN
dpc-5749	38	36	depending	depend	VERB
dpc-5749	38	37	on	on	ADP
dpc-5749	38	38	the	the	DET
dpc-5749	38	39	risk	risk	NOUN
dpc-5749	38	40	category	category	NOUN
dpc-5749	38	41	;	;	PUNCT
dpc-5749	38	42	the	the	DET
dpc-5749	38	43	guidelines	guideline	NOUN
dpc-5749	38	44	of	of	ADP
dpc-5749	38	45	the	the	DET
dpc-5749	38	46	french	french	ADJ
dpc-5749	38	47	society	society	NOUN
dpc-5749	38	48	of	of	ADP
dpc-5749	38	49	dermatology	dermatology	NOUN
dpc-5749	38	50	[	[	X
dpc-5749	38	51	6	6	NUM
dpc-5749	38	52	]	]	PUNCT
dpc-5749	38	53	are	be	AUX
dpc-5749	38	54	based	base	VERB
dpc-5749	38	55	on	on	ADP
dpc-5749	38	56	the	the	DET
dpc-5749	38	57	location	location	NOUN
dpc-5749	38	58	and	and	CCONJ
dpc-5749	38	59	disease	disease	NOUN
dpc-5749	38	60	severity	severity	NOUN
dpc-5749	38	61	.	.	PUNCT
dpc-5749	39	1	the	the	DET
dpc-5749	39	2	european	european	PROPN
dpc-5749	39	3	guidelines	guideline	NOUN
dpc-5749	39	4	(	(	PUNCT
dpc-5749	39	5	s3	s3	PROPN
dpc-5749	39	6	)	)	PUNCT
dpc-5749	40	1	[	[	X
dpc-5749	40	2	7	7	X
dpc-5749	40	3	]	]	PUNCT
dpc-5749	40	4	and	and	CCONJ
dpc-5749	40	5	the	the	DET
dpc-5749	40	6	s2k	s2k	PROPN
dpc-5749	40	7	guideline	guideline	NOUN
dpc-5749	40	8	[	[	X
dpc-5749	40	9	8	8	NUM
dpc-5749	40	10	]	]	PUNCT
dpc-5749	40	11	offer	offer	VERB
dpc-5749	40	12	lines	line	NOUN
dpc-5749	40	13	of	of	ADP
dpc-5749	40	14	therapy	therapy	NOUN
dpc-5749	40	15	,	,	PUNCT
dpc-5749	40	16	alternative	alternative	ADJ
dpc-5749	40	17	combinations	combination	NOUN
dpc-5749	40	18	,	,	PUNCT
dpc-5749	40	19	and	and	CCONJ
dpc-5749	40	20	treatment	treatment	NOUN
dpc-5749	40	21	options	option	NOUN
dpc-5749	40	22	,	,	PUNCT
dpc-5749	40	23	depending	depend	VERB
dpc-5749	40	24	on	on	ADP
dpc-5749	40	25	the	the	DET
dpc-5749	40	26	clinical	clinical	ADJ
dpc-5749	40	27	course	course	NOUN
dpc-5749	40	28	,	,	PUNCT
dpc-5749	40	29	location	location	NOUN
dpc-5749	40	30	,	,	PUNCT
dpc-5749	40	31	and	and	CCONJ
dpc-5749	40	32	response	response	NOUN
dpc-5749	40	33	.	.	PUNCT
dpc-5749	41	1	given	give	VERB
dpc-5749	41	2	the	the	DET
dpc-5749	41	3	risk	risk	NOUN
dpc-5749	41	4	of	of	ADP
dpc-5749	41	5	disease	disease	NOUN
dpc-5749	41	6	progression	progression	NOUN
dpc-5749	41	7	and	and	CCONJ
dpc-5749	41	8	complications	complication	NOUN
dpc-5749	41	9	,	,	PUNCT
dpc-5749	41	10	early	early	ADJ
dpc-5749	41	11	initiation	initiation	NOUN
dpc-5749	41	12	of	of	ADP
dpc-5749	41	13	immunosuppressive	immunosuppressive	ADJ
dpc-5749	41	14	therapy	therapy	NOUN
dpc-5749	41	15	is	be	AUX
dpc-5749	41	16	of	of	ADP
dpc-5749	41	17	vital	vital	ADJ
dpc-5749	41	18	importance	importance	NOUN
dpc-5749	41	19	;	;	PUNCT
dpc-5749	41	20	in	in	ADP
dpc-5749	41	21	severe	severe	ADJ
dpc-5749	41	22	cases	case	NOUN
dpc-5749	41	23	,	,	PUNCT
dpc-5749	41	24	surgical	surgical	ADJ
dpc-5749	41	25	treatment	treatment	NOUN
dpc-5749	41	26	is	be	AUX
dpc-5749	41	27	considered	consider	VERB
dpc-5749	41	28	.	.	PUNCT
dpc-5749	42	1	nonetheless	nonetheless	ADV
dpc-5749	42	2	,	,	PUNCT
dpc-5749	42	3	there	there	PRON
dpc-5749	42	4	is	be	VERB
dpc-5749	42	5	no	no	DET
dpc-5749	42	6	gold	gold	ADJ
dpc-5749	42	7	standard	standard	NOUN
dpc-5749	42	8	for	for	ADP
dpc-5749	42	9	treatment	treatment	NOUN
dpc-5749	42	10	.	.	PUNCT
dpc-5749	43	1	this	this	DET
dpc-5749	43	2	narrative	narrative	NOUN
dpc-5749	43	3	review	review	NOUN
dpc-5749	43	4	aimed	aim	VERB
dpc-5749	43	5	to	to	PART
dpc-5749	43	6	summarize	summarize	VERB
dpc-5749	43	7	the	the	DET
dpc-5749	43	8	pharmacological	pharmacological	ADJ
dpc-5749	43	9	agents	agent	NOUN
dpc-5749	43	10	which	which	PRON
dpc-5749	43	11	showed	show	VERB
dpc-5749	43	12	efficacy	efficacy	NOUN
dpc-5749	43	13	in	in	ADP
dpc-5749	43	14	the	the	DET
dpc-5749	43	15	management	management	NOUN
dpc-5749	43	16	of	of	ADP
dpc-5749	43	17	mmp	mmp	PROPN
dpc-5749	43	18	but	but	CCONJ
dpc-5749	43	19	that	that	PRON
dpc-5749	43	20	are	be	AUX
dpc-5749	43	21	not	not	PART
dpc-5749	43	22	included	include	VERB
dpc-5749	43	23	in	in	ADP
dpc-5749	43	24	the	the	DET
dpc-5749	43	25	earlier	early	ADV
dpc-5749	43	26	published	publish	VERB
dpc-5749	43	27	guidelines	guideline	NOUN
dpc-5749	43	28	.	.	PUNCT
dpc-5749	44	1	we	we	PRON
dpc-5749	44	2	conducted	conduct	VERB
dpc-5749	44	3	a	a	DET
dpc-5749	44	4	search	search	NOUN
dpc-5749	44	5	on	on	ADP
dpc-5749	44	6	google	google	PROPN
dpc-5749	44	7	scholar	scholar	NOUN
dpc-5749	44	8	,	,	PUNCT
dpc-5749	44	9	pubmed	pubmed	PROPN
dpc-5749	44	10	,	,	PUNCT
dpc-5749	44	11	and	and	CCONJ
dpc-5749	44	12	the	the	DET
dpc-5749	44	13	web	web	NOUN
dpc-5749	44	14	of	of	ADP
dpc-5749	44	15	science	science	NOUN
dpc-5749	44	16	databases	database	NOUN
dpc-5749	44	17	concerning	concern	VERB
dpc-5749	44	18	articles	article	NOUN
dpc-5749	44	19	published	publish	VERB
dpc-5749	44	20	in	in	ADP
dpc-5749	44	21	english	english	PROPN
dpc-5749	44	22	on	on	ADP
dpc-5749	44	23	the	the	DET
dpc-5749	44	24	management	management	NOUN
dpc-5749	44	25	of	of	ADP
dpc-5749	44	26	mmp	mmp	PROPN
dpc-5749	44	27	between	between	ADP
dpc-5749	44	28	january	january	PROPN
dpc-5749	44	29	2000	2000	NUM
dpc-5749	44	30	and	and	CCONJ
dpc-5749	44	31	february	february	PROPN
dpc-5749	44	32	2025	2025	NUM
dpc-5749	44	33	,	,	PUNCT
dpc-5749	44	34	using	use	VERB
dpc-5749	44	35	the	the	DET
dpc-5749	44	36	search	search	NOUN
dpc-5749	44	37	terms	term	NOUN
dpc-5749	44	38	“	"	PUNCT
dpc-5749	44	39	mucous	mucous	ADJ
dpc-5749	44	40	membrane	membrane	NOUN
dpc-5749	44	41	pemphigoid	pemphigoid	NOUN
dpc-5749	44	42	”	"	PUNCT
dpc-5749	44	43	,	,	PUNCT
dpc-5749	44	44	“	"	PUNCT
dpc-5749	44	45	cicatricial	cicatricial	ADJ
dpc-5749	44	46	pemphigoid	pemphigoid	NOUN
dpc-5749	44	47	”	"	PUNCT
dpc-5749	44	48	,	,	PUNCT
dpc-5749	44	49	“	"	PUNCT
dpc-5749	44	50	brunsting	brunsting	NOUN
dpc-5749	44	51	-	-	PUNCT
dpc-5749	44	52	perry	perry	NOUN
dpc-5749	44	53	pemphigoid	pemphigoid	NOUN
dpc-5749	44	54	”	"	PUNCT
dpc-5749	44	55	,	,	PUNCT
dpc-5749	44	56	“	"	PUNCT
dpc-5749	44	57	management	management	NOUN
dpc-5749	44	58	”	"	PUNCT
dpc-5749	44	59	,	,	PUNCT
dpc-5749	44	60	“	"	PUNCT
dpc-5749	44	61	guidelines	guideline	NOUN
dpc-5749	44	62	”	"	PUNCT
dpc-5749	44	63	.	.	PUNCT
dpc-5749	45	1	all	all	DET
dpc-5749	45	2	the	the	DET
dpc-5749	45	3	sourced	source	VERB
dpc-5749	45	4	articles	article	NOUN
dpc-5749	45	5	were	be	AUX
dpc-5749	45	6	full	full	ADJ
dpc-5749	45	7	-	-	PUNCT
dpc-5749	45	8	text	text	NOUN
dpc-5749	45	9	reviewed	review	VERB
dpc-5749	45	10	.	.	PUNCT
dpc-5749	46	1	the	the	DET
dpc-5749	46	2	criteria	criterion	NOUN
dpc-5749	46	3	for	for	ADP
dpc-5749	46	4	inclusion	inclusion	NOUN
dpc-5749	46	5	of	of	ADP
dpc-5749	46	6	the	the	DET
dpc-5749	46	7	articles	article	NOUN
dpc-5749	46	8	were	be	AUX
dpc-5749	46	9	publication	publication	NOUN
dpc-5749	46	10	in	in	ADP
dpc-5749	46	11	english	english	PROPN
dpc-5749	46	12	and	and	CCONJ
dpc-5749	46	13	the	the	DET
dpc-5749	46	14	use	use	NOUN
dpc-5749	46	15	of	of	ADP
dpc-5749	46	16	pharmacological	pharmacological	ADJ
dpc-5749	46	17	options	option	NOUN
dpc-5749	46	18	not	not	PART
dpc-5749	46	19	included	include	VERB
dpc-5749	46	20	in	in	ADP
dpc-5749	46	21	the	the	DET
dpc-5749	46	22	published	publish	VERB
dpc-5749	46	23	guidelines	guideline	NOUN
dpc-5749	46	24	.	.	PUNCT
dpc-5749	47	1	drug	drug	NOUN
dpc-5749	47	2	review	review	NOUN
dpc-5749	47	3	we	we	PRON
dpc-5749	47	4	included	include	VERB
dpc-5749	47	5	13	13	NUM
dpc-5749	47	6	articles	article	NOUN
dpc-5749	47	7	in	in	ADP
dpc-5749	47	8	english	english	PROPN
dpc-5749	47	9	in	in	ADP
dpc-5749	47	10	which	which	PRON
dpc-5749	47	11	the	the	DET
dpc-5749	47	12	diagnosis	diagnosis	NOUN
dpc-5749	47	13	of	of	ADP
dpc-5749	47	14	mmp	mmp	PROPN
dpc-5749	47	15	was	be	AUX
dpc-5749	47	16	verified	verify	VERB
dpc-5749	47	17	and	and	CCONJ
dpc-5749	47	18	the	the	DET
dpc-5749	47	19	data	datum	NOUN
dpc-5749	47	20	on	on	ADP
dpc-5749	47	21	the	the	DET
dpc-5749	47	22	capacity	capacity	NOUN
dpc-5749	47	23	to	to	PART
dpc-5749	47	24	induce	induce	VERB
dpc-5749	47	25	disease	disease	NOUN
dpc-5749	47	26	control	control	NOUN
dpc-5749	47	27	and	and	CCONJ
dpc-5749	47	28	improvement	improvement	NOUN
dpc-5749	47	29	and	and	CCONJ
dpc-5749	47	30	the	the	DET
dpc-5749	47	31	absence	absence	NOUN
dpc-5749	47	32	of	of	ADP
dpc-5749	47	33	reported	report	VERB
dpc-5749	47	34	severe	severe	ADJ
dpc-5749	47	35	adverse	adverse	ADJ
dpc-5749	47	36	effects	effect	NOUN
dpc-5749	47	37	of	of	ADP
dpc-5749	47	38	the	the	DET
dpc-5749	47	39	suggested	suggest	VERB
dpc-5749	47	40	pharmacological	pharmacological	ADJ
dpc-5749	47	41	options	option	NOUN
dpc-5749	47	42	were	be	AUX
dpc-5749	47	43	available	available	ADJ
dpc-5749	47	44	(	(	PUNCT
dpc-5749	47	45	table	table	NOUN
dpc-5749	47	46	1	1	NUM
dpc-5749	47	47	)	)	PUNCT
dpc-5749	47	48	.	.	PUNCT
dpc-5749	48	1	the	the	DET
dpc-5749	48	2	studied	study	VERB
dpc-5749	48	3	pharmacological	pharmacological	ADJ
dpc-5749	48	4	agents	agent	NOUN
dpc-5749	48	5	are	be	AUX
dpc-5749	48	6	classified	classify	VERB
dpc-5749	48	7	as	as	ADP
dpc-5749	48	8	immunosuppressive	immunosuppressive	ADJ
dpc-5749	48	9	agents	agent	NOUN
dpc-5749	48	10	(	(	PUNCT
dpc-5749	48	11	leflunomide	leflunomide	ADJ
dpc-5749	48	12	,	,	PUNCT
dpc-5749	48	13	sirolimus	sirolimus	NOUN
dpc-5749	48	14	,	,	PUNCT
dpc-5749	48	15	daclizumab	daclizumab	NOUN
dpc-5749	48	16	)	)	PUNCT
dpc-5749	48	17	and	and	CCONJ
dpc-5749	48	18	biologics	biologic	NOUN
dpc-5749	48	19	(	(	PUNCT
dpc-5749	48	20	daclizumab	daclizumab	NOUN
dpc-5749	48	21	,	,	PUNCT
dpc-5749	48	22	dupilumab	dupilumab	NOUN
dpc-5749	48	23	,	,	PUNCT
dpc-5749	48	24	omalizumab	omalizumab	NOUN
dpc-5749	48	25	,	,	PUNCT
dpc-5749	48	26	bevacizumab	bevacizumab	NOUN
dpc-5749	48	27	,	,	PUNCT
dpc-5749	48	28	aflibercept	aflibercept	ADJ
dpc-5749	48	29	,	,	PUNCT
dpc-5749	48	30	cenegermin	cenegermin	NOUN
dpc-5749	48	31	)	)	PUNCT
dpc-5749	48	32	;	;	PUNCT
dpc-5749	48	33	the	the	DET
dpc-5749	48	34	immunosuppressant	immunosuppressant	PROPN
dpc-5749	48	35	leflunomide	leflunomide	NOUN
dpc-5749	48	36	and	and	CCONJ
dpc-5749	48	37	the	the	DET
dpc-5749	48	38	antimalarial	antimalarial	ADJ
dpc-5749	48	39	agent	agent	NOUN
dpc-5749	48	40	hydroxychloroquine	hydroxychloroquine	PROPN
dpc-5749	48	41	are	be	AUX
dpc-5749	48	42	also	also	ADV
dpc-5749	48	43	classified	classify	VERB
dpc-5749	48	44	as	as	ADP
dpc-5749	48	45	disease	disease	NOUN
dpc-5749	48	46	-	-	PUNCT
dpc-5749	48	47	modifying	modify	VERB
dpc-5749	48	48	antirheumatic	antirheumatic	ADJ
dpc-5749	48	49	drugs	drug	NOUN
dpc-5749	48	50	.	.	PUNCT
dpc-5749	49	1	other	other	ADJ
dpc-5749	49	2	groups	group	NOUN
dpc-5749	49	3	of	of	ADP
dpc-5749	49	4	pharmacological	pharmacological	ADJ
dpc-5749	49	5	agents	agent	NOUN
dpc-5749	49	6	(	(	PUNCT
dpc-5749	49	7	colchicine	colchicine	PROPN
dpc-5749	49	8	,	,	PUNCT
dpc-5749	49	9	corticotropin	corticotropin	NOUN
dpc-5749	49	10	,	,	PUNCT
dpc-5749	49	11	varenicline	varenicline	NOUN
dpc-5749	49	12	,	,	PUNCT
dpc-5749	49	13	lifitegrast	lifitegrast	NOUN
dpc-5749	49	14	)	)	PUNCT
dpc-5749	49	15	exert	exert	VERB
dpc-5749	49	16	miscellaneous	miscellaneous	ADJ
dpc-5749	49	17	mechanisms	mechanism	NOUN
dpc-5749	49	18	,	,	PUNCT
dpc-5749	49	19	which	which	PRON
dpc-5749	49	20	are	be	AUX
dpc-5749	49	21	specified	specify	VERB
dpc-5749	49	22	bellow	bellow	ADJ
dpc-5749	49	23	.	.	PUNCT
dpc-5749	50	1	interleukin	interleukin	NOUN
dpc-5749	50	2	(	(	PUNCT
dpc-5749	50	3	il)-2	il)-2	PROPN
dpc-5749	50	4	is	be	AUX
dpc-5749	50	5	a	a	DET
dpc-5749	50	6	pro	pro	ADJ
dpc-5749	50	7	-	-	ADJ
dpc-5749	50	8	inflammatory	inflammatory	ADJ
dpc-5749	50	9	cytokine	cytokine	NOUN
dpc-5749	50	10	,	,	PUNCT
dpc-5749	50	11	also	also	ADV
dpc-5749	50	12	known	know	VERB
dpc-5749	50	13	as	as	ADP
dpc-5749	50	14	t	t	PROPN
dpc-5749	50	15	cell	cell	NOUN
dpc-5749	50	16	growth	growth	NOUN
dpc-5749	50	17	factor	factor	NOUN
dpc-5749	50	18	;	;	PUNCT
dpc-5749	50	19	positive	positive	ADJ
dpc-5749	50	20	expression	expression	NOUN
dpc-5749	50	21	of	of	ADP
dpc-5749	50	22	il-2	il-2	PROPN
dpc-5749	50	23	is	be	AUX
dpc-5749	50	24	observed	observe	VERB
dpc-5749	50	25	in	in	ADP
dpc-5749	50	26	t	t	NOUN
dpc-5749	50	27	cells	cell	NOUN
dpc-5749	50	28	,	,	PUNCT
dpc-5749	50	29	infiltrating	infiltrate	VERB
dpc-5749	50	30	the	the	DET
dpc-5749	50	31	mmp	mmp	PROPN
dpc-5749	50	32	-	-	PUNCT
dpc-5749	50	33	affected	affect	VERB
dpc-5749	50	34	conjunctiva	conjunctiva	NOUN
dpc-5749	51	1	[	[	X
dpc-5749	51	2	9	9	NUM
dpc-5749	51	3	]	]	PUNCT
dpc-5749	51	4	.	.	PUNCT
dpc-5749	52	1	daclizumab	daclizumab	NOUN
dpc-5749	52	2	,	,	PUNCT
dpc-5749	52	3	a	a	DET
dpc-5749	52	4	monoclonal	monoclonal	NOUN
dpc-5749	52	5	anti	anti	ADJ
dpc-5749	52	6	-	-	ADJ
dpc-5749	52	7	cd25	cd25	ADJ
dpc-5749	52	8	antibody	antibody	NOUN
dpc-5749	52	9	,	,	PUNCT
dpc-5749	52	10	binds	bind	VERB
dpc-5749	52	11	to	to	ADP
dpc-5749	52	12	the	the	DET
dpc-5749	52	13	human	human	ADJ
dpc-5749	52	14	il-2	il-2	ADJ
dpc-5749	52	15	receptor	receptor	NOUN
dpc-5749	52	16	(	(	PUNCT
dpc-5749	52	17	il-2rα	il-2rα	NOUN
dpc-5749	52	18	)	)	PUNCT
dpc-5749	52	19	in	in	ADP
dpc-5749	52	20	the	the	DET
dpc-5749	52	21	il-2rα	il-2rα	ADJ
dpc-5749	52	22	conclusion	conclusion	NOUN
dpc-5749	52	23	:	:	PUNCT
dpc-5749	52	24	considering	consider	VERB
dpc-5749	52	25	the	the	DET
dpc-5749	52	26	severity	severity	NOUN
dpc-5749	52	27	of	of	ADP
dpc-5749	52	28	the	the	DET
dpc-5749	52	29	condition	condition	NOUN
dpc-5749	52	30	,	,	PUNCT
dpc-5749	52	31	progressive	progressive	ADJ
dpc-5749	52	32	fibrosis	fibrosis	NOUN
dpc-5749	52	33	,	,	PUNCT
dpc-5749	52	34	and	and	CCONJ
dpc-5749	52	35	resistance	resistance	NOUN
dpc-5749	52	36	to	to	ADP
dpc-5749	52	37	therapy	therapy	NOUN
dpc-5749	52	38	,	,	PUNCT
dpc-5749	52	39	more	more	ADJ
dpc-5749	52	40	research	research	NOUN
dpc-5749	52	41	is	be	AUX
dpc-5749	52	42	required	require	VERB
dpc-5749	52	43	in	in	ADP
dpc-5749	52	44	relation	relation	NOUN
dpc-5749	52	45	to	to	ADP
dpc-5749	52	46	the	the	DET
dpc-5749	52	47	pathogenesis	pathogenesis	NOUN
dpc-5749	52	48	of	of	ADP
dpc-5749	52	49	mmp	mmp	PROPN
dpc-5749	52	50	and	and	CCONJ
dpc-5749	52	51	the	the	DET
dpc-5749	52	52	efficacy	efficacy	NOUN
dpc-5749	52	53	and	and	CCONJ
dpc-5749	52	54	safety	safety	NOUN
dpc-5749	52	55	profile	profile	NOUN
dpc-5749	52	56	of	of	ADP
dpc-5749	52	57	novel	novel	ADJ
dpc-5749	52	58	pharmacological	pharmacological	ADJ
dpc-5749	52	59	options	option	NOUN
dpc-5749	52	60	.	.	PUNCT
dpc-5749	53	1	pharmacological	pharmacological	ADJ
dpc-5749	53	2	agents	agent	NOUN
dpc-5749	53	3	should	should	AUX
dpc-5749	53	4	provide	provide	VERB
dpc-5749	53	5	the	the	DET
dpc-5749	53	6	achievement	achievement	NOUN
dpc-5749	53	7	and	and	CCONJ
dpc-5749	53	8	maintenance	maintenance	NOUN
dpc-5749	53	9	of	of	ADP
dpc-5749	53	10	remission	remission	NOUN
dpc-5749	53	11	with	with	ADP
dpc-5749	53	12	minimal	minimal	ADJ
dpc-5749	53	13	adverse	adverse	ADJ
dpc-5749	53	14	effects	effect	NOUN
dpc-5749	53	15	.	.	PUNCT
dpc-5749	54	1	a	a	DET
dpc-5749	54	2	broader	broad	ADJ
dpc-5749	54	3	spectrum	spectrum	NOUN
dpc-5749	54	4	of	of	ADP
dpc-5749	54	5	pharmacological	pharmacological	ADJ
dpc-5749	54	6	agents	agent	NOUN
dpc-5749	54	7	will	will	AUX
dpc-5749	54	8	allow	allow	VERB
dpc-5749	54	9	a	a	DET
dpc-5749	54	10	personalized	personalized	ADJ
dpc-5749	54	11	approach	approach	NOUN
dpc-5749	54	12	and	and	CCONJ
dpc-5749	54	13	more	more	ADJ
dpc-5749	54	14	alternatives	alternative	NOUN
dpc-5749	54	15	,	,	PUNCT
dpc-5749	54	16	in	in	ADP
dpc-5749	54	17	particular	particular	ADJ
dpc-5749	54	18	for	for	ADP
dpc-5749	54	19	recalcitrant	recalcitrant	ADJ
dpc-5749	54	20	cases	case	NOUN
dpc-5749	54	21	,	,	PUNCT
dpc-5749	54	22	failure	failure	NOUN
dpc-5749	54	23	of	of	ADP
dpc-5749	54	24	the	the	DET
dpc-5749	54	25	previous	previous	ADJ
dpc-5749	54	26	therapy	therapy	NOUN
dpc-5749	54	27	,	,	PUNCT
dpc-5749	54	28	and	and	CCONJ
dpc-5749	54	29	in	in	ADP
dpc-5749	54	30	patients	patient	NOUN
dpc-5749	54	31	with	with	ADP
dpc-5749	54	32	mmp	mmp	PROPN
dpc-5749	54	33	and	and	CCONJ
dpc-5749	54	34	malignancy	malignancy	NOUN
dpc-5749	54	35	.	.	PUNCT
dpc-5749	55	1	review	review	NOUN
dpc-5749	55	2	|	|	ADV
dpc-5749	55	3	dermatol	dermatol	ADJ
dpc-5749	55	4	pract	pract	NOUN
dpc-5749	55	5	concept	concept	NOUN
dpc-5749	55	6	.	.	PUNCT
dpc-5749	56	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	56	2	3	3	NUM
dpc-5749	56	3	table	table	NOUN
dpc-5749	56	4	1	1	NUM
dpc-5749	56	5	.	.	PUNCT
dpc-5749	56	6	pharmacological	pharmacological	ADJ
dpc-5749	56	7	agents	agent	NOUN
dpc-5749	56	8	reported	report	VERB
dpc-5749	56	9	in	in	ADP
dpc-5749	56	10	the	the	DET
dpc-5749	56	11	management	management	NOUN
dpc-5749	56	12	of	of	ADP
dpc-5749	56	13	mucous	mucous	ADJ
dpc-5749	56	14	membrane	membrane	NOUN
dpc-5749	56	15	pemphigoid	pemphigoid	NOUN
dpc-5749	56	16	.	.	PUNCT
dpc-5749	57	1	drug	drug	NOUN
dpc-5749	57	2	drug	drug	NOUN
dpc-5749	57	3	class	class	NOUN
dpc-5749	57	4	condition	condition	NOUN
dpc-5749	57	5	no	no	INTJ
dpc-5749	57	6	.	.	PUNCT
dpc-5749	57	7	of	of	ADP
dpc-5749	57	8	reported	report	VERB
dpc-5749	57	9	patients	patient	NOUN
dpc-5749	58	1	no	no	INTJ
dpc-5749	58	2	.	.	PUNCT
dpc-5749	59	1	of	of	ADP
dpc-5749	59	2	patients	patient	NOUN
dpc-5749	59	3	with	with	ADP
dpc-5749	59	4	improvement	improvement	NOUN
dpc-5749	59	5	references	reference	NOUN
dpc-5749	59	6	omalizumab	omalizumab	NOUN
dpc-5749	59	7	monoclonal	monoclonal	NOUN
dpc-5749	59	8	anti	anti	ADJ
dpc-5749	59	9	-	-	ADJ
dpc-5749	59	10	ige	ige	ADJ
dpc-5749	59	11	antibody	antibody	NOUN
dpc-5749	59	12	mmp	mmp	PROPN
dpc-5749	59	13	5	5	NUM
dpc-5749	60	1	3	3	NUM
dpc-5749	60	2	alexandre	alexandre	NOUN
dpc-5749	60	3	et	et	PROPN
dpc-5749	60	4	al	al	PROPN
dpc-5749	60	5	.	.	PROPN
dpc-5749	60	6	(	(	PUNCT
dpc-5749	60	7	2022	2022	NUM
dpc-5749	60	8	)	)	PUNCT
dpc-5749	60	9	daclizumab	daclizumab	NOUN
dpc-5749	60	10	monoclonal	monoclonal	NOUN
dpc-5749	60	11	anti	anti	ADJ
dpc-5749	60	12	-	-	ADJ
dpc-5749	60	13	cd25	cd25	ADJ
dpc-5749	60	14	antibody	antibody	NOUN
dpc-5749	60	15	/	/	SYM
dpc-5749	60	16	il-2r	il-2r	NOUN
dpc-5749	60	17	antagonist	antagonist	NOUN
dpc-5749	60	18	ocmmp	ocmmp	NOUN
dpc-5749	60	19	1	1	NUM
dpc-5749	60	20	1	1	NUM
dpc-5749	60	21	papaliodis	papaliodi	NOUN
dpc-5749	60	22	et	et	PROPN
dpc-5749	60	23	al	al	PROPN
dpc-5749	60	24	.	.	PROPN
dpc-5749	61	1	(	(	PUNCT
dpc-5749	61	2	2003	2003	NUM
dpc-5749	61	3	)	)	PUNCT
dpc-5749	61	4	dupilumab	dupilumab	NOUN
dpc-5749	61	5	il-4	il-4	NOUN
dpc-5749	61	6	/	/	SYM
dpc-5749	61	7	il-13	il-13	NOUN
dpc-5749	61	8	-	-	PUNCT
dpc-5749	61	9	inhibitor	inhibitor	NOUN
dpc-5749	61	10	mmp	mmp	PROPN
dpc-5749	61	11	bpp	bpp	NOUN
dpc-5749	61	12	1	1	NUM
dpc-5749	61	13	1	1	NUM
dpc-5749	61	14	1	1	NUM
dpc-5749	61	15	1	1	NUM
dpc-5749	61	16	wang	wang	PROPN
dpc-5749	61	17	et	et	PROPN
dpc-5749	61	18	al	al	PROPN
dpc-5749	61	19	.	.	PROPN
dpc-5749	62	1	(	(	PUNCT
dpc-5749	62	2	2024	2024	NUM
dpc-5749	62	3	)	)	PUNCT
dpc-5749	62	4	raef	raef	NOUN
dpc-5749	62	5	et	et	PROPN
dpc-5749	62	6	al	al	PROPN
dpc-5749	62	7	.	.	PROPN
dpc-5749	63	1	(	(	PUNCT
dpc-5749	63	2	2021	2021	NUM
dpc-5749	63	3	)	)	PUNCT
dpc-5749	63	4	cenegermin	cenegermin	NOUN
dpc-5749	63	5	rhngf	rhngf	PROPN
dpc-5749	63	6	ocmmp	ocmmp	NOUN
dpc-5749	63	7	1	1	NUM
dpc-5749	63	8	1	1	NUM
dpc-5749	63	9	1	1	NUM
dpc-5749	63	10	1	1	NUM
dpc-5749	63	11	abbot	abbot	NOUN
dpc-5749	63	12	et	et	PROPN
dpc-5749	63	13	al	al	PROPN
dpc-5749	63	14	.	.	PROPN
dpc-5749	64	1	(	(	PUNCT
dpc-5749	64	2	2024	2024	NUM
dpc-5749	64	3	)	)	PUNCT
dpc-5749	64	4	surico	surico	NOUN
dpc-5749	64	5	et	et	PROPN
dpc-5749	64	6	al	al	PROPN
dpc-5749	64	7	.	.	PROPN
dpc-5749	65	1	(	(	PUNCT
dpc-5749	65	2	2024	2024	NUM
dpc-5749	65	3	)	)	PUNCT
dpc-5749	65	4	colchicine	colchicine	PROPN
dpc-5749	65	5	anti	anti	ADJ
dpc-5749	65	6	-	-	ADJ
dpc-5749	65	7	mitotic	mitotic	ADJ
dpc-5749	65	8	agent	agent	NOUN
dpc-5749	65	9	ormmp	ormmp	PROPN
dpc-5749	65	10	mmp	mmp	PROPN
dpc-5749	65	11	6	6	NUM
dpc-5749	65	12	12	12	NUM
dpc-5749	65	13	5	5	NUM
dpc-5749	65	14	8	8	NUM
dpc-5749	65	15	fribourg	fribourg	NOUN
dpc-5749	65	16	et	et	NOUN
dpc-5749	65	17	al	al	PROPN
dpc-5749	65	18	.	.	PROPN
dpc-5749	66	1	(	(	PUNCT
dpc-5749	66	2	2024	2024	NUM
dpc-5749	66	3	)	)	PUNCT
dpc-5749	66	4	chaidemenos	chaidemeno	VERB
dpc-5749	66	5	et	et	PROPN
dpc-5749	66	6	al	al	PROPN
dpc-5749	66	7	.	.	PUNCT
dpc-5749	67	1	(	(	PUNCT
dpc-5749	67	2	2011	2011	NUM
dpc-5749	67	3	)	)	PUNCT
dpc-5749	67	4	leflunomide	leflunomide	ADJ
dpc-5749	67	5	pyrimidine	pyrimidine	NOUN
dpc-5749	67	6	synthesis	synthesis	NOUN
dpc-5749	67	7	inhibitor	inhibitor	NOUN
dpc-5749	67	8	ocmmp	ocmmp	PROPN
dpc-5749	67	9	mmp	mmp	PROPN
dpc-5749	67	10	1	1	NUM
dpc-5749	67	11	1	1	NUM
dpc-5749	67	12	1	1	NUM
dpc-5749	67	13	1	1	NUM
dpc-5749	67	14	smichowski	smichowski	NOUN
dpc-5749	67	15	et	et	PROPN
dpc-5749	67	16	al	al	PROPN
dpc-5749	67	17	.	.	PROPN
dpc-5749	68	1	(	(	PUNCT
dpc-5749	68	2	2020	2020	NUM
dpc-5749	68	3	)	)	PUNCT
dpc-5749	68	4	boedeker	boedeker	PROPN
dpc-5749	68	5	et	et	PROPN
dpc-5749	68	6	al	al	PROPN
dpc-5749	68	7	.	.	PROPN
dpc-5749	69	1	(	(	PUNCT
dpc-5749	69	2	2003	2003	NUM
dpc-5749	69	3	)	)	PUNCT
dpc-5749	69	4	hydroxychloroquine	hydroxychloroquine	ADJ
dpc-5749	69	5	antimalarial	antimalarial	ADJ
dpc-5749	69	6	agent	agent	NOUN
dpc-5749	69	7	ocmmp	ocmmp	NOUN
dpc-5749	69	8	bpp	bpp	NOUN
dpc-5749	69	9	1	1	NUM
dpc-5749	69	10	1	1	NUM
dpc-5749	69	11	1	1	NUM
dpc-5749	69	12	1	1	NUM
dpc-5749	69	13	morel	morel	NOUN
dpc-5749	69	14	et	et	PROPN
dpc-5749	69	15	al	al	PROPN
dpc-5749	69	16	.	.	PROPN
dpc-5749	70	1	(	(	PUNCT
dpc-5749	70	2	2022	2022	NUM
dpc-5749	70	3	)	)	PUNCT
dpc-5749	70	4	guerrero	guerrero	PROPN
dpc-5749	70	5	et	et	PROPN
dpc-5749	70	6	al	al	PROPN
dpc-5749	70	7	.	.	PROPN
dpc-5749	71	1	(	(	PUNCT
dpc-5749	71	2	2025	2025	NUM
dpc-5749	71	3	)	)	PUNCT
dpc-5749	71	4	corticotropin	corticotropin	NOUN
dpc-5749	71	5	adrenocorticotropic	adrenocorticotropic	NOUN
dpc-5749	71	6	hormone	hormone	NOUN
dpc-5749	71	7	formulation	formulation	NOUN
dpc-5749	71	8	ocmmp	ocmmp	NOUN
dpc-5749	71	9	15	15	NUM
dpc-5749	71	10	9	9	NUM
dpc-5749	71	11	sharon	sharon	PROPN
dpc-5749	71	12	et	et	PROPN
dpc-5749	71	13	al	al	PROPN
dpc-5749	71	14	.	.	PROPN
dpc-5749	72	1	(	(	PUNCT
dpc-5749	72	2	2022	2022	NUM
dpc-5749	72	3	)	)	PUNCT
dpc-5749	72	4	varenicline	varenicline	NOUN
dpc-5749	72	5	selective	selective	ADJ
dpc-5749	72	6	nachr	nachr	PROPN
dpc-5749	72	7	partial	partial	ADJ
dpc-5749	72	8	agonist	agonist	NOUN
dpc-5749	72	9	ocmmp	ocmmp	NOUN
dpc-5749	72	10	4	4	NUM
dpc-5749	72	11	1	1	NUM
dpc-5749	72	12	abbot	abbot	NOUN
dpc-5749	72	13	et	et	PROPN
dpc-5749	72	14	al	al	PROPN
dpc-5749	72	15	.	.	PROPN
dpc-5749	73	1	(	(	PUNCT
dpc-5749	73	2	2024	2024	NUM
dpc-5749	73	3	)	)	PUNCT
dpc-5749	73	4	lifitegrast	lifitegrast	VERB
dpc-5749	73	5	icam-1	icam-1	NUM
dpc-5749	73	6	and	and	CCONJ
dpc-5749	73	7	lfa-1	lfa-1	PUNCT
dpc-5749	73	8	antagonist	antagonist	NOUN
dpc-5749	73	9	ocmmp	ocmmp	NOUN
dpc-5749	73	10	10	10	NUM
dpc-5749	73	11	2	2	NUM
dpc-5749	73	12	abbot	abbot	NOUN
dpc-5749	73	13	et	et	PROPN
dpc-5749	73	14	al	al	PROPN
dpc-5749	73	15	.	.	PROPN
dpc-5749	74	1	(	(	PUNCT
dpc-5749	74	2	2024	2024	NUM
dpc-5749	74	3	)	)	PUNCT
dpc-5749	74	4	ectodomain	ectodomain	NOUN
dpc-5749	74	5	,	,	PUNCT
dpc-5749	74	6	the	the	DET
dpc-5749	74	7	binding	bind	VERB
dpc-5749	74	8	site	site	NOUN
dpc-5749	74	9	of	of	ADP
dpc-5749	74	10	il-2	il-2	NUM
dpc-5749	74	11	to	to	ADP
dpc-5749	74	12	immune	immune	ADJ
dpc-5749	74	13	cells	cell	NOUN
dpc-5749	74	14	,	,	PUNCT
dpc-5749	74	15	and	and	CCONJ
dpc-5749	74	16	inhibits	inhibit	VERB
dpc-5749	74	17	b	b	NOUN
dpc-5749	74	18	cell	cell	NOUN
dpc-5749	74	19	proliferation	proliferation	NOUN
dpc-5749	74	20	and	and	CCONJ
dpc-5749	74	21	il-2	il-2	NOUN
dpc-5749	74	22	-	-	PUNCT
dpc-5749	74	23	mediated	mediate	VERB
dpc-5749	74	24	t	t	NOUN
dpc-5749	74	25	cell	cell	NOUN
dpc-5749	74	26	activation	activation	NOUN
dpc-5749	74	27	.	.	PUNCT
dpc-5749	75	1	papaliodis	papaliodi	NOUN
dpc-5749	75	2	et	et	PROPN
dpc-5749	75	3	al	al	PROPN
dpc-5749	75	4	.	.	PROPN
dpc-5749	76	1	(	(	PUNCT
dpc-5749	76	2	2003	2003	NUM
dpc-5749	76	3	)	)	PUNCT
dpc-5749	76	4	reported	report	VERB
dpc-5749	76	5	one	one	NUM
dpc-5749	76	6	patient	patient	NOUN
dpc-5749	76	7	diagnosed	diagnose	VERB
dpc-5749	76	8	with	with	ADP
dpc-5749	76	9	ocular	ocular	ADJ
dpc-5749	76	10	mmp	mmp	PROPN
dpc-5749	76	11	(	(	PUNCT
dpc-5749	76	12	ocmmp	ocmmp	NOUN
dpc-5749	76	13	)	)	PUNCT
dpc-5749	76	14	and	and	CCONJ
dpc-5749	76	15	successfully	successfully	ADV
dpc-5749	76	16	treated	treat	VERB
dpc-5749	76	17	with	with	ADP
dpc-5749	76	18	daclizumab	daclizumab	NOUN
dpc-5749	76	19	[	[	X
dpc-5749	76	20	10	10	NUM
dpc-5749	76	21	]	]	PUNCT
dpc-5749	76	22	.	.	PUNCT
dpc-5749	77	1	an	an	DET
dpc-5749	77	2	increased	increase	VERB
dpc-5749	77	3	expression	expression	NOUN
dpc-5749	77	4	of	of	ADP
dpc-5749	77	5	il-4	il-4	NOUN
dpc-5749	77	6	was	be	AUX
dpc-5749	77	7	noted	note	VERB
dpc-5749	77	8	in	in	ADP
dpc-5749	77	9	conjunctival	conjunctival	ADJ
dpc-5749	77	10	sections	section	NOUN
dpc-5749	77	11	of	of	ADP
dpc-5749	77	12	patients	patient	NOUN
dpc-5749	77	13	with	with	ADP
dpc-5749	77	14	ocmmp	ocmmp	NOUN
dpc-5749	77	15	and	and	CCONJ
dpc-5749	77	16	in	in	ADP
dpc-5749	77	17	isolated	isolated	ADJ
dpc-5749	77	18	fibroblasts	fibroblast	NOUN
dpc-5749	77	19	;	;	PUNCT
dpc-5749	77	20	il-4	il-4	PRON
dpc-5749	77	21	may	may	AUX
dpc-5749	77	22	exert	exert	VERB
dpc-5749	77	23	a	a	DET
dpc-5749	77	24	modulatory	modulatory	ADJ
dpc-5749	77	25	effect	effect	NOUN
dpc-5749	77	26	on	on	ADP
dpc-5749	77	27	macrophages	macrophage	NOUN
dpc-5749	77	28	via	via	ADP
dpc-5749	77	29	inducing	induce	VERB
dpc-5749	77	30	m	m	NOUN
dpc-5749	77	31	-	-	ADJ
dpc-5749	77	32	csf	csf	ADJ
dpc-5749	77	33	as	as	ADV
dpc-5749	77	34	well	well	ADV
dpc-5749	77	35	as	as	ADP
dpc-5749	77	36	uncontrolled	uncontrolled	ADJ
dpc-5749	77	37	extracellular	extracellular	ADJ
dpc-5749	77	38	matrix	matrix	NOUN
dpc-5749	77	39	accumulation	accumulation	NOUN
dpc-5749	77	40	[	[	X
dpc-5749	77	41	11	11	NUM
dpc-5749	77	42	]	]	PUNCT
dpc-5749	77	43	.	.	PUNCT
dpc-5749	78	1	an	an	DET
dpc-5749	78	2	elevated	elevated	ADJ
dpc-5749	78	3	stromal	stromal	ADJ
dpc-5749	78	4	expression	expression	NOUN
dpc-5749	78	5	of	of	ADP
dpc-5749	78	6	il-13	il-13	PUNCT
dpc-5749	78	7	is	be	AUX
dpc-5749	78	8	seen	see	VERB
dpc-5749	78	9	in	in	ADP
dpc-5749	78	10	active	active	ADJ
dpc-5749	78	11	ocmmp	ocmmp	NOUN
dpc-5749	78	12	,	,	PUNCT
dpc-5749	78	13	suggesting	suggest	VERB
dpc-5749	78	14	profibrotic	profibrotic	ADJ
dpc-5749	78	15	and	and	CCONJ
dpc-5749	78	16	pro	pro	ADJ
dpc-5749	78	17	-	-	ADJ
dpc-5749	78	18	inflammatory	inflammatory	ADJ
dpc-5749	78	19	effects	effect	NOUN
dpc-5749	78	20	on	on	ADP
dpc-5749	78	21	human	human	ADJ
dpc-5749	78	22	conjunctival	conjunctival	NOUN
dpc-5749	78	23	fibroblasts	fibroblast	VERB
dpc-5749	78	24	[	[	X
dpc-5749	78	25	12	12	NUM
dpc-5749	78	26	]	]	PUNCT
dpc-5749	78	27	.	.	PUNCT
dpc-5749	79	1	dupilumab	dupilumab	NOUN
dpc-5749	79	2	,	,	PUNCT
dpc-5749	79	3	a	a	DET
dpc-5749	79	4	recombinant	recombinant	ADJ
dpc-5749	79	5	fully	fully	ADV
dpc-5749	79	6	human	human	ADJ
dpc-5749	79	7	igg4	igg4	NOUN
dpc-5749	79	8	monoclonal	monoclonal	NOUN
dpc-5749	79	9	antibody	antibody	NOUN
dpc-5749	79	10	,	,	PUNCT
dpc-5749	79	11	suppresses	suppress	VERB
dpc-5749	79	12	inflammatory	inflammatory	ADJ
dpc-5749	79	13	signaling	signal	VERB
dpc-5749	79	14	via	via	ADP
dpc-5749	79	15	binding	bind	VERB
dpc-5749	79	16	to	to	ADP
dpc-5749	79	17	the	the	DET
dpc-5749	79	18	il-4rα	il-4rα	ADJ
dpc-5749	79	19	subunit	subunit	NOUN
dpc-5749	79	20	of	of	ADP
dpc-5749	79	21	il-4	il-4	NOUN
dpc-5749	79	22	and	and	CCONJ
dpc-5749	79	23	il-13	il-13	ADP
dpc-5749	79	24	receptor	receptor	NOUN
dpc-5749	79	25	complexes	complex	NOUN
dpc-5749	79	26	.	.	PUNCT
dpc-5749	80	1	dupilumab	dupilumab	NOUN
dpc-5749	80	2	combined	combine	VERB
dpc-5749	80	3	with	with	ADP
dpc-5749	80	4	systemic	systemic	ADJ
dpc-5749	80	5	corticosteroids	corticosteroid	NOUN
dpc-5749	80	6	was	be	AUX
dpc-5749	80	7	reported	report	VERB
dpc-5749	80	8	as	as	ADP
dpc-5749	80	9	effective	effective	ADJ
dpc-5749	80	10	in	in	ADP
dpc-5749	80	11	a	a	DET
dpc-5749	80	12	patient	patient	NOUN
dpc-5749	80	13	with	with	ADP
dpc-5749	80	14	multisite	multisite	ADJ
dpc-5749	80	15	mmp	mmp	PROPN
dpc-5749	80	16	(	(	PUNCT
dpc-5749	80	17	oral	oral	ADJ
dpc-5749	80	18	,	,	PUNCT
dpc-5749	80	19	genital	genital	ADJ
dpc-5749	80	20	,	,	PUNCT
dpc-5749	80	21	and	and	CCONJ
dpc-5749	80	22	cutaneous	cutaneous	ADJ
dpc-5749	80	23	involvement	involvement	NOUN
dpc-5749	80	24	)	)	PUNCT
dpc-5749	81	1	[	[	X
dpc-5749	81	2	13	13	NUM
dpc-5749	81	3	]	]	PUNCT
dpc-5749	81	4	and	and	CCONJ
dpc-5749	81	5	brunsting	brunste	VERB
dpc-5749	81	6	-	-	PUNCT
dpc-5749	81	7	perry	perry	NOUN
dpc-5749	81	8	pemphigoid	pemphigoid	PROPN
dpc-5749	81	9	[	[	X
dpc-5749	81	10	14	14	NUM
dpc-5749	81	11	]	]	PUNCT
dpc-5749	81	12	.	.	PUNCT
dpc-5749	82	1	the	the	DET
dpc-5749	82	2	circulation	circulation	NOUN
dpc-5749	82	3	of	of	ADP
dpc-5749	82	4	sera	sera	NOUN
dpc-5749	82	5	ige	ige	NOUN
dpc-5749	82	6	autoantibodies	autoantibody	NOUN
dpc-5749	82	7	against	against	ADP
dpc-5749	82	8	the	the	DET
dpc-5749	82	9	bm	bm	PROPN
dpc-5749	82	10	components	component	NOUN
dpc-5749	83	1	[	[	X
dpc-5749	83	2	15,16	15,16	NUM
dpc-5749	83	3	]	]	PUNCT
dpc-5749	83	4	as	as	ADV
dpc-5749	83	5	well	well	ADV
dpc-5749	83	6	as	as	ADP
dpc-5749	83	7	linear	linear	PROPN
dpc-5749	83	8	ige	ige	PROPN
dpc-5749	83	9	depositions	deposition	NOUN
dpc-5749	83	10	along	along	ADP
dpc-5749	83	11	bm	bm	PROPN
dpc-5749	83	12	on	on	ADP
dpc-5749	83	13	immunofluorescence	immunofluorescence	NOUN
dpc-5749	83	14	[	[	X
dpc-5749	83	15	15,17	15,17	NUM
dpc-5749	83	16	]	]	PUNCT
dpc-5749	83	17	have	have	AUX
dpc-5749	83	18	been	be	AUX
dpc-5749	83	19	observed	observe	VERB
dpc-5749	83	20	in	in	ADP
dpc-5749	83	21	patients	patient	NOUN
dpc-5749	83	22	with	with	ADP
dpc-5749	83	23	mmp	mmp	PROPN
dpc-5749	83	24	.	.	PROPN
dpc-5749	83	25	omalizumab	omalizumab	NOUN
dpc-5749	83	26	is	be	AUX
dpc-5749	83	27	a	a	DET
dpc-5749	83	28	humanized	humanize	VERB
dpc-5749	83	29	monoclonal	monoclonal	NOUN
dpc-5749	83	30	anti	anti	ADJ
dpc-5749	83	31	-	-	ADJ
dpc-5749	83	32	ige	ige	ADJ
dpc-5749	83	33	antibody	antibody	NOUN
dpc-5749	83	34	which	which	PRON
dpc-5749	83	35	neutralizes	neutralize	VERB
dpc-5749	83	36	total	total	ADJ
dpc-5749	83	37	serum	serum	NOUN
dpc-5749	83	38	ige	ige	PROPN
dpc-5749	83	39	via	via	ADP
dpc-5749	83	40	forming	form	VERB
dpc-5749	83	41	interactions	interaction	NOUN
dpc-5749	83	42	with	with	ADP
dpc-5749	83	43	ige	ige	PROPN
dpc-5749	83	44	cɛ3	cɛ3	PROPN
dpc-5749	83	45	domains	domain	NOUN
dpc-5749	83	46	outside	outside	ADP
dpc-5749	83	47	the	the	DET
dpc-5749	83	48	fcɛri	fcɛri	NOUN
dpc-5749	83	49	-	-	PUNCT
dpc-5749	83	50	binding	bind	VERB
dpc-5749	83	51	site	site	NOUN
dpc-5749	83	52	and	and	CCONJ
dpc-5749	83	53	inhibiting	inhibit	VERB
dpc-5749	83	54	fcɛri	fcɛri	NOUN
dpc-5749	83	55	and	and	CCONJ
dpc-5749	83	56	cd23	cd23	PROPN
dpc-5749	83	57	binding	bind	VERB
dpc-5749	83	58	.	.	PUNCT
dpc-5749	84	1	omalizumab	omalizumab	NOUN
dpc-5749	84	2	was	be	AUX
dpc-5749	84	3	reported	report	VERB
dpc-5749	84	4	to	to	PART
dpc-5749	84	5	induce	induce	VERB
dpc-5749	84	6	complete	complete	ADJ
dpc-5749	84	7	remission	remission	NOUN
dpc-5749	84	8	in	in	ADP
dpc-5749	84	9	three	three	NUM
dpc-5749	84	10	out	out	ADP
dpc-5749	84	11	of	of	ADP
dpc-5749	84	12	5	5	NUM
dpc-5749	84	13	patients	patient	NOUN
dpc-5749	84	14	with	with	ADP
dpc-5749	84	15	mmp	mmp	PROPN
dpc-5749	84	16	(	(	PUNCT
dpc-5749	84	17	with	with	ADP
dpc-5749	84	18	oral	oral	ADJ
dpc-5749	84	19	,	,	PUNCT
dpc-5749	84	20	laryngeal	laryngeal	ADJ
dpc-5749	84	21	,	,	PUNCT
dpc-5749	84	22	and	and	CCONJ
dpc-5749	84	23	genital	genital	ADJ
dpc-5749	84	24	mmp	mmp	PROPN
dpc-5749	84	25	-	-	PUNCT
dpc-5749	84	26	related	relate	VERB
dpc-5749	84	27	lesions	lesion	NOUN
dpc-5749	84	28	)	)	PUNCT
dpc-5749	85	1	[	[	X
dpc-5749	85	2	18	18	NUM
dpc-5749	85	3	]	]	PUNCT
dpc-5749	85	4	.	.	PUNCT
dpc-5749	86	1	neutrophils	neutrophil	NOUN
dpc-5749	86	2	are	be	AUX
dpc-5749	86	3	present	present	ADJ
dpc-5749	86	4	in	in	ADP
dpc-5749	86	5	inflammatory	inflammatory	ADJ
dpc-5749	86	6	infiltrates	infiltrate	NOUN
dpc-5749	86	7	at	at	ADP
dpc-5749	86	8	the	the	DET
dpc-5749	86	9	acute	acute	ADJ
dpc-5749	86	10	stage	stage	NOUN
dpc-5749	86	11	and	and	CCONJ
dpc-5749	86	12	persist	persist	VERB
dpc-5749	86	13	in	in	ADP
dpc-5749	86	14	mmp	mmp	PROPN
dpc-5749	86	15	-	-	PUNCT
dpc-5749	86	16	affected	affect	VERB
dpc-5749	86	17	tissues	tissue	NOUN
dpc-5749	86	18	even	even	ADV
dpc-5749	86	19	when	when	SCONJ
dpc-5749	86	20	inflammation	inflammation	NOUN
dpc-5749	86	21	is	be	AUX
dpc-5749	86	22	visually	visually	ADV
dpc-5749	86	23	resolved	resolve	VERB
dpc-5749	86	24	[	[	X
dpc-5749	86	25	9,19	9,19	NUM
dpc-5749	86	26	]	]	PUNCT
dpc-5749	86	27	,	,	PUNCT
dpc-5749	86	28	and	and	CCONJ
dpc-5749	86	29	the	the	DET
dpc-5749	86	30	involvement	involvement	NOUN
dpc-5749	86	31	of	of	ADP
dpc-5749	86	32	other	other	ADJ
dpc-5749	86	33	mechanisms	mechanism	NOUN
dpc-5749	86	34	(	(	PUNCT
dpc-5749	86	35	i.e.	i.e.	X
dpc-5749	86	36	,	,	PUNCT
dpc-5749	86	37	neutrophil	neutrophil	ADJ
dpc-5749	86	38	recruitment	recruitment	NOUN
dpc-5749	86	39	)	)	PUNCT
dpc-5749	86	40	has	have	AUX
dpc-5749	86	41	been	be	AUX
dpc-5749	86	42	suggested	suggest	VERB
dpc-5749	86	43	in	in	ADP
dpc-5749	86	44	the	the	DET
dpc-5749	86	45	pathogenesis	pathogenesis	NOUN
dpc-5749	86	46	of	of	ADP
dpc-5749	86	47	mmp	mmp	PROPN
dpc-5749	87	1	[	[	X
dpc-5749	87	2	20	20	NUM
dpc-5749	87	3	]	]	PUNCT
dpc-5749	87	4	.	.	PUNCT
dpc-5749	88	1	colchicine	colchicine	PROPN
dpc-5749	88	2	,	,	PUNCT
dpc-5749	88	3	a	a	DET
dpc-5749	88	4	bioactive	bioactive	ADJ
dpc-5749	88	5	plant	plant	NOUN
dpc-5749	88	6	alkaloid	alkaloid	NOUN
dpc-5749	88	7	derived	derive	VERB
dpc-5749	88	8	from	from	ADP
dpc-5749	88	9	colchicum	colchicum	NOUN
dpc-5749	88	10	autumnale	autumnale	NOUN
dpc-5749	88	11	,	,	PUNCT
dpc-5749	88	12	is	be	AUX
dpc-5749	88	13	commonly	commonly	ADV
dpc-5749	88	14	used	use	VERB
dpc-5749	88	15	in	in	ADP
dpc-5749	88	16	gout	gout	NOUN
dpc-5749	88	17	flares	flare	NOUN
dpc-5749	88	18	,	,	PUNCT
dpc-5749	88	19	familial	familial	ADJ
dpc-5749	88	20	mediterranean	mediterranean	ADJ
dpc-5749	88	21	fever	fever	NOUN
dpc-5749	88	22	,	,	PUNCT
dpc-5749	88	23	behçet	behçet	PROPN
dpc-5749	88	24	’s	’s	PART
dpc-5749	88	25	disease	disease	NOUN
dpc-5749	88	26	,	,	PUNCT
dpc-5749	88	27	psoriasis	psoriasis	NOUN
dpc-5749	88	28	,	,	PUNCT
dpc-5749	88	29	sweet	sweet	ADJ
dpc-5749	88	30	’s	’s	PART
dpc-5749	88	31	syndrome	syndrome	NOUN
dpc-5749	88	32	,	,	PUNCT
dpc-5749	88	33	and	and	CCONJ
dpc-5749	88	34	erythema	erythema	ADV
dpc-5749	88	35	nodosum	nodosum	NOUN
dpc-5749	89	1	[	[	X
dpc-5749	89	2	21	21	NUM
dpc-5749	89	3	]	]	PUNCT
dpc-5749	89	4	.	.	PUNCT
dpc-5749	90	1	colchicine	colchicine	PROPN
dpc-5749	90	2	inhibits	inhibit	VERB
dpc-5749	90	3	neutrophil	neutrophil	ADJ
dpc-5749	90	4	recruitment	recruitment	NOUN
dpc-5749	90	5	and	and	CCONJ
dpc-5749	90	6	disrupts	disrupt	VERB
dpc-5749	90	7	the	the	DET
dpc-5749	90	8	nlrp3	nlrp3	NOUN
dpc-5749	90	9	inflammasome	inflammasome	NOUN
dpc-5749	90	10	assembly	assembly	NOUN
dpc-5749	90	11	in	in	ADP
dpc-5749	90	12	neutrophils	neutrophil	NOUN
dpc-5749	90	13	and	and	CCONJ
dpc-5749	90	14	monocytes	monocyte	VERB
dpc-5749	90	15	through	through	ADP
dpc-5749	90	16	the	the	DET
dpc-5749	90	17	inhibition	inhibition	NOUN
dpc-5749	90	18	of	of	ADP
dpc-5749	90	19	cellular	cellular	ADJ
dpc-5749	90	20	p2x7	p2x7	NOUN
dpc-5749	90	21	receptors	receptor	NOUN
dpc-5749	90	22	;	;	PUNCT
dpc-5749	90	23	the	the	DET
dpc-5749	90	24	suppression	suppression	NOUN
dpc-5749	90	25	of	of	ADP
dpc-5749	90	26	β	β	NOUN
dpc-5749	90	27	-	-	ADJ
dpc-5749	90	28	tubulin	tubulin	NOUN
dpc-5749	90	29	polymerization	polymerization	NOUN
dpc-5749	90	30	and	and	CCONJ
dpc-5749	90	31	synthesis	synthesis	NOUN
dpc-5749	90	32	of	of	ADP
dpc-5749	90	33	microtubules	microtubule	NOUN
dpc-5749	90	34	is	be	AUX
dpc-5749	90	35	related	relate	VERB
dpc-5749	90	36	to	to	ADP
dpc-5749	90	37	anti	anti	ADJ
dpc-5749	90	38	-	-	ADJ
dpc-5749	90	39	mitotic	mitotic	ADJ
dpc-5749	90	40	properties	property	NOUN
dpc-5749	90	41	[	[	X
dpc-5749	90	42	22	22	NUM
dpc-5749	90	43	]	]	PUNCT
dpc-5749	90	44	.	.	PUNCT
dpc-5749	91	1	colchicine	colchicine	PROPN
dpc-5749	91	2	has	have	AUX
dpc-5749	91	3	been	be	AUX
dpc-5749	91	4	offered	offer	VERB
dpc-5749	91	5	as	as	ADP
dpc-5749	91	6	a	a	DET
dpc-5749	91	7	second	second	ADJ
dpc-5749	91	8	-	-	PUNCT
dpc-5749	91	9	line	line	NOUN
dpc-5749	91	10	option	option	NOUN
dpc-5749	91	11	in	in	ADP
dpc-5749	91	12	oral	oral	ADJ
dpc-5749	91	13	mmp	mmp	PROPN
dpc-5749	92	1	[	[	X
dpc-5749	92	2	23	23	NUM
dpc-5749	92	3	]	]	X
dpc-5749	92	4	;	;	PUNCT
dpc-5749	92	5	earlier	early	ADV
dpc-5749	92	6	colchicine	colchicine	PROPN
dpc-5749	92	7	was	be	AUX
dpc-5749	92	8	also	also	ADV
dpc-5749	92	9	suggested	suggest	VERB
dpc-5749	92	10	as	as	ADP
dpc-5749	92	11	a	a	DET
dpc-5749	92	12	first	first	ADJ
dpc-5749	92	13	-	-	PUNCT
dpc-5749	92	14	line	line	NOUN
dpc-5749	92	15	corticosteroid	corticosteroid	NOUN
dpc-5749	92	16	-	-	PUNCT
dpc-5749	92	17	sparing	spare	VERB
dpc-5749	92	18	agent	agent	NOUN
dpc-5749	92	19	in	in	ADP
dpc-5749	92	20	mmp	mmp	PROPN
dpc-5749	93	1	[	[	X
dpc-5749	93	2	24	24	NUM
dpc-5749	93	3	]	]	PUNCT
dpc-5749	93	4	.	.	PUNCT
dpc-5749	94	1	adverse	adverse	ADJ
dpc-5749	94	2	effects	effect	NOUN
dpc-5749	94	3	(	(	PUNCT
dpc-5749	94	4	aes	aes	NOUN
dpc-5749	94	5	)	)	PUNCT
dpc-5749	94	6	of	of	ADP
dpc-5749	94	7	colchicine	colchicine	PROPN
dpc-5749	94	8	include	include	VERB
dpc-5749	94	9	cardiomyopathy	cardiomyopathy	ADJ
dpc-5749	94	10	,	,	PUNCT
dpc-5749	94	11	cytopenia	cytopenia	NOUN
dpc-5749	94	12	,	,	PUNCT
dpc-5749	94	13	elevation	elevation	NOUN
dpc-5749	94	14	of	of	ADP
dpc-5749	94	15	hepatic	hepatic	ADJ
dpc-5749	94	16	transaminases	transaminase	NOUN
dpc-5749	94	17	,	,	PUNCT
dpc-5749	94	18	maculopapular	maculopapular	ADJ
dpc-5749	94	19	rash	rash	NOUN
dpc-5749	94	20	,	,	PUNCT
dpc-5749	94	21	and	and	CCONJ
dpc-5749	94	22	alopecia	alopecia	NOUN
dpc-5749	94	23	[	[	X
dpc-5749	94	24	21	21	NUM
dpc-5749	94	25	]	]	PUNCT
dpc-5749	94	26	.	.	PUNCT
dpc-5749	95	1	4	4	NUM
dpc-5749	95	2	review	review	NOUN
dpc-5749	95	3	|	|	ADV
dpc-5749	95	4	dermatol	dermatol	ADJ
dpc-5749	95	5	pract	pract	NOUN
dpc-5749	95	6	concept	concept	NOUN
dpc-5749	95	7	.	.	PUNCT
dpc-5749	96	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	96	2	vascular	vascular	ADJ
dpc-5749	96	3	endothelial	endothelial	ADJ
dpc-5749	96	4	growth	growth	NOUN
dpc-5749	96	5	factor	factor	NOUN
dpc-5749	96	6	(	(	PUNCT
dpc-5749	96	7	vegf	vegf	PROPN
dpc-5749	96	8	)	)	PUNCT
dpc-5749	96	9	is	be	AUX
dpc-5749	96	10	involved	involve	VERB
dpc-5749	96	11	in	in	ADP
dpc-5749	96	12	immune	immune	ADJ
dpc-5749	96	13	responses	response	NOUN
dpc-5749	96	14	and	and	CCONJ
dpc-5749	96	15	proliferation	proliferation	NOUN
dpc-5749	96	16	,	,	PUNCT
dpc-5749	96	17	exerting	exert	VERB
dpc-5749	96	18	signaling	signal	VERB
dpc-5749	96	19	by	by	ADP
dpc-5749	96	20	binding	bind	VERB
dpc-5749	96	21	to	to	ADP
dpc-5749	96	22	tyrosine	tyrosine	PROPN
dpc-5749	96	23	kinase	kinase	PROPN
dpc-5749	96	24	receptors	receptor	NOUN
dpc-5749	96	25	,	,	PUNCT
dpc-5749	96	26	and	and	CCONJ
dpc-5749	96	27	bevacizumab	bevacizumab	NOUN
dpc-5749	96	28	and	and	CCONJ
dpc-5749	96	29	aflibercept	aflibercept	PRON
dpc-5749	96	30	neutralize	neutralize	VERB
dpc-5749	96	31	vegf	vegf	PROPN
dpc-5749	96	32	via	via	ADP
dpc-5749	96	33	forming	form	VERB
dpc-5749	96	34	interactions	interaction	NOUN
dpc-5749	96	35	with	with	ADP
dpc-5749	96	36	the	the	DET
dpc-5749	96	37	receptor	receptor	NOUN
dpc-5749	96	38	-	-	PUNCT
dpc-5749	96	39	binding	bind	VERB
dpc-5749	96	40	regions	region	NOUN
dpc-5749	96	41	.	.	PUNCT
dpc-5749	97	1	subconjunctival	subconjunctival	NOUN
dpc-5749	97	2	and	and	CCONJ
dpc-5749	97	3	intravitreal	intravitreal	ADJ
dpc-5749	97	4	injections	injection	NOUN
dpc-5749	97	5	of	of	ADP
dpc-5749	97	6	bevacizumab	bevacizumab	NOUN
dpc-5749	97	7	and	and	CCONJ
dpc-5749	97	8	aflibercept	aflibercept	ADJ
dpc-5749	97	9	[	[	X
dpc-5749	97	10	39,40	39,40	NOUN
dpc-5749	97	11	]	]	PUNCT
dpc-5749	97	12	have	have	AUX
dpc-5749	97	13	been	be	AUX
dpc-5749	97	14	reported	report	VERB
dpc-5749	97	15	in	in	ADP
dpc-5749	97	16	ocmmp	ocmmp	NOUN
dpc-5749	97	17	;	;	PUNCT
dpc-5749	97	18	in	in	ADP
dpc-5749	97	19	the	the	DET
dpc-5749	97	20	mentioned	mention	VERB
dpc-5749	97	21	cases	case	NOUN
dpc-5749	97	22	,	,	PUNCT
dpc-5749	97	23	these	these	DET
dpc-5749	97	24	agents	agent	NOUN
dpc-5749	97	25	did	do	AUX
dpc-5749	97	26	not	not	PART
dpc-5749	97	27	alter	alter	VERB
dpc-5749	97	28	the	the	DET
dpc-5749	97	29	severity	severity	NOUN
dpc-5749	97	30	of	of	ADP
dpc-5749	97	31	the	the	DET
dpc-5749	97	32	disease	disease	NOUN
dpc-5749	97	33	course	course	NOUN
dpc-5749	97	34	.	.	PUNCT
dpc-5749	98	1	however	however	ADV
dpc-5749	98	2	,	,	PUNCT
dpc-5749	98	3	hypothetically	hypothetically	ADV
dpc-5749	98	4	,	,	PUNCT
dpc-5749	98	5	given	give	VERB
dpc-5749	98	6	their	their	PRON
dpc-5749	98	7	capacity	capacity	NOUN
dpc-5749	98	8	to	to	PART
dpc-5749	98	9	suppress	suppress	VERB
dpc-5749	98	10	angiogenesis	angiogenesis	NOUN
dpc-5749	98	11	and	and	CCONJ
dpc-5749	98	12	tissue	tissue	NOUN
dpc-5749	98	13	remodeling	remodeling	NOUN
dpc-5749	98	14	,	,	PUNCT
dpc-5749	98	15	these	these	DET
dpc-5749	98	16	agents	agent	NOUN
dpc-5749	98	17	may	may	AUX
dpc-5749	98	18	represent	represent	VERB
dpc-5749	98	19	an	an	DET
dpc-5749	98	20	opportunity	opportunity	NOUN
dpc-5749	98	21	to	to	PART
dpc-5749	98	22	improve	improve	VERB
dpc-5749	98	23	quality	quality	NOUN
dpc-5749	98	24	of	of	ADP
dpc-5749	98	25	life	life	NOUN
dpc-5749	98	26	of	of	ADP
dpc-5749	98	27	patients	patient	NOUN
dpc-5749	98	28	with	with	ADP
dpc-5749	98	29	mmp	mmp	PROPN
dpc-5749	98	30	as	as	ADP
dpc-5749	98	31	adjuvant	adjuvant	ADJ
dpc-5749	98	32	therapy	therapy	NOUN
dpc-5749	98	33	,	,	PUNCT
dpc-5749	98	34	although	although	SCONJ
dpc-5749	98	35	clinicians	clinician	NOUN
dpc-5749	98	36	must	must	AUX
dpc-5749	98	37	be	be	AUX
dpc-5749	98	38	aware	aware	ADJ
dpc-5749	98	39	of	of	ADP
dpc-5749	98	40	drug	drug	NOUN
dpc-5749	98	41	-	-	PUNCT
dpc-5749	98	42	induced	induce	VERB
dpc-5749	98	43	mmp	mmp	PROPN
dpc-5749	99	1	[	[	X
dpc-5749	99	2	1	1	NUM
dpc-5749	99	3	]	]	PUNCT
dpc-5749	99	4	.	.	PUNCT
dpc-5749	99	5	dry	dry	ADJ
dpc-5749	99	6	eye	eye	NOUN
dpc-5749	99	7	disease	disease	NOUN
dpc-5749	99	8	is	be	AUX
dpc-5749	99	9	frequently	frequently	ADV
dpc-5749	99	10	associated	associate	VERB
dpc-5749	99	11	with	with	ADP
dpc-5749	99	12	ocmmp	ocmmp	PROPN
dpc-5749	99	13	.	.	PUNCT
dpc-5749	100	1	varenicline	varenicline	PROPN
dpc-5749	100	2	,	,	PUNCT
dpc-5749	100	3	a	a	DET
dpc-5749	100	4	selective	selective	ADJ
dpc-5749	100	5	nicotinic	nicotinic	ADJ
dpc-5749	100	6	acetylcholine	acetylcholine	NOUN
dpc-5749	100	7	receptor	receptor	NOUN
dpc-5749	100	8	(	(	PUNCT
dpc-5749	100	9	nachr	nachr	NOUN
dpc-5749	100	10	)	)	PUNCT
dpc-5749	100	11	partial	partial	ADJ
dpc-5749	100	12	antagonist	antagonist	NOUN
dpc-5749	100	13	,	,	PUNCT
dpc-5749	100	14	induces	induce	VERB
dpc-5749	100	15	the	the	DET
dpc-5749	100	16	basal	basal	ADJ
dpc-5749	100	17	tear	tear	NOUN
dpc-5749	100	18	film	film	NOUN
dpc-5749	100	19	formation	formation	NOUN
dpc-5749	100	20	by	by	ADP
dpc-5749	100	21	the	the	DET
dpc-5749	100	22	lacrimal	lacrimal	ADJ
dpc-5749	100	23	gland	gland	NOUN
dpc-5749	100	24	via	via	ADP
dpc-5749	100	25	the	the	DET
dpc-5749	100	26	stimulation	stimulation	NOUN
dpc-5749	100	27	of	of	ADP
dpc-5749	100	28	the	the	DET
dpc-5749	100	29	trigeminal	trigeminal	ADJ
dpc-5749	100	30	parasympathetic	parasympathetic	ADJ
dpc-5749	100	31	nerve	nerve	NOUN
dpc-5749	100	32	pathway	pathway	NOUN
dpc-5749	101	1	[	[	X
dpc-5749	101	2	41	41	NUM
dpc-5749	101	3	]	]	PUNCT
dpc-5749	101	4	.	.	PUNCT
dpc-5749	102	1	lifitegrast	lifitegrast	PROPN
dpc-5749	102	2	binds	bind	VERB
dpc-5749	102	3	to	to	ADP
dpc-5749	102	4	the	the	DET
dpc-5749	102	5	integrin	integrin	NOUN
dpc-5749	102	6	lymphocyte	lymphocyte	ADJ
dpc-5749	102	7	function	function	NOUN
dpc-5749	102	8	-	-	PUNCT
dpc-5749	102	9	associated	associate	VERB
dpc-5749	102	10	antigen-1	antigen-1	NOUN
dpc-5749	102	11	,	,	PUNCT
dpc-5749	102	12	preventing	prevent	VERB
dpc-5749	102	13	its	its	PRON
dpc-5749	102	14	interaction	interaction	NOUN
dpc-5749	102	15	with	with	ADP
dpc-5749	102	16	the	the	DET
dpc-5749	102	17	intercellular	intercellular	ADJ
dpc-5749	102	18	adhesion	adhesion	NOUN
dpc-5749	102	19	molecule-1	molecule-1	PROPN
dpc-5749	102	20	,	,	PUNCT
dpc-5749	102	21	blocking	block	VERB
dpc-5749	102	22	the	the	DET
dpc-5749	102	23	formation	formation	NOUN
dpc-5749	102	24	of	of	ADP
dpc-5749	102	25	immunological	immunological	ADJ
dpc-5749	102	26	synapse	synapse	NOUN
dpc-5749	102	27	,	,	PUNCT
dpc-5749	102	28	t	t	NOUN
dpc-5749	102	29	cell	cell	NOUN
dpc-5749	102	30	activation	activation	NOUN
dpc-5749	102	31	,	,	PUNCT
dpc-5749	102	32	and	and	CCONJ
dpc-5749	102	33	suppressing	suppress	VERB
dpc-5749	102	34	inflammatory	inflammatory	ADJ
dpc-5749	102	35	cascades	cascade	NOUN
dpc-5749	102	36	[	[	X
dpc-5749	102	37	42	42	NUM
dpc-5749	102	38	]	]	PUNCT
dpc-5749	102	39	.	.	PUNCT
dpc-5749	103	1	these	these	DET
dpc-5749	103	2	agents	agent	NOUN
dpc-5749	103	3	are	be	AUX
dpc-5749	103	4	employed	employ	VERB
dpc-5749	103	5	in	in	ADP
dpc-5749	103	6	dry	dry	ADJ
dpc-5749	103	7	eye	eye	NOUN
dpc-5749	103	8	disease	disease	NOUN
dpc-5749	103	9	;	;	PUNCT
dpc-5749	103	10	however	however	ADV
dpc-5749	103	11	,	,	PUNCT
dpc-5749	103	12	their	their	PRON
dpc-5749	103	13	efficacy	efficacy	NOUN
dpc-5749	103	14	was	be	AUX
dpc-5749	103	15	limited	limit	VERB
dpc-5749	103	16	in	in	ADP
dpc-5749	103	17	ocmmp	ocmmp	NOUN
dpc-5749	103	18	[	[	X
dpc-5749	103	19	35	35	NUM
dpc-5749	103	20	]	]	PUNCT
dpc-5749	103	21	.	.	PUNCT
dpc-5749	104	1	mucous	mucous	ADJ
dpc-5749	104	2	membrane	membrane	NOUN
dpc-5749	104	3	pemphigoid	pemphigoid	NOUN
dpc-5749	104	4	and	and	CCONJ
dpc-5749	104	5	malignancy	malignancy	NOUN
dpc-5749	104	6	in	in	ADP
dpc-5749	104	7	mmp	mmp	PROPN
dpc-5749	104	8	,	,	PUNCT
dpc-5749	104	9	malignancy	malignancy	NOUN
dpc-5749	104	10	is	be	AUX
dpc-5749	104	11	reported	report	VERB
dpc-5749	104	12	in	in	ADP
dpc-5749	104	13	15.5	15.5	NUM
dpc-5749	104	14	%	%	NOUN
dpc-5749	104	15	of	of	ADP
dpc-5749	104	16	cases	case	NOUN
dpc-5749	104	17	[	[	X
dpc-5749	104	18	43	43	NUM
dpc-5749	104	19	]	]	PUNCT
dpc-5749	104	20	,	,	PUNCT
dpc-5749	104	21	while	while	SCONJ
dpc-5749	104	22	in	in	ADP
dpc-5749	104	23	patients	patient	NOUN
dpc-5749	104	24	with	with	ADP
dpc-5749	104	25	sera	sera	NOUN
dpc-5749	104	26	anti	anti	ADJ
dpc-5749	104	27	-	-	ADJ
dpc-5749	104	28	laminin	laminin	ADJ
dpc-5749	104	29	332	332	NUM
dpc-5749	104	30	antibodies	antibody	NOUN
dpc-5749	104	31	(	(	PUNCT
dpc-5749	104	32	anti	anti	ADJ
dpc-5749	104	33	-	-	ADJ
dpc-5749	104	34	laminin-332	laminin-332	ADJ
dpc-5749	104	35	mmp	mmp	PROPN
dpc-5749	104	36	)	)	PUNCT
dpc-5749	104	37	,	,	PUNCT
dpc-5749	104	38	the	the	DET
dpc-5749	104	39	malignancy	malignancy	NOUN
dpc-5749	104	40	rate	rate	NOUN
dpc-5749	104	41	is	be	AUX
dpc-5749	104	42	21–21.8	21–21.8	NUM
dpc-5749	104	43	%	%	NOUN
dpc-5749	105	1	[	[	X
dpc-5749	105	2	43,44	43,44	X
dpc-5749	105	3	]	]	PUNCT
dpc-5749	105	4	.	.	PUNCT
dpc-5749	106	1	laminin-332	laminin-332	PROPN
dpc-5749	106	2	is	be	AUX
dpc-5749	106	3	a	a	DET
dpc-5749	106	4	structural	structural	ADJ
dpc-5749	106	5	glycoprotein	glycoprotein	NOUN
dpc-5749	106	6	of	of	ADP
dpc-5749	106	7	bm	bm	PROPN
dpc-5749	106	8	which	which	PRON
dpc-5749	106	9	is	be	AUX
dpc-5749	106	10	involved	involve	VERB
dpc-5749	106	11	in	in	ADP
dpc-5749	106	12	extracellular	extracellular	ADJ
dpc-5749	106	13	matrix	matrix	NOUN
dpc-5749	106	14	formation	formation	NOUN
dpc-5749	106	15	,	,	PUNCT
dpc-5749	106	16	cell	cell	NOUN
dpc-5749	106	17	proliferation	proliferation	NOUN
dpc-5749	106	18	and	and	CCONJ
dpc-5749	106	19	migration	migration	NOUN
dpc-5749	106	20	;	;	PUNCT
dpc-5749	106	21	its	its	PRON
dpc-5749	106	22	elevation	elevation	NOUN
dpc-5749	106	23	has	have	AUX
dpc-5749	106	24	been	be	AUX
dpc-5749	106	25	observed	observe	VERB
dpc-5749	106	26	in	in	ADP
dpc-5749	106	27	some	some	DET
dpc-5749	106	28	tumors	tumor	NOUN
dpc-5749	106	29	and	and	CCONJ
dpc-5749	106	30	may	may	AUX
dpc-5749	106	31	trigger	trigger	VERB
dpc-5749	106	32	autoimmune	autoimmune	ADJ
dpc-5749	106	33	reactions	reaction	NOUN
dpc-5749	106	34	and	and	CCONJ
dpc-5749	106	35	cross	cross	NOUN
dpc-5749	106	36	-	-	NOUN
dpc-5749	106	37	reactivity	reactivity	NOUN
dpc-5749	106	38	with	with	ADP
dpc-5749	106	39	bm	bm	PROPN
dpc-5749	106	40	proteins	protein	NOUN
dpc-5749	107	1	[	[	X
dpc-5749	107	2	45,46	45,46	NOUN
dpc-5749	107	3	]	]	X
dpc-5749	107	4	;	;	PUNCT
dpc-5749	107	5	thus	thus	ADV
dpc-5749	107	6	,	,	PUNCT
dpc-5749	107	7	various	various	ADJ
dpc-5749	107	8	studies	study	NOUN
dpc-5749	107	9	highlight	highlight	VERB
dpc-5749	107	10	an	an	DET
dpc-5749	107	11	elevated	elevated	ADJ
dpc-5749	107	12	malignancy	malignancy	NOUN
dpc-5749	107	13	risk	risk	NOUN
dpc-5749	107	14	in	in	ADP
dpc-5749	107	15	anti	anti	ADJ
dpc-5749	107	16	-	-	ADJ
dpc-5749	107	17	laminin-332	laminin-332	ADJ
dpc-5749	107	18	mmp	mmp	PROPN
dpc-5749	108	1	[	[	X
dpc-5749	108	2	44,47	44,47	PROPN
dpc-5749	108	3	]	]	X
dpc-5749	108	4	.	.	PUNCT
dpc-5749	109	1	another	another	DET
dpc-5749	109	2	issue	issue	NOUN
dpc-5749	109	3	is	be	AUX
dpc-5749	109	4	mmp	mmp	PROPN
dpc-5749	109	5	induced	induce	VERB
dpc-5749	109	6	by	by	ADP
dpc-5749	109	7	malignancy	malignancy	NOUN
dpc-5749	109	8	treatment	treatment	NOUN
dpc-5749	109	9	(	(	PUNCT
dpc-5749	109	10	e.g.	e.g.	ADV
dpc-5749	109	11	,	,	PUNCT
dpc-5749	109	12	radiation	radiation	NOUN
dpc-5749	109	13	[	[	X
dpc-5749	109	14	48	48	NUM
dpc-5749	109	15	]	]	PUNCT
dpc-5749	109	16	and	and	CCONJ
dpc-5749	109	17	immune	immune	ADJ
dpc-5749	109	18	checkpoint	checkpoint	NOUN
dpc-5749	109	19	inhibitors	inhibitor	NOUN
dpc-5749	109	20	[	[	X
dpc-5749	109	21	49	49	NUM
dpc-5749	109	22	]	]	PUNCT
dpc-5749	109	23	)	)	PUNCT
dpc-5749	109	24	.	.	PUNCT
dpc-5749	110	1	the	the	DET
dpc-5749	110	2	current	current	ADJ
dpc-5749	110	3	guidelines	guideline	NOUN
dpc-5749	110	4	do	do	AUX
dpc-5749	110	5	not	not	PART
dpc-5749	110	6	contain	contain	VERB
dpc-5749	110	7	sections	section	NOUN
dpc-5749	110	8	on	on	ADP
dpc-5749	110	9	the	the	DET
dpc-5749	110	10	management	management	NOUN
dpc-5749	110	11	of	of	ADP
dpc-5749	110	12	anti	anti	ADJ
dpc-5749	110	13	-	-	ADJ
dpc-5749	110	14	laminin-332	laminin-332	ADJ
dpc-5749	110	15	mmp	mmp	PROPN
dpc-5749	110	16	or	or	CCONJ
dpc-5749	110	17	of	of	ADP
dpc-5749	110	18	mmp	mmp	PROPN
dpc-5749	110	19	in	in	ADP
dpc-5749	110	20	patients	patient	NOUN
dpc-5749	110	21	with	with	ADP
dpc-5749	110	22	a	a	DET
dpc-5749	110	23	history	history	NOUN
dpc-5749	110	24	of	of	ADP
dpc-5749	110	25	previous	previous	ADJ
dpc-5749	110	26	or	or	CCONJ
dpc-5749	110	27	concurrent	concurrent	ADJ
dpc-5749	110	28	malignancy	malignancy	NOUN
dpc-5749	110	29	,	,	PUNCT
dpc-5749	110	30	and	and	CCONJ
dpc-5749	110	31	the	the	DET
dpc-5749	110	32	selection	selection	NOUN
dpc-5749	110	33	of	of	ADP
dpc-5749	110	34	therapy	therapy	NOUN
dpc-5749	110	35	depends	depend	VERB
dpc-5749	110	36	on	on	ADP
dpc-5749	110	37	lesion	lesion	NOUN
dpc-5749	110	38	location	location	NOUN
dpc-5749	110	39	and	and	CCONJ
dpc-5749	110	40	severity	severity	NOUN
dpc-5749	110	41	of	of	ADP
dpc-5749	110	42	the	the	DET
dpc-5749	110	43	disease	disease	NOUN
dpc-5749	110	44	course	course	NOUN
dpc-5749	110	45	.	.	PUNCT
dpc-5749	111	1	the	the	DET
dpc-5749	111	2	use	use	NOUN
dpc-5749	111	3	of	of	ADP
dpc-5749	111	4	immunosuppressive	immunosuppressive	ADJ
dpc-5749	111	5	agents	agent	NOUN
dpc-5749	111	6	raises	raise	VERB
dpc-5749	111	7	concerns	concern	NOUN
dpc-5749	111	8	over	over	ADP
dpc-5749	111	9	tumorigenesis	tumorigenesis	NOUN
dpc-5749	111	10	risks	risk	NOUN
dpc-5749	111	11	[	[	X
dpc-5749	111	12	43,50,51	43,50,51	NOUN
dpc-5749	111	13	]	]	X
dpc-5749	111	14	,	,	PUNCT
dpc-5749	111	15	and	and	CCONJ
dpc-5749	111	16	several	several	ADJ
dpc-5749	111	17	studies	study	NOUN
dpc-5749	111	18	warn	warn	VERB
dpc-5749	111	19	about	about	ADP
dpc-5749	111	20	elevated	elevated	ADJ
dpc-5749	111	21	malignancy	malignancy	NOUN
dpc-5749	111	22	risks	risk	NOUN
dpc-5749	111	23	[	[	X
dpc-5749	111	24	52	52	NUM
dpc-5749	111	25	]	]	PUNCT
dpc-5749	111	26	.	.	PUNCT
dpc-5749	112	1	on	on	ADP
dpc-5749	112	2	the	the	DET
dpc-5749	112	3	other	other	ADJ
dpc-5749	112	4	hand	hand	NOUN
dpc-5749	112	5	,	,	PUNCT
dpc-5749	112	6	malignancy	malignancy	NOUN
dpc-5749	112	7	was	be	AUX
dpc-5749	112	8	detected	detect	VERB
dpc-5749	112	9	before	before	ADP
dpc-5749	112	10	establishing	establish	VERB
dpc-5749	112	11	the	the	DET
dpc-5749	112	12	diagnosis	diagnosis	NOUN
dpc-5749	112	13	of	of	ADP
dpc-5749	112	14	mmp	mmp	PROPN
dpc-5749	112	15	in	in	ADP
dpc-5749	112	16	47.1	47.1	NUM
dpc-5749	112	17	%	%	NOUN
dpc-5749	112	18	of	of	ADP
dpc-5749	112	19	patients	patient	NOUN
dpc-5749	112	20	[	[	X
dpc-5749	112	21	43	43	NUM
dpc-5749	112	22	]	]	PUNCT
dpc-5749	112	23	,	,	PUNCT
dpc-5749	112	24	and	and	CCONJ
dpc-5749	112	25	immunosuppressive	immunosuppressive	ADJ
dpc-5749	112	26	agents	agent	NOUN
dpc-5749	112	27	have	have	AUX
dpc-5749	112	28	also	also	ADV
dpc-5749	112	29	been	be	AUX
dpc-5749	112	30	reported	report	VERB
dpc-5749	112	31	to	to	PART
dpc-5749	112	32	have	have	VERB
dpc-5749	112	33	antineoplastic	antineoplastic	ADJ
dpc-5749	112	34	effects	effect	NOUN
dpc-5749	113	1	[	[	X
dpc-5749	113	2	51,53,54,55	51,53,54,55	NUM
dpc-5749	113	3	]	]	PUNCT
dpc-5749	113	4	.	.	PUNCT
dpc-5749	114	1	corticosteroids	corticosteroid	NOUN
dpc-5749	114	2	remain	remain	VERB
dpc-5749	114	3	among	among	ADP
dpc-5749	114	4	the	the	DET
dpc-5749	114	5	most	most	ADV
dpc-5749	114	6	frequently	frequently	ADV
dpc-5749	114	7	indicated	indicate	VERB
dpc-5749	114	8	drugs	drug	NOUN
dpc-5749	114	9	in	in	ADP
dpc-5749	114	10	oncological	oncological	ADJ
dpc-5749	114	11	conditions	condition	NOUN
dpc-5749	114	12	[	[	X
dpc-5749	114	13	56	56	NUM
dpc-5749	114	14	]	]	PUNCT
dpc-5749	114	15	.	.	PUNCT
dpc-5749	115	1	in	in	ADP
dpc-5749	115	2	paraneoplastic	paraneoplastic	ADJ
dpc-5749	115	3	pemphigus	pemphigus	NOUN
dpc-5749	115	4	,	,	PUNCT
dpc-5749	115	5	another	another	DET
dpc-5749	115	6	autoimmune	autoimmune	ADJ
dpc-5749	115	7	blistering	blister	VERB
dpc-5749	115	8	disease	disease	NOUN
dpc-5749	115	9	,	,	PUNCT
dpc-5749	115	10	the	the	DET
dpc-5749	115	11	guidelines	guideline	NOUN
dpc-5749	115	12	indicate	indicate	VERB
dpc-5749	115	13	systemic	systemic	ADJ
dpc-5749	115	14	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-5749	115	15	,	,	PUNCT
dpc-5749	115	16	an	an	DET
dpc-5749	115	17	antimalarial	antimalarial	ADJ
dpc-5749	115	18	and	and	CCONJ
dpc-5749	115	19	antirheumatic	antirheumatic	ADJ
dpc-5749	115	20	agent	agent	NOUN
dpc-5749	115	21	,	,	PUNCT
dpc-5749	115	22	exerts	exert	VERB
dpc-5749	115	23	anti	anti	ADJ
dpc-5749	115	24	-	-	ADJ
dpc-5749	115	25	inflammatory	inflammatory	ADJ
dpc-5749	115	26	action	action	NOUN
dpc-5749	115	27	via	via	ADP
dpc-5749	115	28	the	the	DET
dpc-5749	115	29	disruption	disruption	NOUN
dpc-5749	115	30	of	of	ADP
dpc-5749	115	31	antigen	antigen	ADJ
dpc-5749	115	32	presentation	presentation	NOUN
dpc-5749	115	33	in	in	ADP
dpc-5749	115	34	the	the	DET
dpc-5749	115	35	background	background	NOUN
dpc-5749	115	36	of	of	ADP
dpc-5749	115	37	intracellular	intracellular	ADJ
dpc-5749	115	38	ph	ph	NOUN
dpc-5749	115	39	alteration	alteration	NOUN
dpc-5749	115	40	,	,	PUNCT
dpc-5749	115	41	processing	processing	NOUN
dpc-5749	115	42	of	of	ADP
dpc-5749	115	43	antigenic	antigenic	ADJ
dpc-5749	115	44	protein	protein	NOUN
dpc-5749	115	45	,	,	PUNCT
dpc-5749	115	46	and	and	CCONJ
dpc-5749	115	47	formation	formation	NOUN
dpc-5749	115	48	of	of	ADP
dpc-5749	115	49	the	the	DET
dpc-5749	115	50	alpha	alpha	NOUN
dpc-5749	115	51	and	and	CCONJ
dpc-5749	115	52	beta	beta	ADJ
dpc-5749	115	53	chains	chain	NOUN
dpc-5749	115	54	of	of	ADP
dpc-5749	115	55	major	major	ADJ
dpc-5749	115	56	histocompatibility	histocompatibility	NOUN
dpc-5749	115	57	complex	complex	ADJ
dpc-5749	115	58	class	class	NOUN
dpc-5749	115	59	ii	ii	NOUN
dpc-5749	115	60	proteins	protein	NOUN
dpc-5749	115	61	,	,	PUNCT
dpc-5749	115	62	reducing	reduce	VERB
dpc-5749	115	63	t	t	NOUN
dpc-5749	115	64	cell	cell	NOUN
dpc-5749	115	65	stimulation	stimulation	NOUN
dpc-5749	115	66	and	and	CCONJ
dpc-5749	115	67	immune	immune	ADJ
dpc-5749	115	68	responses	response	NOUN
dpc-5749	115	69	[	[	X
dpc-5749	115	70	25	25	NUM
dpc-5749	115	71	]	]	PUNCT
dpc-5749	115	72	.	.	PUNCT
dpc-5749	116	1	hydroxychloroquine	hydroxychloroquine	PROPN
dpc-5749	116	2	has	have	AUX
dpc-5749	116	3	been	be	AUX
dpc-5749	116	4	reported	report	VERB
dpc-5749	116	5	to	to	PART
dpc-5749	116	6	induce	induce	VERB
dpc-5749	116	7	disease	disease	NOUN
dpc-5749	116	8	control	control	NOUN
dpc-5749	116	9	in	in	ADP
dpc-5749	116	10	mmp	mmp	PROPN
dpc-5749	117	1	[	[	X
dpc-5749	117	2	26	26	NUM
dpc-5749	117	3	]	]	PUNCT
dpc-5749	117	4	and	and	CCONJ
dpc-5749	117	5	brunsting	brunste	VERB
dpc-5749	117	6	-	-	PUNCT
dpc-5749	117	7	perry	perry	NOUN
dpc-5749	117	8	pemphigoid	pemphigoid	NOUN
dpc-5749	118	1	[	[	X
dpc-5749	118	2	27	27	NUM
dpc-5749	118	3	]	]	X
dpc-5749	118	4	;	;	PUNCT
dpc-5749	118	5	however	however	ADV
dpc-5749	118	6	,	,	PUNCT
dpc-5749	118	7	retinopathy	retinopathy	ADJ
dpc-5749	118	8	,	,	PUNCT
dpc-5749	118	9	as	as	ADV
dpc-5749	118	10	well	well	ADV
dpc-5749	118	11	as	as	ADP
dpc-5749	118	12	cardiac	cardiac	ADJ
dpc-5749	118	13	and	and	CCONJ
dpc-5749	118	14	auditory	auditory	ADJ
dpc-5749	118	15	toxicity	toxicity	NOUN
dpc-5749	118	16	[	[	X
dpc-5749	118	17	28	28	NUM
dpc-5749	118	18	]	]	PUNCT
dpc-5749	118	19	and	and	CCONJ
dpc-5749	118	20	dermatological	dermatological	ADJ
dpc-5749	118	21	aes	aes	PROPN
dpc-5749	118	22	,	,	PUNCT
dpc-5749	118	23	in	in	ADP
dpc-5749	118	24	particular	particular	ADJ
dpc-5749	118	25	in	in	ADP
dpc-5749	118	26	autoimmune	autoimmune	ADJ
dpc-5749	118	27	conditions	condition	NOUN
dpc-5749	118	28	[	[	X
dpc-5749	118	29	29	29	NUM
dpc-5749	118	30	]	]	PUNCT
dpc-5749	118	31	,	,	PUNCT
dpc-5749	118	32	are	be	AUX
dpc-5749	118	33	linked	link	VERB
dpc-5749	118	34	to	to	ADP
dpc-5749	118	35	hydroxychloroquine	hydroxychloroquine	PROPN
dpc-5749	118	36	.	.	PUNCT
dpc-5749	119	1	leflunomide	leflunomide	PROPN
dpc-5749	119	2	is	be	AUX
dpc-5749	119	3	an	an	DET
dpc-5749	119	4	isoxazole	isoxazole	NOUN
dpc-5749	119	5	derivative	derivative	ADJ
dpc-5749	119	6	and	and	CCONJ
dpc-5749	119	7	pyrimidine	pyrimidine	NOUN
dpc-5749	119	8	synthesis	synthesis	NOUN
dpc-5749	119	9	inhibitor	inhibitor	NOUN
dpc-5749	119	10	used	use	VERB
dpc-5749	119	11	in	in	ADP
dpc-5749	119	12	mmp	mmp	PROPN
dpc-5749	119	13	.	.	PUNCT
dpc-5749	120	1	the	the	DET
dpc-5749	120	2	drug	drug	NOUN
dpc-5749	120	3	inhibits	inhibit	VERB
dpc-5749	120	4	the	the	DET
dpc-5749	120	5	mitochondrial	mitochondrial	ADJ
dpc-5749	120	6	enzyme	enzyme	NOUN
dpc-5749	120	7	dihydroorotate	dihydroorotate	NOUN
dpc-5749	120	8	dehydrogenase	dehydrogenase	NOUN
dpc-5749	120	9	,	,	PUNCT
dpc-5749	120	10	disrupting	disrupt	VERB
dpc-5749	120	11	de	de	ADJ
dpc-5749	120	12	novo	novo	NOUN
dpc-5749	120	13	synthesis	synthesis	NOUN
dpc-5749	120	14	of	of	ADP
dpc-5749	120	15	pyrimidine	pyrimidine	NOUN
dpc-5749	120	16	ribonucleotide	ribonucleotide	NOUN
dpc-5749	120	17	uridine	uridine	NOUN
dpc-5749	120	18	monophosphate	monophosphate	NOUN
dpc-5749	120	19	,	,	PUNCT
dpc-5749	120	20	required	require	VERB
dpc-5749	120	21	for	for	ADP
dpc-5749	120	22	the	the	DET
dpc-5749	120	23	progression	progression	NOUN
dpc-5749	120	24	from	from	ADP
dpc-5749	120	25	g1	g1	PROPN
dpc-5749	120	26	to	to	ADP
dpc-5749	120	27	s	s	PRON
dpc-5749	120	28	phase	phase	NOUN
dpc-5749	120	29	in	in	ADP
dpc-5749	120	30	activated	activate	VERB
dpc-5749	120	31	lymphocytes	lymphocyte	NOUN
dpc-5749	120	32	;	;	PUNCT
dpc-5749	120	33	these	these	DET
dpc-5749	120	34	cytostatic	cytostatic	ADJ
dpc-5749	120	35	and	and	CCONJ
dpc-5749	120	36	anti	anti	ADJ
dpc-5749	120	37	-	-	ADJ
dpc-5749	120	38	proliferative	proliferative	ADJ
dpc-5749	120	39	effects	effect	NOUN
dpc-5749	120	40	may	may	AUX
dpc-5749	120	41	contribute	contribute	VERB
dpc-5749	120	42	to	to	ADP
dpc-5749	120	43	disease	disease	NOUN
dpc-5749	120	44	control	control	NOUN
dpc-5749	120	45	in	in	ADP
dpc-5749	120	46	patients	patient	NOUN
dpc-5749	120	47	with	with	ADP
dpc-5749	120	48	mmp	mmp	PROPN
dpc-5749	121	1	[	[	X
dpc-5749	121	2	30,31	30,31	PROPN
dpc-5749	121	3	]	]	PUNCT
dpc-5749	121	4	.	.	PUNCT
dpc-5749	122	1	diarrhea	diarrhea	PROPN
dpc-5749	122	2	,	,	PUNCT
dpc-5749	122	3	elevation	elevation	NOUN
dpc-5749	122	4	of	of	ADP
dpc-5749	122	5	liver	liver	NOUN
dpc-5749	122	6	enzymes	enzyme	NOUN
dpc-5749	122	7	,	,	PUNCT
dpc-5749	122	8	rash	rash	NOUN
dpc-5749	122	9	,	,	PUNCT
dpc-5749	122	10	and	and	CCONJ
dpc-5749	122	11	alopecia	alopecia	NOUN
dpc-5749	122	12	are	be	AUX
dpc-5749	122	13	the	the	DET
dpc-5749	122	14	most	most	ADV
dpc-5749	122	15	frequent	frequent	ADJ
dpc-5749	122	16	aes	aes	NOUN
dpc-5749	122	17	of	of	ADP
dpc-5749	122	18	leflunomide	leflunomide	NOUN
dpc-5749	122	19	in	in	ADP
dpc-5749	122	20	rheumatoid	rheumatoid	NOUN
dpc-5749	122	21	arthritis	arthritis	NOUN
dpc-5749	122	22	[	[	X
dpc-5749	122	23	32	32	NUM
dpc-5749	122	24	]	]	PUNCT
dpc-5749	122	25	.	.	PUNCT
dpc-5749	123	1	melanocortins	melanocortin	NOUN
dpc-5749	123	2	exert	exert	VERB
dpc-5749	123	3	anti	anti	ADJ
dpc-5749	123	4	-	-	ADJ
dpc-5749	123	5	inflammatory	inflammatory	ADJ
dpc-5749	123	6	effects	effect	NOUN
dpc-5749	123	7	via	via	ADP
dpc-5749	123	8	the	the	DET
dpc-5749	123	9	stimulation	stimulation	NOUN
dpc-5749	123	10	of	of	ADP
dpc-5749	123	11	glucocorticoid	glucocorticoid	NOUN
dpc-5749	123	12	-	-	PUNCT
dpc-5749	123	13	dependent	dependent	ADJ
dpc-5749	123	14	and	and	CCONJ
dpc-5749	123	15	glucocorticoid	glucocorticoid	ADJ
dpc-5749	123	16	-	-	PUNCT
dpc-5749	123	17	independent	independent	ADJ
dpc-5749	123	18	pathways	pathway	NOUN
dpc-5749	123	19	,	,	PUNCT
dpc-5749	123	20	reducing	reduce	VERB
dpc-5749	123	21	the	the	DET
dpc-5749	123	22	release	release	NOUN
dpc-5749	123	23	of	of	ADP
dpc-5749	123	24	pro	pro	ADJ
dpc-5749	123	25	-	-	ADJ
dpc-5749	123	26	inflammatory	inflammatory	ADJ
dpc-5749	123	27	cytokines	cytokine	NOUN
dpc-5749	123	28	and	and	CCONJ
dpc-5749	124	1	ros	ros	PROPN
dpc-5749	124	2	.	.	PUNCT
dpc-5749	125	1	repository	repository	NOUN
dpc-5749	125	2	corticotropin	corticotropin	NOUN
dpc-5749	125	3	injection	injection	NOUN
dpc-5749	125	4	(	(	PUNCT
dpc-5749	125	5	rci	rci	NOUN
dpc-5749	125	6	)	)	PUNCT
dpc-5749	125	7	was	be	AUX
dpc-5749	125	8	earlier	early	ADV
dpc-5749	125	9	offered	offer	VERB
dpc-5749	125	10	for	for	ADP
dpc-5749	125	11	systemic	systemic	ADJ
dpc-5749	125	12	lupus	lupus	PROPN
dpc-5749	125	13	erythematosus	erythematosus	NOUN
dpc-5749	125	14	,	,	PUNCT
dpc-5749	125	15	given	give	VERB
dpc-5749	125	16	the	the	DET
dpc-5749	125	17	reduction	reduction	NOUN
dpc-5749	125	18	of	of	ADP
dpc-5749	125	19	b	b	NOUN
dpc-5749	125	20	cell	cell	NOUN
dpc-5749	125	21	proliferation	proliferation	NOUN
dpc-5749	125	22	(	(	PUNCT
dpc-5749	125	23	possibly	possibly	ADV
dpc-5749	125	24	,	,	PUNCT
dpc-5749	125	25	via	via	ADP
dpc-5749	125	26	suppressing	suppress	VERB
dpc-5749	125	27	the	the	DET
dpc-5749	125	28	activity	activity	NOUN
dpc-5749	125	29	of	of	ADP
dpc-5749	125	30	il-6	il-6	NUM
dpc-5749	125	31	and	and	CCONJ
dpc-5749	125	32	b	b	X
dpc-5749	125	33	-	-	PUNCT
dpc-5749	125	34	cell	cell	NOUN
dpc-5749	125	35	-	-	PUNCT
dpc-5749	125	36	activating	activate	VERB
dpc-5749	125	37	factor	factor	NOUN
dpc-5749	125	38	of	of	ADP
dpc-5749	125	39	the	the	DET
dpc-5749	125	40	tumor	tumor	NOUN
dpc-5749	125	41	necrosis	necrosis	NOUN
dpc-5749	125	42	factor	factor	NOUN
dpc-5749	125	43	(	(	PUNCT
dpc-5749	125	44	tnf	tnf	PROPN
dpc-5749	125	45	)	)	PUNCT
dpc-5749	125	46	family	family	NOUN
dpc-5749	125	47	signaling	signal	VERB
dpc-5749	125	48	)	)	PUNCT
dpc-5749	126	1	[	[	X
dpc-5749	126	2	33	33	NUM
dpc-5749	126	3	]	]	PUNCT
dpc-5749	126	4	.	.	PUNCT
dpc-5749	127	1	furthermore	furthermore	ADV
dpc-5749	127	2	,	,	PUNCT
dpc-5749	127	3	rci	rci	PROPN
dpc-5749	127	4	has	have	AUX
dpc-5749	127	5	been	be	AUX
dpc-5749	127	6	suggested	suggest	VERB
dpc-5749	127	7	as	as	ADP
dpc-5749	127	8	a	a	DET
dpc-5749	127	9	safe	safe	ADJ
dpc-5749	127	10	and	and	CCONJ
dpc-5749	127	11	well	well	ADV
dpc-5749	127	12	-	-	PUNCT
dpc-5749	127	13	tolerated	tolerate	VERB
dpc-5749	127	14	alternative	alternative	ADJ
dpc-5749	127	15	or	or	CCONJ
dpc-5749	127	16	adjunctive	adjunctive	ADJ
dpc-5749	127	17	option	option	NOUN
dpc-5749	127	18	for	for	ADP
dpc-5749	127	19	patients	patient	NOUN
dpc-5749	127	20	with	with	ADP
dpc-5749	127	21	severe	severe	ADJ
dpc-5749	127	22	and	and	CCONJ
dpc-5749	127	23	refractory	refractory	NOUN
dpc-5749	127	24	ocmmp	ocmmp	NOUN
dpc-5749	127	25	,	,	PUNCT
dpc-5749	127	26	inducing	induce	VERB
dpc-5749	127	27	improvement	improvement	NOUN
dpc-5749	127	28	in	in	ADP
dpc-5749	127	29	60	60	NUM
dpc-5749	127	30	%	%	NOUN
dpc-5749	127	31	of	of	ADP
dpc-5749	127	32	cases	case	NOUN
dpc-5749	127	33	;	;	PUNCT
dpc-5749	127	34	no	no	DET
dpc-5749	127	35	serious	serious	ADJ
dpc-5749	127	36	ae	ae	PROPN
dpc-5749	127	37	has	have	AUX
dpc-5749	127	38	been	be	AUX
dpc-5749	127	39	reported	report	VERB
dpc-5749	127	40	[	[	X
dpc-5749	127	41	34	34	NUM
dpc-5749	127	42	]	]	PUNCT
dpc-5749	127	43	.	.	PUNCT
dpc-5749	128	1	the	the	DET
dpc-5749	128	2	recombinant	recombinant	ADJ
dpc-5749	128	3	human	human	ADJ
dpc-5749	128	4	nerve	nerve	NOUN
dpc-5749	128	5	growth	growth	NOUN
dpc-5749	128	6	factor	factor	NOUN
dpc-5749	128	7	(	(	PUNCT
dpc-5749	128	8	rhngf	rhngf	NOUN
dpc-5749	128	9	)	)	PUNCT
dpc-5749	128	10	cenegermin	cenegermin	NOUN
dpc-5749	128	11	improves	improve	VERB
dpc-5749	128	12	corneal	corneal	ADJ
dpc-5749	128	13	healing	healing	NOUN
dpc-5749	128	14	via	via	ADP
dpc-5749	128	15	binding	bind	VERB
dpc-5749	128	16	to	to	ADP
dpc-5749	128	17	the	the	DET
dpc-5749	128	18	tyrosine	tyrosine	NOUN
dpc-5749	128	19	kinase	kinase	PROPN
dpc-5749	128	20	receptor	receptor	NOUN
dpc-5749	128	21	trka	trka	NOUN
dpc-5749	128	22	and	and	CCONJ
dpc-5749	128	23	to	to	ADP
dpc-5749	128	24	p75ntr	p75ntr	VERB
dpc-5749	128	25	,	,	PUNCT
dpc-5749	128	26	promoting	promote	VERB
dpc-5749	128	27	neuronal	neuronal	ADJ
dpc-5749	128	28	and	and	CCONJ
dpc-5749	128	29	epithelial	epithelial	ADJ
dpc-5749	128	30	cell	cell	NOUN
dpc-5749	128	31	growth	growth	NOUN
dpc-5749	128	32	.	.	PUNCT
dpc-5749	129	1	abbot	abbot	PROPN
dpc-5749	129	2	et	et	PROPN
dpc-5749	129	3	al	al	PROPN
dpc-5749	129	4	.	.	PROPN
dpc-5749	130	1	(	(	PUNCT
dpc-5749	130	2	2024	2024	NUM
dpc-5749	130	3	)	)	PUNCT
dpc-5749	130	4	reported	report	VERB
dpc-5749	130	5	the	the	DET
dpc-5749	130	6	resolution	resolution	NOUN
dpc-5749	130	7	of	of	ADP
dpc-5749	130	8	mmp	mmp	PROPN
dpc-5749	130	9	-	-	PUNCT
dpc-5749	130	10	associated	associate	VERB
dpc-5749	130	11	large	large	ADJ
dpc-5749	130	12	,	,	PUNCT
dpc-5749	130	13	non	non	ADJ
dpc-5749	130	14	-	-	ADJ
dpc-5749	130	15	healing	healing	ADJ
dpc-5749	130	16	corneal	corneal	ADJ
dpc-5749	130	17	defect	defect	NOUN
dpc-5749	130	18	in	in	ADP
dpc-5749	130	19	two	two	NUM
dpc-5749	130	20	patients	patient	NOUN
dpc-5749	130	21	treated	treat	VERB
dpc-5749	130	22	with	with	ADP
dpc-5749	130	23	cenegermin	cenegermin	NOUN
dpc-5749	131	1	[	[	X
dpc-5749	131	2	35,36	35,36	NUM
dpc-5749	131	3	]	]	PUNCT
dpc-5749	131	4	,	,	PUNCT
dpc-5749	131	5	but	but	CCONJ
dpc-5749	131	6	surico	surico	NOUN
dpc-5749	131	7	et	et	PROPN
dpc-5749	131	8	al	al	PROPN
dpc-5749	131	9	.	.	PROPN
dpc-5749	132	1	(	(	PUNCT
dpc-5749	132	2	2024	2024	NUM
dpc-5749	132	3	)	)	PUNCT
dpc-5749	132	4	highlighted	highlight	VERB
dpc-5749	132	5	patient	patient	ADJ
dpc-5749	132	6	monitoring	monitoring	NOUN
dpc-5749	132	7	due	due	ADP
dpc-5749	132	8	to	to	ADP
dpc-5749	132	9	the	the	DET
dpc-5749	132	10	formation	formation	NOUN
dpc-5749	132	11	of	of	ADP
dpc-5749	132	12	corneal	corneal	ADJ
dpc-5749	132	13	superficial	superficial	ADJ
dpc-5749	132	14	plaque	plaque	NOUN
dpc-5749	132	15	linked	link	VERB
dpc-5749	132	16	to	to	ADP
dpc-5749	132	17	posttreatment	posttreatment	NOUN
dpc-5749	132	18	epithelial	epithelial	ADJ
dpc-5749	132	19	hyperplasia	hyperplasia	NOUN
dpc-5749	132	20	[	[	X
dpc-5749	132	21	36	36	NUM
dpc-5749	132	22	]	]	PUNCT
dpc-5749	132	23	.	.	PUNCT
dpc-5749	133	1	sirolimus	sirolimus	PROPN
dpc-5749	133	2	,	,	PUNCT
dpc-5749	133	3	a	a	DET
dpc-5749	133	4	mammalian	mammalian	ADJ
dpc-5749	133	5	target	target	NOUN
dpc-5749	133	6	of	of	ADP
dpc-5749	133	7	rapamycin	rapamycin	NOUN
dpc-5749	133	8	(	(	PUNCT
dpc-5749	133	9	m	m	NOUN
dpc-5749	133	10	-	-	PUNCT
dpc-5749	133	11	tor	tor	ADJ
dpc-5749	133	12	)	)	PUNCT
dpc-5749	133	13	inhibitor	inhibitor	NOUN
dpc-5749	133	14	,	,	PUNCT
dpc-5749	133	15	suppresses	suppress	VERB
dpc-5749	133	16	cytokine	cytokine	ADJ
dpc-5749	133	17	and	and	CCONJ
dpc-5749	133	18	growth	growth	NOUN
dpc-5749	133	19	factor	factor	NOUN
dpc-5749	133	20	receptor	receptor	NOUN
dpc-5749	133	21	signaling	signal	VERB
dpc-5749	133	22	and	and	CCONJ
dpc-5749	133	23	t	t	NOUN
dpc-5749	133	24	cell	cell	NOUN
dpc-5749	133	25	progression	progression	NOUN
dpc-5749	133	26	from	from	ADP
dpc-5749	133	27	g1	g1	PROPN
dpc-5749	133	28	to	to	ADP
dpc-5749	133	29	s	s	PRON
dpc-5749	133	30	[	[	X
dpc-5749	133	31	30	30	NUM
dpc-5749	133	32	]	]	PUNCT
dpc-5749	133	33	.	.	PUNCT
dpc-5749	134	1	sirolimus	sirolimus	PROPN
dpc-5749	134	2	was	be	AUX
dpc-5749	134	3	reported	report	VERB
dpc-5749	134	4	in	in	ADP
dpc-5749	134	5	combined	combine	VERB
dpc-5749	134	6	and	and	CCONJ
dpc-5749	134	7	rotation	rotation	NOUN
dpc-5749	134	8	therapy	therapy	NOUN
dpc-5749	134	9	in	in	ADP
dpc-5749	134	10	ocmmp	ocmmp	PROPN
dpc-5749	134	11	[	[	X
dpc-5749	134	12	37	37	NUM
dpc-5749	134	13	]	]	PUNCT
dpc-5749	134	14	.	.	PUNCT
dpc-5749	135	1	on	on	ADP
dpc-5749	135	2	the	the	DET
dpc-5749	135	3	other	other	ADJ
dpc-5749	135	4	hand	hand	NOUN
dpc-5749	135	5	,	,	PUNCT
dpc-5749	135	6	sirolimus	sirolimus	NOUN
dpc-5749	135	7	-	-	PUNCT
dpc-5749	135	8	induced	induce	VERB
dpc-5749	135	9	bullous	bullous	ADJ
dpc-5749	135	10	pemphigoid	pemphigoid	NOUN
dpc-5749	135	11	was	be	AUX
dpc-5749	135	12	reported	report	VERB
dpc-5749	135	13	in	in	ADP
dpc-5749	135	14	two	two	NUM
dpc-5749	135	15	renal	renal	ADJ
dpc-5749	135	16	transplant	transplant	NOUN
dpc-5749	135	17	recipients	recipient	NOUN
dpc-5749	135	18	[	[	X
dpc-5749	135	19	38	38	NUM
dpc-5749	135	20	]	]	PUNCT
dpc-5749	135	21	;	;	PUNCT
dpc-5749	135	22	consequently	consequently	ADV
dpc-5749	135	23	,	,	PUNCT
dpc-5749	135	24	sirolimus	sirolimus	NOUN
dpc-5749	135	25	should	should	AUX
dpc-5749	135	26	be	be	AUX
dpc-5749	135	27	employed	employ	VERB
dpc-5749	135	28	with	with	ADP
dpc-5749	135	29	caution	caution	NOUN
dpc-5749	135	30	in	in	ADP
dpc-5749	135	31	autoimmune	autoimmune	ADJ
dpc-5749	135	32	skin	skin	NOUN
dpc-5749	135	33	blistering	blister	VERB
dpc-5749	135	34	diseases	disease	NOUN
dpc-5749	135	35	(	(	PUNCT
dpc-5749	135	36	aibds	aibds	NOUN
dpc-5749	135	37	)	)	PUNCT
dpc-5749	135	38	.	.	PUNCT
dpc-5749	136	1	review	review	VERB
dpc-5749	136	2	|	|	ADV
dpc-5749	136	3	dermatol	dermatol	ADJ
dpc-5749	136	4	pract	pract	NOUN
dpc-5749	136	5	concept	concept	NOUN
dpc-5749	136	6	.	.	PUNCT
dpc-5749	137	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	137	2	5	5	NUM
dpc-5749	137	3	potential	potential	NOUN
dpc-5749	137	4	of	of	ADP
dpc-5749	137	5	omalizumab	omalizumab	NOUN
dpc-5749	137	6	;	;	PUNCT
dpc-5749	137	7	additionally	additionally	ADV
dpc-5749	137	8	,	,	PUNCT
dpc-5749	137	9	omalizumab	omalizumab	NOUN
dpc-5749	137	10	can	can	AUX
dpc-5749	137	11	be	be	AUX
dpc-5749	137	12	employed	employ	VERB
dpc-5749	137	13	in	in	ADP
dpc-5749	137	14	desensitization	desensitization	NOUN
dpc-5749	137	15	to	to	ADP
dpc-5749	137	16	chemotherapeutic	chemotherapeutic	ADJ
dpc-5749	137	17	agents	agent	NOUN
dpc-5749	137	18	[	[	X
dpc-5749	137	19	75	75	NUM
dpc-5749	137	20	]	]	PUNCT
dpc-5749	137	21	.	.	PUNCT
dpc-5749	138	1	the	the	DET
dpc-5749	138	2	rarity	rarity	NOUN
dpc-5749	138	3	of	of	ADP
dpc-5749	138	4	mmp	mmp	PROPN
dpc-5749	138	5	and	and	CCONJ
dpc-5749	138	6	its	its	PRON
dpc-5749	138	7	comorbidity	comorbidity	NOUN
dpc-5749	138	8	with	with	ADP
dpc-5749	138	9	malignancy	malignancy	NOUN
dpc-5749	138	10	complicates	complicate	VERB
dpc-5749	138	11	the	the	DET
dpc-5749	138	12	collection	collection	NOUN
dpc-5749	138	13	of	of	ADP
dpc-5749	138	14	further	further	ADJ
dpc-5749	138	15	data	datum	NOUN
dpc-5749	138	16	on	on	ADP
dpc-5749	138	17	the	the	DET
dpc-5749	138	18	association	association	NOUN
dpc-5749	138	19	between	between	ADP
dpc-5749	138	20	mmp	mmp	PROPN
dpc-5749	138	21	and	and	CCONJ
dpc-5749	138	22	malignant	malignant	ADJ
dpc-5749	138	23	tumors	tumor	NOUN
dpc-5749	138	24	and	and	CCONJ
dpc-5749	138	25	the	the	DET
dpc-5749	138	26	impact	impact	NOUN
dpc-5749	138	27	of	of	ADP
dpc-5749	138	28	immunosuppressive	immunosuppressive	ADJ
dpc-5749	138	29	and	and	CCONJ
dpc-5749	138	30	other	other	ADJ
dpc-5749	138	31	pharmacological	pharmacological	ADJ
dpc-5749	138	32	agents	agent	NOUN
dpc-5749	138	33	on	on	ADP
dpc-5749	138	34	malignancy	malignancy	NOUN
dpc-5749	138	35	risks	risk	NOUN
dpc-5749	138	36	.	.	PUNCT
dpc-5749	139	1	future	future	ADJ
dpc-5749	139	2	perspectives	perspective	NOUN
dpc-5749	139	3	considering	consider	VERB
dpc-5749	139	4	that	that	SCONJ
dpc-5749	139	5	the	the	DET
dpc-5749	139	6	mechanisms	mechanism	NOUN
dpc-5749	139	7	of	of	ADP
dpc-5749	139	8	action	action	NOUN
dpc-5749	139	9	of	of	ADP
dpc-5749	139	10	the	the	DET
dpc-5749	139	11	above	above	ADJ
dpc-5749	139	12	mentioned	mention	VERB
dpc-5749	139	13	agents	agent	NOUN
dpc-5749	139	14	are	be	AUX
dpc-5749	139	15	directed	direct	VERB
dpc-5749	139	16	against	against	ADP
dpc-5749	139	17	the	the	DET
dpc-5749	139	18	earlier	early	ADV
dpc-5749	139	19	discussed	discuss	VERB
dpc-5749	139	20	or	or	CCONJ
dpc-5749	139	21	hypothesized	hypothesized	ADJ
dpc-5749	139	22	components	component	NOUN
dpc-5749	139	23	of	of	ADP
dpc-5749	139	24	the	the	DET
dpc-5749	139	25	pathogenesis	pathogenesis	NOUN
dpc-5749	139	26	of	of	ADP
dpc-5749	139	27	mmp	mmp	PROPN
dpc-5749	139	28	and	and	CCONJ
dpc-5749	139	29	its	its	PRON
dpc-5749	139	30	complications	complication	NOUN
dpc-5749	139	31	,	,	PUNCT
dpc-5749	139	32	the	the	DET
dpc-5749	139	33	studied	study	VERB
dpc-5749	139	34	drugs	drug	NOUN
dpc-5749	139	35	possess	possess	VERB
dpc-5749	139	36	the	the	DET
dpc-5749	139	37	potential	potential	NOUN
dpc-5749	139	38	for	for	ADP
dpc-5749	139	39	additional	additional	ADJ
dpc-5749	139	40	research	research	NOUN
dpc-5749	139	41	concerning	concern	VERB
dpc-5749	139	42	their	their	PRON
dpc-5749	139	43	efficacy	efficacy	NOUN
dpc-5749	139	44	and	and	CCONJ
dpc-5749	139	45	safety	safety	NOUN
dpc-5749	139	46	profile	profile	NOUN
dpc-5749	139	47	.	.	PUNCT
dpc-5749	140	1	the	the	DET
dpc-5749	140	2	analysis	analysis	NOUN
dpc-5749	140	3	of	of	ADP
dpc-5749	140	4	the	the	DET
dpc-5749	140	5	guidelines	guideline	NOUN
dpc-5749	140	6	shows	show	VERB
dpc-5749	140	7	the	the	DET
dpc-5749	140	8	susceptibility	susceptibility	NOUN
dpc-5749	140	9	to	to	ADP
dpc-5749	140	10	therapeutic	therapeutic	ADJ
dpc-5749	140	11	novelties	novelty	NOUN
dpc-5749	140	12	.	.	PUNCT
dpc-5749	141	1	azathioprine	azathioprine	PROPN
dpc-5749	141	2	,	,	PUNCT
dpc-5749	141	3	cyclophosphamide	cyclophosphamide	NOUN
dpc-5749	141	4	,	,	PUNCT
dpc-5749	141	5	and	and	CCONJ
dpc-5749	141	6	mitomycin	mitomycin	NOUN
dpc-5749	141	7	c	c	PROPN
dpc-5749	141	8	were	be	AUX
dpc-5749	141	9	included	include	VERB
dpc-5749	141	10	in	in	ADP
dpc-5749	141	11	the	the	DET
dpc-5749	141	12	first	first	ADJ
dpc-5749	141	13	international	international	ADJ
dpc-5749	141	14	consensus	consensus	NOUN
dpc-5749	141	15	on	on	ADP
dpc-5749	141	16	mmp	mmp	PROPN
dpc-5749	141	17	,	,	PUNCT
dpc-5749	141	18	while	while	SCONJ
dpc-5749	141	19	mycophenolate	mycophenolate	PROPN
dpc-5749	141	20	mofetil	mofetil	PROPN
dpc-5749	141	21	,	,	PUNCT
dpc-5749	141	22	rituximab	rituximab	NOUN
dpc-5749	141	23	,	,	PUNCT
dpc-5749	141	24	intravenous	intravenous	ADJ
dpc-5749	141	25	immunoglobulin	immunoglobulin	NOUN
dpc-5749	141	26	,	,	PUNCT
dpc-5749	141	27	ciclosporin	ciclosporin	NOUN
dpc-5749	141	28	a	a	NOUN
dpc-5749	141	29	,	,	PUNCT
dpc-5749	141	30	and	and	CCONJ
dpc-5749	141	31	etanercept	etanercept	NOUN
dpc-5749	141	32	were	be	AUX
dpc-5749	141	33	introduced	introduce	VERB
dpc-5749	141	34	by	by	ADP
dpc-5749	141	35	the	the	DET
dpc-5749	141	36	guidelines	guideline	NOUN
dpc-5749	141	37	of	of	ADP
dpc-5749	141	38	the	the	DET
dpc-5749	141	39	french	french	ADJ
dpc-5749	141	40	society	society	NOUN
dpc-5749	141	41	of	of	ADP
dpc-5749	141	42	dermatology	dermatology	NOUN
dpc-5749	141	43	;	;	PUNCT
dpc-5749	141	44	a	a	DET
dpc-5749	141	45	broader	broad	ADJ
dpc-5749	141	46	term	term	NOUN
dpc-5749	141	47	“	"	PUNCT
dpc-5749	141	48	tnf	tnf	PROPN
dpc-5749	141	49	-	-	PUNCT
dpc-5749	141	50	inhibitors	inhibitor	NOUN
dpc-5749	141	51	”	"	PUNCT
dpc-5749	141	52	was	be	AUX
dpc-5749	141	53	later	later	ADV
dpc-5749	141	54	included	include	VERB
dpc-5749	141	55	in	in	ADP
dpc-5749	141	56	the	the	DET
dpc-5749	141	57	s3	s3	PROPN
dpc-5749	141	58	and	and	CCONJ
dpc-5749	141	59	s2k	s2k	PROPN
dpc-5749	141	60	guidelines	guideline	NOUN
dpc-5749	141	61	,	,	PUNCT
dpc-5749	141	62	janus	janus	PROPN
dpc-5749	141	63	kinase	kinase	PROPN
dpc-5749	141	64	inhibitors	inhibitor	NOUN
dpc-5749	141	65	were	be	AUX
dpc-5749	141	66	indicated	indicate	VERB
dpc-5749	141	67	by	by	ADP
dpc-5749	141	68	the	the	DET
dpc-5749	141	69	s2k	s2k	PROPN
dpc-5749	141	70	guidelines	guideline	NOUN
dpc-5749	141	71	for	for	ADP
dpc-5749	141	72	severe	severe	ADJ
dpc-5749	141	73	and	and	CCONJ
dpc-5749	141	74	recalcitrant	recalcitrant	ADJ
dpc-5749	141	75	cases	case	NOUN
dpc-5749	141	76	.	.	PUNCT
dpc-5749	142	1	corticosteroids	corticosteroid	NOUN
dpc-5749	142	2	are	be	AUX
dpc-5749	142	3	the	the	DET
dpc-5749	142	4	most	most	ADV
dpc-5749	142	5	frequently	frequently	ADV
dpc-5749	142	6	employed	employ	VERB
dpc-5749	142	7	immunosuppressive	immunosuppressive	ADJ
dpc-5749	142	8	agents	agent	NOUN
dpc-5749	142	9	owning	own	VERB
dpc-5749	142	10	to	to	ADP
dpc-5749	142	11	their	their	PRON
dpc-5749	142	12	availability	availability	NOUN
dpc-5749	142	13	and	and	CCONJ
dpc-5749	142	14	efficiency	efficiency	NOUN
dpc-5749	142	15	.	.	PUNCT
dpc-5749	143	1	however	however	ADV
dpc-5749	143	2	,	,	PUNCT
dpc-5749	143	3	the	the	DET
dpc-5749	143	4	unacceptance	unacceptance	NOUN
dpc-5749	143	5	of	of	ADP
dpc-5749	143	6	long	long	ADJ
dpc-5749	143	7	-	-	PUNCT
dpc-5749	143	8	term	term	NOUN
dpc-5749	143	9	use	use	NOUN
dpc-5749	143	10	of	of	ADP
dpc-5749	143	11	systemic	systemic	ADJ
dpc-5749	143	12	corticosteroids	corticosteroid	NOUN
dpc-5749	143	13	due	due	ADP
dpc-5749	143	14	to	to	ADP
dpc-5749	143	15	severe	severe	ADJ
dpc-5749	143	16	aes	aes	PROPN
dpc-5749	143	17	(	(	PUNCT
dpc-5749	143	18	e.g.	e.g.	ADV
dpc-5749	143	19	,	,	PUNCT
dpc-5749	143	20	aseptic	aseptic	ADJ
dpc-5749	143	21	hip	hip	NOUN
dpc-5749	143	22	necrosis	necrosis	NOUN
dpc-5749	143	23	,	,	PUNCT
dpc-5749	143	24	uncontrolled	uncontrolled	ADJ
dpc-5749	143	25	diabetes	diabetes	NOUN
dpc-5749	143	26	mellitus	mellitus	NOUN
dpc-5749	143	27	,	,	PUNCT
dpc-5749	143	28	and	and	CCONJ
dpc-5749	143	29	hypertension	hypertension	NOUN
dpc-5749	143	30	)	)	PUNCT
dpc-5749	143	31	was	be	AUX
dpc-5749	143	32	earlier	early	ADV
dpc-5749	143	33	highlighted	highlight	VERB
dpc-5749	143	34	in	in	ADP
dpc-5749	143	35	patients	patient	NOUN
dpc-5749	143	36	diagnosed	diagnose	VERB
dpc-5749	143	37	with	with	ADP
dpc-5749	143	38	ocmmp	ocmmp	NOUN
dpc-5749	143	39	[	[	X
dpc-5749	143	40	76	76	NUM
dpc-5749	143	41	]	]	X
dpc-5749	143	42	,	,	PUNCT
dpc-5749	143	43	and	and	CCONJ
dpc-5749	143	44	there	there	PRON
dpc-5749	143	45	is	be	VERB
dpc-5749	143	46	a	a	DET
dpc-5749	143	47	wide	wide	ADJ
dpc-5749	143	48	range	range	NOUN
dpc-5749	143	49	of	of	ADP
dpc-5749	143	50	both	both	CCONJ
dpc-5749	143	51	topical	topical	ADJ
dpc-5749	143	52	and	and	CCONJ
dpc-5749	143	53	systemic	systemic	ADJ
dpc-5749	143	54	steroid	steroid	NOUN
dpc-5749	143	55	-	-	PUNCT
dpc-5749	143	56	sparing	spare	VERB
dpc-5749	143	57	immunosuppressants	immunosuppressant	NOUN
dpc-5749	143	58	,	,	PUNCT
dpc-5749	143	59	which	which	PRON
dpc-5749	143	60	are	be	AUX
dpc-5749	143	61	included	include	VERB
dpc-5749	143	62	in	in	ADP
dpc-5749	143	63	the	the	DET
dpc-5749	143	64	guidelines	guideline	NOUN
dpc-5749	143	65	and	and	CCONJ
dpc-5749	143	66	which	which	PRON
dpc-5749	143	67	exert	exert	VERB
dpc-5749	143	68	effects	effect	NOUN
dpc-5749	143	69	through	through	ADP
dpc-5749	143	70	various	various	ADJ
dpc-5749	143	71	pathways	pathway	NOUN
dpc-5749	143	72	,	,	PUNCT
dpc-5749	143	73	reduce	reduce	VERB
dpc-5749	143	74	proliferation	proliferation	NOUN
dpc-5749	143	75	of	of	ADP
dpc-5749	143	76	immune	immune	ADJ
dpc-5749	143	77	cells	cell	NOUN
dpc-5749	143	78	,	,	PUNCT
dpc-5749	143	79	and	and	CCONJ
dpc-5749	143	80	release	release	NOUN
dpc-5749	143	81	of	of	ADP
dpc-5749	143	82	pathogenic	pathogenic	ADJ
dpc-5749	143	83	autoantibodies	autoantibody	NOUN
dpc-5749	143	84	,	,	PUNCT
dpc-5749	143	85	with	with	ADP
dpc-5749	143	86	the	the	DET
dpc-5749	143	87	underlying	underlie	VERB
dpc-5749	143	88	risk	risk	NOUN
dpc-5749	143	89	of	of	ADP
dpc-5749	143	90	complications	complication	NOUN
dpc-5749	143	91	,	,	PUNCT
dpc-5749	143	92	therapy	therapy	NOUN
dpc-5749	143	93	resistance	resistance	NOUN
dpc-5749	143	94	,	,	PUNCT
dpc-5749	143	95	and	and	CCONJ
dpc-5749	143	96	recalcitrant	recalcitrant	ADJ
dpc-5749	143	97	disease	disease	NOUN
dpc-5749	143	98	course	course	NOUN
dpc-5749	143	99	.	.	PUNCT
dpc-5749	144	1	the	the	DET
dpc-5749	144	2	search	search	NOUN
dpc-5749	144	3	for	for	ADP
dpc-5749	144	4	new	new	ADJ
dpc-5749	144	5	options	option	NOUN
dpc-5749	144	6	with	with	ADP
dpc-5749	144	7	minimal	minimal	ADJ
dpc-5749	144	8	aes	aes	NOUN
dpc-5749	144	9	continues	continue	VERB
dpc-5749	144	10	,	,	PUNCT
dpc-5749	144	11	and	and	CCONJ
dpc-5749	144	12	time	time	NOUN
dpc-5749	144	13	will	will	AUX
dpc-5749	144	14	show	show	VERB
dpc-5749	144	15	which	which	DET
dpc-5749	144	16	pharmacological	pharmacological	ADJ
dpc-5749	144	17	agents	agent	NOUN
dpc-5749	144	18	will	will	AUX
dpc-5749	144	19	be	be	AUX
dpc-5749	144	20	included	include	VERB
dpc-5749	144	21	in	in	ADP
dpc-5749	144	22	new	new	ADJ
dpc-5749	144	23	guidelines	guideline	NOUN
dpc-5749	144	24	;	;	PUNCT
dpc-5749	144	25	some	some	DET
dpc-5749	144	26	options	option	NOUN
dpc-5749	144	27	will	will	AUX
dpc-5749	144	28	remain	remain	VERB
dpc-5749	144	29	outside	outside	ADP
dpc-5749	144	30	the	the	DET
dpc-5749	144	31	list	list	NOUN
dpc-5749	144	32	of	of	ADP
dpc-5749	144	33	recommended	recommend	VERB
dpc-5749	144	34	agents	agent	NOUN
dpc-5749	144	35	(	(	PUNCT
dpc-5749	144	36	e.g.	e.g.	ADV
dpc-5749	144	37	,	,	PUNCT
dpc-5749	144	38	thalidomide	thalidomide	NOUN
dpc-5749	144	39	)	)	PUNCT
dpc-5749	144	40	,	,	PUNCT
dpc-5749	144	41	while	while	SCONJ
dpc-5749	144	42	others	other	NOUN
dpc-5749	144	43	may	may	AUX
dpc-5749	144	44	fade	fade	VERB
dpc-5749	144	45	away	away	ADV
dpc-5749	144	46	.	.	PUNCT
dpc-5749	145	1	furthermore	furthermore	ADV
dpc-5749	145	2	,	,	PUNCT
dpc-5749	145	3	in	in	ADP
dpc-5749	145	4	preclinical	preclinical	ADJ
dpc-5749	145	5	studies	study	NOUN
dpc-5749	145	6	,	,	PUNCT
dpc-5749	145	7	additional	additional	ADJ
dpc-5749	145	8	pharmacological	pharmacological	ADJ
dpc-5749	145	9	targets	target	NOUN
dpc-5749	145	10	have	have	AUX
dpc-5749	145	11	been	be	AUX
dpc-5749	145	12	proposed	propose	VERB
dpc-5749	145	13	.	.	PUNCT
dpc-5749	146	1	in	in	ADP
dpc-5749	146	2	a	a	DET
dpc-5749	146	3	murine	murine	ADJ
dpc-5749	146	4	model	model	NOUN
dpc-5749	146	5	of	of	ADP
dpc-5749	146	6	anti	anti	ADJ
dpc-5749	146	7	-	-	NOUN
dpc-5749	146	8	laminin-332	laminin-332	ADJ
dpc-5749	146	9	mmp	mmp	PROPN
dpc-5749	146	10	the	the	DET
dpc-5749	146	11	inhibition	inhibition	NOUN
dpc-5749	146	12	of	of	ADP
dpc-5749	146	13	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-5749	146	14	,	,	PUNCT
dpc-5749	146	15	responsible	responsible	ADJ
dpc-5749	146	16	for	for	ADP
dpc-5749	146	17	cell	cell	NOUN
dpc-5749	146	18	signaling	signal	VERB
dpc-5749	146	19	,	,	PUNCT
dpc-5749	146	20	resulted	result	VERB
dpc-5749	146	21	in	in	ADP
dpc-5749	146	22	the	the	DET
dpc-5749	146	23	improvement	improvement	NOUN
dpc-5749	146	24	of	of	ADP
dpc-5749	146	25	oral	oral	ADJ
dpc-5749	146	26	lesions	lesion	NOUN
dpc-5749	146	27	[	[	X
dpc-5749	146	28	77	77	NUM
dpc-5749	146	29	]	]	PUNCT
dpc-5749	146	30	.	.	PUNCT
dpc-5749	147	1	phosphatidylinositol-3	phosphatidylinositol-3	PROPN
dpc-5749	147	2	-	-	PUNCT
dpc-5749	147	3	kinase	kinase	NOUN
dpc-5749	147	4	-	-	PUNCT
dpc-5749	147	5	δ	δ	PROPN
dpc-5749	147	6	(	(	PUNCT
dpc-5749	147	7	pi3kδ	pi3kδ	NOUN
dpc-5749	147	8	)	)	PUNCT
dpc-5749	147	9	is	be	AUX
dpc-5749	147	10	involved	involve	VERB
dpc-5749	147	11	in	in	ADP
dpc-5749	147	12	cutaneous	cutaneous	ADJ
dpc-5749	147	13	blistering	blister	VERB
dpc-5749	147	14	following	follow	VERB
dpc-5749	147	15	leukocyte	leukocyte	ADJ
dpc-5749	147	16	activation	activation	NOUN
dpc-5749	147	17	after	after	ADP
dpc-5749	147	18	fc	fc	PROPN
dpc-5749	147	19	gamma	gamma	PROPN
dpc-5749	147	20	receptor	receptor	NOUN
dpc-5749	147	21	-	-	PUNCT
dpc-5749	147	22	dependent	dependent	ADJ
dpc-5749	147	23	binding	binding	NOUN
dpc-5749	147	24	to	to	ADP
dpc-5749	147	25	the	the	DET
dpc-5749	147	26	skin	skin	NOUN
dpc-5749	147	27	-	-	PUNCT
dpc-5749	147	28	located	locate	VERB
dpc-5749	147	29	immune	immune	ADJ
dpc-5749	147	30	complexes	complex	NOUN
dpc-5749	147	31	and	and	CCONJ
dpc-5749	147	32	subsequent	subsequent	ADJ
dpc-5749	147	33	production	production	NOUN
dpc-5749	147	34	of	of	ADP
dpc-5749	147	35	proteases	protease	NOUN
dpc-5749	147	36	and	and	CCONJ
dpc-5749	147	37	ros	ros	PROPN
dpc-5749	147	38	.	.	PROPN
dpc-5749	147	39	parsaclisib	parsaclisib	PROPN
dpc-5749	147	40	,	,	PUNCT
dpc-5749	147	41	a	a	DET
dpc-5749	147	42	pi3kδ	pi3kδ	NOUN
dpc-5749	147	43	-	-	PUNCT
dpc-5749	147	44	selective	selective	ADJ
dpc-5749	147	45	inhibitor	inhibitor	NOUN
dpc-5749	147	46	,	,	PUNCT
dpc-5749	147	47	showed	show	VERB
dpc-5749	147	48	the	the	DET
dpc-5749	147	49	amelioration	amelioration	NOUN
dpc-5749	147	50	of	of	ADP
dpc-5749	147	51	cutaneous	cutaneous	ADJ
dpc-5749	147	52	lesions	lesion	NOUN
dpc-5749	147	53	in	in	ADP
dpc-5749	147	54	the	the	DET
dpc-5749	147	55	mmp	mmp	PROPN
dpc-5749	147	56	-	-	PUNCT
dpc-5749	147	57	induced	induce	VERB
dpc-5749	147	58	mouse	mouse	NOUN
dpc-5749	147	59	model	model	NOUN
dpc-5749	147	60	[	[	X
dpc-5749	147	61	78	78	NUM
dpc-5749	147	62	]	]	PUNCT
dpc-5749	147	63	.	.	PUNCT
dpc-5749	148	1	additionally	additionally	ADV
dpc-5749	148	2	,	,	PUNCT
dpc-5749	148	3	laminin-332	laminin-332	NOUN
dpc-5749	148	4	is	be	AUX
dpc-5749	148	5	linked	link	VERB
dpc-5749	148	6	to	to	ADP
dpc-5749	148	7	corticosteroids	corticosteroid	NOUN
dpc-5749	148	8	and	and	CCONJ
dpc-5749	148	9	steroid	steroid	NOUN
dpc-5749	148	10	-	-	PUNCT
dpc-5749	148	11	paring	pare	VERB
dpc-5749	148	12	agents	agent	NOUN
dpc-5749	148	13	:	:	PUNCT
dpc-5749	148	14	cyclophosphamide	cyclophosphamide	PROPN
dpc-5749	148	15	,	,	PUNCT
dpc-5749	148	16	azathioprine	azathioprine	PROPN
dpc-5749	148	17	,	,	PUNCT
dpc-5749	148	18	mycophenolate	mycophenolate	PROPN
dpc-5749	148	19	mofetil	mofetil	PROPN
dpc-5749	148	20	,	,	PUNCT
dpc-5749	148	21	rituximab	rituximab	NOUN
dpc-5749	148	22	,	,	PUNCT
dpc-5749	148	23	intravenous	intravenous	ADJ
dpc-5749	148	24	immunoglobulin	immunoglobulin	NOUN
dpc-5749	148	25	(	(	PUNCT
dpc-5749	148	26	ivig	ivig	NOUN
dpc-5749	148	27	)	)	PUNCT
dpc-5749	149	1	[	[	X
dpc-5749	149	2	57,58	57,58	NUM
dpc-5749	149	3	]	]	PUNCT
dpc-5749	149	4	.	.	PUNCT
dpc-5749	150	1	the	the	DET
dpc-5749	150	2	latter	latter	ADJ
dpc-5749	150	3	two	two	NUM
dpc-5749	150	4	were	be	AUX
dpc-5749	150	5	recently	recently	ADV
dpc-5749	150	6	reported	report	VERB
dpc-5749	150	7	in	in	ADP
dpc-5749	150	8	anti	anti	ADJ
dpc-5749	150	9	-	-	ADJ
dpc-5749	150	10	laminin-332	laminin-332	ADJ
dpc-5749	150	11	mmp	mmp	PROPN
dpc-5749	150	12	[	[	X
dpc-5749	150	13	59,60,61	59,60,61	X
dpc-5749	150	14	]	]	PUNCT
dpc-5749	150	15	,	,	PUNCT
dpc-5749	150	16	while	while	SCONJ
dpc-5749	150	17	cyclophosphamide	cyclophosphamide	PROPN
dpc-5749	150	18	is	be	AUX
dpc-5749	150	19	associated	associate	VERB
dpc-5749	150	20	with	with	ADP
dpc-5749	150	21	bladder	bladder	NOUN
dpc-5749	150	22	malignancy	malignancy	NOUN
dpc-5749	150	23	[	[	X
dpc-5749	150	24	62	62	NUM
dpc-5749	150	25	]	]	PUNCT
dpc-5749	150	26	.	.	PUNCT
dpc-5749	151	1	the	the	DET
dpc-5749	151	2	use	use	NOUN
dpc-5749	151	3	of	of	ADP
dpc-5749	151	4	mycophenolate	mycophenolate	PROPN
dpc-5749	151	5	mofetil	mofetil	PROPN
dpc-5749	151	6	raises	raise	VERB
dpc-5749	151	7	concerns	concern	NOUN
dpc-5749	151	8	[	[	X
dpc-5749	151	9	52	52	NUM
dpc-5749	151	10	]	]	PUNCT
dpc-5749	151	11	but	but	CCONJ
dpc-5749	151	12	may	may	AUX
dpc-5749	151	13	also	also	ADV
dpc-5749	151	14	be	be	AUX
dpc-5749	151	15	associated	associate	VERB
dpc-5749	151	16	with	with	ADP
dpc-5749	151	17	lower	low	ADJ
dpc-5749	151	18	cancer	cancer	NOUN
dpc-5749	151	19	risks	risk	NOUN
dpc-5749	151	20	[	[	X
dpc-5749	151	21	52,63	52,63	X
dpc-5749	151	22	]	]	PUNCT
dpc-5749	151	23	.	.	PUNCT
dpc-5749	152	1	curiously	curiously	ADV
dpc-5749	152	2	,	,	PUNCT
dpc-5749	152	3	in	in	ADP
dpc-5749	152	4	inflammatory	inflammatory	ADJ
dpc-5749	152	5	bowel	bowel	NOUN
dpc-5749	152	6	disease	disease	NOUN
dpc-5749	152	7	,	,	PUNCT
dpc-5749	152	8	thiopurines	thiopurine	NOUN
dpc-5749	152	9	(	(	PUNCT
dpc-5749	152	10	azathioprine	azathioprine	NOUN
dpc-5749	152	11	)	)	PUNCT
dpc-5749	152	12	should	should	AUX
dpc-5749	152	13	be	be	AUX
dpc-5749	152	14	withdrawn	withdraw	VERB
dpc-5749	152	15	in	in	ADP
dpc-5749	152	16	patients	patient	NOUN
dpc-5749	152	17	with	with	ADP
dpc-5749	152	18	active	active	ADJ
dpc-5749	152	19	cancer	cancer	NOUN
dpc-5749	152	20	,	,	PUNCT
dpc-5749	152	21	and	and	CCONJ
dpc-5749	152	22	the	the	DET
dpc-5749	152	23	combination	combination	NOUN
dpc-5749	152	24	of	of	ADP
dpc-5749	152	25	thiopurines	thiopurine	NOUN
dpc-5749	152	26	and	and	CCONJ
dpc-5749	152	27	tnf	tnf	PROPN
dpc-5749	152	28	-	-	PUNCT
dpc-5749	152	29	alpha	alpha	NOUN
dpc-5749	152	30	inhibitors	inhibitor	NOUN
dpc-5749	152	31	is	be	AUX
dpc-5749	152	32	linked	link	VERB
dpc-5749	152	33	to	to	ADP
dpc-5749	152	34	a	a	DET
dpc-5749	152	35	higher	high	ADJ
dpc-5749	152	36	lymphoma	lymphoma	NOUN
dpc-5749	152	37	risk	risk	NOUN
dpc-5749	152	38	,	,	PUNCT
dpc-5749	152	39	which	which	PRON
dpc-5749	152	40	should	should	AUX
dpc-5749	152	41	be	be	AUX
dpc-5749	152	42	considered	consider	VERB
dpc-5749	152	43	before	before	ADP
dpc-5749	152	44	the	the	DET
dpc-5749	152	45	therapy	therapy	NOUN
dpc-5749	152	46	selection	selection	NOUN
dpc-5749	153	1	[	[	X
dpc-5749	153	2	64	64	NUM
dpc-5749	153	3	]	]	PUNCT
dpc-5749	153	4	.	.	PUNCT
dpc-5749	154	1	the	the	DET
dpc-5749	154	2	pharmacological	pharmacological	ADJ
dpc-5749	154	3	agents	agent	NOUN
dpc-5749	154	4	discussed	discuss	VERB
dpc-5749	154	5	in	in	ADP
dpc-5749	154	6	this	this	DET
dpc-5749	154	7	review	review	NOUN
dpc-5749	154	8	may	may	AUX
dpc-5749	154	9	also	also	ADV
dpc-5749	154	10	be	be	AUX
dpc-5749	154	11	of	of	ADP
dpc-5749	154	12	interest	interest	NOUN
dpc-5749	154	13	in	in	ADP
dpc-5749	154	14	the	the	DET
dpc-5749	154	15	management	management	NOUN
dpc-5749	154	16	of	of	ADP
dpc-5749	154	17	mmp	mmp	PROPN
dpc-5749	154	18	and	and	CCONJ
dpc-5749	154	19	malignancy	malignancy	NOUN
dpc-5749	154	20	.	.	PUNCT
dpc-5749	155	1	the	the	DET
dpc-5749	155	2	antitumor	antitumor	PROPN
dpc-5749	155	3	effect	effect	NOUN
dpc-5749	155	4	of	of	ADP
dpc-5749	155	5	leflunomide	leflunomide	ADJ
dpc-5749	155	6	has	have	AUX
dpc-5749	155	7	been	be	AUX
dpc-5749	155	8	confirmed	confirm	VERB
dpc-5749	155	9	in	in	ADP
dpc-5749	155	10	myeloma	myeloma	PROPN
dpc-5749	155	11	(	(	PUNCT
dpc-5749	155	12	nct02509052	nct02509052	ADJ
dpc-5749	155	13	)	)	PUNCT
dpc-5749	155	14	and	and	CCONJ
dpc-5749	155	15	will	will	AUX
dpc-5749	155	16	be	be	AUX
dpc-5749	155	17	examined	examine	VERB
dpc-5749	155	18	in	in	ADP
dpc-5749	155	19	other	other	ADJ
dpc-5749	155	20	clinical	clinical	ADJ
dpc-5749	155	21	trials	trial	NOUN
dpc-5749	155	22	(	(	PUNCT
dpc-5749	155	23	nct06540937	nct06540937	NOUN
dpc-5749	155	24	,	,	PUNCT
dpc-5749	155	25	nct04997993	nct04997993	NOUN
dpc-5749	155	26	,	,	PUNCT
dpc-5749	155	27	nct03709446	nct03709446	NOUN
dpc-5749	155	28	,	,	PUNCT
dpc-5749	155	29	nct04508790	nct04508790	NOUN
dpc-5749	155	30	,	,	PUNCT
dpc-5749	155	31	nct06229340	nct06229340	NOUN
dpc-5749	155	32	,	,	PUNCT
dpc-5749	155	33	nct06454383	nct06454383	ADV
dpc-5749	155	34	)	)	PUNCT
dpc-5749	155	35	;	;	PUNCT
dpc-5749	155	36	the	the	DET
dpc-5749	155	37	evaluation	evaluation	NOUN
dpc-5749	155	38	of	of	ADP
dpc-5749	155	39	the	the	DET
dpc-5749	155	40	effect	effect	NOUN
dpc-5749	155	41	of	of	ADP
dpc-5749	155	42	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-5749	155	43	in	in	ADP
dpc-5749	155	44	melanoma	melanoma	NOUN
dpc-5749	155	45	and	and	CCONJ
dpc-5749	155	46	various	various	ADJ
dpc-5749	155	47	cancer	cancer	NOUN
dpc-5749	155	48	types	type	NOUN
dpc-5749	155	49	in	in	ADP
dpc-5749	155	50	different	different	ADJ
dpc-5749	155	51	regimes	regime	NOUN
dpc-5749	155	52	is	be	AUX
dpc-5749	155	53	planned	plan	VERB
dpc-5749	155	54	for	for	ADP
dpc-5749	155	55	clinical	clinical	ADJ
dpc-5749	155	56	trials	trial	NOUN
dpc-5749	155	57	(	(	PUNCT
dpc-5749	155	58	nct04464759	nct04464759	X
dpc-5749	155	59	,	,	PUNCT
dpc-5749	155	60	nct05647330	nct05647330	NOUN
dpc-5749	155	61	,	,	PUNCT
dpc-5749	155	62	nct0632	nct0632	NOUN
dpc-5749	155	63	8387	8387	NUM
dpc-5749	155	64	,	,	PUNCT
dpc-5749	155	65	nct07061717	nct07061717	ADJ
dpc-5749	155	66	,	,	PUNCT
dpc-5749	155	67	nct06949982	nct06949982	NOUN
dpc-5749	155	68	,	,	PUNCT
dpc-5749	155	69	nct05518110	nct05518110	ADJ
dpc-5749	155	70	,	,	PUNCT
dpc-5749	155	71	nct06229340	nct06229340	ADJ
dpc-5749	155	72	,	,	PUNCT
dpc-5749	155	73	nct06408298	nct06408298	NOUN
dpc-5749	155	74	,	,	PUNCT
dpc-5749	155	75	nct05733000	nct05733000	NOUN
dpc-5749	155	76	,	,	PUNCT
dpc-5749	155	77	nct0584	nct0584	PROPN
dpc-5749	155	78	3188	3188	NUM
dpc-5749	155	79	,	,	PUNCT
dpc-5749	155	80	nct04841148	nct04841148	NOUN
dpc-5749	155	81	)	)	PUNCT
dpc-5749	155	82	.	.	PUNCT
dpc-5749	156	1	the	the	DET
dpc-5749	156	2	expression	expression	NOUN
dpc-5749	156	3	of	of	ADP
dpc-5749	156	4	cd25	cd25	PROPN
dpc-5749	156	5	is	be	AUX
dpc-5749	156	6	observed	observe	VERB
dpc-5749	156	7	in	in	ADP
dpc-5749	156	8	activated	activate	VERB
dpc-5749	156	9	t	t	NOUN
dpc-5749	156	10	cells	cell	NOUN
dpc-5749	156	11	and	and	CCONJ
dpc-5749	156	12	some	some	DET
dpc-5749	156	13	malignancies	malignancy	NOUN
dpc-5749	156	14	;	;	PUNCT
dpc-5749	156	15	regulatory	regulatory	ADJ
dpc-5749	156	16	t	t	NOUN
dpc-5749	156	17	lymphocytes	lymphocyte	NOUN
dpc-5749	156	18	(	(	PUNCT
dpc-5749	156	19	tregs	treg	NOUN
dpc-5749	156	20	)	)	PUNCT
dpc-5749	156	21	constitute	constitute	VERB
dpc-5749	156	22	the	the	DET
dpc-5749	156	23	tumor	tumor	NOUN
dpc-5749	156	24	microenvironment	microenvironment	NOUN
dpc-5749	156	25	,	,	PUNCT
dpc-5749	156	26	contributing	contribute	VERB
dpc-5749	156	27	to	to	ADP
dpc-5749	156	28	drug	drug	NOUN
dpc-5749	156	29	resistance	resistance	NOUN
dpc-5749	156	30	via	via	ADP
dpc-5749	156	31	the	the	DET
dpc-5749	156	32	suppression	suppression	NOUN
dpc-5749	156	33	of	of	ADP
dpc-5749	156	34	immune	immune	ADJ
dpc-5749	156	35	surveillance	surveillance	NOUN
dpc-5749	157	1	[	[	X
dpc-5749	157	2	65	65	NUM
dpc-5749	157	3	]	]	PUNCT
dpc-5749	157	4	.	.	PUNCT
dpc-5749	158	1	before	before	ADP
dpc-5749	158	2	its	its	PRON
dpc-5749	158	3	global	global	ADJ
dpc-5749	158	4	withdrawal	withdrawal	NOUN
dpc-5749	158	5	,	,	PUNCT
dpc-5749	158	6	daclizumab	daclizumab	NOUN
dpc-5749	158	7	was	be	AUX
dpc-5749	158	8	reported	report	VERB
dpc-5749	158	9	in	in	ADP
dpc-5749	158	10	combination	combination	NOUN
dpc-5749	158	11	with	with	ADP
dpc-5749	158	12	chemotherapy	chemotherapy	NOUN
dpc-5749	158	13	and	and	CCONJ
dpc-5749	158	14	as	as	ADP
dpc-5749	158	15	an	an	DET
dpc-5749	158	16	option	option	NOUN
dpc-5749	158	17	to	to	PART
dpc-5749	158	18	overcome	overcome	VERB
dpc-5749	158	19	the	the	DET
dpc-5749	158	20	tregs	treg	NOUN
dpc-5749	158	21	-	-	PUNCT
dpc-5749	158	22	mediated	mediate	VERB
dpc-5749	158	23	drug	drug	NOUN
dpc-5749	158	24	resistance	resistance	NOUN
dpc-5749	158	25	[	[	X
dpc-5749	158	26	66,67	66,67	ADP
dpc-5749	158	27	]	]	PUNCT
dpc-5749	158	28	.	.	PUNCT
dpc-5749	159	1	developing	develop	VERB
dpc-5749	159	2	pharmacological	pharmacological	ADJ
dpc-5749	159	3	agents	agent	NOUN
dpc-5749	159	4	which	which	PRON
dpc-5749	159	5	target	target	VERB
dpc-5749	159	6	cd25	cd25	PROPN
dpc-5749	159	7	may	may	AUX
dpc-5749	159	8	be	be	AUX
dpc-5749	159	9	of	of	ADP
dpc-5749	159	10	use	use	NOUN
dpc-5749	159	11	for	for	ADP
dpc-5749	159	12	the	the	DET
dpc-5749	159	13	management	management	NOUN
dpc-5749	159	14	of	of	ADP
dpc-5749	159	15	both	both	DET
dpc-5749	159	16	malignancy	malignancy	NOUN
dpc-5749	159	17	and	and	CCONJ
dpc-5749	159	18	mmp	mmp	PROPN
dpc-5749	159	19	.	.	PUNCT
dpc-5749	160	1	given	give	VERB
dpc-5749	160	2	the	the	DET
dpc-5749	160	3	link	link	NOUN
dpc-5749	160	4	between	between	ADP
dpc-5749	160	5	the	the	DET
dpc-5749	160	6	pi3k	pi3k	PROPN
dpc-5749	160	7	/	/	SYM
dpc-5749	160	8	mtor	mtor	NOUN
dpc-5749	160	9	signaling	signal	VERB
dpc-5749	160	10	pathway	pathway	NOUN
dpc-5749	160	11	and	and	CCONJ
dpc-5749	160	12	genetic	genetic	ADJ
dpc-5749	160	13	mutations	mutation	NOUN
dpc-5749	160	14	[	[	X
dpc-5749	160	15	51,68	51,68	NUM
dpc-5749	160	16	]	]	PUNCT
dpc-5749	160	17	,	,	PUNCT
dpc-5749	160	18	sirolimus	sirolimus	PROPN
dpc-5749	160	19	is	be	AUX
dpc-5749	160	20	a	a	DET
dpc-5749	160	21	curious	curious	ADJ
dpc-5749	160	22	option	option	NOUN
dpc-5749	160	23	.	.	PUNCT
dpc-5749	161	1	colchicine	colchicine	PROPN
dpc-5749	161	2	exerts	exert	VERB
dpc-5749	161	3	anti	anti	ADJ
dpc-5749	161	4	-	-	ADJ
dpc-5749	161	5	mitotic	mitotic	ADJ
dpc-5749	161	6	properties	property	NOUN
dpc-5749	161	7	[	[	X
dpc-5749	161	8	69	69	NUM
dpc-5749	161	9	]	]	PUNCT
dpc-5749	161	10	and	and	CCONJ
dpc-5749	161	11	has	have	AUX
dpc-5749	161	12	been	be	AUX
dpc-5749	161	13	associated	associate	VERB
dpc-5749	161	14	with	with	ADP
dpc-5749	161	15	a	a	DET
dpc-5749	161	16	lower	low	ADJ
dpc-5749	161	17	risk	risk	NOUN
dpc-5749	161	18	of	of	ADP
dpc-5749	161	19	colorectal	colorectal	ADJ
dpc-5749	161	20	cancer	cancer	NOUN
dpc-5749	161	21	in	in	ADP
dpc-5749	161	22	immune	immune	NOUN
dpc-5749	161	23	-	-	PUNCT
dpc-5749	161	24	mediated	mediate	VERB
dpc-5749	161	25	inflammatory	inflammatory	ADJ
dpc-5749	161	26	diseases	disease	NOUN
dpc-5749	161	27	[	[	X
dpc-5749	161	28	70	70	NUM
dpc-5749	161	29	]	]	PUNCT
dpc-5749	161	30	.	.	PUNCT
dpc-5749	162	1	dupilumab	dupilumab	NOUN
dpc-5749	162	2	is	be	AUX
dpc-5749	162	3	generally	generally	ADV
dpc-5749	162	4	considered	consider	VERB
dpc-5749	162	5	safe	safe	ADJ
dpc-5749	162	6	,	,	PUNCT
dpc-5749	162	7	but	but	CCONJ
dpc-5749	162	8	caution	caution	NOUN
dpc-5749	162	9	is	be	AUX
dpc-5749	162	10	required	require	VERB
dpc-5749	162	11	in	in	ADP
dpc-5749	162	12	patients	patient	NOUN
dpc-5749	162	13	with	with	ADP
dpc-5749	162	14	cutaneous	cutaneous	ADJ
dpc-5749	162	15	t	t	PROPN
dpc-5749	162	16	-	-	PUNCT
dpc-5749	162	17	cell	cell	NOUN
dpc-5749	162	18	lymphoma	lymphoma	NOUN
dpc-5749	162	19	[	[	X
dpc-5749	162	20	71,72	71,72	NOUN
dpc-5749	162	21	]	]	X
dpc-5749	162	22	.	.	PUNCT
dpc-5749	163	1	however	however	ADV
dpc-5749	163	2	,	,	PUNCT
dpc-5749	163	3	the	the	DET
dpc-5749	163	4	initially	initially	ADV
dpc-5749	163	5	incorrect	incorrect	ADJ
dpc-5749	163	6	diagnosis	diagnosis	NOUN
dpc-5749	163	7	of	of	ADP
dpc-5749	163	8	atopic	atopic	NOUN
dpc-5749	163	9	dermatitis	dermatitis	NOUN
dpc-5749	163	10	was	be	AUX
dpc-5749	163	11	suggested	suggest	VERB
dpc-5749	163	12	as	as	ADP
dpc-5749	163	13	an	an	DET
dpc-5749	163	14	explanation	explanation	NOUN
dpc-5749	163	15	for	for	ADP
dpc-5749	163	16	the	the	DET
dpc-5749	163	17	poor	poor	ADJ
dpc-5749	163	18	prognosis	prognosis	NOUN
dpc-5749	163	19	in	in	ADP
dpc-5749	163	20	such	such	ADJ
dpc-5749	163	21	cases	case	NOUN
dpc-5749	163	22	[	[	X
dpc-5749	163	23	52	52	NUM
dpc-5749	163	24	]	]	PUNCT
dpc-5749	163	25	.	.	PUNCT
dpc-5749	164	1	patient	patient	ADJ
dpc-5749	164	2	monitoring	monitoring	NOUN
dpc-5749	164	3	is	be	AUX
dpc-5749	164	4	recommended	recommend	VERB
dpc-5749	164	5	for	for	ADP
dpc-5749	164	6	cenegermin	cenegermin	NOUN
dpc-5749	164	7	,	,	PUNCT
dpc-5749	164	8	given	give	VERB
dpc-5749	164	9	its	its	PRON
dpc-5749	164	10	growth	growth	NOUN
dpc-5749	164	11	factor	factor	NOUN
dpc-5749	164	12	properties	property	NOUN
dpc-5749	164	13	[	[	X
dpc-5749	164	14	73	73	NUM
dpc-5749	164	15	]	]	PUNCT
dpc-5749	164	16	.	.	PUNCT
dpc-5749	165	1	the	the	DET
dpc-5749	165	2	anti	anti	ADJ
dpc-5749	165	3	-	-	ADJ
dpc-5749	165	4	angiogenic	angiogenic	ADJ
dpc-5749	165	5	agent	agent	NOUN
dpc-5749	165	6	bevacizumab	bevacizumab	NOUN
dpc-5749	165	7	is	be	AUX
dpc-5749	165	8	used	use	VERB
dpc-5749	165	9	in	in	ADP
dpc-5749	165	10	combination	combination	NOUN
dpc-5749	165	11	with	with	ADP
dpc-5749	165	12	immune	immune	ADJ
dpc-5749	165	13	and	and	CCONJ
dpc-5749	165	14	chemotherapy	chemotherapy	NOUN
dpc-5749	165	15	,	,	PUNCT
dpc-5749	165	16	but	but	CCONJ
dpc-5749	165	17	patient	patient	ADJ
dpc-5749	165	18	selection	selection	NOUN
dpc-5749	165	19	criteria	criterion	NOUN
dpc-5749	165	20	should	should	AUX
dpc-5749	165	21	be	be	AUX
dpc-5749	165	22	developed	develop	VERB
dpc-5749	165	23	due	due	ADP
dpc-5749	165	24	to	to	ADP
dpc-5749	165	25	the	the	DET
dpc-5749	165	26	risk	risk	NOUN
dpc-5749	165	27	of	of	ADP
dpc-5749	165	28	hemorrhage	hemorrhage	NOUN
dpc-5749	165	29	and	and	CCONJ
dpc-5749	165	30	to	to	ADP
dpc-5749	165	31	high	high	ADJ
dpc-5749	165	32	mortality	mortality	NOUN
dpc-5749	165	33	rates	rate	NOUN
dpc-5749	165	34	[	[	X
dpc-5749	165	35	74	74	NUM
dpc-5749	165	36	]	]	PUNCT
dpc-5749	165	37	.	.	PUNCT
dpc-5749	166	1	the	the	DET
dpc-5749	166	2	presence	presence	NOUN
dpc-5749	166	3	of	of	ADP
dpc-5749	166	4	ige	ige	PROPN
dpc-5749	166	5	antibodies	antibodie	VERB
dpc-5749	166	6	to	to	ADP
dpc-5749	166	7	bm	bm	PROPN
dpc-5749	166	8	proteins	protein	NOUN
dpc-5749	166	9	(	(	PUNCT
dpc-5749	166	10	e.g.	e.g.	ADV
dpc-5749	166	11	,	,	PUNCT
dpc-5749	166	12	laminin-332	laminin-332	NOUN
dpc-5749	166	13	[	[	X
dpc-5749	166	14	17	17	NUM
dpc-5749	166	15	]	]	PUNCT
dpc-5749	166	16	)	)	PUNCT
dpc-5749	166	17	were	be	AUX
dpc-5749	166	18	earlier	early	ADV
dpc-5749	166	19	reported	report	VERB
dpc-5749	166	20	in	in	ADP
dpc-5749	166	21	mmp	mmp	PROPN
dpc-5749	166	22	,	,	PUNCT
dpc-5749	166	23	suggesting	suggest	VERB
dpc-5749	166	24	the	the	DET
dpc-5749	166	25	6	6	NUM
dpc-5749	166	26	review	review	NOUN
dpc-5749	166	27	|	|	ADV
dpc-5749	166	28	dermatol	dermatol	ADJ
dpc-5749	166	29	pract	pract	NOUN
dpc-5749	166	30	concept	concept	NOUN
dpc-5749	166	31	.	.	PUNCT
dpc-5749	167	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	167	2	intercellular	intercellular	ADJ
dpc-5749	167	3	adhesion	adhesion	NOUN
dpc-5749	167	4	molecule-1	molecule-1	PROPN
dpc-5749	167	5	(	(	PUNCT
dpc-5749	167	6	icam-1	icam-1	NUM
dpc-5749	167	7	)	)	PUNCT
dpc-5749	167	8	;	;	PUNCT
dpc-5749	167	9	interleukin-2	interleukin-2	NUM
dpc-5749	167	10	receptor	receptor	NOUN
dpc-5749	167	11	(	(	PUNCT
dpc-5749	167	12	il-2r	il-2r	NOUN
dpc-5749	167	13	)	)	PUNCT
dpc-5749	167	14	;	;	PUNCT
dpc-5749	167	15	il-4	il-4	VERB
dpc-5749	167	16	receptor	receptor	NOUN
dpc-5749	167	17	alpha	alpha	NOUN
dpc-5749	167	18	chain	chain	NOUN
dpc-5749	167	19	(	(	PUNCT
dpc-5749	167	20	il-4rα	il-4rα	NOUN
dpc-5749	167	21	)	)	PUNCT
dpc-5749	167	22	;	;	PUNCT
dpc-5749	167	23	adrenocorticotropic	adrenocorticotropic	NOUN
dpc-5749	167	24	hormone	hormone	NOUN
dpc-5749	167	25	(	(	PUNCT
dpc-5749	167	26	acth	acth	NOUN
dpc-5749	167	27	)	)	PUNCT
dpc-5749	167	28	;	;	PUNCT
dpc-5749	167	29	tropomyosin	tropomyosin	PROPN
dpc-5749	167	30	receptor	receptor	PROPN
dpc-5749	167	31	kinase	kinase	PROPN
dpc-5749	167	32	a	a	DET
dpc-5749	167	33	(	(	PUNCT
dpc-5749	167	34	trka	trka	NOUN
dpc-5749	167	35	)	)	PUNCT
dpc-5749	167	36	;	;	PUNCT
dpc-5749	167	37	nerve	nerve	NOUN
dpc-5749	167	38	growth	growth	NOUN
dpc-5749	167	39	factor	factor	NOUN
dpc-5749	167	40	receptor	receptor	NOUN
dpc-5749	167	41	(	(	PUNCT
dpc-5749	167	42	p75ntr	p75ntr	PROPN
dpc-5749	167	43	)	)	PUNCT
dpc-5749	167	44	;	;	PUNCT
dpc-5749	167	45	mucous	mucous	ADJ
dpc-5749	167	46	membrane	membrane	NOUN
dpc-5749	167	47	pemphigoid	pemphigoid	NOUN
dpc-5749	167	48	(	(	PUNCT
dpc-5749	167	49	mmp	mmp	PROPN
dpc-5749	167	50	)	)	PUNCT
dpc-5749	167	51	;	;	PUNCT
dpc-5749	167	52	ocular	ocular	ADJ
dpc-5749	167	53	mucous	mucous	ADJ
dpc-5749	167	54	membrane	membrane	NOUN
dpc-5749	167	55	pemphigoid	pemphigoid	NOUN
dpc-5749	167	56	(	(	PUNCT
dpc-5749	167	57	ocmmp	ocmmp	NOUN
dpc-5749	167	58	)	)	PUNCT
dpc-5749	167	59	;	;	PUNCT
dpc-5749	167	60	oral	oral	ADJ
dpc-5749	167	61	mucous	mucous	ADJ
dpc-5749	167	62	membrane	membrane	NOUN
dpc-5749	167	63	pemphigoid	pemphigoid	NOUN
dpc-5749	167	64	(	(	PUNCT
dpc-5749	167	65	ormmp	ormmp	NOUN
dpc-5749	167	66	)	)	PUNCT
dpc-5749	167	67	;	;	PUNCT
dpc-5749	167	68	brunsting	brunste	VERB
dpc-5749	167	69	-	-	PUNCT
dpc-5749	167	70	perry	perry	NOUN
dpc-5749	167	71	pemphigoid	pemphigoid	PROPN
dpc-5749	167	72	(	(	PUNCT
dpc-5749	167	73	bpp	bpp	NOUN
dpc-5749	167	74	)	)	PUNCT
dpc-5749	167	75	.	.	PUNCT
dpc-5749	168	1	references	reference	NOUN
dpc-5749	168	2	1	1	NUM
dpc-5749	168	3	.	.	PUNCT
dpc-5749	168	4	rashid	rashid	PROPN
dpc-5749	168	5	h	h	PROPN
dpc-5749	168	6	,	,	PUNCT
dpc-5749	168	7	lamberts	lamberts	PROPN
dpc-5749	168	8	a	a	X
dpc-5749	168	9	,	,	PUNCT
dpc-5749	168	10	borradori	borradori	PROPN
dpc-5749	168	11	l	l	NOUN
dpc-5749	168	12	,	,	PUNCT
dpc-5749	168	13	et	et	PROPN
dpc-5749	168	14	al	al	PROPN
dpc-5749	168	15	.	.	PUNCT
dpc-5749	169	1	european	european	PROPN
dpc-5749	169	2	guidelines	guideline	NOUN
dpc-5749	169	3	(	(	PUNCT
dpc-5749	169	4	s3	s3	PROPN
dpc-5749	169	5	)	)	PUNCT
dpc-5749	169	6	on	on	ADP
dpc-5749	169	7	diagnosis	diagnosis	NOUN
dpc-5749	169	8	and	and	CCONJ
dpc-5749	169	9	management	management	NOUN
dpc-5749	169	10	of	of	ADP
dpc-5749	169	11	mucous	mucous	ADJ
dpc-5749	169	12	membrane	membrane	NOUN
dpc-5749	169	13	pemphigoid	pemphigoid	NOUN
dpc-5749	169	14	,	,	PUNCT
dpc-5749	169	15	initiated	initiate	VERB
dpc-5749	169	16	by	by	ADP
dpc-5749	169	17	the	the	DET
dpc-5749	169	18	european	european	PROPN
dpc-5749	169	19	academy	academy	PROPN
dpc-5749	169	20	of	of	ADP
dpc-5749	169	21	dermatology	dermatology	NOUN
dpc-5749	169	22	and	and	CCONJ
dpc-5749	169	23	venereology	venereology	NOUN
dpc-5749	169	24	–	–	PUNCT
dpc-5749	169	25	part	part	NOUN
dpc-5749	169	26	i.	i.	PROPN
dpc-5749	169	27	j	j	PROPN
dpc-5749	169	28	eur	eur	PROPN
dpc-5749	169	29	acad	acad	PROPN
dpc-5749	169	30	dermatol	dermatol	NOUN
dpc-5749	169	31	venereol	venereol	NOUN
dpc-5749	169	32	.	.	PUNCT
dpc-5749	170	1	2021;35(9):1750	2021;35(9):1750	NUM
dpc-5749	170	2	-	-	SYM
dpc-5749	170	3	1764	1764	NUM
dpc-5749	170	4	.	.	PUNCT
dpc-5749	171	1	doi	doi	NOUN
dpc-5749	171	2	:	:	PUNCT
dpc-5749	171	3	10.1111	10.1111	NUM
dpc-5749	171	4	/	/	SYM
dpc-5749	171	5	jdv.17397	jdv.17397	NOUN
dpc-5749	171	6	.	.	PUNCT
dpc-5749	172	1	pmid	pmid	NOUN
dpc-5749	172	2	:	:	PUNCT
dpc-5749	172	3	34245180	34245180	NUM
dpc-5749	172	4	.	.	PUNCT
dpc-5749	173	1	2	2	X
dpc-5749	173	2	.	.	X
dpc-5749	173	3	di	di	PROPN
dpc-5749	173	4	zazzo	zazzo	PROPN
dpc-5749	173	5	a	a	PROPN
dpc-5749	173	6	,	,	PUNCT
dpc-5749	173	7	cutrupi	cutrupi	NOUN
dpc-5749	173	8	f	f	X
dpc-5749	173	9	,	,	PUNCT
dpc-5749	173	10	de	de	X
dpc-5749	173	11	antoniis	antoniis	NOUN
dpc-5749	173	12	mg	mg	PROPN
dpc-5749	173	13	,	,	PUNCT
dpc-5749	173	14	et	et	PROPN
dpc-5749	173	15	al	al	PROPN
dpc-5749	173	16	.	.	PUNCT
dpc-5749	173	17	tissue	tissue	NOUN
dpc-5749	173	18	remodeling	remodeling	NOUN
dpc-5749	173	19	in	in	ADP
dpc-5749	173	20	ocular	ocular	ADJ
dpc-5749	173	21	mucous	mucous	ADJ
dpc-5749	173	22	membrane	membrane	NOUN
dpc-5749	173	23	pemphigoid	pemphigoid	NOUN
dpc-5749	173	24	.	.	PUNCT
dpc-5749	174	1	invest	invest	VERB
dpc-5749	174	2	ophthalmol	ophthalmol	PROPN
dpc-5749	174	3	vis	vis	X
dpc-5749	174	4	sci	sci	PROPN
dpc-5749	174	5	.	.	PUNCT
dpc-5749	175	1	2023;64(15):17	2023;64(15):17	NUM
dpc-5749	175	2	.	.	PUNCT
dpc-5749	176	1	doi	doi	NOUN
dpc-5749	176	2	:	:	PUNCT
dpc-5749	176	3	10.1167	10.1167	NUM
dpc-5749	176	4	/	/	SYM
dpc-5749	176	5	iovs.64.15.17	iovs.64.15.17	PROPN
dpc-5749	176	6	.	.	PUNCT
dpc-5749	177	1	pmid	pmid	NOUN
dpc-5749	177	2	:	:	PUNCT
dpc-5749	177	3	38095906	38095906	NUM
dpc-5749	177	4	.	.	PUNCT
dpc-5749	178	1	3	3	X
dpc-5749	178	2	.	.	X
dpc-5749	178	3	chan	chan	PROPN
dpc-5749	178	4	ls	ls	PROPN
dpc-5749	178	5	,	,	PUNCT
dpc-5749	178	6	ahmed	ahmed	PROPN
dpc-5749	178	7	ar	ar	PROPN
dpc-5749	178	8	,	,	PUNCT
dpc-5749	178	9	anhalt	anhalt	PROPN
dpc-5749	178	10	gj	gj	PROPN
dpc-5749	178	11	,	,	PUNCT
dpc-5749	178	12	et	et	PROPN
dpc-5749	178	13	al	al	PROPN
dpc-5749	178	14	.	.	PUNCT
dpc-5749	179	1	the	the	DET
dpc-5749	179	2	first	first	ADJ
dpc-5749	179	3	international	international	ADJ
dpc-5749	179	4	consensus	consensus	NOUN
dpc-5749	179	5	on	on	ADP
dpc-5749	179	6	mucous	mucous	ADJ
dpc-5749	179	7	membrane	membrane	NOUN
dpc-5749	179	8	pemphigoid	pemphigoid	NOUN
dpc-5749	179	9	:	:	PUNCT
dpc-5749	179	10	definition	definition	NOUN
dpc-5749	179	11	,	,	PUNCT
dpc-5749	179	12	diagnostic	diagnostic	ADJ
dpc-5749	179	13	criteria	criterion	NOUN
dpc-5749	179	14	,	,	PUNCT
dpc-5749	179	15	pathogenic	pathogenic	ADJ
dpc-5749	179	16	factors	factor	NOUN
dpc-5749	179	17	,	,	PUNCT
dpc-5749	179	18	medical	medical	ADJ
dpc-5749	179	19	treatment	treatment	NOUN
dpc-5749	179	20	,	,	PUNCT
dpc-5749	179	21	and	and	CCONJ
dpc-5749	179	22	prognostic	prognostic	ADJ
dpc-5749	179	23	indicators	indicator	NOUN
dpc-5749	179	24	.	.	PUNCT
dpc-5749	180	1	arch	arch	ADJ
dpc-5749	180	2	dermatol	dermatol	NOUN
dpc-5749	180	3	.	.	PUNCT
dpc-5749	181	1	2002;138(3):370	2002;138(3):370	NUM
dpc-5749	181	2	-	-	SYM
dpc-5749	181	3	9	9	NUM
dpc-5749	181	4	.	.	PUNCT
dpc-5749	181	5	doi	doi	NOUN
dpc-5749	181	6	:	:	PUNCT
dpc-5749	181	7	10.1001	10.1001	NUM
dpc-5749	181	8	/archderm.138.3.370	/archderm.138.3.370	NOUN
dpc-5749	181	9	.	.	PUNCT
dpc-5749	182	1	pmid	pmid	NOUN
dpc-5749	182	2	:	:	PUNCT
dpc-5749	182	3	11902988	11902988	NUM
dpc-5749	182	4	.	.	PUNCT
dpc-5749	183	1	4	4	X
dpc-5749	183	2	.	.	X
dpc-5749	183	3	santi	santi	PROPN
dpc-5749	183	4	cg	cg	PROPN
dpc-5749	183	5	,	,	PUNCT
dpc-5749	183	6	gripp	gripp	PROPN
dpc-5749	183	7	ac	ac	PROPN
dpc-5749	183	8	,	,	PUNCT
dpc-5749	183	9	roselino	roselino	PROPN
dpc-5749	183	10	am	be	AUX
dpc-5749	183	11	,	,	PUNCT
dpc-5749	184	1	et	et	PROPN
dpc-5749	184	2	al	al	PROPN
dpc-5749	184	3	.	.	PUNCT
dpc-5749	184	4	consensus	consensus	NOUN
dpc-5749	184	5	on	on	ADP
dpc-5749	184	6	the	the	DET
dpc-5749	184	7	treatment	treatment	NOUN
dpc-5749	184	8	of	of	ADP
dpc-5749	184	9	autoimmune	autoimmune	ADJ
dpc-5749	184	10	bullous	bullous	ADJ
dpc-5749	184	11	dermatoses	dermatosis	NOUN
dpc-5749	184	12	:	:	PUNCT
dpc-5749	184	13	bullous	bullous	ADJ
dpc-5749	184	14	pemphigoid	pemphigoid	ADJ
dpc-5749	184	15	,	,	PUNCT
dpc-5749	184	16	mucous	mucous	ADJ
dpc-5749	184	17	membrane	membrane	NOUN
dpc-5749	184	18	pemphigoid	pemphigoid	NOUN
dpc-5749	184	19	and	and	CCONJ
dpc-5749	184	20	epidermolysis	epidermolysis	NOUN
dpc-5749	184	21	bullosa	bullosa	NOUN
dpc-5749	184	22	acquisita	acquisita	PROPN
dpc-5749	184	23	–	–	PUNCT
dpc-5749	184	24	brazilian	brazilian	ADJ
dpc-5749	184	25	society	society	NOUN
dpc-5749	184	26	of	of	ADP
dpc-5749	184	27	dermatology	dermatology	NOUN
dpc-5749	184	28	.	.	PUNCT
dpc-5749	185	1	an	an	DET
dpc-5749	185	2	bras	bras	NOUN
dpc-5749	185	3	dermatol	dermatol	NOUN
dpc-5749	185	4	.	.	PUNCT
dpc-5749	186	1	2019;94(2	2019;94(2	NUM
dpc-5749	186	2	suppl	suppl	ADJ
dpc-5749	186	3	1):33	1):33	NUM
dpc-5749	186	4	-	-	SYM
dpc-5749	186	5	47	47	NUM
dpc-5749	186	6	.	.	PUNCT
dpc-5749	187	1	doi	doi	NOUN
dpc-5749	187	2	:	:	PUNCT
dpc-5749	187	3	10.1590	10.1590	NUM
dpc-5749	187	4	/	/	SYM
dpc-5749	187	5	abd18064841.2019940207	abd18064841.2019940207	NOUN
dpc-5749	187	6	.	.	PUNCT
dpc-5749	188	1	pmid	pmid	NOUN
dpc-5749	188	2	:	:	PUNCT
dpc-5749	188	3	31166405	31166405	NUM
dpc-5749	188	4	.	.	PUNCT
dpc-5749	189	1	5	5	NUM
dpc-5749	189	2	.	.	X
dpc-5749	189	3	ujiie	ujiie	ADJ
dpc-5749	189	4	h	h	PROPN
dpc-5749	189	5	,	,	PUNCT
dpc-5749	189	6	iwata	iwata	PROPN
dpc-5749	189	7	h	h	PROPN
dpc-5749	189	8	,	,	PUNCT
dpc-5749	189	9	yamagami	yamagami	PROPN
dpc-5749	189	10	j	j	PROPN
dpc-5749	189	11	,	,	PUNCT
dpc-5749	189	12	et	et	PROPN
dpc-5749	189	13	al	al	PROPN
dpc-5749	189	14	.	.	PUNCT
dpc-5749	190	1	japanese	japanese	ADJ
dpc-5749	190	2	guidelines	guideline	NOUN
dpc-5749	190	3	for	for	ADP
dpc-5749	190	4	the	the	DET
dpc-5749	190	5	management	management	NOUN
dpc-5749	190	6	of	of	ADP
dpc-5749	190	7	pemphigoid	pemphigoid	NOUN
dpc-5749	190	8	(	(	PUNCT
dpc-5749	190	9	including	include	VERB
dpc-5749	190	10	epidermolysis	epidermolysis	NOUN
dpc-5749	190	11	bullosa	bullosa	PROPN
dpc-5749	190	12	acquisita	acquisita	PROPN
dpc-5749	190	13	)	)	PUNCT
dpc-5749	190	14	.	.	PUNCT
dpc-5749	191	1	j	j	PROPN
dpc-5749	191	2	dermatol	dermatol	NOUN
dpc-5749	191	3	.	.	PUNCT
dpc-5749	192	1	2019;46(12):1102	2019;46(12):1102	NUM
dpc-5749	192	2	-	-	SYM
dpc-5749	192	3	1135	1135	NUM
dpc-5749	192	4	.	.	PUNCT
dpc-5749	193	1	doi	doi	NOUN
dpc-5749	193	2	:	:	PUNCT
dpc-5749	193	3	10.1111/1346	10.1111/1346	NUM
dpc-5749	193	4	-	-	SYM
dpc-5749	193	5	8138.15111	8138.15111	NUM
dpc-5749	193	6	.	.	PUNCT
dpc-5749	194	1	pmid	pmid	NOUN
dpc-5749	194	2	:	:	PUNCT
dpc-5749	194	3	31646663	31646663	NUM
dpc-5749	194	4	.	.	PUNCT
dpc-5749	195	1	6	6	X
dpc-5749	195	2	.	.	X
dpc-5749	195	3	bedane	bedane	PROPN
dpc-5749	195	4	c	c	PROPN
dpc-5749	195	5	,	,	PUNCT
dpc-5749	195	6	prost	prost	PROPN
dpc-5749	195	7	c	c	PROPN
dpc-5749	195	8	,	,	PUNCT
dpc-5749	195	9	ingen	ingen	PROPN
dpc-5749	195	10	-	-	PUNCT
dpc-5749	195	11	housz	housz	PROPN
dpc-5749	195	12	-	-	PUNCT
dpc-5749	195	13	oro	oro	NOUN
dpc-5749	195	14	s	s	PROPN
dpc-5749	195	15	,	,	PUNCT
dpc-5749	195	16	joly	joly	PROPN
dpc-5749	195	17	p	p	PROPN
dpc-5749	195	18	,	,	PUNCT
dpc-5749	195	19	bernard	bernard	PROPN
dpc-5749	195	20	p	p	NOUN
dpc-5749	195	21	;	;	PUNCT
dpc-5749	195	22	centres	centre	NOUN
dpc-5749	195	23	de	de	ADP
dpc-5749	195	24	référence	référence	PROPN
dpc-5749	195	25	des	des	PROPN
dpc-5749	195	26	maladies	malady	NOUN
dpc-5749	195	27	bulleuses	bulleuse	VERB
dpc-5749	195	28	auto	auto	NOUN
dpc-5749	195	29	-	-	PUNCT
dpc-5749	195	30	immunes	immune	NOUN
dpc-5749	195	31	.	.	PUNCT
dpc-5749	196	1	société	société	PROPN
dpc-5749	196	2	française	française	PROPN
dpc-5749	196	3	de	de	X
dpc-5749	196	4	dermatologie	dermatologie	NOUN
dpc-5749	196	5	.	.	PUNCT
dpc-5749	197	1	recommandations	recommandation	NOUN
dpc-5749	197	2	des	des	PROPN
dpc-5749	197	3	centres	centres	PROPN
dpc-5749	197	4	de	de	ADP
dpc-5749	197	5	référence	référence	PROPN
dpc-5749	197	6	des	des	PROPN
dpc-5749	197	7	maladies	malady	NOUN
dpc-5749	197	8	bulleuses	bulleuse	VERB
dpc-5749	197	9	auto	auto	NOUN
dpc-5749	197	10	-	-	PUNCT
dpc-5749	197	11	immunes	immune	NOUN
dpc-5749	197	12	pour	pour	VERB
dpc-5749	197	13	le	le	X
dpc-5749	197	14	diagnostic	diagnostic	PROPN
dpc-5749	197	15	et	et	PROPN
dpc-5749	197	16	la	la	PROPN
dpc-5749	197	17	prise	prise	PROPN
dpc-5749	197	18	en	en	PROPN
dpc-5749	197	19	charge	charge	PROPN
dpc-5749	197	20	de	de	X
dpc-5749	197	21	la	la	X
dpc-5749	197	22	pemphigoïde	pemphigoïde	PROPN
dpc-5749	197	23	cicatricielle	cicatricielle	NOUN
dpc-5749	198	1	[	[	X
dpc-5749	198	2	mucous	mucous	ADJ
dpc-5749	198	3	membrane	membrane	NOUN
dpc-5749	198	4	pemphigoid	pemphigoid	NOUN
dpc-5749	198	5	.	.	PUNCT
dpc-5749	199	1	guidelines	guideline	NOUN
dpc-5749	199	2	for	for	ADP
dpc-5749	199	3	the	the	DET
dpc-5749	199	4	diagnosis	diagnosis	NOUN
dpc-5749	199	5	and	and	CCONJ
dpc-5749	199	6	treatment	treatment	NOUN
dpc-5749	199	7	.	.	PUNCT
dpc-5749	200	1	centres	centre	NOUN
dpc-5749	200	2	de	de	ADP
dpc-5749	200	3	référence	référence	PROPN
dpc-5749	200	4	des	des	PROPN
dpc-5749	200	5	maladies	malady	NOUN
dpc-5749	200	6	bulleuses	bulleuse	VERB
dpc-5749	200	7	auto	auto	NOUN
dpc-5749	200	8	-	-	PUNCT
dpc-5749	200	9	immunes	immune	NOUN
dpc-5749	200	10	.	.	PUNCT
dpc-5749	201	1	société	société	PROPN
dpc-5749	201	2	française	française	PROPN
dpc-5749	201	3	de	de	X
dpc-5749	201	4	dermatologie	dermatologie	PROPN
dpc-5749	201	5	]	]	PUNCT
dpc-5749	201	6	.	.	PUNCT
dpc-5749	202	1	ann	ann	PROPN
dpc-5749	202	2	dermatol	dermatol	NOUN
dpc-5749	202	3	venereol	venereol	NOUN
dpc-5749	202	4	.	.	PUNCT
dpc-5749	203	1	2011;138(3):259	2011;138(3):259	NUM
dpc-5749	203	2	-	-	SYM
dpc-5749	203	3	63	63	NUM
dpc-5749	203	4	.	.	PUNCT
dpc-5749	204	1	french	french	PROPN
dpc-5749	204	2	.	.	PUNCT
dpc-5749	205	1	doi	doi	PROPN
dpc-5749	205	2	:	:	PUNCT
dpc-5749	205	3	10.1016	10.1016	NUM
dpc-5749	205	4	/j.annder.2011.01.014	/j.annder.2011.01.014	PUNCT
dpc-5749	205	5	.	.	PUNCT
dpc-5749	206	1	pmid	pmid	NOUN
dpc-5749	206	2	:	:	PUNCT
dpc-5749	206	3	21397156	21397156	NUM
dpc-5749	206	4	.	.	PUNCT
dpc-5749	207	1	7	7	X
dpc-5749	207	2	.	.	X
dpc-5749	207	3	schmidt	schmidt	PROPN
dpc-5749	207	4	e	e	PROPN
dpc-5749	207	5	,	,	PUNCT
dpc-5749	207	6	rashid	rashid	PROPN
dpc-5749	207	7	h	h	PROPN
dpc-5749	207	8	,	,	PUNCT
dpc-5749	207	9	marzano	marzano	PROPN
dpc-5749	207	10	av	av	PROPN
dpc-5749	207	11	,	,	PUNCT
dpc-5749	207	12	lamberts	lamberts	PROPN
dpc-5749	207	13	a	a	PROPN
dpc-5749	207	14	,	,	PUNCT
dpc-5749	207	15	di	di	NOUN
dpc-5749	207	16	zenzo	zenzo	NOUN
dpc-5749	207	17	g	g	NOUN
dpc-5749	207	18	,	,	PUNCT
dpc-5749	207	19	diercks	diercks	PROPN
dpc-5749	207	20	gfh	gfh	PROPN
dpc-5749	207	21	,	,	PUNCT
dpc-5749	207	22	et	et	PROPN
dpc-5749	207	23	al	al	PROPN
dpc-5749	207	24	.	.	PUNCT
dpc-5749	207	25	european	european	PROPN
dpc-5749	207	26	guidelines	guideline	NOUN
dpc-5749	207	27	(	(	PUNCT
dpc-5749	207	28	s3	s3	PROPN
dpc-5749	207	29	)	)	PUNCT
dpc-5749	207	30	on	on	ADP
dpc-5749	207	31	diagnosis	diagnosis	NOUN
dpc-5749	207	32	and	and	CCONJ
dpc-5749	207	33	management	management	NOUN
dpc-5749	207	34	of	of	ADP
dpc-5749	207	35	mucous	mucous	ADJ
dpc-5749	207	36	membrane	membrane	NOUN
dpc-5749	207	37	pemphigoid	pemphigoid	NOUN
dpc-5749	207	38	,	,	PUNCT
dpc-5749	207	39	initiated	initiate	VERB
dpc-5749	207	40	by	by	ADP
dpc-5749	207	41	the	the	DET
dpc-5749	207	42	european	european	PROPN
dpc-5749	207	43	academy	academy	PROPN
dpc-5749	207	44	of	of	ADP
dpc-5749	207	45	dermatology	dermatology	NOUN
dpc-5749	207	46	and	and	CCONJ
dpc-5749	207	47	venereology	venereology	NOUN
dpc-5749	207	48	–	–	PUNCT
dpc-5749	207	49	part	part	PROPN
dpc-5749	207	50	ii	ii	PROPN
dpc-5749	207	51	.	.	PUNCT
dpc-5749	208	1	j	j	PROPN
dpc-5749	208	2	eur	eur	PROPN
dpc-5749	208	3	acad	acad	PROPN
dpc-5749	208	4	dermatol	dermatol	NOUN
dpc-5749	208	5	venereol	venereol	NOUN
dpc-5749	208	6	.	.	PUNCT
dpc-5749	209	1	2021;35(10):1926	2021;35(10):1926	NOUN
dpc-5749	209	2	-	-	SYM
dpc-5749	209	3	1948	1948	NUM
dpc-5749	209	4	.	.	PUNCT
dpc-5749	210	1	doi	doi	NOUN
dpc-5749	210	2	:	:	PUNCT
dpc-5749	210	3	10.1111	10.1111	NUM
dpc-5749	210	4	/	/	SYM
dpc-5749	210	5	jdv.17395	jdv.17395	PROPN
dpc-5749	210	6	.	.	PUNCT
dpc-5749	211	1	pmid	pmid	NOUN
dpc-5749	211	2	:	:	PUNCT
dpc-5749	211	3	34309078	34309078	NUM
dpc-5749	211	4	.	.	PUNCT
dpc-5749	212	1	8	8	NUM
dpc-5749	212	2	.	.	X
dpc-5749	212	3	hofmann	hofmann	PROPN
dpc-5749	212	4	sc	sc	PROPN
dpc-5749	212	5	,	,	PUNCT
dpc-5749	212	6	günther	günther	NOUN
dpc-5749	212	7	c	c	NOUN
dpc-5749	212	8	,	,	PUNCT
dpc-5749	212	9	böckle	böckle	PROPN
dpc-5749	212	10	bc	bc	PROPN
dpc-5749	212	11	,	,	PUNCT
dpc-5749	212	12	et	et	PROPN
dpc-5749	212	13	al	al	PROPN
dpc-5749	212	14	.	.	PUNCT
dpc-5749	213	1	s2k	s2k	PROPN
dpc-5749	213	2	guideline	guideline	PROPN
dpc-5749	213	3	for	for	ADP
dpc-5749	213	4	the	the	DET
dpc-5749	213	5	diagnosis	diagnosis	NOUN
dpc-5749	213	6	and	and	CCONJ
dpc-5749	213	7	treatment	treatment	NOUN
dpc-5749	213	8	of	of	ADP
dpc-5749	213	9	mucous	mucous	ADJ
dpc-5749	213	10	membrane	membrane	NOUN
dpc-5749	213	11	pemphigoid	pemphigoid	NOUN
dpc-5749	213	12	.	.	PUNCT
dpc-5749	214	1	j	j	PROPN
dpc-5749	214	2	dtsch	dtsch	PROPN
dpc-5749	214	3	dermatol	dermatol	NOUN
dpc-5749	214	4	ges	ge	NOUN
dpc-5749	214	5	.	.	PUNCT
dpc-5749	215	1	2022;20(11):1530	2022;20(11):1530	NUM
dpc-5749	215	2	-	-	SYM
dpc-5749	215	3	1550	1550	NUM
dpc-5749	215	4	.	.	PUNCT
dpc-5749	216	1	doi	doi	NOUN
dpc-5749	216	2	:	:	PUNCT
dpc-5749	216	3	10.1111	10.1111	NUM
dpc-5749	216	4	/ddg.14905	/ddg.14905	PROPN
dpc-5749	216	5	.	.	PUNCT
dpc-5749	217	1	pmid	pmid	NOUN
dpc-5749	217	2	:	:	PUNCT
dpc-5749	217	3	36354061	36354061	NUM
dpc-5749	217	4	.	.	PUNCT
dpc-5749	218	1	9	9	X
dpc-5749	218	2	.	.	X
dpc-5749	218	3	elder	elder	PROPN
dpc-5749	218	4	mj	mj	PROPN
dpc-5749	218	5	,	,	PUNCT
dpc-5749	218	6	lightman	lightman	PROPN
dpc-5749	218	7	s.	s.	PROPN
dpc-5749	218	8	the	the	DET
dpc-5749	218	9	immunological	immunological	ADJ
dpc-5749	218	10	features	feature	NOUN
dpc-5749	218	11	and	and	CCONJ
dpc-5749	218	12	pathophysiology	pathophysiology	NOUN
dpc-5749	218	13	of	of	ADP
dpc-5749	218	14	ocular	ocular	ADJ
dpc-5749	218	15	cicatricial	cicatricial	ADJ
dpc-5749	218	16	pemphigoid	pemphigoid	NOUN
dpc-5749	218	17	.	.	PUNCT
dpc-5749	219	1	eye	eye	NOUN
dpc-5749	219	2	(	(	PUNCT
dpc-5749	219	3	lond	lond	PROPN
dpc-5749	219	4	)	)	PUNCT
dpc-5749	219	5	.	.	PUNCT
dpc-5749	219	6	1994	1994	NUM
dpc-5749	219	7	;	;	PUNCT
dpc-5749	219	8	8(pt	8(pt	NUM
dpc-5749	219	9	2):196	2):196	NUM
dpc-5749	219	10	-	-	SYM
dpc-5749	219	11	9	9	NUM
dpc-5749	219	12	.	.	PUNCT
dpc-5749	219	13	doi	doi	NOUN
dpc-5749	219	14	:	:	PUNCT
dpc-5749	219	15	10.1038	10.1038	NUM
dpc-5749	219	16	/	/	SYM
dpc-5749	219	17	eye.1994.45	eye.1994.45	NUM
dpc-5749	219	18	.	.	PUNCT
dpc-5749	220	1	pmid	pmid	NOUN
dpc-5749	220	2	:	:	PUNCT
dpc-5749	220	3	7958021	7958021	NUM
dpc-5749	220	4	.	.	PUNCT
dpc-5749	221	1	malignancy	malignancy	NOUN
dpc-5749	221	2	development	development	NOUN
dpc-5749	221	3	through	through	ADP
dpc-5749	221	4	the	the	DET
dpc-5749	221	5	activation	activation	NOUN
dpc-5749	221	6	of	of	ADP
dpc-5749	221	7	pi3k	pi3k	PROPN
dpc-5749	221	8	and	and	CCONJ
dpc-5749	221	9	the	the	DET
dpc-5749	221	10	rho	rho	ADJ
dpc-5749	221	11	family	family	NOUN
dpc-5749	221	12	of	of	ADP
dpc-5749	221	13	small	small	ADJ
dpc-5749	221	14	gtpases	gtpase	NOUN
dpc-5749	222	1	[	[	X
dpc-5749	222	2	45,46	45,46	NOUN
dpc-5749	222	3	]	]	PUNCT
dpc-5749	222	4	,	,	PUNCT
dpc-5749	222	5	with	with	ADP
dpc-5749	222	6	decreased	decrease	VERB
dpc-5749	222	7	signaling	signal	VERB
dpc-5749	222	8	of	of	ADP
dpc-5749	222	9	the	the	DET
dpc-5749	222	10	latter	latter	ADJ
dpc-5749	222	11	after	after	SCONJ
dpc-5749	222	12	the	the	DET
dpc-5749	222	13	administration	administration	NOUN
dpc-5749	222	14	of	of	ADP
dpc-5749	222	15	ivig	ivig	NOUN
dpc-5749	222	16	demonstrated	demonstrate	VERB
dpc-5749	222	17	by	by	ADP
dpc-5749	222	18	murthy	murthy	PROPN
dpc-5749	222	19	et	et	PROPN
dpc-5749	222	20	al	al	PROPN
dpc-5749	222	21	.	.	PROPN
dpc-5749	223	1	(	(	PUNCT
dpc-5749	223	2	2024	2024	NUM
dpc-5749	223	3	)	)	PUNCT
dpc-5749	224	1	[	[	X
dpc-5749	224	2	20	20	NUM
dpc-5749	224	3	]	]	PUNCT
dpc-5749	224	4	.	.	PUNCT
dpc-5749	225	1	thus	thus	ADV
dpc-5749	225	2	,	,	PUNCT
dpc-5749	225	3	the	the	DET
dpc-5749	225	4	role	role	NOUN
dpc-5749	225	5	of	of	ADP
dpc-5749	225	6	these	these	DET
dpc-5749	225	7	pathways	pathway	NOUN
dpc-5749	225	8	should	should	AUX
dpc-5749	225	9	be	be	AUX
dpc-5749	225	10	further	far	ADV
dpc-5749	225	11	clarified	clarify	VERB
dpc-5749	225	12	in	in	ADP
dpc-5749	225	13	mmp	mmp	PROPN
dpc-5749	225	14	.	.	PUNCT
dpc-5749	226	1	mmp	mmp	PROPN
dpc-5749	226	2	-	-	PUNCT
dpc-5749	226	3	associated	associate	VERB
dpc-5749	226	4	fibrosis	fibrosis	NOUN
dpc-5749	226	5	may	may	AUX
dpc-5749	226	6	be	be	AUX
dpc-5749	226	7	linked	link	VERB
dpc-5749	226	8	to	to	ADP
dpc-5749	226	9	the	the	DET
dpc-5749	226	10	aldehyde	aldehyde	NOUN
dpc-5749	226	11	dehydrogenase	dehydrogenase	NOUN
dpc-5749	226	12	/	/	SYM
dpc-5749	226	13	retinoic	retinoic	NOUN
dpc-5749	226	14	acid	acid	NOUN
dpc-5749	226	15	(	(	PUNCT
dpc-5749	226	16	aldh	aldh	NOUN
dpc-5749	226	17	/	/	SYM
dpc-5749	226	18	ra)-mediated	ra)-mediate	VERB
dpc-5749	226	19	dendritic	dendritic	ADJ
dpc-5749	226	20	cell	cell	NOUN
dpc-5749	226	21	paracrine	paracrine	NOUN
dpc-5749	226	22	effect	effect	NOUN
dpc-5749	226	23	and	and	CCONJ
dpc-5749	226	24	activation	activation	NOUN
dpc-5749	226	25	of	of	ADP
dpc-5749	226	26	a	a	DET
dpc-5749	226	27	pro	pro	ADJ
dpc-5749	226	28	-	-	ADJ
dpc-5749	226	29	fibrotic	fibrotic	ADJ
dpc-5749	226	30	phenotype	phenotype	NOUN
dpc-5749	226	31	of	of	ADP
dpc-5749	226	32	fibroblasts	fibroblast	NOUN
dpc-5749	226	33	.	.	PUNCT
dpc-5749	227	1	patzelt	patzelt	VERB
dpc-5749	227	2	et	et	PROPN
dpc-5749	227	3	al	al	PROPN
dpc-5749	227	4	.	.	PROPN
dpc-5749	228	1	(	(	PUNCT
dpc-5749	228	2	2021	2021	NUM
dpc-5749	228	3	)	)	PUNCT
dpc-5749	228	4	concluded	conclude	VERB
dpc-5749	228	5	that	that	SCONJ
dpc-5749	228	6	the	the	DET
dpc-5749	228	7	aldh	aldh	ADJ
dpc-5749	228	8	inhibitor	inhibitor	NOUN
dpc-5749	228	9	disulfiram	disulfiram	NOUN
dpc-5749	228	10	does	do	AUX
dpc-5749	228	11	not	not	PART
dpc-5749	228	12	reduce	reduce	VERB
dpc-5749	228	13	fibrosis	fibrosis	NOUN
dpc-5749	228	14	in	in	ADP
dpc-5749	228	15	ocular	ocular	ADJ
dpc-5749	228	16	and	and	CCONJ
dpc-5749	228	17	oral	oral	ADJ
dpc-5749	228	18	lesions	lesion	NOUN
dpc-5749	228	19	in	in	ADP
dpc-5749	228	20	mmp	mmp	PROPN
dpc-5749	228	21	-	-	PUNCT
dpc-5749	228	22	induced	induce	VERB
dpc-5749	228	23	mice	mouse	NOUN
dpc-5749	228	24	but	but	CCONJ
dpc-5749	228	25	improved	improve	VERB
dpc-5749	228	26	cutaneous	cutaneous	ADJ
dpc-5749	228	27	lesions	lesion	NOUN
dpc-5749	228	28	[	[	X
dpc-5749	228	29	79	79	NUM
dpc-5749	228	30	]	]	PUNCT
dpc-5749	228	31	.	.	PUNCT
dpc-5749	229	1	however	however	ADV
dpc-5749	229	2	,	,	PUNCT
dpc-5749	229	3	earlier	early	ADJ
dpc-5749	229	4	disulfiram	disulfiram	PROPN
dpc-5749	229	5	effectively	effectively	ADV
dpc-5749	229	6	alleviated	alleviate	VERB
dpc-5749	229	7	fibrotic	fibrotic	ADJ
dpc-5749	229	8	changes	change	NOUN
dpc-5749	229	9	in	in	ADP
dpc-5749	229	10	human	human	ADJ
dpc-5749	229	11	ocmmp	ocmmp	NOUN
dpc-5749	229	12	fibroblasts	fibroblast	NOUN
dpc-5749	229	13	and	and	CCONJ
dpc-5749	229	14	in	in	ADP
dpc-5749	229	15	a	a	DET
dpc-5749	229	16	mouse	mouse	NOUN
dpc-5749	229	17	model	model	NOUN
dpc-5749	229	18	[	[	X
dpc-5749	229	19	80	80	NUM
dpc-5749	229	20	]	]	PUNCT
dpc-5749	229	21	.	.	PUNCT
dpc-5749	230	1	in	in	ADP
dpc-5749	230	2	patients	patient	NOUN
dpc-5749	230	3	with	with	ADP
dpc-5749	230	4	mmp	mmp	PROPN
dpc-5749	230	5	,	,	PUNCT
dpc-5749	230	6	high	high	ADJ
dpc-5749	230	7	serum	serum	NOUN
dpc-5749	230	8	levels	level	NOUN
dpc-5749	230	9	of	of	ADP
dpc-5749	230	10	il-1	il-1	ADP
dpc-5749	231	1	[	[	X
dpc-5749	231	2	81	81	NUM
dpc-5749	231	3	]	]	PUNCT
dpc-5749	231	4	and	and	CCONJ
dpc-5749	231	5	il-5	il-5	PRON
dpc-5749	232	1	[	[	X
dpc-5749	232	2	82	82	X
dpc-5749	232	3	]	]	PUNCT
dpc-5749	232	4	and	and	CCONJ
dpc-5749	232	5	an	an	DET
dpc-5749	232	6	elevated	elevated	ADJ
dpc-5749	232	7	expression	expression	NOUN
dpc-5749	232	8	of	of	ADP
dpc-5749	232	9	il-6	il-6	NOUN
dpc-5749	232	10	,	,	PUNCT
dpc-5749	232	11	il-12	il-12	NOUN
dpc-5749	232	12	,	,	PUNCT
dpc-5749	232	13	il-17	il-17	X
dpc-5749	233	1	[	[	X
dpc-5749	233	2	83	83	NUM
dpc-5749	233	3	]	]	PUNCT
dpc-5749	233	4	,	,	PUNCT
dpc-5749	233	5	and	and	CCONJ
dpc-5749	233	6	il-5	il-5	PRON
dpc-5749	233	7	mrna	mrna	VERB
dpc-5749	234	1	[	[	X
dpc-5749	234	2	84	84	NUM
dpc-5749	234	3	]	]	PUNCT
dpc-5749	234	4	in	in	ADP
dpc-5749	234	5	biopsy	biopsy	NOUN
dpc-5749	234	6	samples	sample	NOUN
dpc-5749	234	7	were	be	AUX
dpc-5749	234	8	reported	report	VERB
dpc-5749	234	9	.	.	PUNCT
dpc-5749	235	1	il-1	il-1	PROPN
dpc-5749	235	2	,	,	PUNCT
dpc-5749	235	3	il-5	il-5	PROPN
dpc-5749	235	4	,	,	PUNCT
dpc-5749	235	5	il-6	il-6	PRON
dpc-5749	235	6	,	,	PUNCT
dpc-5749	235	7	il-12	il-12	NOUN
dpc-5749	235	8	,	,	PUNCT
dpc-5749	235	9	and	and	CCONJ
dpc-5749	235	10	il-17	il-17	NUM
dpc-5749	235	11	inhibitors	inhibitor	NOUN
dpc-5749	235	12	are	be	AUX
dpc-5749	235	13	employed	employ	VERB
dpc-5749	235	14	in	in	ADP
dpc-5749	235	15	dermatology	dermatology	NOUN
dpc-5749	235	16	;	;	PUNCT
dpc-5749	235	17	il-5	il-5	NUM
dpc-5749	235	18	,	,	PUNCT
dpc-5749	235	19	il-12/23	il-12/23	PROPN
dpc-5749	235	20	,	,	PUNCT
dpc-5749	235	21	and	and	CCONJ
dpc-5749	235	22	il-17	il-17	NUM
dpc-5749	235	23	inhibitors	inhibitor	NOUN
dpc-5749	235	24	were	be	AUX
dpc-5749	235	25	used	use	VERB
dpc-5749	235	26	in	in	ADP
dpc-5749	235	27	bullous	bullous	ADJ
dpc-5749	235	28	pemphigoid	pemphigoid	NOUN
dpc-5749	236	1	[	[	X
dpc-5749	236	2	85,86	85,86	NUM
dpc-5749	236	3	]	]	PUNCT
dpc-5749	236	4	.	.	PUNCT
dpc-5749	237	1	nonetheless	nonetheless	ADV
dpc-5749	237	2	,	,	PUNCT
dpc-5749	237	3	these	these	DET
dpc-5749	237	4	agents	agent	NOUN
dpc-5749	237	5	occasionally	occasionally	ADV
dpc-5749	237	6	paradoxically	paradoxically	ADV
dpc-5749	237	7	induce	induce	VERB
dpc-5749	237	8	bp	bp	PROPN
dpc-5749	238	1	[	[	X
dpc-5749	238	2	87,88	87,88	NUM
dpc-5749	238	3	]	]	PUNCT
dpc-5749	238	4	.	.	PUNCT
dpc-5749	239	1	moreover	moreover	ADV
dpc-5749	239	2	,	,	PUNCT
dpc-5749	239	3	complement	complement	VERB
dpc-5749	239	4	inhibitors	inhibitor	NOUN
dpc-5749	239	5	have	have	AUX
dpc-5749	239	6	been	be	AUX
dpc-5749	239	7	suggested	suggest	VERB
dpc-5749	239	8	for	for	ADP
dpc-5749	239	9	bp	bp	PROPN
dpc-5749	239	10	[	[	X
dpc-5749	239	11	85,86	85,86	NUM
dpc-5749	239	12	]	]	PUNCT
dpc-5749	239	13	;	;	PUNCT
dpc-5749	239	14	no	no	DET
dpc-5749	239	15	report	report	NOUN
dpc-5749	239	16	on	on	ADP
dpc-5749	239	17	the	the	DET
dpc-5749	239	18	use	use	NOUN
dpc-5749	239	19	of	of	ADP
dpc-5749	239	20	these	these	DET
dpc-5749	239	21	agents	agent	NOUN
dpc-5749	239	22	in	in	ADP
dpc-5749	239	23	mmp	mmp	PROPN
dpc-5749	239	24	was	be	AUX
dpc-5749	239	25	found	find	VERB
dpc-5749	239	26	.	.	PUNCT
dpc-5749	240	1	summarizing	summarize	VERB
dpc-5749	240	2	the	the	DET
dpc-5749	240	3	above	above	ADV
dpc-5749	240	4	-	-	PUNCT
dpc-5749	240	5	mentioned	mention	VERB
dpc-5749	240	6	data	datum	NOUN
dpc-5749	240	7	,	,	PUNCT
dpc-5749	240	8	a	a	DET
dpc-5749	240	9	broader	broad	ADJ
dpc-5749	240	10	spectrum	spectrum	NOUN
dpc-5749	240	11	of	of	ADP
dpc-5749	240	12	pharmacological	pharmacological	ADJ
dpc-5749	240	13	agents	agent	NOUN
dpc-5749	240	14	will	will	AUX
dpc-5749	240	15	allow	allow	VERB
dpc-5749	240	16	a	a	DET
dpc-5749	240	17	personalized	personalized	ADJ
dpc-5749	240	18	approach	approach	NOUN
dpc-5749	240	19	and	and	CCONJ
dpc-5749	240	20	more	more	ADJ
dpc-5749	240	21	alternatives	alternative	NOUN
dpc-5749	240	22	,	,	PUNCT
dpc-5749	240	23	in	in	ADP
dpc-5749	240	24	particular	particular	ADJ
dpc-5749	240	25	for	for	ADP
dpc-5749	240	26	recalcitrant	recalcitrant	ADJ
dpc-5749	240	27	cases	case	NOUN
dpc-5749	240	28	and	and	CCONJ
dpc-5749	240	29	failure	failure	NOUN
dpc-5749	240	30	of	of	ADP
dpc-5749	240	31	previous	previous	ADJ
dpc-5749	240	32	therapy	therapy	NOUN
dpc-5749	240	33	.	.	PUNCT
dpc-5749	241	1	moreover	moreover	ADV
dpc-5749	241	2	,	,	PUNCT
dpc-5749	241	3	given	give	VERB
dpc-5749	241	4	the	the	DET
dpc-5749	241	5	participation	participation	NOUN
dpc-5749	241	6	of	of	ADP
dpc-5749	241	7	mechanisms	mechanism	NOUN
dpc-5749	241	8	other	other	ADJ
dpc-5749	241	9	than	than	ADP
dpc-5749	241	10	the	the	DET
dpc-5749	241	11	formation	formation	NOUN
dpc-5749	241	12	of	of	ADP
dpc-5749	241	13	autoantibodies	autoantibody	NOUN
dpc-5749	241	14	in	in	ADP
dpc-5749	241	15	the	the	DET
dpc-5749	241	16	pathogenesis	pathogenesis	NOUN
dpc-5749	241	17	of	of	ADP
dpc-5749	241	18	mmp	mmp	PROPN
dpc-5749	241	19	[	[	X
dpc-5749	241	20	20	20	NUM
dpc-5749	241	21	]	]	PUNCT
dpc-5749	241	22	,	,	PUNCT
dpc-5749	241	23	it	it	PRON
dpc-5749	241	24	is	be	AUX
dpc-5749	241	25	advisable	advisable	ADJ
dpc-5749	241	26	to	to	PART
dpc-5749	241	27	collect	collect	VERB
dpc-5749	241	28	more	more	ADJ
dpc-5749	241	29	data	datum	NOUN
dpc-5749	241	30	on	on	ADP
dpc-5749	241	31	the	the	DET
dpc-5749	241	32	impact	impact	NOUN
dpc-5749	241	33	of	of	ADP
dpc-5749	241	34	cytokines	cytokine	NOUN
dpc-5749	241	35	,	,	PUNCT
dpc-5749	241	36	complement	complement	NOUN
dpc-5749	241	37	,	,	PUNCT
dpc-5749	241	38	proteases	protease	NOUN
dpc-5749	241	39	,	,	PUNCT
dpc-5749	241	40	immune	immune	ADJ
dpc-5749	241	41	cells	cell	NOUN
dpc-5749	241	42	,	,	PUNCT
dpc-5749	241	43	and	and	CCONJ
dpc-5749	241	44	other	other	ADJ
dpc-5749	241	45	agents	agent	NOUN
dpc-5749	241	46	in	in	ADP
dpc-5749	241	47	search	search	NOUN
dpc-5749	241	48	of	of	ADP
dpc-5749	241	49	solutions	solution	NOUN
dpc-5749	241	50	to	to	PART
dpc-5749	241	51	avoid	avoid	VERB
dpc-5749	241	52	severe	severe	ADJ
dpc-5749	241	53	complications	complication	NOUN
dpc-5749	241	54	and	and	CCONJ
dpc-5749	241	55	overcome	overcome	VERB
dpc-5749	241	56	therapy	therapy	NOUN
dpc-5749	241	57	resistance	resistance	NOUN
dpc-5749	241	58	.	.	PUNCT
dpc-5749	242	1	conclusion	conclusion	NOUN
dpc-5749	242	2	we	we	PRON
dpc-5749	242	3	present	present	VERB
dpc-5749	242	4	the	the	DET
dpc-5749	242	5	analysis	analysis	NOUN
dpc-5749	242	6	of	of	ADP
dpc-5749	242	7	pharmacological	pharmacological	ADJ
dpc-5749	242	8	agents	agent	NOUN
dpc-5749	242	9	used	use	VERB
dpc-5749	242	10	in	in	ADP
dpc-5749	242	11	the	the	DET
dpc-5749	242	12	management	management	NOUN
dpc-5749	242	13	of	of	ADP
dpc-5749	242	14	mmp	mmp	PROPN
dpc-5749	242	15	but	but	CCONJ
dpc-5749	242	16	that	that	PRON
dpc-5749	242	17	are	be	AUX
dpc-5749	242	18	not	not	PART
dpc-5749	242	19	included	include	VERB
dpc-5749	242	20	in	in	ADP
dpc-5749	242	21	earlier	early	ADJ
dpc-5749	242	22	published	publish	VERB
dpc-5749	242	23	guidelines	guideline	NOUN
dpc-5749	242	24	.	.	PUNCT
dpc-5749	243	1	considering	consider	VERB
dpc-5749	243	2	the	the	DET
dpc-5749	243	3	severity	severity	NOUN
dpc-5749	243	4	of	of	ADP
dpc-5749	243	5	the	the	DET
dpc-5749	243	6	condition	condition	NOUN
dpc-5749	243	7	,	,	PUNCT
dpc-5749	243	8	progressive	progressive	ADJ
dpc-5749	243	9	fibrosis	fibrosis	NOUN
dpc-5749	243	10	,	,	PUNCT
dpc-5749	243	11	and	and	CCONJ
dpc-5749	243	12	resistance	resistance	NOUN
dpc-5749	243	13	to	to	ADP
dpc-5749	243	14	therapy	therapy	NOUN
dpc-5749	243	15	,	,	PUNCT
dpc-5749	243	16	more	more	ADJ
dpc-5749	243	17	research	research	NOUN
dpc-5749	243	18	is	be	AUX
dpc-5749	243	19	required	require	VERB
dpc-5749	243	20	in	in	ADP
dpc-5749	243	21	relation	relation	NOUN
dpc-5749	243	22	to	to	ADP
dpc-5749	243	23	the	the	DET
dpc-5749	243	24	pathogenesis	pathogenesis	NOUN
dpc-5749	243	25	of	of	ADP
dpc-5749	243	26	mmp	mmp	PROPN
dpc-5749	243	27	and	and	CCONJ
dpc-5749	243	28	the	the	DET
dpc-5749	243	29	efficacy	efficacy	NOUN
dpc-5749	243	30	and	and	CCONJ
dpc-5749	243	31	safety	safety	NOUN
dpc-5749	243	32	profile	profile	NOUN
dpc-5749	243	33	of	of	ADP
dpc-5749	243	34	novel	novel	ADJ
dpc-5749	243	35	pharmacological	pharmacological	ADJ
dpc-5749	243	36	options	option	NOUN
dpc-5749	243	37	.	.	PUNCT
dpc-5749	244	1	pharmacological	pharmacological	ADJ
dpc-5749	244	2	agents	agent	NOUN
dpc-5749	244	3	should	should	AUX
dpc-5749	244	4	provide	provide	VERB
dpc-5749	244	5	the	the	DET
dpc-5749	244	6	achievement	achievement	NOUN
dpc-5749	244	7	and	and	CCONJ
dpc-5749	244	8	maintenance	maintenance	NOUN
dpc-5749	244	9	of	of	ADP
dpc-5749	244	10	remission	remission	NOUN
dpc-5749	244	11	with	with	ADP
dpc-5749	244	12	minimal	minimal	ADJ
dpc-5749	244	13	adverse	adverse	ADJ
dpc-5749	244	14	effects	effect	NOUN
dpc-5749	244	15	.	.	PUNCT
dpc-5749	245	1	a	a	DET
dpc-5749	245	2	broader	broad	ADJ
dpc-5749	245	3	spectrum	spectrum	NOUN
dpc-5749	245	4	of	of	ADP
dpc-5749	245	5	pharmacological	pharmacological	ADJ
dpc-5749	245	6	agents	agent	NOUN
dpc-5749	245	7	will	will	AUX
dpc-5749	245	8	allow	allow	VERB
dpc-5749	245	9	a	a	DET
dpc-5749	245	10	personalized	personalized	ADJ
dpc-5749	245	11	approach	approach	NOUN
dpc-5749	245	12	and	and	CCONJ
dpc-5749	245	13	more	more	ADJ
dpc-5749	245	14	alternatives	alternative	NOUN
dpc-5749	245	15	,	,	PUNCT
dpc-5749	245	16	in	in	ADP
dpc-5749	245	17	particular	particular	ADJ
dpc-5749	245	18	for	for	ADP
dpc-5749	245	19	recalcitrant	recalcitrant	ADJ
dpc-5749	245	20	cases	case	NOUN
dpc-5749	245	21	,	,	PUNCT
dpc-5749	245	22	failure	failure	NOUN
dpc-5749	245	23	of	of	ADP
dpc-5749	245	24	the	the	DET
dpc-5749	245	25	previous	previous	ADJ
dpc-5749	245	26	therapy	therapy	NOUN
dpc-5749	245	27	,	,	PUNCT
dpc-5749	245	28	and	and	CCONJ
dpc-5749	245	29	patients	patient	NOUN
dpc-5749	245	30	with	with	ADP
dpc-5749	245	31	mmp	mmp	PROPN
dpc-5749	245	32	and	and	CCONJ
dpc-5749	245	33	malignancy	malignancy	NOUN
dpc-5749	245	34	.	.	PUNCT
dpc-5749	246	1	abbreviations	abbreviation	NOUN
dpc-5749	246	2	:	:	PUNCT
dpc-5749	246	3	recombinant	recombinant	ADJ
dpc-5749	246	4	human	human	ADJ
dpc-5749	246	5	nerve	nerve	NOUN
dpc-5749	246	6	growth	growth	NOUN
dpc-5749	246	7	factor	factor	NOUN
dpc-5749	246	8	(	(	PUNCT
dpc-5749	246	9	rhngf	rhngf	NOUN
dpc-5749	246	10	)	)	PUNCT
dpc-5749	246	11	;	;	PUNCT
dpc-5749	246	12	nicotinic	nicotinic	ADJ
dpc-5749	246	13	acetylcholine	acetylcholine	NOUN
dpc-5749	246	14	receptor	receptor	NOUN
dpc-5749	246	15	(	(	PUNCT
dpc-5749	246	16	nachr	nachr	PROPN
dpc-5749	246	17	)	)	PUNCT
dpc-5749	246	18	;	;	PUNCT
dpc-5749	246	19	lymphocyte	lymphocyte	ADJ
dpc-5749	246	20	function	function	NOUN
dpc-5749	246	21	-	-	PUNCT
dpc-5749	246	22	associated	associate	VERB
dpc-5749	246	23	antigen-1	antigen-1	X
dpc-5749	246	24	(	(	PUNCT
dpc-5749	246	25	lfa-1	lfa-1	NUM
dpc-5749	246	26	)	)	PUNCT
dpc-5749	246	27	;	;	PUNCT
dpc-5749	246	28	review	review	VERB
dpc-5749	246	29	|	|	ADV
dpc-5749	246	30	dermatol	dermatol	ADJ
dpc-5749	246	31	pract	pract	NOUN
dpc-5749	246	32	concept	concept	NOUN
dpc-5749	246	33	.	.	PUNCT
dpc-5749	247	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	247	2	7	7	NUM
dpc-5749	247	3	pemphigoid	pemphigoid	ADJ
dpc-5749	247	4	?	?	PUNCT
dpc-5749	248	1	oral	oral	ADJ
dpc-5749	248	2	dis	dis	PROPN
dpc-5749	248	3	.	.	PUNCT
dpc-5749	249	1	2025;31(4):1237	2025;31(4):1237	NUM
dpc-5749	249	2	-	-	SYM
dpc-5749	249	3	1240	1240	NUM
dpc-5749	249	4	.	.	PUNCT
dpc-5749	250	1	doi	doi	NOUN
dpc-5749	250	2	:	:	PUNCT
dpc-5749	250	3	10.1111	10.1111	NUM
dpc-5749	250	4	/odi.15193	/odi.15193	NOUN
dpc-5749	250	5	.	.	PUNCT
dpc-5749	251	1	pmid	pmid	NOUN
dpc-5749	251	2	:	:	PUNCT
dpc-5749	251	3	39497341	39497341	NUM
dpc-5749	251	4	.	.	PUNCT
dpc-5749	252	1	24	24	NUM
dpc-5749	252	2	.	.	PUNCT
dpc-5749	253	1	chaidemenos	chaidemeno	VERB
dpc-5749	253	2	g	g	PROPN
dpc-5749	253	3	,	,	PUNCT
dpc-5749	253	4	sidiropoulos	sidiropoulos	PROPN
dpc-5749	253	5	t	t	PROPN
dpc-5749	253	6	,	,	PUNCT
dpc-5749	253	7	katsioula	katsioula	PROPN
dpc-5749	253	8	p	p	PRON
dpc-5749	253	9	,	,	PUNCT
dpc-5749	253	10	koussidou	koussidou	X
dpc-5749	253	11	eremondi	eremondi	PROPN
dpc-5749	253	12	t.	t.	PROPN
dpc-5749	253	13	colchicine	colchicine	PROPN
dpc-5749	253	14	in	in	ADP
dpc-5749	253	15	the	the	DET
dpc-5749	253	16	management	management	NOUN
dpc-5749	253	17	of	of	ADP
dpc-5749	253	18	mucous	mucous	ADJ
dpc-5749	253	19	membrane	membrane	NOUN
dpc-5749	253	20	pemphigoid	pemphigoid	NOUN
dpc-5749	253	21	.	.	PUNCT
dpc-5749	254	1	dermatol	dermatol	NOUN
dpc-5749	254	2	ther	ther	ADV
dpc-5749	254	3	.	.	PUNCT
dpc-5749	255	1	2011;24(4):443	2011;24(4):443	NUM
dpc-5749	255	2	-	-	SYM
dpc-5749	255	3	5	5	NUM
dpc-5749	255	4	.	.	PUNCT
dpc-5749	255	5	doi	doi	NOUN
dpc-5749	255	6	:	:	PUNCT
dpc-5749	255	7	10.1111	10.1111	NUM
dpc-5749	255	8	/	/	SYM
dpc-5749	255	9	j.1529	j.1529	NOUN
dpc-5749	255	10	-	-	PUNCT
dpc-5749	255	11	8019.2011.01438.x	8019.2011.01438.x	NUM
dpc-5749	255	12	.	.	PUNCT
dpc-5749	256	1	pmid	pmid	NOUN
dpc-5749	256	2	:	:	PUNCT
dpc-5749	256	3	21910802	21910802	NUM
dpc-5749	256	4	.	.	PUNCT
dpc-5749	257	1	25	25	NUM
dpc-5749	257	2	.	.	PUNCT
dpc-5749	257	3	fox	fox	PROPN
dpc-5749	257	4	ri	ri	PROPN
dpc-5749	257	5	.	.	PUNCT
dpc-5749	257	6	mechanism	mechanism	NOUN
dpc-5749	257	7	of	of	ADP
dpc-5749	257	8	action	action	NOUN
dpc-5749	257	9	of	of	ADP
dpc-5749	257	10	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-5749	257	11	as	as	ADP
dpc-5749	257	12	an	an	DET
dpc-5749	257	13	antirheumatic	antirheumatic	ADJ
dpc-5749	257	14	drug	drug	NOUN
dpc-5749	257	15	.	.	PUNCT
dpc-5749	258	1	semin	semin	PROPN
dpc-5749	258	2	arthritis	arthritis	PROPN
dpc-5749	258	3	rheum	rheum	PROPN
dpc-5749	258	4	.	.	PUNCT
dpc-5749	259	1	1993;23(2):82	1993;23(2):82	NUM
dpc-5749	259	2	-	-	SYM
dpc-5749	259	3	91	91	NUM
dpc-5749	259	4	.	.	PUNCT
dpc-5749	260	1	doi	doi	NOUN
dpc-5749	260	2	:	:	PUNCT
dpc-5749	260	3	10.1016	10.1016	NUM
dpc-5749	260	4	/	/	SYM
dpc-5749	260	5	s0049	s0049	PROPN
dpc-5749	260	6	-	-	PUNCT
dpc-5749	260	7	0172(10)80012	0172(10)80012	NOUN
dpc-5749	260	8	-	-	PUNCT
dpc-5749	260	9	5	5	NUM
dpc-5749	260	10	.	.	PUNCT
dpc-5749	261	1	pmid	pmid	NOUN
dpc-5749	261	2	:	:	PUNCT
dpc-5749	261	3	8278823	8278823	NUM
dpc-5749	261	4	.	.	PUNCT
dpc-5749	262	1	26	26	NUM
dpc-5749	262	2	.	.	PUNCT
dpc-5749	262	3	morel	morel	PROPN
dpc-5749	262	4	m	m	PROPN
dpc-5749	262	5	,	,	PUNCT
dpc-5749	262	6	degrazia	degrazia	PROPN
dpc-5749	262	7	t	t	PROPN
dpc-5749	262	8	,	,	PUNCT
dpc-5749	262	9	ward	ward	NOUN
dpc-5749	262	10	l	l	PROPN
dpc-5749	262	11	,	,	PUNCT
dpc-5749	262	12	behshad	behshad	PROPN
dpc-5749	262	13	s	s	PROPN
dpc-5749	262	14	,	,	PUNCT
dpc-5749	262	15	kim	kim	PROPN
dpc-5749	262	16	hj	hj	PROPN
dpc-5749	262	17	,	,	PUNCT
dpc-5749	262	18	feldman	feldman	PROPN
dpc-5749	262	19	r.	r.	PROPN
dpc-5749	262	20	single	single	PROPN
dpc-5749	262	21	center	center	PROPN
dpc-5749	262	22	retrospective	retrospective	ADJ
dpc-5749	262	23	study	study	NOUN
dpc-5749	262	24	of	of	ADP
dpc-5749	262	25	patients	patient	NOUN
dpc-5749	262	26	with	with	ADP
dpc-5749	262	27	ocular	ocular	ADJ
dpc-5749	262	28	mucous	mucous	ADJ
dpc-5749	262	29	membrane	membrane	NOUN
dpc-5749	262	30	pemphigoid	pemphigoid	NOUN
dpc-5749	262	31	(	(	PUNCT
dpc-5749	262	32	mmp	mmp	PROPN
dpc-5749	262	33	)	)	PUNCT
dpc-5749	262	34	.	.	PUNCT
dpc-5749	263	1	ocul	ocul	PROPN
dpc-5749	263	2	immunol	immunol	PROPN
dpc-5749	263	3	inflamm	inflamm	PROPN
dpc-5749	263	4	.	.	PUNCT
dpc-5749	264	1	2022	2022	NUM
dpc-5749	264	2	;	;	PUNCT
dpc-5749	265	1	30(1):256	30(1):256	X
dpc-5749	265	2	-	-	SYM
dpc-5749	265	3	261	261	NUM
dpc-5749	265	4	.	.	PUNCT
dpc-5749	266	1	doi	doi	NOUN
dpc-5749	266	2	:	:	PUNCT
dpc-5749	266	3	10.1080/09273948.2020.1783322	10.1080/09273948.2020.1783322	PROPN
dpc-5749	266	4	.	.	PUNCT
dpc-5749	267	1	pmid	pmid	NOUN
dpc-5749	267	2	:	:	PUNCT
dpc-5749	267	3	32835566	32835566	NUM
dpc-5749	267	4	.	.	PUNCT
dpc-5749	268	1	27	27	NUM
dpc-5749	268	2	.	.	PUNCT
dpc-5749	269	1	guerrero	guerrero	PROPN
dpc-5749	269	2	jcs	jcs	PROPN
dpc-5749	269	3	,	,	PUNCT
dpc-5749	269	4	vincenzi	vincenzi	PROPN
dpc-5749	269	5	k	k	PROPN
dpc-5749	269	6	,	,	PUNCT
dpc-5749	269	7	buñay	buñay	PROPN
dpc-5749	269	8	pgp	pgp	PROPN
dpc-5749	269	9	,	,	PUNCT
dpc-5749	269	10	et	et	PROPN
dpc-5749	269	11	al	al	PROPN
dpc-5749	269	12	.	.	PROPN
dpc-5749	269	13	brunsting	brunsting	PROPN
dpc-5749	269	14	-	-	PUNCT
dpc-5749	269	15	perry	perry	PROPN
dpc-5749	269	16	cicatricial	cicatricial	PROPN
dpc-5749	269	17	pemphigoid	pemphigoid	NOUN
dpc-5749	269	18	of	of	ADP
dpc-5749	269	19	the	the	DET
dpc-5749	269	20	scalp	scalp	NOUN
dpc-5749	269	21	.	.	PUNCT
dpc-5749	270	1	ijcmcr	ijcmcr	PROPN
dpc-5749	270	2	.	.	PUNCT
dpc-5749	271	1	2025;48(3):005	2025;48(3):005	NUM
dpc-5749	271	2	.	.	PUNCT
dpc-5749	272	1	doi	doi	NOUN
dpc-5749	272	2	:	:	PUNCT
dpc-5749	272	3	10.46998	10.46998	NUM
dpc-5749	272	4	/	/	SYM
dpc-5749	272	5	ijcmcr.2025.49.001210	ijcmcr.2025.49.001210	PROPN
dpc-5749	272	6	.	.	PUNCT
dpc-5749	273	1	28	28	NUM
dpc-5749	273	2	.	.	PUNCT
dpc-5749	274	1	misra	misra	PROPN
dpc-5749	274	2	dp	dp	PROPN
dpc-5749	274	3	,	,	PUNCT
dpc-5749	274	4	gasparyan	gasparyan	PROPN
dpc-5749	274	5	ay	ay	PROPN
dpc-5749	274	6	,	,	PUNCT
dpc-5749	274	7	zimba	zimba	NOUN
dpc-5749	274	8	o.	o.	PROPN
dpc-5749	274	9	benefits	benefit	NOUN
dpc-5749	274	10	and	and	CCONJ
dpc-5749	274	11	adverse	adverse	ADJ
dpc-5749	274	12	effects	effect	NOUN
dpc-5749	274	13	of	of	ADP
dpc-5749	274	14	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-5749	274	15	,	,	PUNCT
dpc-5749	274	16	methotrexate	methotrexate	NOUN
dpc-5749	274	17	and	and	CCONJ
dpc-5749	274	18	colchicine	colchicine	PROPN
dpc-5749	274	19	:	:	PUNCT
dpc-5749	274	20	searching	search	VERB
dpc-5749	274	21	for	for	ADP
dpc-5749	274	22	repurposable	repurposable	ADJ
dpc-5749	274	23	drug	drug	NOUN
dpc-5749	274	24	candidates	candidate	NOUN
dpc-5749	274	25	.	.	PUNCT
dpc-5749	275	1	rheumatol	rheumatol	PROPN
dpc-5749	275	2	int	int	NOUN
dpc-5749	275	3	.	.	PUNCT
dpc-5749	276	1	2020;40(11):17411751	2020;40(11):17411751	NUM
dpc-5749	276	2	.	.	PUNCT
dpc-5749	277	1	doi	doi	NOUN
dpc-5749	277	2	:	:	PUNCT
dpc-5749	277	3	10.1007	10.1007	NUM
dpc-5749	277	4	/	/	SYM
dpc-5749	277	5	s00296	s00296	PROPN
dpc-5749	277	6	-	-	PUNCT
dpc-5749	277	7	020	020	NUM
dpc-5749	277	8	-	-	PUNCT
dpc-5749	277	9	04694	04694	NUM
dpc-5749	277	10	-	-	PUNCT
dpc-5749	277	11	2	2	NUM
dpc-5749	277	12	.	.	PUNCT
dpc-5749	278	1	pmid	pmid	NOUN
dpc-5749	278	2	:	:	PUNCT
dpc-5749	278	3	32880032	32880032	NUM
dpc-5749	278	4	.	.	PUNCT
dpc-5749	279	1	29	29	NUM
dpc-5749	279	2	.	.	PUNCT
dpc-5749	280	1	sharma	sharma	PROPN
dpc-5749	280	2	an	an	PROPN
dpc-5749	280	3	,	,	PUNCT
dpc-5749	280	4	mesinkovska	mesinkovska	PROPN
dpc-5749	280	5	na	na	NOUN
dpc-5749	280	6	,	,	PUNCT
dpc-5749	280	7	paravar	paravar	NOUN
dpc-5749	280	8	t.	t.	NOUN
dpc-5749	280	9	characterizing	characterize	VERB
dpc-5749	280	10	the	the	DET
dpc-5749	280	11	adverse	adverse	ADJ
dpc-5749	280	12	dermatologic	dermatologic	ADJ
dpc-5749	280	13	effects	effect	NOUN
dpc-5749	280	14	of	of	ADP
dpc-5749	280	15	hydroxychloroquine	hydroxychloroquine	NOUN
dpc-5749	280	16	:	:	PUNCT
dpc-5749	280	17	a	a	DET
dpc-5749	280	18	systematic	systematic	ADJ
dpc-5749	280	19	review	review	NOUN
dpc-5749	280	20	.	.	PUNCT
dpc-5749	281	1	j	j	PROPN
dpc-5749	281	2	am	be	AUX
dpc-5749	281	3	acad	acad	ADJ
dpc-5749	281	4	dermatol	dermatol	NOUN
dpc-5749	281	5	.	.	PUNCT
dpc-5749	282	1	2020;83(2):563	2020;83(2):563	NOUN
dpc-5749	282	2	-	-	PUNCT
dpc-5749	282	3	578	578	NUM
dpc-5749	282	4	.	.	PUNCT
dpc-5749	283	1	doi	doi	NOUN
dpc-5749	283	2	:	:	PUNCT
dpc-5749	283	3	10.1016	10.1016	NUM
dpc-5749	283	4	/	/	SYM
dpc-5749	283	5	j.jaad.2020.04.024	j.jaad.2020.04.024	PROPN
dpc-5749	283	6	.	.	PUNCT
dpc-5749	284	1	pmid	pmid	NOUN
dpc-5749	284	2	:	:	PUNCT
dpc-5749	284	3	32289395	32289395	NUM
dpc-5749	284	4	.	.	PUNCT
dpc-5749	285	1	30	30	NUM
dpc-5749	285	2	.	.	PUNCT
dpc-5749	286	1	smichowski	smichowski	PROPN
dpc-5749	286	2	am	am	PROPN
dpc-5749	286	3	,	,	PUNCT
dpc-5749	286	4	caputo	caputo	PROPN
dpc-5749	286	5	vd	vd	PROPN
dpc-5749	286	6	,	,	PUNCT
dpc-5749	286	7	romeo	romeo	PROPN
dpc-5749	286	8	c	c	PROPN
dpc-5749	286	9	,	,	PUNCT
dpc-5749	286	10	rivero	rivero	PROPN
dpc-5749	286	11	e	e	PROPN
dpc-5749	286	12	,	,	PUNCT
dpc-5749	286	13	morales	morales	PROPN
dpc-5749	286	14	ns	ns	NUM
dpc-5749	286	15	,	,	PUNCT
dpc-5749	286	16	casado	casado	NOUN
dpc-5749	286	17	g.	g.	PROPN
dpc-5749	286	18	ocular	ocular	ADJ
dpc-5749	286	19	cicatricial	cicatricial	ADJ
dpc-5749	286	20	pemphigoid	pemphigoid	NOUN
dpc-5749	286	21	:	:	PUNCT
dpc-5749	286	22	methotrexate	methotrexate	VERB
dpc-5749	286	23	as	as	ADP
dpc-5749	286	24	an	an	DET
dpc-5749	286	25	initial	initial	ADJ
dpc-5749	286	26	treatment	treatment	NOUN
dpc-5749	286	27	?	?	PUNCT
dpc-5749	287	1	reumatol	reumatol	PROPN
dpc-5749	287	2	clin	clin	PROPN
dpc-5749	287	3	(	(	PUNCT
dpc-5749	287	4	engl	engl	PROPN
dpc-5749	287	5	ed	ed	NOUN
dpc-5749	287	6	)	)	PUNCT
dpc-5749	287	7	.	.	PUNCT
dpc-5749	288	1	2022;18(1):30	2022;18(1):30	NUM
dpc-5749	288	2	-	-	SYM
dpc-5749	288	3	32	32	NUM
dpc-5749	288	4	.	.	PUNCT
dpc-5749	289	1	doi	doi	NOUN
dpc-5749	289	2	:	:	PUNCT
dpc-5749	289	3	10.1016	10.1016	NUM
dpc-5749	289	4	/	/	SYM
dpc-5749	289	5	j.reumae.2020.10.003	j.reumae.2020.10.003	PROPN
dpc-5749	289	6	.	.	PUNCT
dpc-5749	290	1	pmid	pmid	NOUN
dpc-5749	290	2	:	:	PUNCT
dpc-5749	290	3	34088654	34088654	NUM
dpc-5749	290	4	.	.	PUNCT
dpc-5749	291	1	31	31	NUM
dpc-5749	291	2	.	.	PUNCT
dpc-5749	291	3	boedeker	boedeker	PROPN
dpc-5749	291	4	cc	cc	PROPN
dpc-5749	291	5	,	,	PUNCT
dpc-5749	291	6	termeer	termeer	PROPN
dpc-5749	291	7	cc	cc	PROPN
dpc-5749	291	8	,	,	PUNCT
dpc-5749	291	9	staats	staats	PROPN
dpc-5749	291	10	r	r	PROPN
dpc-5749	291	11	,	,	PUNCT
dpc-5749	291	12	ridder	ridder	PROPN
dpc-5749	291	13	gj	gj	PROPN
dpc-5749	291	14	.	.	PROPN
dpc-5749	291	15	cicatricial	cicatricial	PROPN
dpc-5749	291	16	pemphigoid	pemphigoid	NOUN
dpc-5749	291	17	in	in	ADP
dpc-5749	291	18	the	the	DET
dpc-5749	291	19	upper	upper	ADJ
dpc-5749	291	20	aerodigestive	aerodigestive	ADJ
dpc-5749	291	21	tract	tract	NOUN
dpc-5749	291	22	:	:	PUNCT
dpc-5749	291	23	diagnosis	diagnosis	NOUN
dpc-5749	291	24	and	and	CCONJ
dpc-5749	291	25	management	management	NOUN
dpc-5749	291	26	in	in	ADP
dpc-5749	291	27	severe	severe	ADJ
dpc-5749	291	28	laryngeal	laryngeal	ADJ
dpc-5749	291	29	stenosis	stenosis	NOUN
dpc-5749	291	30	.	.	PUNCT
dpc-5749	292	1	ann	ann	PROPN
dpc-5749	292	2	otol	otol	PROPN
dpc-5749	292	3	rhinol	rhinol	NOUN
dpc-5749	292	4	laryngol	laryngol	NOUN
dpc-5749	292	5	.	.	PUNCT
dpc-5749	293	1	2003;112(3):271	2003;112(3):271	NUM
dpc-5749	293	2	-	-	SYM
dpc-5749	293	3	5	5	NUM
dpc-5749	293	4	.	.	PUNCT
dpc-5749	293	5	doi	doi	NOUN
dpc-5749	293	6	:	:	PUNCT
dpc-5749	293	7	10.1177/000348940311200314	10.1177/000348940311200314	NUM
dpc-5749	293	8	.	.	PUNCT
dpc-5749	294	1	pmid	pmid	NOUN
dpc-5749	294	2	:	:	PUNCT
dpc-5749	294	3	12656421	12656421	NUM
dpc-5749	294	4	.	.	PUNCT
dpc-5749	295	1	32	32	NUM
dpc-5749	295	2	.	.	PUNCT
dpc-5749	296	1	kaltwasser	kaltwasser	PROPN
dpc-5749	296	2	jp	jp	PROPN
dpc-5749	296	3	,	,	PUNCT
dpc-5749	296	4	behrens	behrens	PROPN
dpc-5749	296	5	f.	f.	PROPN
dpc-5749	296	6	leflunomide	leflunomide	PROPN
dpc-5749	296	7	:	:	PUNCT
dpc-5749	296	8	long	long	ADJ
dpc-5749	296	9	-	-	PUNCT
dpc-5749	296	10	term	term	NOUN
dpc-5749	296	11	clinical	clinical	ADJ
dpc-5749	296	12	experience	experience	NOUN
dpc-5749	296	13	and	and	CCONJ
dpc-5749	296	14	new	new	ADJ
dpc-5749	296	15	uses	use	NOUN
dpc-5749	296	16	.	.	PUNCT
dpc-5749	297	1	expert	expert	NOUN
dpc-5749	297	2	opin	opin	NOUN
dpc-5749	297	3	pharmacother	pharmacother	NOUN
dpc-5749	297	4	.	.	PUNCT
dpc-5749	298	1	2005;6(5	2005;6(5	NUM
dpc-5749	298	2	):	):	PUNCT
dpc-5749	298	3	787	787	NUM
dpc-5749	298	4	-	-	SYM
dpc-5749	298	5	801	801	NUM
dpc-5749	298	6	.	.	PUNCT
dpc-5749	299	1	doi	doi	NOUN
dpc-5749	299	2	:	:	PUNCT
dpc-5749	299	3	10.1517/14656566.6.5.787	10.1517/14656566.6.5.787	NOUN
dpc-5749	299	4	.	.	PUNCT
dpc-5749	300	1	pmid	pmid	NOUN
dpc-5749	300	2	:	:	PUNCT
dpc-5749	300	3	15934905	15934905	NUM
dpc-5749	300	4	.	.	PUNCT
dpc-5749	301	1	33	33	NUM
dpc-5749	301	2	.	.	PUNCT
dpc-5749	302	1	askanase	askanase	NOUN
dpc-5749	302	2	ad	ad	NOUN
dpc-5749	302	3	,	,	PUNCT
dpc-5749	302	4	furie	furie	PROPN
dpc-5749	302	5	ra	ra	PROPN
dpc-5749	302	6	.	.	PUNCT
dpc-5749	303	1	a	a	DET
dpc-5749	303	2	narrative	narrative	ADJ
dpc-5749	303	3	review	review	NOUN
dpc-5749	303	4	of	of	ADP
dpc-5749	303	5	repository	repository	NOUN
dpc-5749	303	6	corticotropin	corticotropin	NOUN
dpc-5749	303	7	injection	injection	NOUN
dpc-5749	303	8	for	for	ADP
dpc-5749	303	9	the	the	DET
dpc-5749	303	10	treatment	treatment	NOUN
dpc-5749	303	11	of	of	ADP
dpc-5749	303	12	systemic	systemic	ADJ
dpc-5749	303	13	lupus	lupus	PROPN
dpc-5749	303	14	erythematosus	erythematosus	PROPN
dpc-5749	303	15	.	.	PUNCT
dpc-5749	304	1	adv	adv	PROPN
dpc-5749	304	2	ther	ther	ADV
dpc-5749	304	3	.	.	PUNCT
dpc-5749	305	1	2022;39(7):3088	2022;39(7):3088	NUM
dpc-5749	305	2	-	-	PUNCT
dpc-5749	305	3	3103	3103	NUM
dpc-5749	305	4	.	.	PUNCT
dpc-5749	306	1	doi	doi	NOUN
dpc-5749	306	2	:	:	PUNCT
dpc-5749	306	3	10.1007	10.1007	NUM
dpc-5749	306	4	/s12325	/s12325	NOUN
dpc-5749	306	5	-	-	PUNCT
dpc-5749	306	6	022	022	NUM
dpc-5749	306	7	-	-	PUNCT
dpc-5749	306	8	02160	02160	NUM
dpc-5749	306	9	-	-	PUNCT
dpc-5749	306	10	y.	y.	NOUN
dpc-5749	306	11	pmid	pmid	PROPN
dpc-5749	306	12	:	:	PUNCT
dpc-5749	306	13	35641860	35641860	NUM
dpc-5749	306	14	.	.	PUNCT
dpc-5749	307	1	34	34	NUM
dpc-5749	307	2	.	.	PUNCT
dpc-5749	308	1	sharon	sharon	PROPN
dpc-5749	308	2	y	y	PROPN
dpc-5749	308	3	,	,	PUNCT
dpc-5749	308	4	anesi	anesi	VERB
dpc-5749	308	5	sd	sd	PROPN
dpc-5749	308	6	,	,	PUNCT
dpc-5749	308	7	martinez	martinez	PROPN
dpc-5749	308	8	ce	ce	PROPN
dpc-5749	308	9	,	,	PUNCT
dpc-5749	308	10	huang	huang	PROPN
dpc-5749	308	11	ajw	ajw	PROPN
dpc-5749	308	12	,	,	PUNCT
dpc-5749	308	13	foster	foster	ADJ
dpc-5749	308	14	cs	cs	PROPN
dpc-5749	308	15	,	,	PUNCT
dpc-5749	308	16	chu	chu	PROPN
dpc-5749	308	17	ds	ds	PROPN
dpc-5749	308	18	.	.	PROPN
dpc-5749	308	19	repository	repository	NOUN
dpc-5749	308	20	corticotropin	corticotropin	NOUN
dpc-5749	308	21	injection	injection	NOUN
dpc-5749	308	22	as	as	ADP
dpc-5749	308	23	an	an	DET
dpc-5749	308	24	alternative	alternative	ADJ
dpc-5749	308	25	treatment	treatment	NOUN
dpc-5749	308	26	for	for	ADP
dpc-5749	308	27	refractory	refractory	NOUN
dpc-5749	308	28	ocular	ocular	ADJ
dpc-5749	308	29	mucous	mucous	ADJ
dpc-5749	308	30	membrane	membrane	NOUN
dpc-5749	308	31	pemphigoid	pemphigoid	NOUN
dpc-5749	308	32	.	.	PUNCT
dpc-5749	309	1	cornea	cornea	INTJ
dpc-5749	309	2	.	.	PUNCT
dpc-5749	310	1	2022;41(1):45	2022;41(1):45	NUM
dpc-5749	310	2	-	-	SYM
dpc-5749	310	3	51	51	NUM
dpc-5749	310	4	.	.	PUNCT
dpc-5749	310	5	doi	doi	NOUN
dpc-5749	310	6	:	:	PUNCT
dpc-5749	310	7	10.1097	10.1097	NUM
dpc-5749	310	8	/	/	SYM
dpc-5749	310	9	ico.000000000000277	ico.000000000000277	NOUN
dpc-5749	310	10	.	.	PUNCT
dpc-5749	311	1	pmid	pmid	NOUN
dpc-5749	311	2	:	:	PUNCT
dpc-5749	311	3	34050065	34050065	NUM
dpc-5749	311	4	.	.	PUNCT
dpc-5749	312	1	35	35	NUM
dpc-5749	312	2	.	.	PUNCT
dpc-5749	313	1	abbott	abbott	PROPN
dpc-5749	313	2	ks	ks	PROPN
dpc-5749	313	3	,	,	PUNCT
dpc-5749	313	4	palestine	palestine	PROPN
dpc-5749	313	5	ag	ag	PROPN
dpc-5749	313	6	,	,	PUNCT
dpc-5749	313	7	hauswirth	hauswirth	NOUN
dpc-5749	313	8	sg	sg	PROPN
dpc-5749	313	9	,	,	PUNCT
dpc-5749	313	10	gregory	gregory	PROPN
dpc-5749	313	11	dg	dg	PROPN
dpc-5749	313	12	,	,	PUNCT
dpc-5749	313	13	patnaik	patnaik	PROPN
dpc-5749	313	14	jl	jl	PROPN
dpc-5749	313	15	,	,	PUNCT
dpc-5749	313	16	reddy	reddy	PROPN
dpc-5749	313	17	ak	ak	PROPN
dpc-5749	313	18	.	.	PROPN
dpc-5749	313	19	treatment	treatment	NOUN
dpc-5749	313	20	of	of	ADP
dpc-5749	313	21	ocular	ocular	ADJ
dpc-5749	313	22	surface	surface	NOUN
dpc-5749	313	23	disease	disease	NOUN
dpc-5749	313	24	in	in	ADP
dpc-5749	313	25	ocular	ocular	ADJ
dpc-5749	313	26	cicatricial	cicatricial	ADJ
dpc-5749	313	27	pemphigoid	pemphigoid	NOUN
dpc-5749	313	28	.	.	PUNCT
dpc-5749	314	1	ocul	ocul	NOUN
dpc-5749	314	2	immunol	immunol	PROPN
dpc-5749	314	3	inflamm	inflamm	PROPN
dpc-5749	314	4	.	.	PUNCT
dpc-5749	315	1	2024	2024	NUM
dpc-5749	315	2	;	;	PUNCT
dpc-5749	315	3	32(10):2479	32(10):2479	NUM
dpc-5749	315	4	-	-	SYM
dpc-5749	315	5	2485	2485	NUM
dpc-5749	315	6	.	.	PUNCT
dpc-5749	316	1	doi	doi	NOUN
dpc-5749	316	2	:	:	PUNCT
dpc-5749	316	3	10.1080/09273948.2024.2413892	10.1080/09273948.2024.2413892	NUM
dpc-5749	316	4	.	.	PUNCT
dpc-5749	317	1	pmid	pmid	NOUN
dpc-5749	317	2	:	:	PUNCT
dpc-5749	317	3	39383489	39383489	NUM
dpc-5749	317	4	.	.	PUNCT
dpc-5749	318	1	36	36	NUM
dpc-5749	318	2	.	.	X
dpc-5749	318	3	surico	surico	PROPN
dpc-5749	318	4	pl	pl	PROPN
dpc-5749	318	5	,	,	PUNCT
dpc-5749	318	6	kaufman	kaufman	PROPN
dpc-5749	318	7	ar	ar	PROPN
dpc-5749	318	8	,	,	PUNCT
dpc-5749	318	9	lin	lin	PROPN
dpc-5749	318	10	j	j	PROPN
dpc-5749	318	11	,	,	PUNCT
dpc-5749	318	12	dehghani	dehghani	PROPN
dpc-5749	318	13	s	s	PROPN
dpc-5749	318	14	,	,	PUNCT
dpc-5749	318	15	dana	dana	PROPN
dpc-5749	318	16	r.	r.	PROPN
dpc-5749	318	17	corneal	corneal	PROPN
dpc-5749	318	18	superficial	superficial	ADJ
dpc-5749	318	19	plaque	plaque	NOUN
dpc-5749	318	20	formation	formation	NOUN
dpc-5749	318	21	after	after	ADP
dpc-5749	318	22	recombinant	recombinant	ADJ
dpc-5749	318	23	human	human	ADJ
dpc-5749	318	24	nerve	nerve	NOUN
dpc-5749	318	25	growth	growth	NOUN
dpc-5749	318	26	factor	factor	NOUN
dpc-5749	318	27	use	use	NOUN
dpc-5749	318	28	in	in	ADP
dpc-5749	318	29	a	a	DET
dpc-5749	318	30	patient	patient	NOUN
dpc-5749	318	31	with	with	ADP
dpc-5749	318	32	neurotrophic	neurotrophic	ADJ
dpc-5749	318	33	keratopathy	keratopathy	ADJ
dpc-5749	318	34	and	and	CCONJ
dpc-5749	318	35	limbal	limbal	ADJ
dpc-5749	318	36	stem	stem	NOUN
dpc-5749	318	37	cell	cell	NOUN
dpc-5749	318	38	deficiency	deficiency	NOUN
dpc-5749	318	39	from	from	ADP
dpc-5749	318	40	mucous	mucous	ADJ
dpc-5749	318	41	membrane	membrane	NOUN
dpc-5749	318	42	pemphigoid	pemphigoid	NOUN
dpc-5749	318	43	.	.	PUNCT
dpc-5749	319	1	cornea	cornea	INTJ
dpc-5749	319	2	.	.	PUNCT
dpc-5749	320	1	2024;43(7):899	2024;43(7):899	NUM
dpc-5749	320	2	-	-	SYM
dpc-5749	320	3	902	902	NUM
dpc-5749	320	4	.	.	PUNCT
dpc-5749	321	1	doi	doi	NOUN
dpc-5749	321	2	:	:	PUNCT
dpc-5749	321	3	10.1097/	10.1097/	NUM
dpc-5749	321	4	ico.0000000000003442	ico.0000000000003442	NUM
dpc-5749	321	5	.	.	PUNCT
dpc-5749	322	1	pmid	pmid	NOUN
dpc-5749	322	2	:	:	PUNCT
dpc-5749	322	3	38015976	38015976	NUM
dpc-5749	322	4	.	.	PUNCT
dpc-5749	323	1	37	37	NUM
dpc-5749	323	2	.	.	PUNCT
dpc-5749	323	3	morelon	morelon	PROPN
dpc-5749	323	4	e	e	PROPN
dpc-5749	323	5	,	,	PUNCT
dpc-5749	323	6	mamzer	mamzer	NOUN
dpc-5749	323	7	-	-	PUNCT
dpc-5749	323	8	bruneel	bruneel	NOUN
dpc-5749	323	9	mf	mf	NOUN
dpc-5749	323	10	,	,	PUNCT
dpc-5749	323	11	peraldi	peraldi	PROPN
dpc-5749	323	12	mn	mn	PROPN
dpc-5749	323	13	,	,	PUNCT
dpc-5749	323	14	kreis	kreis	PROPN
dpc-5749	323	15	h.	h.	PROPN
dpc-5749	323	16	sirolimus	sirolimus	PROPN
dpc-5749	323	17	:	:	PUNCT
dpc-5749	323	18	a	a	DET
dpc-5749	323	19	new	new	ADJ
dpc-5749	323	20	promising	promising	ADJ
dpc-5749	323	21	immunosuppressive	immunosuppressive	ADJ
dpc-5749	323	22	drug	drug	NOUN
dpc-5749	323	23	.	.	PUNCT
dpc-5749	324	1	towards	towards	ADP
dpc-5749	324	2	a	a	DET
dpc-5749	324	3	rationale	rationale	NOUN
dpc-5749	324	4	for	for	ADP
dpc-5749	324	5	its	its	PRON
dpc-5749	324	6	use	use	NOUN
dpc-5749	324	7	in	in	ADP
dpc-5749	324	8	renal	renal	ADJ
dpc-5749	324	9	transplantation	transplantation	NOUN
dpc-5749	324	10	.	.	PUNCT
dpc-5749	325	1	nephrol	nephrol	PROPN
dpc-5749	325	2	dial	dial	NOUN
dpc-5749	325	3	transplant	transplant	NOUN
dpc-5749	325	4	.	.	PUNCT
dpc-5749	326	1	2001;16(1):18	2001;16(1):18	NUM
dpc-5749	326	2	-	-	SYM
dpc-5749	326	3	20	20	NUM
dpc-5749	326	4	.	.	PUNCT
dpc-5749	327	1	doi	doi	NOUN
dpc-5749	327	2	:	:	PUNCT
dpc-5749	327	3	10.1093	10.1093	NUM
dpc-5749	327	4	/	/	SYM
dpc-5749	327	5	ndt/16.1.18	ndt/16.1.18	PROPN
dpc-5749	327	6	.	.	PUNCT
dpc-5749	328	1	pmid	pmid	NOUN
dpc-5749	328	2	:	:	PUNCT
dpc-5749	328	3	11208987	11208987	NUM
dpc-5749	328	4	.	.	PUNCT
dpc-5749	329	1	10	10	NUM
dpc-5749	329	2	.	.	PUNCT
dpc-5749	330	1	papaliodis	papaliodis	PROPN
dpc-5749	330	2	gn	gn	PROPN
dpc-5749	330	3	,	,	PUNCT
dpc-5749	330	4	chu	chu	PROPN
dpc-5749	330	5	d	d	PROPN
dpc-5749	330	6	,	,	PUNCT
dpc-5749	330	7	foster	foster	PROPN
dpc-5749	330	8	cs	cs	PROPN
dpc-5749	330	9	.	.	PROPN
dpc-5749	330	10	treatment	treatment	NOUN
dpc-5749	330	11	of	of	ADP
dpc-5749	330	12	ocular	ocular	ADJ
dpc-5749	330	13	inflammatory	inflammatory	ADJ
dpc-5749	330	14	disorders	disorder	NOUN
dpc-5749	330	15	with	with	ADP
dpc-5749	330	16	daclizumab	daclizumab	NOUN
dpc-5749	330	17	.	.	PUNCT
dpc-5749	330	18	ophthalmology	ophthalmology	PROPN
dpc-5749	330	19	.	.	PUNCT
dpc-5749	331	1	2003	2003	NUM
dpc-5749	331	2	;	;	PUNCT
dpc-5749	331	3	110(4):786	110(4):786	NUM
dpc-5749	331	4	-	-	SYM
dpc-5749	331	5	9	9	NUM
dpc-5749	331	6	.	.	PUNCT
dpc-5749	331	7	doi	doi	NOUN
dpc-5749	331	8	:	:	PUNCT
dpc-5749	331	9	10.1016	10.1016	NUM
dpc-5749	331	10	/	/	SYM
dpc-5749	331	11	s0161	s0161	VERB
dpc-5749	331	12	-	-	PUNCT
dpc-5749	331	13	6420(02)01932	6420(02)01932	NUM
dpc-5749	331	14	-	-	PUNCT
dpc-5749	331	15	2	2	NUM
dpc-5749	331	16	.	.	PUNCT
dpc-5749	332	1	pmid	pmid	NOUN
dpc-5749	332	2	:	:	PUNCT
dpc-5749	332	3	12689903	12689903	NUM
dpc-5749	332	4	.	.	PUNCT
dpc-5749	333	1	11	11	NUM
dpc-5749	333	2	.	.	X
dpc-5749	334	1	razzaque	razzaque	VERB
dpc-5749	334	2	ms	ms	PROPN
dpc-5749	334	3	,	,	PUNCT
dpc-5749	334	4	ahmed	ahmed	PROPN
dpc-5749	334	5	bs	bs	PROPN
dpc-5749	334	6	,	,	PUNCT
dpc-5749	334	7	foster	foster	ADJ
dpc-5749	334	8	cs	cs	PROPN
dpc-5749	334	9	,	,	PUNCT
dpc-5749	334	10	ahmed	ahmed	PROPN
dpc-5749	334	11	ar	ar	PROPN
dpc-5749	334	12	.	.	PROPN
dpc-5749	334	13	effects	effect	NOUN
dpc-5749	334	14	of	of	ADP
dpc-5749	334	15	il-4	il-4	NOUN
dpc-5749	334	16	on	on	ADP
dpc-5749	334	17	conjunctival	conjunctival	ADJ
dpc-5749	334	18	fibroblasts	fibroblast	NOUN
dpc-5749	334	19	:	:	PUNCT
dpc-5749	334	20	possible	possible	ADJ
dpc-5749	334	21	role	role	NOUN
dpc-5749	334	22	in	in	ADP
dpc-5749	334	23	ocular	ocular	ADJ
dpc-5749	334	24	cicatricial	cicatricial	ADJ
dpc-5749	334	25	pemphigoid	pemphigoid	NOUN
dpc-5749	334	26	.	.	PUNCT
dpc-5749	335	1	invest	invest	VERB
dpc-5749	335	2	ophthalmol	ophthalmol	PROPN
dpc-5749	335	3	vis	vis	X
dpc-5749	335	4	sci	sci	PROPN
dpc-5749	335	5	.	.	PUNCT
dpc-5749	336	1	2003;44(8):3417	2003;44(8):3417	NUM
dpc-5749	336	2	-	-	SYM
dpc-5749	336	3	23	23	NUM
dpc-5749	336	4	.	.	PUNCT
dpc-5749	337	1	doi	doi	NOUN
dpc-5749	337	2	:	:	PUNCT
dpc-5749	337	3	10.1167	10.1167	NUM
dpc-5749	337	4	/	/	SYM
dpc-5749	337	5	iovs.02	iovs.02	PROPN
dpc-5749	337	6	-	-	PUNCT
dpc-5749	337	7	1084	1084	NUM
dpc-5749	337	8	.	.	PUNCT
dpc-5749	338	1	pmid	pmid	NOUN
dpc-5749	338	2	:	:	PUNCT
dpc-5749	338	3	12882790	12882790	NUM
dpc-5749	338	4	.	.	PUNCT
dpc-5749	339	1	12	12	NUM
dpc-5749	339	2	.	.	PUNCT
dpc-5749	340	1	saw	see	VERB
dpc-5749	340	2	vp	vp	PROPN
dpc-5749	340	3	,	,	PUNCT
dpc-5749	340	4	offiah	offiah	PROPN
dpc-5749	340	5	i	i	PRON
dpc-5749	340	6	,	,	PUNCT
dpc-5749	340	7	dart	dart	PROPN
dpc-5749	340	8	rj	rj	PROPN
dpc-5749	340	9	,	,	PUNCT
dpc-5749	340	10	et	et	PROPN
dpc-5749	340	11	al	al	PROPN
dpc-5749	340	12	.	.	PUNCT
dpc-5749	341	1	conjunctival	conjunctival	NOUN
dpc-5749	341	2	interleukin-13	interleukin-13	NUM
dpc-5749	341	3	expression	expression	NOUN
dpc-5749	341	4	in	in	ADP
dpc-5749	341	5	mucous	mucous	ADJ
dpc-5749	341	6	membrane	membrane	NOUN
dpc-5749	341	7	pemphigoid	pemphigoid	NOUN
dpc-5749	341	8	and	and	CCONJ
dpc-5749	341	9	functional	functional	ADJ
dpc-5749	341	10	effects	effect	NOUN
dpc-5749	341	11	of	of	ADP
dpc-5749	341	12	interleukin-13	interleukin-13	PRON
dpc-5749	341	13	on	on	ADP
dpc-5749	341	14	conjunctival	conjunctival	ADJ
dpc-5749	341	15	fibroblasts	fibroblast	NOUN
dpc-5749	341	16	in	in	ADP
dpc-5749	341	17	vitro	vitro	VERB
dpc-5749	341	18	.	.	PUNCT
dpc-5749	342	1	am	be	AUX
dpc-5749	342	2	j	j	PROPN
dpc-5749	342	3	pathol	pathol	NOUN
dpc-5749	342	4	.	.	PUNCT
dpc-5749	343	1	2009;175(6):2406	2009;175(6):2406	NUM
dpc-5749	343	2	-	-	SYM
dpc-5749	343	3	15	15	NUM
dpc-5749	343	4	.	.	PUNCT
dpc-5749	343	5	doi	doi	NOUN
dpc-5749	343	6	:	:	PUNCT
dpc-5749	343	7	10.2353	10.2353	NUM
dpc-5749	343	8	/	/	SYM
dpc-5749	343	9	ajpath.2009	ajpath.2009	PROPN
dpc-5749	343	10	.090579	.090579	PROPN
dpc-5749	343	11	.	.	PUNCT
dpc-5749	344	1	pmid	pmid	NOUN
dpc-5749	344	2	:	:	PUNCT
dpc-5749	344	3	19910508	19910508	NUM
dpc-5749	344	4	.	.	PUNCT
dpc-5749	345	1	13	13	NUM
dpc-5749	345	2	.	.	PUNCT
dpc-5749	346	1	wang	wang	PROPN
dpc-5749	346	2	z	z	PROPN
dpc-5749	346	3	,	,	PUNCT
dpc-5749	346	4	liu	liu	PROPN
dpc-5749	346	5	x	x	PROPN
dpc-5749	346	6	,	,	PUNCT
dpc-5749	346	7	ni	ni	PROPN
dpc-5749	346	8	j	j	PROPN
dpc-5749	346	9	,	,	PUNCT
dpc-5749	346	10	qi	qi	PROPN
dpc-5749	346	11	y	y	PROPN
dpc-5749	346	12	,	,	PUNCT
dpc-5749	346	13	song	song	NOUN
dpc-5749	346	14	z	z	PROPN
dpc-5749	346	15	,	,	PUNCT
dpc-5749	346	16	piao	piao	NOUN
dpc-5749	346	17	y.	y.	PROPN
dpc-5749	346	18	successful	successful	ADJ
dpc-5749	346	19	treatment	treatment	NOUN
dpc-5749	346	20	of	of	ADP
dpc-5749	346	21	mucous	mucous	ADJ
dpc-5749	346	22	membrane	membrane	NOUN
dpc-5749	346	23	pemphigoid	pemphigoid	NOUN
dpc-5749	346	24	with	with	ADP
dpc-5749	346	25	dupilumab	dupilumab	NOUN
dpc-5749	346	26	:	:	PUNCT
dpc-5749	346	27	a	a	DET
dpc-5749	346	28	case	case	NOUN
dpc-5749	346	29	report	report	NOUN
dpc-5749	346	30	.	.	PUNCT
dpc-5749	347	1	acta	acta	PROPN
dpc-5749	347	2	derm	derm	PROPN
dpc-5749	347	3	venereol	venereol	NOUN
dpc-5749	347	4	.	.	PUNCT
dpc-5749	348	1	2024;104	2024;104	ADJ
dpc-5749	348	2	:	:	PUNCT
dpc-5749	348	3	adv40162	adv40162	ADJ
dpc-5749	348	4	.	.	PUNCT
dpc-5749	349	1	doi	doi	NOUN
dpc-5749	349	2	:	:	PUNCT
dpc-5749	349	3	10.2340	10.2340	NUM
dpc-5749	349	4	/actadv.v104.40162	/actadv.v104.40162	NOUN
dpc-5749	349	5	.	.	PUNCT
dpc-5749	350	1	pmid	pmid	NOUN
dpc-5749	350	2	:	:	PUNCT
dpc-5749	350	3	39188088	39188088	NUM
dpc-5749	350	4	.	.	PUNCT
dpc-5749	351	1	14	14	NUM
dpc-5749	351	2	.	.	X
dpc-5749	352	1	raef	raef	PROPN
dpc-5749	352	2	hs	hs	PROPN
dpc-5749	352	3	,	,	PUNCT
dpc-5749	352	4	elmariah	elmariah	PROPN
dpc-5749	352	5	sb	sb	PROPN
dpc-5749	352	6	.	.	PROPN
dpc-5749	352	7	successful	successful	ADJ
dpc-5749	352	8	treatment	treatment	NOUN
dpc-5749	352	9	of	of	ADP
dpc-5749	352	10	brunsting	brunsting	NOUN
dpc-5749	352	11	-	-	PUNCT
dpc-5749	352	12	perry	perry	PROPN
dpc-5749	352	13	cicatricial	cicatricial	PROPN
dpc-5749	352	14	pemphigoid	pemphigoid	ADJ
dpc-5749	352	15	with	with	ADP
dpc-5749	352	16	dupilumab	dupilumab	NOUN
dpc-5749	352	17	.	.	PUNCT
dpc-5749	353	1	j	j	PROPN
dpc-5749	353	2	drugs	drug	NOUN
dpc-5749	353	3	dermatol	dermatol	NOUN
dpc-5749	353	4	.	.	PUNCT
dpc-5749	354	1	2021;20(10):1113	2021;20(10):1113	NUM
dpc-5749	354	2	-	-	SYM
dpc-5749	354	3	1115	1115	NUM
dpc-5749	354	4	.	.	PUNCT
dpc-5749	355	1	doi	doi	NOUN
dpc-5749	355	2	:	:	PUNCT
dpc-5749	355	3	10.36849	10.36849	NUM
dpc-5749	355	4	/	/	SYM
dpc-5749	355	5	jdd.6032	jdd.6032	PART
dpc-5749	355	6	.	.	PUNCT
dpc-5749	356	1	pmid	pmid	NOUN
dpc-5749	356	2	:	:	PUNCT
dpc-5749	356	3	34636516	34636516	NUM
dpc-5749	356	4	.	.	PUNCT
dpc-5749	357	1	15	15	NUM
dpc-5749	357	2	.	.	X
dpc-5749	357	3	corti	corti	PROPN
dpc-5749	357	4	l	l	PROPN
dpc-5749	357	5	,	,	PUNCT
dpc-5749	357	6	fanoni	fanoni	NOUN
dpc-5749	357	7	d	d	PROPN
dpc-5749	357	8	,	,	PUNCT
dpc-5749	357	9	venegoni	venegoni	X
dpc-5749	357	10	l	l	NOUN
dpc-5749	357	11	,	,	PUNCT
dpc-5749	357	12	muratori	muratori	PROPN
dpc-5749	357	13	s	s	PROPN
dpc-5749	357	14	,	,	PUNCT
dpc-5749	357	15	recalcati	recalcati	PROPN
dpc-5749	357	16	s	s	PROPN
dpc-5749	357	17	,	,	PUNCT
dpc-5749	357	18	berti	berti	PROPN
dpc-5749	357	19	e.	e.	PROPN
dpc-5749	357	20	detection	detection	PROPN
dpc-5749	357	21	of	of	ADP
dpc-5749	357	22	ige	ige	PROPN
dpc-5749	357	23	autoantibodies	autoantibody	NOUN
dpc-5749	357	24	in	in	ADP
dpc-5749	357	25	mucous	mucous	ADJ
dpc-5749	357	26	membrane	membrane	NOUN
dpc-5749	357	27	pemphigoid	pemphigoid	NOUN
dpc-5749	357	28	and	and	CCONJ
dpc-5749	357	29	their	their	PRON
dpc-5749	357	30	association	association	NOUN
dpc-5749	357	31	with	with	ADP
dpc-5749	357	32	disease	disease	NOUN
dpc-5749	357	33	severity	severity	NOUN
dpc-5749	357	34	.	.	PUNCT
dpc-5749	358	1	g	g	PROPN
dpc-5749	358	2	ital	ital	ADJ
dpc-5749	358	3	dermatol	dermatol	NOUN
dpc-5749	358	4	venereol	venereol	NOUN
dpc-5749	358	5	.	.	PUNCT
dpc-5749	359	1	2020;155(6):754	2020;155(6):754	NUM
dpc-5749	359	2	-	-	SYM
dpc-5749	359	3	759	759	NUM
dpc-5749	359	4	.	.	PUNCT
dpc-5749	360	1	doi	doi	NOUN
dpc-5749	360	2	:	:	PUNCT
dpc-5749	360	3	10.23736	10.23736	NUM
dpc-5749	360	4	/	/	SYM
dpc-5749	360	5	s0392	s0392	NOUN
dpc-5749	360	6	-0488.18.06167	-0488.18.06167	ADJ
dpc-5749	360	7	-	-	PUNCT
dpc-5749	360	8	9	9	NUM
dpc-5749	360	9	.	.	PUNCT
dpc-5749	361	1	pmid	pmid	NOUN
dpc-5749	361	2	:	:	PUNCT
dpc-5749	361	3	30298707	30298707	NUM
dpc-5749	361	4	.	.	PUNCT
dpc-5749	362	1	16	16	NUM
dpc-5749	362	2	.	.	PUNCT
dpc-5749	363	1	yayli	yayli	PROPN
dpc-5749	363	2	s	s	PROPN
dpc-5749	363	3	,	,	PUNCT
dpc-5749	363	4	pelivani	pelivani	PROPN
dpc-5749	363	5	n	n	CCONJ
dpc-5749	363	6	,	,	PUNCT
dpc-5749	363	7	beltraminelli	beltraminelli	PROPN
dpc-5749	363	8	h	h	NOUN
dpc-5749	363	9	,	,	PUNCT
dpc-5749	363	10	et	et	PROPN
dpc-5749	363	11	al	al	PROPN
dpc-5749	363	12	.	.	PUNCT
dpc-5749	363	13	detection	detection	NOUN
dpc-5749	363	14	of	of	ADP
dpc-5749	363	15	linear	linear	PROPN
dpc-5749	363	16	ige	ige	PROPN
dpc-5749	363	17	deposits	deposit	NOUN
dpc-5749	363	18	in	in	ADP
dpc-5749	363	19	bullous	bullous	ADJ
dpc-5749	363	20	pemphigoid	pemphigoid	NOUN
dpc-5749	363	21	and	and	CCONJ
dpc-5749	363	22	mucous	mucous	ADJ
dpc-5749	363	23	membrane	membrane	NOUN
dpc-5749	363	24	pemphigoid	pemphigoid	NOUN
dpc-5749	363	25	:	:	PUNCT
dpc-5749	363	26	a	a	DET
dpc-5749	363	27	useful	useful	ADJ
dpc-5749	363	28	clue	clue	NOUN
dpc-5749	363	29	for	for	ADP
dpc-5749	363	30	diagnosis	diagnosis	NOUN
dpc-5749	363	31	.	.	PUNCT
dpc-5749	364	1	br	br	PROPN
dpc-5749	364	2	j	j	PROPN
dpc-5749	364	3	dermatol	dermatol	NOUN
dpc-5749	364	4	.	.	PUNCT
dpc-5749	365	1	2011;165(5):1133	2011;165(5):1133	NUM
dpc-5749	365	2	-	-	SYM
dpc-5749	365	3	7	7	NUM
dpc-5749	365	4	.	.	PUNCT
dpc-5749	365	5	doi	doi	NOUN
dpc-5749	365	6	:	:	PUNCT
dpc-5749	365	7	10.1111	10.1111	NUM
dpc-5749	365	8	/	/	SYM
dpc-5749	365	9	j.1365	j.1365	NOUN
dpc-5749	365	10	-	-	PUNCT
dpc-5749	365	11	2133.2011.10481.x	2133.2011.10481.x	NUM
dpc-5749	365	12	.	.	PUNCT
dpc-5749	366	1	pmid	pmid	NOUN
dpc-5749	366	2	:	:	PUNCT
dpc-5749	366	3	21711326	21711326	NUM
dpc-5749	366	4	.	.	PUNCT
dpc-5749	367	1	17	17	NUM
dpc-5749	367	2	.	.	PUNCT
dpc-5749	368	1	natsuga	natsuga	PROPN
dpc-5749	368	2	k	k	PROPN
dpc-5749	368	3	,	,	PUNCT
dpc-5749	368	4	nishie	nishie	PROPN
dpc-5749	368	5	w	w	PROPN
dpc-5749	368	6	,	,	PUNCT
dpc-5749	368	7	shinkuma	shinkuma	PROPN
dpc-5749	368	8	s	s	PROPN
dpc-5749	368	9	,	,	PUNCT
dpc-5749	368	10	et	et	PROPN
dpc-5749	368	11	al	al	PROPN
dpc-5749	368	12	.	.	PROPN
dpc-5749	368	13	circulating	circulate	VERB
dpc-5749	368	14	iga	iga	PROPN
dpc-5749	368	15	and	and	CCONJ
dpc-5749	368	16	ige	ige	PROPN
dpc-5749	368	17	autoantibodies	autoantibody	NOUN
dpc-5749	368	18	in	in	ADP
dpc-5749	368	19	antilaminin-332	antilaminin-332	ADJ
dpc-5749	368	20	mucous	mucous	ADJ
dpc-5749	368	21	membrane	membrane	NOUN
dpc-5749	368	22	pemphigoid	pemphigoid	NOUN
dpc-5749	368	23	.	.	PUNCT
dpc-5749	369	1	br	br	PROPN
dpc-5749	369	2	j	j	PROPN
dpc-5749	369	3	dermatol	dermatol	NOUN
dpc-5749	369	4	.	.	PUNCT
dpc-5749	370	1	2010;162(3):513	2010;162(3):513	NUM
dpc-5749	370	2	-	-	SYM
dpc-5749	370	3	7	7	NUM
dpc-5749	370	4	.	.	PUNCT
dpc-5749	370	5	doi	doi	NOUN
dpc-5749	370	6	:	:	PUNCT
dpc-5749	370	7	10.1111	10.1111	NUM
dpc-5749	370	8	/	/	SYM
dpc-5749	370	9	j.1365	j.1365	NOUN
dpc-5749	370	10	-2133.2009.09508.x	-2133.2009.09508.x	ADJ
dpc-5749	370	11	.	.	PUNCT
dpc-5749	371	1	pmid	pmid	NOUN
dpc-5749	371	2	:	:	PUNCT
dpc-5749	371	3	19751242	19751242	NUM
dpc-5749	371	4	.	.	PUNCT
dpc-5749	372	1	18	18	NUM
dpc-5749	372	2	.	.	X
dpc-5749	372	3	alexandre	alexandre	PROPN
dpc-5749	372	4	m	m	PROPN
dpc-5749	372	5	,	,	PUNCT
dpc-5749	372	6	bohelay	bohelay	ADP
dpc-5749	372	7	g	g	PROPN
dpc-5749	372	8	,	,	PUNCT
dpc-5749	372	9	gille	gille	NOUN
dpc-5749	372	10	t	t	PROPN
dpc-5749	372	11	,	,	PUNCT
dpc-5749	372	12	et	et	PROPN
dpc-5749	372	13	al	al	PROPN
dpc-5749	372	14	.	.	PROPN
dpc-5749	373	1	rapid	rapid	ADJ
dpc-5749	373	2	disease	disease	NOUN
dpc-5749	373	3	control	control	NOUN
dpc-5749	373	4	in	in	ADP
dpc-5749	373	5	first	first	ADJ
dpc-5749	373	6	-	-	PUNCT
dpc-5749	373	7	line	line	NOUN
dpc-5749	373	8	therapy	therapy	NOUN
dpc-5749	373	9	-	-	PUNCT
dpc-5749	373	10	resistant	resistant	ADJ
dpc-5749	373	11	mucous	mucous	ADJ
dpc-5749	373	12	membrane	membrane	NOUN
dpc-5749	373	13	pemphigoid	pemphigoid	NOUN
dpc-5749	373	14	and	and	CCONJ
dpc-5749	373	15	bullous	bullous	ADJ
dpc-5749	373	16	pemphigoid	pemphigoid	NOUN
dpc-5749	373	17	with	with	ADP
dpc-5749	373	18	omalizumab	omalizumab	NOUN
dpc-5749	373	19	as	as	ADP
dpc-5749	373	20	add	add	VERB
dpc-5749	373	21	-	-	PUNCT
dpc-5749	373	22	on	on	ADP
dpc-5749	373	23	therapy	therapy	NOUN
dpc-5749	373	24	:	:	PUNCT
dpc-5749	373	25	a	a	DET
dpc-5749	373	26	case	case	NOUN
dpc-5749	373	27	series	series	NOUN
dpc-5749	373	28	of	of	ADP
dpc-5749	373	29	13	13	NUM
dpc-5749	373	30	patients	patient	NOUN
dpc-5749	373	31	.	.	PUNCT
dpc-5749	374	1	front	front	ADJ
dpc-5749	374	2	immunol	immunol	NOUN
dpc-5749	374	3	.	.	PUNCT
dpc-5749	375	1	2022;13:874108	2022;13:874108	X
dpc-5749	375	2	.	.	PUNCT
dpc-5749	375	3	doi	doi	NOUN
dpc-5749	375	4	:	:	PUNCT
dpc-5749	375	5	10.3389	10.3389	NUM
dpc-5749	375	6	/	/	SYM
dpc-5749	375	7	fimmu.2022.874108	fimmu.2022.874108	PROPN
dpc-5749	375	8	.	.	PUNCT
dpc-5749	376	1	pmid	pmid	NOUN
dpc-5749	376	2	:	:	PUNCT
dpc-5749	376	3	35514989	35514989	NUM
dpc-5749	376	4	.	.	PUNCT
dpc-5749	377	1	19	19	NUM
dpc-5749	377	2	.	.	PUNCT
dpc-5749	377	3	williams	williams	PROPN
dpc-5749	377	4	gp	gp	PROPN
dpc-5749	377	5	,	,	PUNCT
dpc-5749	377	6	nightingale	nightingale	PROPN
dpc-5749	377	7	p	p	X
dpc-5749	377	8	,	,	PUNCT
dpc-5749	377	9	southworth	southworth	NOUN
dpc-5749	377	10	s	s	PROPN
dpc-5749	377	11	,	,	PUNCT
dpc-5749	377	12	et	et	PROPN
dpc-5749	377	13	al	al	PROPN
dpc-5749	377	14	.	.	PUNCT
dpc-5749	377	15	conjunctival	conjunctival	PROPN
dpc-5749	377	16	neutrophils	neutrophil	NOUN
dpc-5749	377	17	predict	predict	VERB
dpc-5749	377	18	progressive	progressive	ADJ
dpc-5749	377	19	scarring	scarring	NOUN
dpc-5749	377	20	in	in	ADP
dpc-5749	377	21	ocular	ocular	ADJ
dpc-5749	377	22	mucous	mucous	ADJ
dpc-5749	377	23	membrane	membrane	NOUN
dpc-5749	377	24	pemphigoid	pemphigoid	NOUN
dpc-5749	377	25	.	.	PUNCT
dpc-5749	378	1	invest	invest	VERB
dpc-5749	378	2	ophthalmol	ophthalmol	PROPN
dpc-5749	378	3	vis	vis	X
dpc-5749	378	4	sci	sci	PROPN
dpc-5749	378	5	.	.	PUNCT
dpc-5749	379	1	2016;57(13):5457	2016;57(13):5457	NUM
dpc-5749	379	2	-	-	SYM
dpc-5749	379	3	5469	5469	NUM
dpc-5749	379	4	.	.	PUNCT
dpc-5749	380	1	doi	doi	NOUN
dpc-5749	380	2	:	:	PUNCT
dpc-5749	380	3	10.1167	10.1167	NUM
dpc-5749	380	4	/	/	SYM
dpc-5749	380	5	iovs.16	iovs.16	PROPN
dpc-5749	380	6	-	-	PUNCT
dpc-5749	380	7	19247	19247	NUM
dpc-5749	380	8	.	.	PUNCT
dpc-5749	381	1	pmid	pmid	NOUN
dpc-5749	381	2	:	:	PUNCT
dpc-5749	381	3	27760272	27760272	NUM
dpc-5749	381	4	.	.	PUNCT
dpc-5749	382	1	20	20	NUM
dpc-5749	382	2	.	.	PUNCT
dpc-5749	383	1	murthy	murthy	PROPN
dpc-5749	383	2	s	s	PROPN
dpc-5749	383	3	,	,	PUNCT
dpc-5749	383	4	patzelt	patzelt	VERB
dpc-5749	383	5	s	s	NOUN
dpc-5749	383	6	,	,	PUNCT
dpc-5749	383	7	künstner	künstner	NOUN
dpc-5749	383	8	a	a	NOUN
dpc-5749	383	9	,	,	PUNCT
dpc-5749	383	10	busch	busch	PROPN
dpc-5749	383	11	h	h	PROPN
dpc-5749	383	12	,	,	PUNCT
dpc-5749	383	13	schmidt	schmidt	PROPN
dpc-5749	383	14	e	e	PROPN
dpc-5749	383	15	,	,	PUNCT
dpc-5749	383	16	sadik	sadik	PROPN
dpc-5749	383	17	cd	cd	PROPN
dpc-5749	383	18	.	.	PROPN
dpc-5749	384	1	intravenous	intravenous	PROPN
dpc-5749	384	2	ig	ig	PROPN
dpc-5749	384	3	ameliorates	ameliorate	VERB
dpc-5749	384	4	disease	disease	NOUN
dpc-5749	384	5	in	in	ADP
dpc-5749	384	6	a	a	DET
dpc-5749	384	7	murine	murine	ADJ
dpc-5749	384	8	model	model	NOUN
dpc-5749	384	9	of	of	ADP
dpc-5749	384	10	anti	anti	ADJ
dpc-5749	384	11	-	-	ADJ
dpc-5749	384	12	laminin	laminin	ADJ
dpc-5749	384	13	332	332	NUM
dpc-5749	384	14	mucous	mucous	ADJ
dpc-5749	384	15	membrane	membrane	NOUN
dpc-5749	384	16	pemphigoid	pemphigoid	NOUN
dpc-5749	384	17	.	.	PUNCT
dpc-5749	385	1	j	j	PROPN
dpc-5749	385	2	invest	invest	VERB
dpc-5749	385	3	dermatol	dermatol	NOUN
dpc-5749	385	4	.	.	PUNCT
dpc-5749	386	1	2024;144(12):2671	2024;144(12):2671	NUM
dpc-5749	386	2	-	-	PUNCT
dpc-5749	386	3	2681.e1	2681.e1	NUM
dpc-5749	386	4	.	.	PUNCT
dpc-5749	386	5	doi	doi	NOUN
dpc-5749	386	6	:	:	PUNCT
dpc-5749	386	7	10.1016	10.1016	NUM
dpc-5749	386	8	/	/	SYM
dpc-5749	386	9	j.jid	j.jid	PROPN
dpc-5749	386	10	.2024.02.038	.2024.02.038	PROPN
dpc-5749	386	11	.	.	PUNCT
dpc-5749	387	1	pmid	pmid	NOUN
dpc-5749	387	2	:	:	PUNCT
dpc-5749	387	3	38692406	38692406	NUM
dpc-5749	387	4	.	.	PUNCT
dpc-5749	388	1	21	21	NUM
dpc-5749	388	2	.	.	X
dpc-5749	389	1	sardana	sardana	PROPN
dpc-5749	389	2	k	k	PROPN
dpc-5749	389	3	,	,	PUNCT
dpc-5749	389	4	sinha	sinha	PROPN
dpc-5749	389	5	s	s	PROPN
dpc-5749	389	6	,	,	PUNCT
dpc-5749	389	7	sachdeva	sachdeva	PROPN
dpc-5749	389	8	s.	s.	PROPN
dpc-5749	389	9	colchicine	colchicine	PROPN
dpc-5749	389	10	in	in	ADP
dpc-5749	389	11	dermatology	dermatology	NOUN
dpc-5749	389	12	:	:	PUNCT
dpc-5749	389	13	rediscovering	rediscover	VERB
dpc-5749	389	14	an	an	DET
dpc-5749	389	15	old	old	ADJ
dpc-5749	389	16	drug	drug	NOUN
dpc-5749	389	17	with	with	ADP
dpc-5749	389	18	novel	novel	ADJ
dpc-5749	389	19	uses	use	NOUN
dpc-5749	389	20	.	.	PUNCT
dpc-5749	390	1	indian	indian	ADJ
dpc-5749	390	2	dermatol	dermatol	NOUN
dpc-5749	390	3	online	online	PROPN
dpc-5749	390	4	j.	j.	PROPN
dpc-5749	390	5	2020	2020	NUM
dpc-5749	390	6	sep	sep	PROPN
dpc-5749	390	7	19;11(5):693	19;11(5):693	NUM
dpc-5749	390	8	-	-	SYM
dpc-5749	390	9	700	700	NUM
dpc-5749	390	10	.	.	PUNCT
dpc-5749	391	1	doi	doi	NOUN
dpc-5749	391	2	:	:	PUNCT
dpc-5749	391	3	10.4103	10.4103	NUM
dpc-5749	391	4	/	/	SYM
dpc-5749	391	5	idoj.idoj	idoj.idoj	NUM
dpc-5749	391	6	_	_	NOUN
dpc-5749	391	7	475_20	475_20	NUM
dpc-5749	391	8	.	.	PUNCT
dpc-5749	392	1	pmid	pmid	NOUN
dpc-5749	392	2	:	:	PUNCT
dpc-5749	392	3	33235833	33235833	NUM
dpc-5749	392	4	.	.	PUNCT
dpc-5749	393	1	22	22	NUM
dpc-5749	393	2	.	.	PUNCT
dpc-5749	394	1	robertson	robertson	PROPN
dpc-5749	394	2	s	s	PROPN
dpc-5749	394	3	,	,	PUNCT
dpc-5749	394	4	martínez	martínez	PROPN
dpc-5749	394	5	gj	gj	PROPN
dpc-5749	394	6	,	,	PUNCT
dpc-5749	394	7	payet	payet	NOUN
dpc-5749	394	8	ca	can	AUX
dpc-5749	394	9	,	,	PUNCT
dpc-5749	394	10	et	et	PROPN
dpc-5749	394	11	al	al	PROPN
dpc-5749	394	12	.	.	PROPN
dpc-5749	394	13	colchicine	colchicine	PROPN
dpc-5749	394	14	therapy	therapy	NOUN
dpc-5749	394	15	in	in	ADP
dpc-5749	394	16	acute	acute	ADJ
dpc-5749	394	17	coronary	coronary	ADJ
dpc-5749	394	18	syndrome	syndrome	NOUN
dpc-5749	394	19	patients	patient	NOUN
dpc-5749	394	20	acts	act	VERB
dpc-5749	394	21	on	on	ADP
dpc-5749	394	22	caspase-1	caspase-1	NOUN
dpc-5749	394	23	to	to	PART
dpc-5749	394	24	suppress	suppress	VERB
dpc-5749	394	25	nlrp3	nlrp3	NOUN
dpc-5749	394	26	inflammasome	inflammasome	NOUN
dpc-5749	394	27	monocyte	monocyte	NOUN
dpc-5749	394	28	activation	activation	NOUN
dpc-5749	394	29	.	.	PUNCT
dpc-5749	395	1	clin	clin	PROPN
dpc-5749	395	2	sci	sci	PROPN
dpc-5749	395	3	(	(	PUNCT
dpc-5749	395	4	lond	lond	PROPN
dpc-5749	395	5	)	)	PUNCT
dpc-5749	395	6	.	.	PUNCT
dpc-5749	396	1	2016;130(14):1237	2016;130(14):1237	NUM
dpc-5749	396	2	-	-	SYM
dpc-5749	396	3	46	46	NUM
dpc-5749	396	4	.	.	PUNCT
dpc-5749	397	1	doi	doi	NOUN
dpc-5749	397	2	:	:	PUNCT
dpc-5749	397	3	10.1042	10.1042	NUM
dpc-5749	397	4	/	/	SYM
dpc-5749	397	5	cs20160090	cs20160090	PROPN
dpc-5749	397	6	.	.	PUNCT
dpc-5749	398	1	pmid	pmid	NOUN
dpc-5749	398	2	:	:	PUNCT
dpc-5749	398	3	27129183	27129183	NUM
dpc-5749	398	4	.	.	PUNCT
dpc-5749	399	1	23	23	NUM
dpc-5749	399	2	.	.	X
dpc-5749	400	1	fribourg	fribourg	NOUN
dpc-5749	400	2	e	e	NOUN
dpc-5749	400	3	,	,	PUNCT
dpc-5749	400	4	chuy	chuy	PROPN
dpc-5749	400	5	v	v	NOUN
dpc-5749	400	6	,	,	PUNCT
dpc-5749	400	7	fenelon	fenelon	NOUN
dpc-5749	400	8	m	m	PROPN
dpc-5749	400	9	,	,	PUNCT
dpc-5749	400	10	catros	catros	PROPN
dpc-5749	400	11	s	s	PART
dpc-5749	400	12	,	,	PUNCT
dpc-5749	400	13	fricain	fricain	PROPN
dpc-5749	400	14	jc	jc	PROPN
dpc-5749	400	15	.	.	PROPN
dpc-5749	400	16	is	be	AUX
dpc-5749	400	17	there	there	PRON
dpc-5749	400	18	a	a	DET
dpc-5749	400	19	role	role	NOUN
dpc-5749	400	20	for	for	ADP
dpc-5749	400	21	colchicine	colchicine	NOUN
dpc-5749	400	22	in	in	ADP
dpc-5749	400	23	the	the	DET
dpc-5749	400	24	treatment	treatment	NOUN
dpc-5749	400	25	of	of	ADP
dpc-5749	400	26	oral	oral	ADJ
dpc-5749	400	27	mucous	mucous	ADJ
dpc-5749	400	28	membrane	membrane	NOUN
dpc-5749	400	29	8	8	NUM
dpc-5749	400	30	review	review	NOUN
dpc-5749	400	31	|	|	ADV
dpc-5749	400	32	dermatol	dermatol	ADJ
dpc-5749	400	33	pract	pract	NOUN
dpc-5749	400	34	concept	concept	NOUN
dpc-5749	400	35	.	.	PUNCT
dpc-5749	401	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	401	2	53	53	NUM
dpc-5749	401	3	.	.	PUNCT
dpc-5749	402	1	fojnica	fojnica	VERB
dpc-5749	402	2	a	a	DET
dpc-5749	402	3	,	,	PUNCT
dpc-5749	402	4	gromilic	gromilic	PROPN
dpc-5749	402	5	z	z	PROPN
dpc-5749	402	6	,	,	PUNCT
dpc-5749	402	7	ali	ali	PROPN
dpc-5749	402	8	mohamed	mohamed	PROPN
dpc-5749	402	9	ya	ya	PROPN
dpc-5749	402	10	,	,	PUNCT
dpc-5749	402	11	akhtar	akhtar	PROPN
dpc-5749	402	12	s	s	PROPN
dpc-5749	402	13	,	,	PUNCT
dpc-5749	402	14	vranic	vranic	ADJ
dpc-5749	402	15	s.	s.	PROPN
dpc-5749	403	1	the	the	DET
dpc-5749	403	2	potential	potential	ADJ
dpc-5749	403	3	role	role	NOUN
dpc-5749	403	4	of	of	ADP
dpc-5749	403	5	cyclosporine	cyclosporine	NOUN
dpc-5749	403	6	a	a	PRON
dpc-5749	403	7	in	in	ADP
dpc-5749	403	8	cancer	cancer	NOUN
dpc-5749	403	9	treatment	treatment	NOUN
dpc-5749	403	10	:	:	PUNCT
dpc-5749	403	11	a	a	DET
dpc-5749	403	12	comprehensive	comprehensive	ADJ
dpc-5749	403	13	literature	literature	NOUN
dpc-5749	403	14	review	review	NOUN
dpc-5749	403	15	.	.	PUNCT
dpc-5749	404	1	contemp	contemp	NOUN
dpc-5749	404	2	oncol	oncol	PROPN
dpc-5749	404	3	(	(	PUNCT
dpc-5749	404	4	pozn	pozn	NOUN
dpc-5749	404	5	)	)	PUNCT
dpc-5749	404	6	.	.	PUNCT
dpc-5749	405	1	2024;28(4	2024;28(4	NUM
dpc-5749	405	2	):	):	PUNCT
dpc-5749	405	3	271	271	NUM
dpc-5749	405	4	-	-	SYM
dpc-5749	405	5	282	282	NUM
dpc-5749	405	6	.	.	PUNCT
dpc-5749	406	1	doi	doi	NOUN
dpc-5749	406	2	:	:	PUNCT
dpc-5749	406	3	10.5114	10.5114	NUM
dpc-5749	406	4	/	/	SYM
dpc-5749	406	5	wo.2024.147009	wo.2024.147009	NOUN
dpc-5749	406	6	.	.	PUNCT
dpc-5749	407	1	pmid	pmid	NOUN
dpc-5749	407	2	:	:	PUNCT
dpc-5749	407	3	39935757	39935757	NUM
dpc-5749	407	4	.	.	PUNCT
dpc-5749	408	1	54	54	NUM
dpc-5749	408	2	.	.	PUNCT
dpc-5749	408	3	benjanuwattra	benjanuwattra	PROPN
dpc-5749	408	4	j	j	PROPN
dpc-5749	408	5	,	,	PUNCT
dpc-5749	408	6	chaiyawat	chaiyawat	VERB
dpc-5749	408	7	p	p	X
dpc-5749	408	8	,	,	PUNCT
dpc-5749	408	9	pruksakorn	pruksakorn	ADJ
dpc-5749	408	10	d	d	PROPN
dpc-5749	408	11	,	,	PUNCT
dpc-5749	408	12	koonrungsesomboon	koonrungsesomboon	PROPN
dpc-5749	408	13	n.	n.	PROPN
dpc-5749	408	14	therapeutic	therapeutic	ADJ
dpc-5749	408	15	potential	potential	ADJ
dpc-5749	408	16	and	and	CCONJ
dpc-5749	408	17	molecular	molecular	ADJ
dpc-5749	408	18	mechanisms	mechanism	NOUN
dpc-5749	408	19	of	of	ADP
dpc-5749	408	20	mycophenolic	mycophenolic	ADJ
dpc-5749	408	21	acid	acid	NOUN
dpc-5749	408	22	as	as	ADP
dpc-5749	408	23	an	an	DET
dpc-5749	408	24	anticancer	anticancer	NOUN
dpc-5749	408	25	agent	agent	NOUN
dpc-5749	408	26	.	.	PUNCT
dpc-5749	409	1	eur	eur	PROPN
dpc-5749	409	2	j	j	PROPN
dpc-5749	409	3	pharmacol	pharmacol	PROPN
dpc-5749	409	4	.	.	PUNCT
dpc-5749	410	1	2020;887:173580	2020;887:173580	X
dpc-5749	410	2	.	.	PUNCT
dpc-5749	411	1	doi	doi	NOUN
dpc-5749	411	2	:	:	PUNCT
dpc-5749	411	3	10.1016	10.1016	NUM
dpc-5749	411	4	/	/	SYM
dpc-5749	411	5	j.ejphar.2020.173580	j.ejphar.2020.173580	PROPN
dpc-5749	411	6	.	.	PUNCT
dpc-5749	412	1	pmid	pmid	NOUN
dpc-5749	412	2	:	:	PUNCT
dpc-5749	412	3	32949604	32949604	NUM
dpc-5749	412	4	.	.	PUNCT
dpc-5749	413	1	55	55	NUM
dpc-5749	413	2	.	.	PUNCT
dpc-5749	414	1	nam	nam	PROPN
dpc-5749	414	2	hj	hj	PROPN
dpc-5749	414	3	,	,	PUNCT
dpc-5749	414	4	kim	kim	PROPN
dpc-5749	414	5	ye	ye	PROPN
dpc-5749	414	6	,	,	PUNCT
dpc-5749	414	7	moon	moon	NOUN
dpc-5749	414	8	bs	bs	NOUN
dpc-5749	414	9	,	,	PUNCT
dpc-5749	414	10	et	et	PROPN
dpc-5749	414	11	al	al	PROPN
dpc-5749	414	12	.	.	PROPN
dpc-5749	415	1	azathioprine	azathioprine	PROPN
dpc-5749	415	2	antagonizes	antagonize	VERB
dpc-5749	415	3	aberrantly	aberrantly	ADV
dpc-5749	415	4	elevated	elevate	VERB
dpc-5749	415	5	lipid	lipid	NOUN
dpc-5749	415	6	metabolism	metabolism	NOUN
dpc-5749	415	7	and	and	CCONJ
dpc-5749	415	8	induces	induce	VERB
dpc-5749	415	9	apoptosis	apoptosis	NOUN
dpc-5749	415	10	in	in	ADP
dpc-5749	415	11	glioblastoma	glioblastoma	NOUN
dpc-5749	415	12	.	.	PUNCT
dpc-5749	416	1	iscience	iscience	NOUN
dpc-5749	416	2	.	.	PUNCT
dpc-5749	417	1	2021;24(3):102238	2021;24(3):102238	NUM
dpc-5749	417	2	.	.	PUNCT
dpc-5749	418	1	doi	doi	NOUN
dpc-5749	418	2	:	:	PUNCT
dpc-5749	418	3	10.1016	10.1016	NUM
dpc-5749	418	4	/	/	SYM
dpc-5749	418	5	j.isci	j.isci	PROPN
dpc-5749	418	6	.2021.102238	.2021.102238	PROPN
dpc-5749	418	7	.	.	PUNCT
dpc-5749	419	1	pmid	pmid	NOUN
dpc-5749	419	2	:	:	PUNCT
dpc-5749	419	3	33748720	33748720	NUM
dpc-5749	419	4	.	.	PUNCT
dpc-5749	420	1	56	56	NUM
dpc-5749	420	2	.	.	X
dpc-5749	420	3	goodman	goodman	PROPN
dpc-5749	420	4	rs	rs	PROPN
dpc-5749	420	5	,	,	PUNCT
dpc-5749	420	6	johnson	johnson	PROPN
dpc-5749	420	7	db	db	PROPN
dpc-5749	420	8	,	,	PUNCT
dpc-5749	420	9	balko	balko	PROPN
dpc-5749	420	10	jm	jm	PROPN
dpc-5749	420	11	.	.	PROPN
dpc-5749	420	12	corticosteroids	corticosteroid	NOUN
dpc-5749	420	13	and	and	CCONJ
dpc-5749	420	14	cancer	cancer	NOUN
dpc-5749	420	15	immunotherapy	immunotherapy	NOUN
dpc-5749	420	16	.	.	PUNCT
dpc-5749	421	1	clin	clin	PROPN
dpc-5749	421	2	cancer	cancer	NOUN
dpc-5749	421	3	res	re	NOUN
dpc-5749	421	4	.	.	PUNCT
dpc-5749	422	1	2023;29(14):2580	2023;29(14):2580	X
dpc-5749	422	2	-	-	SYM
dpc-5749	422	3	2587	2587	NUM
dpc-5749	422	4	.	.	PUNCT
dpc-5749	423	1	doi	doi	NOUN
dpc-5749	423	2	:	:	PUNCT
dpc-5749	423	3	10.1158/1078	10.1158/1078	NUM
dpc-5749	423	4	-	-	SYM
dpc-5749	423	5	0432.ccr-22	0432.ccr-22	NOUN
dpc-5749	423	6	-	-	NOUN
dpc-5749	423	7	3181	3181	NUM
dpc-5749	423	8	.	.	PUNCT
dpc-5749	424	1	pmid	pmid	NOUN
dpc-5749	424	2	:	:	PUNCT
dpc-5749	424	3	36648402	36648402	NUM
dpc-5749	424	4	.	.	PUNCT
dpc-5749	425	1	57	57	NUM
dpc-5749	425	2	.	.	PUNCT
dpc-5749	426	1	huang	huang	PROPN
dpc-5749	426	2	s	s	PROPN
dpc-5749	426	3	,	,	PUNCT
dpc-5749	426	4	anderson	anderson	PROPN
dpc-5749	426	5	hj	hj	PROPN
dpc-5749	426	6	,	,	PUNCT
dpc-5749	426	7	lee	lee	PROPN
dpc-5749	426	8	jb	jb	PROPN
dpc-5749	426	9	.	.	PUNCT
dpc-5749	427	1	paraneoplastic	paraneoplastic	ADJ
dpc-5749	427	2	pemphigus	pemphigus	NOUN
dpc-5749	427	3	/	/	SYM
dpc-5749	427	4	paraneoplastic	paraneoplastic	ADJ
dpc-5749	427	5	autoimmune	autoimmune	ADJ
dpc-5749	427	6	multiorgan	multiorgan	NOUN
dpc-5749	427	7	syndrome	syndrome	NOUN
dpc-5749	427	8	:	:	PUNCT
dpc-5749	427	9	part	part	PROPN
dpc-5749	427	10	ii	ii	PROPN
dpc-5749	427	11	.	.	PUNCT
dpc-5749	427	12	diagnosis	diagnosis	NOUN
dpc-5749	427	13	and	and	CCONJ
dpc-5749	427	14	management	management	NOUN
dpc-5749	427	15	.	.	PUNCT
dpc-5749	428	1	j	j	PROPN
dpc-5749	428	2	am	be	AUX
dpc-5749	428	3	acad	acad	ADJ
dpc-5749	428	4	dermatol	dermatol	NOUN
dpc-5749	428	5	.	.	PUNCT
dpc-5749	429	1	2024;91(1):13	2024;91(1):13	NUM
dpc-5749	429	2	-	-	SYM
dpc-5749	429	3	22	22	NUM
dpc-5749	429	4	.	.	PUNCT
dpc-5749	430	1	doi	doi	NOUN
dpc-5749	430	2	:	:	PUNCT
dpc-5749	430	3	10.1016	10.1016	NUM
dpc-5749	430	4	/	/	SYM
dpc-5749	430	5	j.jaad.2023.08.084	j.jaad.2023.08.084	PROPN
dpc-5749	430	6	.	.	PUNCT
dpc-5749	431	1	pmid	pmid	NOUN
dpc-5749	431	2	:	:	PUNCT
dpc-5749	431	3	37714216	37714216	NUM
dpc-5749	431	4	.	.	PUNCT
dpc-5749	432	1	58	58	NUM
dpc-5749	432	2	.	.	PUNCT
dpc-5749	433	1	antiga	antiga	PROPN
dpc-5749	433	2	e	e	PROPN
dpc-5749	433	3	,	,	PUNCT
dpc-5749	433	4	bech	bech	PROPN
dpc-5749	433	5	r	r	PROPN
dpc-5749	433	6	,	,	PUNCT
dpc-5749	433	7	maglie	maglie	PROPN
dpc-5749	433	8	r	r	NOUN
dpc-5749	433	9	,	,	PUNCT
dpc-5749	433	10	et	et	PROPN
dpc-5749	433	11	al	al	PROPN
dpc-5749	433	12	.	.	PUNCT
dpc-5749	434	1	s2k	s2k	PROPN
dpc-5749	434	2	guidelines	guideline	NOUN
dpc-5749	434	3	on	on	ADP
dpc-5749	434	4	the	the	DET
dpc-5749	434	5	management	management	NOUN
dpc-5749	434	6	of	of	ADP
dpc-5749	434	7	paraneoplastic	paraneoplastic	ADJ
dpc-5749	434	8	pemphigus	pemphigus	NOUN
dpc-5749	434	9	/	/	SYM
dpc-5749	434	10	paraneoplastic	paraneoplastic	ADJ
dpc-5749	434	11	autoimmune	autoimmune	ADJ
dpc-5749	434	12	multiorgan	multiorgan	NOUN
dpc-5749	434	13	syndrome	syndrome	NOUN
dpc-5749	434	14	initiated	initiate	VERB
dpc-5749	434	15	by	by	ADP
dpc-5749	434	16	the	the	DET
dpc-5749	434	17	european	european	PROPN
dpc-5749	434	18	academy	academy	PROPN
dpc-5749	434	19	of	of	ADP
dpc-5749	434	20	dermatology	dermatology	NOUN
dpc-5749	434	21	and	and	CCONJ
dpc-5749	434	22	venereology	venereology	NOUN
dpc-5749	434	23	(	(	PUNCT
dpc-5749	434	24	eadv	eadv	ADJ
dpc-5749	434	25	)	)	PUNCT
dpc-5749	434	26	.	.	PUNCT
dpc-5749	435	1	j	j	PROPN
dpc-5749	435	2	eur	eur	PROPN
dpc-5749	435	3	acad	acad	PROPN
dpc-5749	435	4	dermatol	dermatol	NOUN
dpc-5749	435	5	venereol	venereol	NOUN
dpc-5749	435	6	.	.	PUNCT
dpc-5749	436	1	2023;37(11):2378	2023;37(11):2378	NUM
dpc-5749	436	2	-	-	SYM
dpc-5749	436	3	2379	2379	NUM
dpc-5749	436	4	.	.	PUNCT
dpc-5749	437	1	doi	doi	NOUN
dpc-5749	437	2	:	:	PUNCT
dpc-5749	437	3	10.1111	10.1111	NUM
dpc-5749	437	4	/	/	SYM
dpc-5749	437	5	jdv.19489	jdv.19489	NOUN
dpc-5749	437	6	.	.	PUNCT
dpc-5749	437	7	 	 	SPACE
dpc-5749	437	8	pmid	pmid	NOUN
dpc-5749	437	9	:	:	PUNCT
dpc-5749	437	10	36965110	36965110	NUM
dpc-5749	437	11	.	.	PUNCT
dpc-5749	438	1	59	59	NUM
dpc-5749	438	2	.	.	PUNCT
dpc-5749	439	1	tarnowietzki	tarnowietzki	PROPN
dpc-5749	439	2	e	e	PROPN
dpc-5749	439	3	,	,	PUNCT
dpc-5749	439	4	peters	peters	PROPN
dpc-5749	439	5	t	t	PROPN
dpc-5749	439	6	,	,	PUNCT
dpc-5749	439	7	kraus	kraus	PROPN
dpc-5749	439	8	l	l	PROPN
dpc-5749	439	9	,	,	PUNCT
dpc-5749	439	10	schmidt	schmidt	PROPN
dpc-5749	439	11	e	e	PROPN
dpc-5749	439	12	,	,	PUNCT
dpc-5749	439	13	scharffetter	scharffetter	NOUN
dpc-5749	439	14	kochanek	kochanek	PROPN
dpc-5749	439	15	k.	k.	PROPN
dpc-5749	439	16	remission	remission	PROPN
dpc-5749	439	17	of	of	ADP
dpc-5749	439	18	anti	anti	ADJ
dpc-5749	439	19	-	-	ADJ
dpc-5749	439	20	laminin	laminin	ADJ
dpc-5749	439	21	332	332	NUM
dpc-5749	439	22	mucous	mucous	ADJ
dpc-5749	439	23	membrane	membrane	NOUN
dpc-5749	439	24	pemphigoid	pemphigoid	NOUN
dpc-5749	439	25	associated	associate	VERB
dpc-5749	439	26	with	with	ADP
dpc-5749	439	27	non	non	ADJ
dpc-5749	439	28	-	-	ADJ
dpc-5749	439	29	small	small	ADJ
dpc-5749	439	30	cell	cell	NOUN
dpc-5749	439	31	lung	lung	NOUN
dpc-5749	439	32	cancer	cancer	NOUN
dpc-5749	439	33	after	after	ADP
dpc-5749	439	34	therapy	therapy	NOUN
dpc-5749	439	35	with	with	ADP
dpc-5749	439	36	rituximab	rituximab	NOUN
dpc-5749	439	37	and	and	CCONJ
dpc-5749	439	38	intravenous	intravenous	ADJ
dpc-5749	439	39	immunoglobulin	immunoglobulin	NOUN
dpc-5749	439	40	.	.	PUNCT
dpc-5749	440	1	acta	acta	PROPN
dpc-5749	440	2	derm	derm	PROPN
dpc-5749	440	3	venereol	venereol	NOUN
dpc-5749	440	4	.	.	PUNCT
dpc-5749	441	1	2020;100(17):adv00301	2020;100(17):adv00301	NOUN
dpc-5749	441	2	.	.	PUNCT
dpc-5749	442	1	doi	doi	NOUN
dpc-5749	442	2	:	:	PUNCT
dpc-5749	442	3	10.2340/00015555	10.2340/00015555	NUM
dpc-5749	442	4	-	-	SYM
dpc-5749	442	5	3621	3621	NUM
dpc-5749	442	6	.	.	PUNCT
dpc-5749	442	7	 	 	SPACE
dpc-5749	443	1	pmid	pmid	NOUN
dpc-5749	443	2	:	:	PUNCT
dpc-5749	443	3	32852563	32852563	NUM
dpc-5749	443	4	.	.	PUNCT
dpc-5749	444	1	60	60	NUM
dpc-5749	444	2	.	.	PUNCT
dpc-5749	445	1	gitin	gitin	VERB
dpc-5749	445	2	a	a	DET
dpc-5749	445	3	,	,	PUNCT
dpc-5749	445	4	porta	porta	NOUN
dpc-5749	445	5	ad	ad	NOUN
dpc-5749	445	6	,	,	PUNCT
dpc-5749	445	7	bisbee	bisbee	PROPN
dpc-5749	445	8	e	e	PROPN
dpc-5749	445	9	,	,	PUNCT
dpc-5749	445	10	braunlich	braunlich	PRON
dpc-5749	445	11	k	k	NOUN
dpc-5749	445	12	,	,	PUNCT
dpc-5749	445	13	motaparthi	motaparthi	PROPN
dpc-5749	445	14	k.	k.	PROPN
dpc-5749	445	15	anti	anti	ADJ
dpc-5749	445	16	-	-	ADJ
dpc-5749	445	17	laminin	laminin	ADJ
dpc-5749	445	18	332	332	NUM
dpc-5749	445	19	mucous	mucous	ADJ
dpc-5749	445	20	membrane	membrane	NOUN
dpc-5749	445	21	pemphigoid	pemphigoid	NOUN
dpc-5749	445	22	in	in	ADP
dpc-5749	445	23	a	a	DET
dpc-5749	445	24	young	young	ADJ
dpc-5749	445	25	woman	woman	NOUN
dpc-5749	445	26	treated	treat	VERB
dpc-5749	445	27	with	with	ADP
dpc-5749	445	28	rituximab	rituximab	NOUN
dpc-5749	445	29	.	.	PUNCT
dpc-5749	446	1	dermatol	dermatol	NOUN
dpc-5749	446	2	online	online	PROPN
dpc-5749	446	3	j.	j.	PROPN
dpc-5749	446	4	2022;28(4	2022;28(4	NUM
dpc-5749	446	5	)	)	PUNCT
dpc-5749	446	6	.	.	PUNCT
dpc-5749	447	1	doi	doi	NOUN
dpc-5749	447	2	:	:	PUNCT
dpc-5749	447	3	10.5070	10.5070	NUM
dpc-5749	447	4	/	/	SYM
dpc-5749	447	5	d328458517	d328458517	PROPN
dpc-5749	447	6	.	.	PUNCT
dpc-5749	447	7	 	 	SPACE
dpc-5749	447	8	pmid	pmid	NOUN
dpc-5749	447	9	:	:	PUNCT
dpc-5749	447	10	36259856	36259856	NUM
dpc-5749	447	11	.	.	PUNCT
dpc-5749	448	1	61	61	NUM
dpc-5749	448	2	.	.	PUNCT
dpc-5749	448	3	hügel	hügel	NOUN
dpc-5749	448	4	r	r	NOUN
dpc-5749	448	5	,	,	PUNCT
dpc-5749	448	6	lang	lang	PROPN
dpc-5749	448	7	a	a	PROPN
dpc-5749	448	8	,	,	PUNCT
dpc-5749	448	9	lhotta	lhotta	PROPN
dpc-5749	448	10	k	k	NOUN
dpc-5749	448	11	,	,	PUNCT
dpc-5749	448	12	et	et	PROPN
dpc-5749	448	13	al	al	PROPN
dpc-5749	448	14	.	.	PUNCT
dpc-5749	449	1	anti	anti	ADJ
dpc-5749	449	2	-	-	ADJ
dpc-5749	449	3	laminin	laminin	ADJ
dpc-5749	449	4	332	332	NUM
dpc-5749	449	5	mucous	mucous	ADJ
dpc-5749	449	6	membrane	membrane	NOUN
dpc-5749	449	7	pemphigoid	pemphigoid	NOUN
dpc-5749	449	8	with	with	ADP
dpc-5749	449	9	laryngeal	laryngeal	ADJ
dpc-5749	449	10	involvement	involvement	NOUN
dpc-5749	449	11	–	–	PUNCT
dpc-5749	449	12	adjuvant	adjuvant	ADJ
dpc-5749	449	13	treatment	treatment	NOUN
dpc-5749	449	14	with	with	ADP
dpc-5749	449	15	immunoadsorption	immunoadsorption	NOUN
dpc-5749	449	16	and	and	CCONJ
dpc-5749	449	17	rituximab	rituximab	NOUN
dpc-5749	449	18	.	.	PUNCT
dpc-5749	450	1	j	j	PROPN
dpc-5749	450	2	dtsch	dtsch	PROPN
dpc-5749	450	3	dermatol	dermatol	NOUN
dpc-5749	450	4	ges	ge	NOUN
dpc-5749	450	5	.	.	PUNCT
dpc-5749	451	1	2018;16(7):897	2018;16(7):897	PROPN
dpc-5749	451	2	-	-	PUNCT
dpc-5749	451	3	900	900	NUM
dpc-5749	451	4	.	.	PUNCT
dpc-5749	452	1	doi	doi	NOUN
dpc-5749	452	2	:	:	PUNCT
dpc-5749	452	3	10.1111	10.1111	NUM
dpc-5749	452	4	/	/	SYM
dpc-5749	452	5	ddg.13569	ddg.13569	NOUN
dpc-5749	452	6	.	.	PUNCT
dpc-5749	453	1	pmid	pmid	NOUN
dpc-5749	453	2	:	:	PUNCT
dpc-5749	453	3	29927519	29927519	NUM
dpc-5749	453	4	.	.	PUNCT
dpc-5749	454	1	62	62	NUM
dpc-5749	454	2	.	.	PUNCT
dpc-5749	455	1	chou	chou	PROPN
dpc-5749	455	2	wh	wh	PROPN
dpc-5749	455	3	,	,	PUNCT
dpc-5749	455	4	mcgregor	mcgregor	PROPN
dpc-5749	455	5	b	b	PROPN
dpc-5749	455	6	,	,	PUNCT
dpc-5749	455	7	schmidt	schmidt	PROPN
dpc-5749	455	8	a	a	X
dpc-5749	455	9	,	,	PUNCT
dpc-5749	455	10	et	et	PROPN
dpc-5749	455	11	al	al	PROPN
dpc-5749	455	12	.	.	PROPN
dpc-5749	455	13	cyclophosphamide	cyclophosphamide	PROPN
dpc-5749	455	14	associated	associate	VERB
dpc-5749	455	15	bladder	bladder	NOUN
dpc-5749	455	16	cancers	cancer	NOUN
dpc-5749	455	17	and	and	CCONJ
dpc-5749	455	18	considerations	consideration	NOUN
dpc-5749	455	19	for	for	ADP
dpc-5749	455	20	survivorship	survivorship	NOUN
dpc-5749	455	21	care	care	NOUN
dpc-5749	455	22	:	:	PUNCT
dpc-5749	455	23	a	a	DET
dpc-5749	455	24	systematic	systematic	ADJ
dpc-5749	455	25	review	review	NOUN
dpc-5749	455	26	.	.	PUNCT
dpc-5749	456	1	urol	urol	PROPN
dpc-5749	456	2	oncol	oncol	PROPN
dpc-5749	456	3	.	.	PUNCT
dpc-5749	457	1	2021;39(10):678	2021;39(10):678	NUM
dpc-5749	457	2	-	-	SYM
dpc-5749	457	3	685	685	NUM
dpc-5749	457	4	.	.	PUNCT
dpc-5749	458	1	doi	doi	NOUN
dpc-5749	458	2	:	:	PUNCT
dpc-5749	458	3	10.1016	10.1016	NUM
dpc-5749	458	4	/	/	SYM
dpc-5749	458	5	j.urolonc.2021.05.017	j.urolonc.2021.05.017	PROPN
dpc-5749	458	6	.	.	PUNCT
dpc-5749	458	7	 	 	SPACE
dpc-5749	458	8	pmid	pmid	NOUN
dpc-5749	458	9	:	:	PUNCT
dpc-5749	458	10	34134927	34134927	NUM
dpc-5749	458	11	.	.	PUNCT
dpc-5749	459	1	63	63	NUM
dpc-5749	459	2	.	.	PUNCT
dpc-5749	460	1	hirunsatitpron	hirunsatitpron	PROPN
dpc-5749	460	2	p	p	X
dpc-5749	460	3	,	,	PUNCT
dpc-5749	460	4	hanprasertpong	hanprasertpong	ADJ
dpc-5749	460	5	n	n	CCONJ
dpc-5749	460	6	,	,	PUNCT
dpc-5749	460	7	noppakun	noppakun	PROPN
dpc-5749	460	8	k	k	PROPN
dpc-5749	460	9	,	,	PUNCT
dpc-5749	460	10	pruksakorn	pruksakorn	ADJ
dpc-5749	460	11	d	d	NOUN
dpc-5749	460	12	,	,	PUNCT
dpc-5749	460	13	teekachunhatean	teekachunhatean	ADJ
dpc-5749	460	14	s	s	PART
dpc-5749	460	15	,	,	PUNCT
dpc-5749	460	16	koonrungsesomboon	koonrungsesomboon	PROPN
dpc-5749	460	17	n.	n.	PROPN
dpc-5749	460	18	mycophenolic	mycophenolic	PROPN
dpc-5749	460	19	acid	acid	PROPN
dpc-5749	460	20	and	and	CCONJ
dpc-5749	460	21	cancer	cancer	NOUN
dpc-5749	460	22	risk	risk	NOUN
dpc-5749	460	23	in	in	ADP
dpc-5749	460	24	solid	solid	ADJ
dpc-5749	460	25	organ	organ	NOUN
dpc-5749	460	26	transplant	transplant	NOUN
dpc-5749	460	27	recipients	recipient	NOUN
dpc-5749	460	28	:	:	PUNCT
dpc-5749	460	29	systematic	systematic	ADJ
dpc-5749	460	30	review	review	NOUN
dpc-5749	460	31	and	and	CCONJ
dpc-5749	460	32	meta	meta	ADJ
dpc-5749	460	33	-	-	PUNCT
dpc-5749	460	34	analysis	analysis	NOUN
dpc-5749	460	35	.	.	PUNCT
dpc-5749	461	1	br	br	PROPN
dpc-5749	462	1	j	j	PROPN
dpc-5749	462	2	clin	clin	PROPN
dpc-5749	462	3	pharmacol	pharmacol	PROPN
dpc-5749	462	4	.	.	PUNCT
dpc-5749	463	1	2022;88(2):476	2022;88(2):476	PROPN
dpc-5749	463	2	-	-	PUNCT
dpc-5749	463	3	489	489	NUM
dpc-5749	463	4	.	.	PUNCT
dpc-5749	464	1	doi	doi	NOUN
dpc-5749	464	2	:	:	PUNCT
dpc-5749	464	3	10.1111	10.1111	NUM
dpc-5749	464	4	/	/	SYM
dpc-5749	464	5	bcp.14979	bcp.14979	PROPN
dpc-5749	464	6	.	.	PUNCT
dpc-5749	465	1	pmid	pmid	NOUN
dpc-5749	465	2	:	:	PUNCT
dpc-5749	465	3	34240462	34240462	NUM
dpc-5749	465	4	.	.	PUNCT
dpc-5749	466	1	64	64	NUM
dpc-5749	466	2	.	.	PUNCT
dpc-5749	467	1	gordon	gordon	PROPN
dpc-5749	467	2	h	h	PROPN
dpc-5749	467	3	,	,	PUNCT
dpc-5749	467	4	biancone	biancone	PROPN
dpc-5749	467	5	l	l	NOUN
dpc-5749	467	6	,	,	PUNCT
dpc-5749	467	7	fiorino	fiorino	NOUN
dpc-5749	467	8	g	g	NOUN
dpc-5749	467	9	,	,	PUNCT
dpc-5749	467	10	et	et	PROPN
dpc-5749	467	11	al	al	PROPN
dpc-5749	467	12	.	.	PROPN
dpc-5749	467	13	ecco	ecco	PROPN
dpc-5749	467	14	guidelines	guideline	NOUN
dpc-5749	467	15	on	on	ADP
dpc-5749	467	16	inflammatory	inflammatory	ADJ
dpc-5749	467	17	bowel	bowel	NOUN
dpc-5749	467	18	disease	disease	NOUN
dpc-5749	467	19	and	and	CCONJ
dpc-5749	467	20	malignancies	malignancy	NOUN
dpc-5749	467	21	.	.	PUNCT
dpc-5749	468	1	j	j	PROPN
dpc-5749	468	2	crohns	crohns	PROPN
dpc-5749	468	3	colitis	colitis	PROPN
dpc-5749	468	4	.	.	PUNCT
dpc-5749	469	1	2023;17(6):827	2023;17(6):827	NUM
dpc-5749	469	2	-	-	SYM
dpc-5749	469	3	854	854	NUM
dpc-5749	469	4	.	.	PUNCT
dpc-5749	470	1	dou	dou	NOUN
dpc-5749	470	2	:	:	PUNCT
dpc-5749	470	3	10.1093	10.1093	NUM
dpc-5749	470	4	/	/	SYM
dpc-5749	470	5	ecco	ecco	PROPN
dpc-5749	470	6	-	-	PUNCT
dpc-5749	470	7	jcc	jcc	PROPN
dpc-5749	470	8	/	/	SYM
dpc-5749	470	9	jjac187	jjac187	PROPN
dpc-5749	470	10	.	.	PUNCT
dpc-5749	471	1	pmid	pmid	PROPN
dpc-5749	471	2	:	:	PUNCT
dpc-5749	471	3	36528797	36528797	NUM
dpc-5749	471	4	.	.	PUNCT
dpc-5749	472	1	65	65	NUM
dpc-5749	472	2	.	.	PUNCT
dpc-5749	473	1	peng	peng	PROPN
dpc-5749	473	2	y	y	PROPN
dpc-5749	473	3	,	,	PUNCT
dpc-5749	473	4	tao	tao	PROPN
dpc-5749	473	5	y	y	PROPN
dpc-5749	473	6	,	,	PUNCT
dpc-5749	473	7	zhang	zhang	PROPN
dpc-5749	473	8	y	y	PROPN
dpc-5749	473	9	,	,	PUNCT
dpc-5749	473	10	wang	wang	PROPN
dpc-5749	473	11	j	j	PROPN
dpc-5749	473	12	,	,	PUNCT
dpc-5749	473	13	yang	yang	PROPN
dpc-5749	473	14	j	j	PROPN
dpc-5749	473	15	,	,	PUNCT
dpc-5749	473	16	wang	wang	PROPN
dpc-5749	473	17	y.	y.	PROPN
dpc-5749	473	18	cd25	cd25	PROPN
dpc-5749	473	19	:	:	PUNCT
dpc-5749	473	20	a	a	DET
dpc-5749	473	21	potential	potential	ADJ
dpc-5749	473	22	tumor	tumor	NOUN
dpc-5749	473	23	therapeutic	therapeutic	ADJ
dpc-5749	473	24	target	target	NOUN
dpc-5749	473	25	.	.	PUNCT
dpc-5749	474	1	int	int	NOUN
dpc-5749	474	2	j	j	PROPN
dpc-5749	474	3	cancer	cancer	NOUN
dpc-5749	474	4	.	.	PUNCT
dpc-5749	475	1	2023;152(7	2023;152(7	NUM
dpc-5749	475	2	):	):	PUNCT
dpc-5749	475	3	1290	1290	NUM
dpc-5749	475	4	-	-	SYM
dpc-5749	475	5	1303	1303	NUM
dpc-5749	475	6	.	.	PUNCT
dpc-5749	476	1	doi	doi	NOUN
dpc-5749	476	2	:	:	PUNCT
dpc-5749	476	3	10.1002	10.1002	NUM
dpc-5749	476	4	/	/	SYM
dpc-5749	476	5	ijc.34281	ijc.34281	PROPN
dpc-5749	476	6	.	.	PUNCT
dpc-5749	476	7	 	 	SPACE
dpc-5749	476	8	pmid	pmid	NOUN
dpc-5749	476	9	:	:	PUNCT
dpc-5749	476	10	36082452	36082452	NUM
dpc-5749	476	11	.	.	PUNCT
dpc-5749	477	1	66	66	NUM
dpc-5749	477	2	.	.	PUNCT
dpc-5749	478	1	ceesay	ceesay	PROPN
dpc-5749	478	2	mm	mm	PROPN
dpc-5749	478	3	,	,	PUNCT
dpc-5749	478	4	matutes	matute	NOUN
dpc-5749	478	5	e	e	PROPN
dpc-5749	478	6	,	,	PUNCT
dpc-5749	478	7	taylor	taylor	PROPN
dpc-5749	478	8	gp	gp	PROPN
dpc-5749	478	9	,	,	PUNCT
dpc-5749	478	10	et	et	PROPN
dpc-5749	478	11	al	al	PROPN
dpc-5749	478	12	.	.	PROPN
dpc-5749	478	13	phase	phase	PROPN
dpc-5749	478	14	ii	ii	PROPN
dpc-5749	478	15	study	study	NOUN
dpc-5749	478	16	on	on	ADP
dpc-5749	478	17	combination	combination	NOUN
dpc-5749	478	18	therapy	therapy	NOUN
dpc-5749	478	19	with	with	ADP
dpc-5749	478	20	chop	chop	NOUN
dpc-5749	478	21	-	-	PUNCT
dpc-5749	478	22	zenapax	zenapax	PROPN
dpc-5749	478	23	for	for	ADP
dpc-5749	478	24	htlv	htlv	PROPN
dpc-5749	478	25	-	-	PUNCT
dpc-5749	478	26	i	i	PRON
dpc-5749	478	27	associated	associate	VERB
dpc-5749	478	28	38	38	NUM
dpc-5749	478	29	.	.	PUNCT
dpc-5749	478	30	atzori	atzori	PROPN
dpc-5749	478	31	l	l	PROPN
dpc-5749	478	32	,	,	PUNCT
dpc-5749	478	33	conti	conti	PROPN
dpc-5749	478	34	b	b	PROPN
dpc-5749	478	35	,	,	PUNCT
dpc-5749	478	36	zucca	zucca	PROPN
dpc-5749	478	37	m	m	PROPN
dpc-5749	478	38	,	,	PUNCT
dpc-5749	478	39	pau	pau	PROPN
dpc-5749	478	40	m.	m.	PROPN
dpc-5749	478	41	bullous	bullous	ADJ
dpc-5749	478	42	pemphigoid	pemphigoid	NOUN
dpc-5749	478	43	induced	induce	VERB
dpc-5749	478	44	by	by	ADP
dpc-5749	478	45	m	m	NOUN
dpc-5749	478	46	-	-	ADJ
dpc-5749	478	47	tor	tor	NOUN
dpc-5749	478	48	inhibitors	inhibitor	NOUN
dpc-5749	478	49	in	in	ADP
dpc-5749	478	50	renal	renal	ADJ
dpc-5749	478	51	transplant	transplant	NOUN
dpc-5749	478	52	recipients	recipient	NOUN
dpc-5749	478	53	.	.	PUNCT
dpc-5749	479	1	j	j	PROPN
dpc-5749	479	2	eur	eur	PROPN
dpc-5749	479	3	acad	acad	PROPN
dpc-5749	479	4	dermatol	dermatol	NOUN
dpc-5749	479	5	venereol	venereol	NOUN
dpc-5749	479	6	.	.	PUNCT
dpc-5749	480	1	2015;29(8):1626	2015;29(8):1626	NUM
dpc-5749	480	2	-	-	SYM
dpc-5749	480	3	30	30	NUM
dpc-5749	480	4	.	.	PUNCT
dpc-5749	481	1	doi	doi	NOUN
dpc-5749	481	2	:	:	PUNCT
dpc-5749	481	3	10.1111	10.1111	NUM
dpc-5749	481	4	/jdv.12662	/jdv.12662	NOUN
dpc-5749	481	5	.	.	PUNCT
dpc-5749	482	1	pmid	pmid	NOUN
dpc-5749	482	2	:	:	PUNCT
dpc-5749	482	3	25174440	25174440	NUM
dpc-5749	482	4	.	.	PUNCT
dpc-5749	483	1	39	39	NUM
dpc-5749	483	2	.	.	PUNCT
dpc-5749	484	1	hwang	hwang	PROPN
dpc-5749	484	2	s	s	PROPN
dpc-5749	484	3	,	,	PUNCT
dpc-5749	484	4	kuo	kuo	PROPN
dpc-5749	484	5	sc	sc	PROPN
dpc-5749	484	6	.	.	PUNCT
dpc-5749	485	1	corneal	corneal	ADJ
dpc-5749	485	2	perforation	perforation	NOUN
dpc-5749	485	3	in	in	ADP
dpc-5749	485	4	ocular	ocular	ADJ
dpc-5749	485	5	cicatricial	cicatricial	ADJ
dpc-5749	485	6	pemphigoid	pemphigoid	NOUN
dpc-5749	485	7	:	:	PUNCT
dpc-5749	485	8	a	a	DET
dpc-5749	485	9	care	care	NOUN
dpc-5749	485	10	-	-	PUNCT
dpc-5749	485	11	compliant	compliant	NOUN
dpc-5749	485	12	case	case	NOUN
dpc-5749	485	13	report	report	NOUN
dpc-5749	485	14	.	.	PUNCT
dpc-5749	486	1	medicine	medicine	NOUN
dpc-5749	486	2	(	(	PUNCT
dpc-5749	486	3	baltimore	baltimore	PROPN
dpc-5749	486	4	)	)	PUNCT
dpc-5749	486	5	.	.	PUNCT
dpc-5749	487	1	2021;100(51):e28266	2021;100(51):e28266	X
dpc-5749	487	2	.	.	PUNCT
dpc-5749	488	1	doi	doi	NOUN
dpc-5749	488	2	:	:	PUNCT
dpc-5749	488	3	10.1097	10.1097	NUM
dpc-5749	488	4	/	/	SYM
dpc-5749	488	5	md.0000000000028266	md.0000000000028266	PROPN
dpc-5749	488	6	.	.	PUNCT
dpc-5749	489	1	pmid	pmid	NOUN
dpc-5749	489	2	:	:	PUNCT
dpc-5749	489	3	34941105	34941105	NUM
dpc-5749	489	4	.	.	PUNCT
dpc-5749	490	1	40	40	NUM
dpc-5749	490	2	.	.	PUNCT
dpc-5749	491	1	stan	stan	PROPN
dpc-5749	491	2	c	c	PROPN
dpc-5749	491	3	,	,	PUNCT
dpc-5749	491	4	diaconu	diaconu	NOUN
dpc-5749	491	5	e	e	PROPN
dpc-5749	491	6	,	,	PUNCT
dpc-5749	491	7	hopirca	hopirca	PROPN
dpc-5749	491	8	l	l	PROPN
dpc-5749	491	9	,	,	PUNCT
dpc-5749	491	10	petra	petra	PROPN
dpc-5749	491	11	n	n	CCONJ
dpc-5749	491	12	,	,	PUNCT
dpc-5749	491	13	rednic	rednic	ADJ
dpc-5749	491	14	a	a	NOUN
dpc-5749	491	15	,	,	PUNCT
dpc-5749	491	16	stan	stan	PROPN
dpc-5749	491	17	c.	c.	PROPN
dpc-5749	491	18	ocular	ocular	PROPN
dpc-5749	491	19	cicatricial	cicatricial	ADJ
dpc-5749	491	20	pemphigoid	pemphigoid	NOUN
dpc-5749	491	21	.	.	PUNCT
dpc-5749	492	1	rom	rom	INTJ
dpc-5749	493	1	j	j	PROPN
dpc-5749	493	2	ophthalmol	ophthalmol	PROPN
dpc-5749	493	3	.	.	PUNCT
dpc-5749	494	1	2020;64(2	2020;64(2	NUM
dpc-5749	494	2	):	):	PUNCT
dpc-5749	494	3	226	226	NUM
dpc-5749	494	4	-	-	SYM
dpc-5749	494	5	230	230	NUM
dpc-5749	494	6	.	.	PUNCT
dpc-5749	495	1	pmid	pmid	NOUN
dpc-5749	495	2	:	:	PUNCT
dpc-5749	495	3	32685792	32685792	NUM
dpc-5749	495	4	.	.	PUNCT
dpc-5749	496	1	41	41	NUM
dpc-5749	496	2	.	.	PUNCT
dpc-5749	496	3	wirta	wirta	PROPN
dpc-5749	496	4	d	d	PROPN
dpc-5749	496	5	,	,	PUNCT
dpc-5749	496	6	lipsky	lipsky	PROPN
dpc-5749	496	7	w	w	PROPN
dpc-5749	496	8	,	,	PUNCT
dpc-5749	496	9	toyos	toyos	PROPN
dpc-5749	496	10	m	m	PROPN
dpc-5749	496	11	,	,	PUNCT
dpc-5749	496	12	et	et	PROPN
dpc-5749	496	13	al	al	PROPN
dpc-5749	496	14	.	.	PROPN
dpc-5749	496	15	recombinant	recombinant	ADJ
dpc-5749	496	16	human	human	ADJ
dpc-5749	496	17	nerve	nerve	NOUN
dpc-5749	496	18	growth	growth	NOUN
dpc-5749	496	19	factor	factor	NOUN
dpc-5749	496	20	(	(	PUNCT
dpc-5749	496	21	cenegermin	cenegermin	NOUN
dpc-5749	496	22	)	)	PUNCT
dpc-5749	496	23	for	for	ADP
dpc-5749	496	24	moderate	moderate	ADJ
dpc-5749	496	25	-	-	PUNCT
dpc-5749	496	26	to	to	ADP
dpc-5749	496	27	-	-	PUNCT
dpc-5749	496	28	severe	severe	ADJ
dpc-5749	496	29	dry	dry	ADJ
dpc-5749	496	30	eye	eye	NOUN
dpc-5749	496	31	:	:	PUNCT
dpc-5749	496	32	phase	phase	NOUN
dpc-5749	496	33	ii	ii	NOUN
dpc-5749	496	34	,	,	PUNCT
dpc-5749	496	35	randomized	randomize	VERB
dpc-5749	496	36	,	,	PUNCT
dpc-5749	496	37	vehicle	vehicle	NOUN
dpc-5749	496	38	-	-	PUNCT
dpc-5749	496	39	controlled	control	VERB
dpc-5749	496	40	,	,	PUNCT
dpc-5749	496	41	dose	dose	NOUN
dpc-5749	496	42	-	-	PUNCT
dpc-5749	496	43	ranging	range	VERB
dpc-5749	496	44	trial	trial	NOUN
dpc-5749	496	45	.	.	PUNCT
dpc-5749	497	1	bmc	bmc	PROPN
dpc-5749	497	2	ophthalmol	ophthalmol	NOUN
dpc-5749	497	3	.	.	PUNCT
dpc-5749	498	1	2024;24(1):290	2024;24(1):290	NUM
dpc-5749	498	2	.	.	PUNCT
dpc-5749	499	1	doi	doi	NOUN
dpc-5749	499	2	:	:	PUNCT
dpc-5749	499	3	10.1186	10.1186	NUM
dpc-5749	499	4	/	/	SYM
dpc-5749	499	5	s12886	s12886	NOUN
dpc-5749	499	6	-	-	PUNCT
dpc-5749	499	7	02403564	02403564	NUM
dpc-5749	499	8	-	-	PUNCT
dpc-5749	499	9	w.	w.	NOUN
dpc-5749	499	10	pmid	pmid	PROPN
dpc-5749	499	11	:	:	PUNCT
dpc-5749	499	12	39020305	39020305	NUM
dpc-5749	499	13	.	.	PUNCT
dpc-5749	500	1	42	42	NUM
dpc-5749	500	2	.	.	PUNCT
dpc-5749	501	1	zhong	zhong	PROPN
dpc-5749	501	2	m	m	PROPN
dpc-5749	501	3	,	,	PUNCT
dpc-5749	501	4	gadek	gadek	NOUN
dpc-5749	501	5	tr	tr	VERB
dpc-5749	501	6	,	,	PUNCT
dpc-5749	501	7	bui	bui	PROPN
dpc-5749	501	8	m	m	PROPN
dpc-5749	501	9	,	,	PUNCT
dpc-5749	501	10	et	et	PROPN
dpc-5749	501	11	al	al	PROPN
dpc-5749	501	12	.	.	PROPN
dpc-5749	501	13	discovery	discovery	PROPN
dpc-5749	501	14	and	and	CCONJ
dpc-5749	501	15	development	development	NOUN
dpc-5749	501	16	of	of	ADP
dpc-5749	501	17	potent	potent	ADJ
dpc-5749	501	18	lfa-1	lfa-1	NOUN
dpc-5749	501	19	/	/	SYM
dpc-5749	501	20	icam-1	icam-1	NOUN
dpc-5749	501	21	antagonist	antagonist	NOUN
dpc-5749	501	22	sar	sar	NOUN
dpc-5749	501	23	1118	1118	NUM
dpc-5749	501	24	as	as	ADP
dpc-5749	501	25	an	an	DET
dpc-5749	501	26	ophthalmic	ophthalmic	ADJ
dpc-5749	501	27	solution	solution	NOUN
dpc-5749	501	28	for	for	ADP
dpc-5749	501	29	treating	treat	VERB
dpc-5749	501	30	dry	dry	ADJ
dpc-5749	501	31	eye	eye	NOUN
dpc-5749	501	32	.	.	PUNCT
dpc-5749	502	1	acs	acs	PROPN
dpc-5749	502	2	med	med	PROPN
dpc-5749	502	3	chem	chem	PROPN
dpc-5749	502	4	lett	lett	PROPN
dpc-5749	502	5	.	.	PUNCT
dpc-5749	503	1	2012;3(3):203	2012;3(3):203	NUM
dpc-5749	503	2	-	-	SYM
dpc-5749	503	3	6	6	NUM
dpc-5749	503	4	.	.	PUNCT
dpc-5749	503	5	doi	doi	NOUN
dpc-5749	503	6	:	:	PUNCT
dpc-5749	503	7	10.1021	10.1021	NUM
dpc-5749	503	8	/	/	SYM
dpc-5749	503	9	ml2002482	ml2002482	PROPN
dpc-5749	503	10	.	.	PUNCT
dpc-5749	504	1	pmid	pmid	NOUN
dpc-5749	504	2	:	:	PUNCT
dpc-5749	504	3	24900456	24900456	NUM
dpc-5749	504	4	.	.	PUNCT
dpc-5749	505	1	43	43	NUM
dpc-5749	505	2	.	.	PUNCT
dpc-5749	506	1	kianfar	kianfar	PROPN
dpc-5749	506	2	n	n	CCONJ
dpc-5749	506	3	,	,	PUNCT
dpc-5749	506	4	dasdar	dasdar	PROPN
dpc-5749	506	5	s	s	PROPN
dpc-5749	506	6	,	,	PUNCT
dpc-5749	506	7	camilleri	camilleri	PROPN
dpc-5749	506	8	mj	mj	PROPN
dpc-5749	506	9	,	,	PUNCT
dpc-5749	506	10	lehman	lehman	PROPN
dpc-5749	506	11	js	js	PROPN
dpc-5749	506	12	.	.	PUNCT
dpc-5749	506	13	mucous	mucous	ADJ
dpc-5749	506	14	membrane	membrane	NOUN
dpc-5749	506	15	pemphigoid	pemphigoid	NOUN
dpc-5749	506	16	and	and	CCONJ
dpc-5749	506	17	malignancy	malignancy	NOUN
dpc-5749	506	18	:	:	PUNCT
dpc-5749	506	19	systematic	systematic	ADJ
dpc-5749	506	20	review	review	NOUN
dpc-5749	506	21	and	and	CCONJ
dpc-5749	506	22	meta	meta	NOUN
dpc-5749	506	23	-	-	PUNCT
dpc-5749	506	24	analysis	analysis	NOUN
dpc-5749	506	25	of	of	ADP
dpc-5749	506	26	1429	1429	NUM
dpc-5749	506	27	patients	patient	NOUN
dpc-5749	506	28	.	.	PUNCT
dpc-5749	507	1	jaad	jaad	NOUN
dpc-5749	507	2	reviews	review	NOUN
dpc-5749	507	3	.	.	PUNCT
dpc-5749	508	1	2024;1:82	2024;1:82	PROPN
dpc-5749	508	2	-	-	PUNCT
dpc-5749	508	3	92	92	NUM
dpc-5749	508	4	.	.	PUNCT
dpc-5749	509	1	doi:10.1016	doi:10.1016	PROPN
dpc-5749	509	2	/	/	SYM
dpc-5749	509	3	j.jdrv.2024.07.003	j.jdrv.2024.07.003	PROPN
dpc-5749	509	4	44	44	NUM
dpc-5749	509	5	.	.	PUNCT
dpc-5749	510	1	shi	shi	PROPN
dpc-5749	510	2	l	l	PROPN
dpc-5749	510	3	,	,	PUNCT
dpc-5749	510	4	li	li	PROPN
dpc-5749	510	5	x	x	PROPN
dpc-5749	510	6	,	,	PUNCT
dpc-5749	510	7	qian	qian	PROPN
dpc-5749	510	8	h.	h.	PROPN
dpc-5749	510	9	anti	anti	ADJ
dpc-5749	510	10	-	-	ADJ
dpc-5749	510	11	laminin	laminin	ADJ
dpc-5749	510	12	332	332	NUM
dpc-5749	510	13	-	-	PUNCT
dpc-5749	510	14	type	type	NOUN
dpc-5749	510	15	mucous	mucous	ADJ
dpc-5749	510	16	membrane	membrane	NOUN
dpc-5749	510	17	pemphigoid	pemphigoid	NOUN
dpc-5749	510	18	.	.	PUNCT
dpc-5749	511	1	biomolecules	biomolecule	NOUN
dpc-5749	511	2	.	.	PUNCT
dpc-5749	512	1	2022;12(10):1461	2022;12(10):1461	NUM
dpc-5749	512	2	.	.	PUNCT
dpc-5749	512	3	doi	doi	PROPN
dpc-5749	512	4	:	:	PUNCT
dpc-5749	512	5	10.3390	10.3390	NUM
dpc-5749	512	6	/biom12101461	/biom12101461	PUNCT
dpc-5749	512	7	.	.	PUNCT
dpc-5749	513	1	pmid	pmid	NOUN
dpc-5749	513	2	:	:	PUNCT
dpc-5749	513	3	36291670	36291670	NUM
dpc-5749	513	4	.	.	PUNCT
dpc-5749	514	1	45	45	NUM
dpc-5749	514	2	.	.	PUNCT
dpc-5749	514	3	nonnast	nonnast	PROPN
dpc-5749	514	4	e	e	PROPN
dpc-5749	514	5	,	,	PUNCT
dpc-5749	514	6	mira	mira	PROPN
dpc-5749	514	7	e	e	PROPN
dpc-5749	514	8	,	,	PUNCT
dpc-5749	514	9	mañes	mañes	PROPN
dpc-5749	514	10	s.	s.	PROPN
dpc-5749	514	11	the	the	DET
dpc-5749	514	12	role	role	NOUN
dpc-5749	514	13	of	of	ADP
dpc-5749	514	14	laminins	laminin	NOUN
dpc-5749	514	15	in	in	ADP
dpc-5749	514	16	cancer	cancer	NOUN
dpc-5749	514	17	pathobiology	pathobiology	NOUN
dpc-5749	514	18	:	:	PUNCT
dpc-5749	514	19	a	a	DET
dpc-5749	514	20	comprehensive	comprehensive	ADJ
dpc-5749	514	21	review	review	NOUN
dpc-5749	514	22	.	.	PUNCT
dpc-5749	515	1	j	j	PROPN
dpc-5749	515	2	transl	transl	PROPN
dpc-5749	515	3	med	med	PROPN
dpc-5749	515	4	.	.	PUNCT
dpc-5749	516	1	2025;23(1):83	2025;23(1):83	X
dpc-5749	516	2	.	.	PUNCT
dpc-5749	517	1	doi	doi	NOUN
dpc-5749	517	2	:	:	PUNCT
dpc-5749	517	3	10.1186	10.1186	NUM
dpc-5749	517	4	/	/	SYM
dpc-5749	517	5	s12967	s12967	NOUN
dpc-5749	517	6	-	-	PUNCT
dpc-5749	517	7	025	025	NUM
dpc-5749	517	8	-	-	PUNCT
dpc-5749	517	9	06079	06079	NUM
dpc-5749	517	10	-	-	SYM
dpc-5749	517	11	0	0	NUM
dpc-5749	517	12	.	.	PUNCT
dpc-5749	517	13	 	 	SPACE
dpc-5749	518	1	pmid	pmid	NOUN
dpc-5749	518	2	:	:	PUNCT
dpc-5749	518	3	39825429	39825429	NUM
dpc-5749	518	4	.	.	PUNCT
dpc-5749	519	1	46	46	NUM
dpc-5749	519	2	.	.	PUNCT
dpc-5749	519	3	patzelt	patzelt	PROPN
dpc-5749	519	4	s	s	PROPN
dpc-5749	519	5	,	,	PUNCT
dpc-5749	519	6	schmidt	schmidt	PROPN
dpc-5749	519	7	e.	e.	PROPN
dpc-5749	519	8	autoimmunity	autoimmunity	PROPN
dpc-5749	519	9	against	against	ADP
dpc-5749	519	10	laminin	laminin	NOUN
dpc-5749	519	11	332	332	NUM
dpc-5749	519	12	.	.	PUNCT
dpc-5749	520	1	front	front	ADJ
dpc-5749	520	2	immunol	immunol	NOUN
dpc-5749	520	3	.	.	PUNCT
dpc-5749	521	1	2023;14:1250115	2023;14:1250115	PROPN
dpc-5749	521	2	.	.	PUNCT
dpc-5749	522	1	doi	doi	NOUN
dpc-5749	522	2	:	:	PUNCT
dpc-5749	522	3	10.3389	10.3389	NUM
dpc-5749	522	4	/	/	SYM
dpc-5749	522	5	fimmu.2023.1250115	fimmu.2023.1250115	NOUN
dpc-5749	522	6	.	.	PUNCT
dpc-5749	523	1	pmid	pmid	NOUN
dpc-5749	523	2	:	:	PUNCT
dpc-5749	523	3	37638011	37638011	NUM
dpc-5749	523	4	.	.	PUNCT
dpc-5749	524	1	47	47	NUM
dpc-5749	524	2	.	.	PUNCT
dpc-5749	525	1	li	li	PROPN
dpc-5749	525	2	x	x	PROPN
dpc-5749	525	3	,	,	PUNCT
dpc-5749	525	4	pas	pas	PROPN
dpc-5749	525	5	hh	hh	PROPN
dpc-5749	525	6	,	,	PUNCT
dpc-5749	525	7	qian	qian	PROPN
dpc-5749	525	8	h	h	PROPN
dpc-5749	525	9	,	,	PUNCT
dpc-5749	525	10	et	et	PROPN
dpc-5749	525	11	al	al	PROPN
dpc-5749	525	12	.	.	PROPN
dpc-5749	525	13	potential	potential	ADJ
dpc-5749	525	14	correlation	correlation	NOUN
dpc-5749	525	15	between	between	ADP
dpc-5749	525	16	anti	anti	ADJ
dpc-5749	525	17	-	-	ADJ
dpc-5749	525	18	laminin	laminin	ADJ
dpc-5749	525	19	332	332	NUM
dpc-5749	525	20	autoantibodies	autoantibody	NOUN
dpc-5749	525	21	and	and	CCONJ
dpc-5749	525	22	malignant	malignant	ADJ
dpc-5749	525	23	tumours	tumour	NOUN
dpc-5749	525	24	in	in	ADP
dpc-5749	525	25	anti	anti	ADJ
dpc-5749	525	26	-	-	ADJ
dpc-5749	525	27	bp180	bp180	ADJ
dpc-5749	525	28	-	-	PUNCT
dpc-5749	525	29	type	type	NOUN
dpc-5749	525	30	mucous	mucous	ADJ
dpc-5749	525	31	membrane	membrane	NOUN
dpc-5749	525	32	pemphigoid	pemphigoid	NOUN
dpc-5749	525	33	.	.	PUNCT
dpc-5749	526	1	clin	clin	PROPN
dpc-5749	526	2	exp	exp	NOUN
dpc-5749	526	3	dermatol	dermatol	NOUN
dpc-5749	526	4	.	.	PUNCT
dpc-5749	527	1	2024;49(9):1075	2024;49(9):1075	NUM
dpc-5749	527	2	-	-	SYM
dpc-5749	527	3	1076	1076	NUM
dpc-5749	527	4	.	.	PUNCT
dpc-5749	528	1	doi	doi	NOUN
dpc-5749	528	2	:	:	PUNCT
dpc-5749	528	3	10.1093	10.1093	NUM
dpc-5749	528	4	/	/	SYM
dpc-5749	528	5	ced	ced	PROPN
dpc-5749	528	6	/	/	SYM
dpc-5749	528	7	llae124	llae124	PROPN
dpc-5749	528	8	.	.	PUNCT
dpc-5749	529	1	pmid	pmid	NOUN
dpc-5749	529	2	:	:	PUNCT
dpc-5749	529	3	38634807	38634807	NUM
dpc-5749	529	4	.	.	PUNCT
dpc-5749	530	1	48	48	NUM
dpc-5749	530	2	.	.	PUNCT
dpc-5749	531	1	syal	syal	PROPN
dpc-5749	531	2	a	a	PROPN
dpc-5749	531	3	,	,	PUNCT
dpc-5749	531	4	lott	lott	PROPN
dpc-5749	531	5	dg	dg	PROPN
dpc-5749	531	6	,	,	PUNCT
dpc-5749	531	7	karle	karle	PROPN
dpc-5749	531	8	we	we	PRON
dpc-5749	531	9	.	.	PUNCT
dpc-5749	532	1	radiation	radiation	NOUN
dpc-5749	532	2	-	-	PUNCT
dpc-5749	532	3	induced	induce	VERB
dpc-5749	532	4	laryngeal	laryngeal	ADJ
dpc-5749	532	5	mucous	mucous	ADJ
dpc-5749	532	6	membrane	membrane	NOUN
dpc-5749	532	7	pemphigoid	pemphigoid	NOUN
dpc-5749	532	8	.	.	PUNCT
dpc-5749	533	1	ann	ann	PROPN
dpc-5749	533	2	otol	otol	PROPN
dpc-5749	533	3	rhinol	rhinol	NOUN
dpc-5749	533	4	laryngol	laryngol	NOUN
dpc-5749	533	5	.	.	PUNCT
dpc-5749	534	1	2023;132(10):1261	2023;132(10):1261	NUM
dpc-5749	534	2	-	-	SYM
dpc-5749	534	3	1264	1264	NUM
dpc-5749	534	4	.	.	PUNCT
dpc-5749	535	1	doi	doi	NOUN
dpc-5749	535	2	:	:	PUNCT
dpc-5749	535	3	10.1177/00034894221139121	10.1177/00034894221139121	NUM
dpc-5749	535	4	.	.	PUNCT
dpc-5749	536	1	pmid	pmid	NOUN
dpc-5749	536	2	:	:	PUNCT
dpc-5749	536	3	36433793	36433793	NUM
dpc-5749	536	4	.	.	PUNCT
dpc-5749	537	1	49	49	NUM
dpc-5749	537	2	.	.	PUNCT
dpc-5749	538	1	kotnik	kotnik	PROPN
dpc-5749	538	2	n	n	CCONJ
dpc-5749	538	3	,	,	PUNCT
dpc-5749	538	4	diercks	diercks	PROPN
dpc-5749	538	5	gfh	gfh	PROPN
dpc-5749	538	6	,	,	PUNCT
dpc-5749	538	7	jalving	jalve	VERB
dpc-5749	538	8	h	h	NOUN
dpc-5749	538	9	,	,	PUNCT
dpc-5749	538	10	et	et	PROPN
dpc-5749	538	11	al	al	PROPN
dpc-5749	538	12	.	.	PROPN
dpc-5749	539	1	pemphigoid	pemphigoid	PROPN
dpc-5749	539	2	diseases	disease	NOUN
dpc-5749	539	3	as	as	ADP
dpc-5749	539	4	immune	immune	NOUN
dpc-5749	539	5	-	-	PUNCT
dpc-5749	539	6	related	relate	VERB
dpc-5749	539	7	adverse	adverse	ADJ
dpc-5749	539	8	effect	effect	NOUN
dpc-5749	539	9	following	follow	VERB
dpc-5749	539	10	immune	immune	ADJ
dpc-5749	539	11	checkpoint	checkpoint	NOUN
dpc-5749	539	12	inhibitors	inhibitor	NOUN
dpc-5749	539	13	:	:	PUNCT
dpc-5749	539	14	a	a	DET
dpc-5749	539	15	clinical	clinical	ADJ
dpc-5749	539	16	case	case	NOUN
dpc-5749	539	17	series	series	NOUN
dpc-5749	539	18	of	of	ADP
dpc-5749	539	19	a	a	DET
dpc-5749	539	20	diverse	diverse	ADJ
dpc-5749	539	21	spectrum	spectrum	NOUN
dpc-5749	539	22	.	.	PUNCT
dpc-5749	540	1	jaad	jaad	NOUN
dpc-5749	540	2	case	case	NOUN
dpc-5749	540	3	rep	rep	PROPN
dpc-5749	540	4	.	.	PROPN
dpc-5749	540	5	2025;61:100	2025;61:100	PROPN
dpc-5749	540	6	-	-	SYM
dpc-5749	540	7	106	106	NUM
dpc-5749	540	8	.	.	PUNCT
dpc-5749	541	1	doi	doi	NOUN
dpc-5749	541	2	:	:	PUNCT
dpc-5749	541	3	10.1016	10.1016	NUM
dpc-5749	541	4	/	/	SYM
dpc-5749	541	5	j.jdcr.2025.03.021	j.jdcr.2025.03.021	PROPN
dpc-5749	541	6	.	.	PUNCT
dpc-5749	542	1	pmid	pmid	NOUN
dpc-5749	542	2	:	:	PUNCT
dpc-5749	542	3	40538786	40538786	NUM
dpc-5749	542	4	.	.	PUNCT
dpc-5749	543	1	50	50	NUM
dpc-5749	543	2	.	.	PUNCT
dpc-5749	544	1	nouri	nouri	PROPN
dpc-5749	544	2	a	a	PROPN
dpc-5749	544	3	,	,	PUNCT
dpc-5749	544	4	olbrich	olbrich	ADJ
dpc-5749	544	5	h	h	NOUN
dpc-5749	544	6	,	,	PUNCT
dpc-5749	544	7	schmidt	schmidt	PROPN
dpc-5749	544	8	e	e	PROPN
dpc-5749	544	9	,	,	PUNCT
dpc-5749	544	10	ludwig	ludwig	PROPN
dpc-5749	544	11	rj	rj	PROPN
dpc-5749	544	12	,	,	PUNCT
dpc-5749	544	13	curman	curman	PROPN
dpc-5749	544	14	p.	p.	PROPN
dpc-5749	544	15	increased	increase	VERB
dpc-5749	544	16	risk	risk	NOUN
dpc-5749	544	17	of	of	ADP
dpc-5749	544	18	skin	skin	NOUN
dpc-5749	544	19	cancers	cancer	NOUN
dpc-5749	544	20	in	in	ADP
dpc-5749	544	21	mucous	mucous	ADJ
dpc-5749	544	22	membrane	membrane	NOUN
dpc-5749	544	23	pemphigoid	pemphigoid	NOUN
dpc-5749	544	24	:	:	PUNCT
dpc-5749	544	25	a	a	DET
dpc-5749	544	26	large	large	ADJ
dpc-5749	544	27	-	-	PUNCT
dpc-5749	544	28	scale	scale	NOUN
dpc-5749	544	29	matched	match	VERB
dpc-5749	544	30	cohort	cohort	NOUN
dpc-5749	544	31	study	study	NOUN
dpc-5749	544	32	of	of	ADP
dpc-5749	544	33	117	117	NUM
dpc-5749	544	34	million	million	NUM
dpc-5749	544	35	us	us	PROPN
dpc-5749	544	36	individuals	individual	NOUN
dpc-5749	544	37	.	.	PUNCT
dpc-5749	545	1	front	front	ADJ
dpc-5749	545	2	med	med	PROPN
dpc-5749	545	3	(	(	PUNCT
dpc-5749	545	4	lausanne	lausanne	PROPN
dpc-5749	545	5	)	)	PUNCT
dpc-5749	545	6	.	.	PUNCT
dpc-5749	546	1	2025;12:1585167	2025;12:1585167	NUM
dpc-5749	546	2	.	.	PUNCT
dpc-5749	546	3	doi	doi	NOUN
dpc-5749	546	4	:	:	PUNCT
dpc-5749	546	5	10.3389	10.3389	NUM
dpc-5749	546	6	/fmed.2025.1585167	/fmed.2025.1585167	NOUN
dpc-5749	546	7	.	.	PUNCT
dpc-5749	546	8	 	 	SPACE
dpc-5749	547	1	pmid	pmid	NOUN
dpc-5749	547	2	:	:	PUNCT
dpc-5749	547	3	40248080	40248080	NUM
dpc-5749	547	4	.	.	PUNCT
dpc-5749	548	1	51	51	NUM
dpc-5749	548	2	.	.	X
dpc-5749	548	3	eckembrecher	eckembrecher	PROPN
dpc-5749	548	4	dg	dg	PROPN
dpc-5749	548	5	,	,	PUNCT
dpc-5749	548	6	eckembrecher	eckembrecher	PROPN
dpc-5749	548	7	fj	fj	PROPN
dpc-5749	548	8	,	,	PUNCT
dpc-5749	548	9	camacho	camacho	PROPN
dpc-5749	548	10	i	i	PROPN
dpc-5749	548	11	,	,	PUNCT
dpc-5749	548	12	et	et	PROPN
dpc-5749	548	13	al	al	PROPN
dpc-5749	548	14	.	.	PUNCT
dpc-5749	549	1	a	a	DET
dpc-5749	549	2	review	review	NOUN
dpc-5749	549	3	of	of	ADP
dpc-5749	549	4	heart	heart	NOUN
dpc-5749	549	5	transplant	transplant	NOUN
dpc-5749	549	6	immunosuppressants	immunosuppressant	NOUN
dpc-5749	549	7	and	and	CCONJ
dpc-5749	549	8	nonmelanoma	nonmelanoma	ADJ
dpc-5749	549	9	skin	skin	NOUN
dpc-5749	549	10	cancer	cancer	NOUN
dpc-5749	549	11	.	.	PUNCT
dpc-5749	550	1	arch	arch	ADJ
dpc-5749	550	2	dermatol	dermatol	NOUN
dpc-5749	550	3	res	re	NOUN
dpc-5749	550	4	.	.	PUNCT
dpc-5749	551	1	2023;315(9):2491	2023;315(9):2491	NUM
dpc-5749	551	2	-	-	SYM
dpc-5749	551	3	2503	2503	NUM
dpc-5749	551	4	.	.	PUNCT
dpc-5749	552	1	doi	doi	NOUN
dpc-5749	552	2	:	:	PUNCT
dpc-5749	552	3	10.1007	10.1007	NUM
dpc-5749	552	4	/	/	SYM
dpc-5749	552	5	s00403	s00403	NOUN
dpc-5749	552	6	-	-	PUNCT
dpc-5749	552	7	023	023	NUM
dpc-5749	552	8	-	-	PUNCT
dpc-5749	552	9	02646	02646	NUM
dpc-5749	552	10	-	-	PUNCT
dpc-5749	552	11	x.	x.	NOUN
dpc-5749	552	12	 	 	SPACE
dpc-5749	552	13	pmid	pmid	PROPN
dpc-5749	552	14	:	:	PUNCT
dpc-5749	552	15	37256379	37256379	NUM
dpc-5749	552	16	.	.	PUNCT
dpc-5749	553	1	52	52	NUM
dpc-5749	553	2	.	.	PUNCT
dpc-5749	554	1	gu	gu	NOUN
dpc-5749	554	2	sl	sl	PROPN
dpc-5749	554	3	,	,	PUNCT
dpc-5749	554	4	nath	nath	PROPN
dpc-5749	554	5	s	s	PROPN
dpc-5749	554	6	,	,	PUNCT
dpc-5749	554	7	markova	markova	X
dpc-5749	554	8	a.	a.	NOUN
dpc-5749	554	9	safety	safety	NOUN
dpc-5749	554	10	of	of	ADP
dpc-5749	554	11	immunomodulatory	immunomodulatory	ADJ
dpc-5749	554	12	systemic	systemic	ADJ
dpc-5749	554	13	therapies	therapy	NOUN
dpc-5749	554	14	used	use	VERB
dpc-5749	554	15	in	in	ADP
dpc-5749	554	16	the	the	DET
dpc-5749	554	17	management	management	NOUN
dpc-5749	554	18	of	of	ADP
dpc-5749	554	19	immune	immune	NOUN
dpc-5749	554	20	-	-	PUNCT
dpc-5749	554	21	related	relate	VERB
dpc-5749	554	22	cutaneous	cutaneous	ADJ
dpc-5749	554	23	adverse	adverse	ADJ
dpc-5749	554	24	events	event	NOUN
dpc-5749	554	25	.	.	PUNCT
dpc-5749	555	1	pharmaceuticals	pharmaceutical	NOUN
dpc-5749	555	2	(	(	PUNCT
dpc-5749	555	3	basel	basel	PROPN
dpc-5749	555	4	)	)	PUNCT
dpc-5749	555	5	.	.	PUNCT
dpc-5749	556	1	2023;16(11):1610	2023;16(11):1610	X
dpc-5749	556	2	.	.	X
dpc-5749	556	3	doi	doi	NOUN
dpc-5749	556	4	:	:	PUNCT
dpc-5749	556	5	10.3390	10.3390	NUM
dpc-5749	556	6	/	/	SYM
dpc-5749	556	7	ph16111610	ph16111610	PROPN
dpc-5749	556	8	.	.	PUNCT
dpc-5749	557	1	pmid	pmid	NOUN
dpc-5749	557	2	:	:	PUNCT
dpc-5749	557	3	38004475	38004475	NUM
dpc-5749	557	4	.	.	PUNCT
dpc-5749	558	1	review	review	VERB
dpc-5749	558	2	|	|	ADV
dpc-5749	558	3	dermatol	dermatol	ADJ
dpc-5749	558	4	pract	pract	NOUN
dpc-5749	558	5	concept	concept	NOUN
dpc-5749	558	6	.	.	PUNCT
dpc-5749	559	1	2025;15(4):5749	2025;15(4):5749	NUM
dpc-5749	559	2	9	9	NUM
dpc-5749	559	3	78	78	NUM
dpc-5749	559	4	.	.	PUNCT
dpc-5749	560	1	ghorbanalipoor	ghorbanalipoor	PROPN
dpc-5749	560	2	s	s	PROPN
dpc-5749	560	3	,	,	PUNCT
dpc-5749	560	4	emtenani	emtenani	PROPN
dpc-5749	560	5	s	s	PROPN
dpc-5749	560	6	,	,	PUNCT
dpc-5749	560	7	parker	parker	PROPN
dpc-5749	560	8	m	m	PROPN
dpc-5749	560	9	,	,	PUNCT
dpc-5749	560	10	et	et	PROPN
dpc-5749	560	11	al	al	PROPN
dpc-5749	560	12	.	.	PUNCT
dpc-5749	561	1	cutaneous	cutaneous	ADJ
dpc-5749	561	2	kinase	kinase	PROPN
dpc-5749	561	3	activity	activity	NOUN
dpc-5749	561	4	correlates	correlate	VERB
dpc-5749	561	5	with	with	ADP
dpc-5749	561	6	treatment	treatment	NOUN
dpc-5749	561	7	outcomes	outcome	NOUN
dpc-5749	561	8	following	follow	VERB
dpc-5749	561	9	pi3k	pi3k	PROPN
dpc-5749	561	10	delta	delta	NOUN
dpc-5749	561	11	inhibition	inhibition	VERB
dpc-5749	561	12	in	in	ADP
dpc-5749	561	13	mice	mouse	NOUN
dpc-5749	561	14	with	with	ADP
dpc-5749	561	15	experimental	experimental	ADJ
dpc-5749	561	16	pemphigoid	pemphigoid	ADJ
dpc-5749	561	17	diseases	disease	NOUN
dpc-5749	561	18	.	.	PUNCT
dpc-5749	562	1	front	front	ADJ
dpc-5749	562	2	immunol	immunol	NOUN
dpc-5749	562	3	.	.	PUNCT
dpc-5749	563	1	2022;13:865241	2022;13:865241	X
dpc-5749	563	2	.	.	PUNCT
dpc-5749	563	3	doi	doi	NOUN
dpc-5749	563	4	:	:	PUNCT
dpc-5749	563	5	10.3389	10.3389	NUM
dpc-5749	563	6	/	/	SYM
dpc-5749	563	7	fimmu.2022.865241	fimmu.2022.865241	PROPN
dpc-5749	563	8	.	.	PUNCT
dpc-5749	564	1	pmid	pmid	NOUN
dpc-5749	564	2	:	:	PUNCT
dpc-5749	564	3	36248903	36248903	NUM
dpc-5749	564	4	.	.	PUNCT
dpc-5749	565	1	79	79	NUM
dpc-5749	565	2	.	.	PUNCT
dpc-5749	566	1	patzelt	patzelt	VERB
dpc-5749	566	2	s	s	NOUN
dpc-5749	566	3	,	,	PUNCT
dpc-5749	566	4	pigors	pigor	NOUN
dpc-5749	566	5	m	m	PRON
dpc-5749	566	6	,	,	PUNCT
dpc-5749	566	7	steenbock	steenbock	ADJ
dpc-5749	566	8	h	h	NOUN
dpc-5749	566	9	,	,	PUNCT
dpc-5749	566	10	et	et	PROPN
dpc-5749	566	11	al	al	PROPN
dpc-5749	566	12	.	.	PROPN
dpc-5749	567	1	increased	increase	VERB
dpc-5749	567	2	fibrosis	fibrosis	NOUN
dpc-5749	567	3	in	in	ADP
dpc-5749	567	4	a	a	DET
dpc-5749	567	5	mouse	mouse	NOUN
dpc-5749	567	6	model	model	NOUN
dpc-5749	567	7	of	of	ADP
dpc-5749	567	8	anti	anti	ADJ
dpc-5749	567	9	-	-	ADJ
dpc-5749	567	10	laminin	laminin	ADJ
dpc-5749	567	11	332	332	NUM
dpc-5749	567	12	mucous	mucous	ADJ
dpc-5749	567	13	membrane	membrane	NOUN
dpc-5749	567	14	pemphigoid	pemphigoid	NOUN
dpc-5749	567	15	remains	remain	VERB
dpc-5749	567	16	unaltered	unaltere	VERB
dpc-5749	567	17	by	by	ADP
dpc-5749	567	18	inhibition	inhibition	NOUN
dpc-5749	567	19	of	of	ADP
dpc-5749	567	20	aldehyde	aldehyde	NOUN
dpc-5749	567	21	dehydrogenase	dehydrogenase	NOUN
dpc-5749	567	22	.	.	PUNCT
dpc-5749	568	1	front	front	ADJ
dpc-5749	568	2	immunol	immunol	NOUN
dpc-5749	568	3	.	.	PUNCT
dpc-5749	569	1	2022;12:812627	2022;12:812627	X
dpc-5749	569	2	.	.	PUNCT
dpc-5749	570	1	doi	doi	NOUN
dpc-5749	570	2	:	:	PUNCT
dpc-5749	570	3	10.3389	10.3389	NUM
dpc-5749	570	4	/fimmu.2021.812627	/fimmu.2021.812627	PUNCT
dpc-5749	570	5	.	.	PUNCT
dpc-5749	571	1	pmid	pmid	NOUN
dpc-5749	571	2	:	:	PUNCT
dpc-5749	571	3	35197965	35197965	NUM
dpc-5749	571	4	.	.	PUNCT
dpc-5749	572	1	80	80	NUM
dpc-5749	572	2	.	.	PUNCT
dpc-5749	573	1	ahadome	ahadome	ADJ
dpc-5749	573	2	sd	sd	NOUN
dpc-5749	573	3	,	,	PUNCT
dpc-5749	573	4	abraham	abraham	PROPN
dpc-5749	573	5	dj	dj	PROPN
dpc-5749	573	6	,	,	PUNCT
dpc-5749	573	7	rayapureddi	rayapureddi	PROPN
dpc-5749	573	8	s	s	PROPN
dpc-5749	573	9	,	,	PUNCT
dpc-5749	573	10	et	et	PROPN
dpc-5749	573	11	al	al	PROPN
dpc-5749	573	12	.	.	PUNCT
dpc-5749	573	13	aldehyde	aldehyde	NOUN
dpc-5749	573	14	dehydrogenase	dehydrogenase	NOUN
dpc-5749	573	15	inhibition	inhibition	NOUN
dpc-5749	573	16	blocks	block	VERB
dpc-5749	573	17	mucosal	mucosal	ADJ
dpc-5749	573	18	fibrosis	fibrosis	NOUN
dpc-5749	573	19	in	in	ADP
dpc-5749	573	20	human	human	ADJ
dpc-5749	573	21	and	and	CCONJ
dpc-5749	573	22	mouse	mouse	NOUN
dpc-5749	573	23	ocular	ocular	ADJ
dpc-5749	573	24	scarring	scarring	NOUN
dpc-5749	573	25	.	.	PUNCT
dpc-5749	574	1	jci	jci	PROPN
dpc-5749	574	2	insight	insight	PROPN
dpc-5749	574	3	.	.	PUNCT
dpc-5749	575	1	2016;1(12):e87001	2016;1(12):e87001	NOUN
dpc-5749	575	2	.	.	PUNCT
dpc-5749	576	1	doi	doi	NOUN
dpc-5749	576	2	:	:	PUNCT
dpc-5749	576	3	10.1172	10.1172	NUM
dpc-5749	576	4	/	/	SYM
dpc-5749	576	5	jci.insight.87001	jci.insight.87001	PROPN
dpc-5749	576	6	.	.	PUNCT
dpc-5749	577	1	pmid	pmid	NOUN
dpc-5749	577	2	:	:	PUNCT
dpc-5749	577	3	27699226	27699226	NUM
dpc-5749	577	4	.	.	PUNCT
dpc-5749	578	1	81	81	NUM
dpc-5749	578	2	.	.	PUNCT
dpc-5749	579	1	kumari	kumari	PROPN
dpc-5749	579	2	s	s	PROPN
dpc-5749	579	3	,	,	PUNCT
dpc-5749	579	4	bhol	bhol	PROPN
dpc-5749	579	5	kc	kc	PROPN
dpc-5749	579	6	,	,	PUNCT
dpc-5749	579	7	rehman	rehman	PROPN
dpc-5749	579	8	f	f	PROPN
dpc-5749	579	9	,	,	PUNCT
dpc-5749	579	10	foster	foster	PROPN
dpc-5749	579	11	cs	cs	PROPN
dpc-5749	579	12	,	,	PUNCT
dpc-5749	579	13	ahmed	ahmed	PROPN
dpc-5749	579	14	ar	ar	PROPN
dpc-5749	579	15	.	.	PROPN
dpc-5749	579	16	interleukin	interleukin	NOUN
dpc-5749	579	17	1	1	NUM
dpc-5749	579	18	components	component	NOUN
dpc-5749	579	19	in	in	ADP
dpc-5749	579	20	cicatricial	cicatricial	ADJ
dpc-5749	579	21	pemphigoid	pemphigoid	NOUN
dpc-5749	579	22	.	.	PUNCT
dpc-5749	580	1	role	role	NOUN
dpc-5749	580	2	in	in	ADP
dpc-5749	580	3	intravenous	intravenous	ADJ
dpc-5749	580	4	immunoglobulin	immunoglobulin	NOUN
dpc-5749	580	5	therapy	therapy	NOUN
dpc-5749	580	6	.	.	PUNCT
dpc-5749	581	1	cytokine	cytokine	NOUN
dpc-5749	581	2	.	.	PUNCT
dpc-5749	582	1	2001;14(4):218	2001;14(4):218	NUM
dpc-5749	582	2	-	-	SYM
dpc-5749	582	3	24	24	NUM
dpc-5749	582	4	.	.	PUNCT
dpc-5749	582	5	doi	doi	NOUN
dpc-5749	582	6	:	:	PUNCT
dpc-5749	582	7	10.1006	10.1006	NUM
dpc-5749	582	8	/	/	SYM
dpc-5749	582	9	cyto.2001.0877	cyto.2001.0877	NOUN
dpc-5749	582	10	.	.	PUNCT
dpc-5749	583	1	pmid	pmid	NOUN
dpc-5749	583	2	:	:	PUNCT
dpc-5749	583	3	11448121	11448121	NUM
dpc-5749	583	4	.	.	PUNCT
dpc-5749	584	1	82	82	NUM
dpc-5749	584	2	.	.	PUNCT
dpc-5749	584	3	letko	letko	PROPN
dpc-5749	584	4	e	e	NOUN
dpc-5749	584	5	,	,	PUNCT
dpc-5749	584	6	bhol	bhol	PROPN
dpc-5749	584	7	k	k	PROPN
dpc-5749	584	8	,	,	PUNCT
dpc-5749	584	9	colon	colon	NOUN
dpc-5749	584	10	j	j	PROPN
dpc-5749	584	11	,	,	PUNCT
dpc-5749	584	12	foster	foster	PROPN
dpc-5749	584	13	cs	cs	PROPN
dpc-5749	584	14	,	,	PUNCT
dpc-5749	584	15	ahmed	ahmed	PROPN
dpc-5749	584	16	ar	ar	PROPN
dpc-5749	584	17	.	.	PROPN
dpc-5749	584	18	biology	biology	NOUN
dpc-5749	584	19	of	of	ADP
dpc-5749	584	20	interleukin-5	interleukin-5	NUM
dpc-5749	584	21	in	in	ADP
dpc-5749	584	22	ocular	ocular	ADJ
dpc-5749	584	23	cicatricial	cicatricial	ADJ
dpc-5749	584	24	pemphigoid	pemphigoid	NOUN
dpc-5749	584	25	.	.	PUNCT
dpc-5749	585	1	graefes	graefe	NOUN
dpc-5749	585	2	arch	arch	PROPN
dpc-5749	585	3	clin	clin	PROPN
dpc-5749	585	4	exp	exp	PROPN
dpc-5749	585	5	ophthalmol	ophthalmol	PROPN
dpc-5749	585	6	.	.	PUNCT
dpc-5749	586	1	2002;240(7):565	2002;240(7):565	NUM
dpc-5749	586	2	-	-	SYM
dpc-5749	586	3	9	9	NUM
dpc-5749	586	4	.	.	PUNCT
dpc-5749	586	5	doi	doi	NOUN
dpc-5749	586	6	:	:	PUNCT
dpc-5749	586	7	10.1007	10.1007	NUM
dpc-5749	586	8	/	/	SYM
dpc-5749	586	9	s00417	s00417	ADJ
dpc-5749	586	10	-002	-002	PROPN
dpc-5749	586	11	-	-	PUNCT
dpc-5749	586	12	0497	0497	NUM
dpc-5749	586	13	-	-	PUNCT
dpc-5749	586	14	4	4	NUM
dpc-5749	586	15	.	.	PUNCT
dpc-5749	586	16	 	 	SPACE
dpc-5749	586	17	pmid	pmid	NOUN
dpc-5749	586	18	:	:	PUNCT
dpc-5749	586	19	12136288	12136288	NUM
dpc-5749	586	20	.	.	PUNCT
dpc-5749	587	1	83	83	NUM
dpc-5749	587	2	.	.	PUNCT
dpc-5749	587	3	suelves	suelve	NOUN
dpc-5749	587	4	am	be	AUX
dpc-5749	587	5	,	,	PUNCT
dpc-5749	587	6	zhao	zhao	PROPN
dpc-5749	587	7	tz	tz	PROPN
dpc-5749	587	8	,	,	PUNCT
dpc-5749	587	9	siddique	siddique	PROPN
dpc-5749	587	10	ss	ss	PROPN
dpc-5749	587	11	,	,	PUNCT
dpc-5749	587	12	foster	foster	PROPN
dpc-5749	587	13	cs	cs	PROPN
dpc-5749	587	14	.	.	PROPN
dpc-5749	587	15	profile	profile	NOUN
dpc-5749	587	16	of	of	ADP
dpc-5749	587	17	local	local	ADJ
dpc-5749	587	18	interleukin	interleukin	NOUN
dpc-5749	587	19	expression	expression	NOUN
dpc-5749	587	20	in	in	ADP
dpc-5749	587	21	a	a	DET
dpc-5749	587	22	cohort	cohort	NOUN
dpc-5749	587	23	of	of	ADP
dpc-5749	587	24	ocular	ocular	ADJ
dpc-5749	587	25	cicatricial	cicatricial	ADJ
dpc-5749	587	26	pemphigoid	pemphigoid	ADJ
dpc-5749	587	27	patients	patient	NOUN
dpc-5749	587	28	.	.	PUNCT
dpc-5749	588	1	invest	invest	VERB
dpc-5749	588	2	ophthalmol	ophthalmol	PROPN
dpc-5749	588	3	vis	vis	X
dpc-5749	588	4	sci	sci	PROPN
dpc-5749	588	5	.	.	PUNCT
dpc-5749	589	1	2012;53(13):8112	2012;53(13):8112	NUM
dpc-5749	589	2	-	-	SYM
dpc-5749	589	3	7	7	NUM
dpc-5749	589	4	.	.	PUNCT
dpc-5749	589	5	doi	doi	NOUN
dpc-5749	589	6	:	:	PUNCT
dpc-5749	589	7	10.1167	10.1167	NUM
dpc-5749	589	8	/	/	SYM
dpc-5749	589	9	iovs.11	iovs.11	NOUN
dpc-5749	589	10	-	-	PUNCT
dpc-5749	589	11	9322	9322	NUM
dpc-5749	589	12	.	.	PUNCT
dpc-5749	590	1	pmid	pmid	NOUN
dpc-5749	590	2	:	:	PUNCT
dpc-5749	590	3	23081979	23081979	NUM
dpc-5749	590	4	.	.	PUNCT
dpc-5749	591	1	84	84	NUM
dpc-5749	591	2	.	.	PUNCT
dpc-5749	592	1	caproni	caproni	PROPN
dpc-5749	592	2	m	m	PROPN
dpc-5749	592	3	,	,	PUNCT
dpc-5749	592	4	calzolari	calzolari	PROPN
dpc-5749	592	5	a	a	X
dpc-5749	592	6	,	,	PUNCT
dpc-5749	592	7	giomi	giomi	NOUN
dpc-5749	592	8	b	b	NOUN
dpc-5749	592	9	,	,	PUNCT
dpc-5749	592	10	santucci	santucci	PROPN
dpc-5749	592	11	m	m	PROPN
dpc-5749	592	12	,	,	PUNCT
dpc-5749	592	13	ficarra	ficarra	VERB
dpc-5749	592	14	g	g	ADP
dpc-5749	592	15	,	,	PUNCT
dpc-5749	592	16	fabbri	fabbri	NOUN
dpc-5749	592	17	p.	p.	PROPN
dpc-5749	592	18	il-4	il-4	NOUN
dpc-5749	592	19	,	,	PUNCT
dpc-5749	592	20	il-5	il-5	PROPN
dpc-5749	592	21	,	,	PUNCT
dpc-5749	592	22	tgf	tgf	NOUN
dpc-5749	592	23	-	-	PUNCT
dpc-5749	592	24	beta1	beta1	NOUN
dpc-5749	592	25	and	and	CCONJ
dpc-5749	592	26	ifn	ifn	PROPN
dpc-5749	592	27	-	-	PUNCT
dpc-5749	592	28	gamma	gamma	NOUN
dpc-5749	592	29	mrnas	mrna	NOUN
dpc-5749	592	30	detected	detect	VERB
dpc-5749	592	31	by	by	ADP
dpc-5749	592	32	a	a	DET
dpc-5749	592	33	new	new	ADJ
dpc-5749	592	34	in	in	ADP
dpc-5749	592	35	situ	situ	ADJ
dpc-5749	592	36	amplification	amplification	NOUN
dpc-5749	592	37	system	system	NOUN
dpc-5749	592	38	in	in	ADP
dpc-5749	592	39	cicatricial	cicatricial	ADJ
dpc-5749	592	40	pemphigoid	pemphigoid	NOUN
dpc-5749	592	41	.	.	PUNCT
dpc-5749	593	1	exp	exp	NOUN
dpc-5749	593	2	dermatol	dermatol	NOUN
dpc-5749	593	3	.	.	PUNCT
dpc-5749	594	1	2002;11(5):421	2002;11(5):421	NUM
dpc-5749	594	2	-	-	SYM
dpc-5749	594	3	7	7	NUM
dpc-5749	594	4	.	.	PUNCT
dpc-5749	594	5	doi	doi	NOUN
dpc-5749	594	6	:	:	PUNCT
dpc-5749	594	7	10.1034	10.1034	NUM
dpc-5749	594	8	/	/	SYM
dpc-5749	594	9	j.1600	j.1600	PROPN
dpc-5749	594	10	-	-	PUNCT
dpc-5749	594	11	0625	0625	NUM
dpc-5749	594	12	.2002.110505.x	.2002.110505.x	NOUN
dpc-5749	594	13	.	.	PUNCT
dpc-5749	594	14	 	 	SPACE
dpc-5749	595	1	pmid	pmid	NOUN
dpc-5749	595	2	:	:	PUNCT
dpc-5749	595	3	12366695	12366695	NUM
dpc-5749	595	4	.	.	PUNCT
dpc-5749	596	1	85	85	NUM
dpc-5749	596	2	.	.	PUNCT
dpc-5749	596	3	karakioulaki	karakioulaki	PROPN
dpc-5749	596	4	m	m	PROPN
dpc-5749	596	5	,	,	PUNCT
dpc-5749	596	6	eyerich	eyerich	PROPN
dpc-5749	596	7	k	k	PROPN
dpc-5749	596	8	,	,	PUNCT
dpc-5749	596	9	patsatsi	patsatsi	PROPN
dpc-5749	596	10	a.	a.	NOUN
dpc-5749	596	11	advancements	advancement	NOUN
dpc-5749	596	12	in	in	ADP
dpc-5749	596	13	bullous	bullous	ADJ
dpc-5749	596	14	pemphigoid	pemphigoid	ADJ
dpc-5749	596	15	treatment	treatment	NOUN
dpc-5749	596	16	:	:	PUNCT
dpc-5749	596	17	a	a	DET
dpc-5749	596	18	comprehensive	comprehensive	ADJ
dpc-5749	596	19	pipeline	pipeline	NOUN
dpc-5749	596	20	update	update	NOUN
dpc-5749	596	21	.	.	PUNCT
dpc-5749	596	22	am	be	AUX
dpc-5749	596	23	j	j	PROPN
dpc-5749	596	24	clin	clin	PROPN
dpc-5749	596	25	dermatol	dermatol	NOUN
dpc-5749	596	26	.	.	PUNCT
dpc-5749	597	1	2024;25(2):195	2024;25(2):195	NUM
dpc-5749	597	2	-	-	PUNCT
dpc-5749	597	3	212	212	NUM
dpc-5749	597	4	.	.	PUNCT
dpc-5749	598	1	doi	doi	NOUN
dpc-5749	598	2	:	:	PUNCT
dpc-5749	598	3	10.1007	10.1007	NUM
dpc-5749	598	4	/	/	SYM
dpc-5749	598	5	s40257023	s40257023	NUM
dpc-5749	598	6	-	-	PUNCT
dpc-5749	598	7	00832	00832	NUM
dpc-5749	598	8	-	-	SYM
dpc-5749	598	9	1	1	NUM
dpc-5749	598	10	.	.	PUNCT
dpc-5749	598	11	 	 	SPACE
dpc-5749	598	12	pmid	pmid	NOUN
dpc-5749	598	13	:	:	PUNCT
dpc-5749	598	14	38157140	38157140	NUM
dpc-5749	598	15	.	.	PUNCT
dpc-5749	599	1	86	86	NUM
dpc-5749	599	2	.	.	PUNCT
dpc-5749	600	1	khalid	khalid	PROPN
dpc-5749	600	2	sn	sn	PROPN
dpc-5749	600	3	,	,	PUNCT
dpc-5749	600	4	khan	khan	PROPN
dpc-5749	600	5	za	za	PROPN
dpc-5749	600	6	,	,	PUNCT
dpc-5749	600	7	ali	ali	PROPN
dpc-5749	600	8	mh	mh	PROPN
dpc-5749	600	9	,	,	PUNCT
dpc-5749	600	10	almas	almas	PROPN
dpc-5749	600	11	t	t	PROPN
dpc-5749	600	12	,	,	PUNCT
dpc-5749	600	13	khedro	khedro	PROPN
dpc-5749	600	14	t	t	PROPN
dpc-5749	600	15	,	,	PUNCT
dpc-5749	600	16	raj	raj	PROPN
dpc-5749	600	17	nagarajan	nagarajan	PROPN
dpc-5749	600	18	v.	v.	ADP
dpc-5749	600	19	a	a	DET
dpc-5749	600	20	blistering	blister	VERB
dpc-5749	600	21	new	new	ADJ
dpc-5749	600	22	era	era	NOUN
dpc-5749	600	23	for	for	ADP
dpc-5749	600	24	bullous	bullous	ADJ
dpc-5749	600	25	pemphigoid	pemphigoid	NOUN
dpc-5749	600	26	:	:	PUNCT
dpc-5749	600	27	a	a	DET
dpc-5749	600	28	scoping	scope	VERB
dpc-5749	600	29	review	review	NOUN
dpc-5749	600	30	of	of	ADP
dpc-5749	600	31	current	current	ADJ
dpc-5749	600	32	therapies	therapy	NOUN
dpc-5749	600	33	,	,	PUNCT
dpc-5749	600	34	ongoing	ongoing	ADJ
dpc-5749	600	35	clinical	clinical	ADJ
dpc-5749	600	36	trials	trial	NOUN
dpc-5749	600	37	,	,	PUNCT
dpc-5749	600	38	and	and	CCONJ
dpc-5749	600	39	future	future	ADJ
dpc-5749	600	40	directions	direction	NOUN
dpc-5749	600	41	.	.	PUNCT
dpc-5749	601	1	ann	ann	PROPN
dpc-5749	601	2	med	med	PROPN
dpc-5749	601	3	surg	surg	PROPN
dpc-5749	601	4	(	(	PUNCT
dpc-5749	601	5	lond	lond	PROPN
dpc-5749	601	6	)	)	PUNCT
dpc-5749	601	7	.	.	PUNCT
dpc-5749	602	1	2021;70:102799	2021;70:102799	X
dpc-5749	602	2	.	.	PUNCT
dpc-5749	602	3	doi	doi	PROPN
dpc-5749	602	4	:	:	PUNCT
dpc-5749	602	5	10.1016	10.1016	NUM
dpc-5749	602	6	/j.amsu.2021.102799	/j.amsu.2021.102799	PUNCT
dpc-5749	602	7	.	.	PUNCT
dpc-5749	603	1	pmid	pmid	NOUN
dpc-5749	603	2	:	:	PUNCT
dpc-5749	603	3	34540212	34540212	NUM
dpc-5749	603	4	.	.	PUNCT
dpc-5749	604	1	87	87	NUM
dpc-5749	604	2	.	.	PUNCT
dpc-5749	605	1	zhang	zhang	PROPN
dpc-5749	605	2	j	j	PROPN
dpc-5749	605	3	,	,	PUNCT
dpc-5749	605	4	wang	wang	PROPN
dpc-5749	605	5	sh	sh	PROPN
dpc-5749	605	6	,	,	PUNCT
dpc-5749	605	7	zuo	zuo	PROPN
dpc-5749	605	8	yg	yg	PROPN
dpc-5749	605	9	.	.	PUNCT
dpc-5749	605	10	paradoxical	paradoxical	ADJ
dpc-5749	605	11	phenomena	phenomenon	NOUN
dpc-5749	605	12	of	of	ADP
dpc-5749	605	13	bullous	bullous	ADJ
dpc-5749	605	14	pemphigoid	pemphigoid	NOUN
dpc-5749	605	15	induced	induce	VERB
dpc-5749	605	16	and	and	CCONJ
dpc-5749	605	17	treated	treat	VERB
dpc-5749	605	18	by	by	ADP
dpc-5749	605	19	identical	identical	ADJ
dpc-5749	605	20	biologics	biologic	NOUN
dpc-5749	605	21	.	.	PUNCT
dpc-5749	606	1	front	front	ADJ
dpc-5749	606	2	immunol	immunol	NOUN
dpc-5749	606	3	.	.	PUNCT
dpc-5749	607	1	2023;13:1050373	2023;13:1050373	X
dpc-5749	607	2	.	.	PUNCT
dpc-5749	607	3	doi	doi	NOUN
dpc-5749	607	4	:	:	PUNCT
dpc-5749	607	5	10.3389	10.3389	NUM
dpc-5749	607	6	/	/	SYM
dpc-5749	607	7	fimmu.2022.1050373	fimmu.2022.1050373	NOUN
dpc-5749	607	8	.	.	PUNCT
dpc-5749	608	1	pmid	pmid	NOUN
dpc-5749	608	2	:	:	PUNCT
dpc-5749	608	3	36685489	36685489	NUM
dpc-5749	608	4	.	.	PUNCT
dpc-5749	609	1	88	88	NUM
dpc-5749	609	2	.	.	PUNCT
dpc-5749	610	1	tanaka	tanaka	PROPN
dpc-5749	610	2	a	a	PROPN
dpc-5749	610	3	,	,	PUNCT
dpc-5749	610	4	fujimura	fujimura	PROPN
dpc-5749	610	5	y	y	PROPN
dpc-5749	610	6	,	,	PUNCT
dpc-5749	610	7	fuke	fuke	PROPN
dpc-5749	610	8	s	s	PROPN
dpc-5749	610	9	,	,	PUNCT
dpc-5749	610	10	izumi	izumi	PROPN
dpc-5749	610	11	k	k	PROPN
dpc-5749	610	12	,	,	PUNCT
dpc-5749	610	13	ujiie	ujiie	ADJ
dpc-5749	610	14	h.	h.	PROPN
dpc-5749	610	15	a	a	DET
dpc-5749	610	16	case	case	NOUN
dpc-5749	610	17	of	of	ADP
dpc-5749	610	18	bullous	bullous	ADJ
dpc-5749	610	19	pemphigoid	pemphigoid	NOUN
dpc-5749	610	20	developing	develop	VERB
dpc-5749	610	21	under	under	ADP
dpc-5749	610	22	treatment	treatment	NOUN
dpc-5749	610	23	with	with	ADP
dpc-5749	610	24	benralizumab	benralizumab	NOUN
dpc-5749	610	25	for	for	ADP
dpc-5749	610	26	bronchial	bronchial	ADJ
dpc-5749	610	27	asthma	asthma	NOUN
dpc-5749	610	28	.	.	PUNCT
dpc-5749	611	1	j	j	PROPN
dpc-5749	611	2	dermatol	dermatol	NOUN
dpc-5749	611	3	.	.	PUNCT
dpc-5749	612	1	2023;50(9):1199	2023;50(9):1199	NUM
dpc-5749	612	2	-	-	SYM
dpc-5749	612	3	1202	1202	NUM
dpc-5749	612	4	.	.	PUNCT
dpc-5749	613	1	doi	doi	NOUN
dpc-5749	613	2	:	:	PUNCT
dpc-5749	613	3	10.1111/1346	10.1111/1346	NUM
dpc-5749	613	4	-	-	SYM
dpc-5749	613	5	8138.16811	8138.16811	NUM
dpc-5749	613	6	.	.	PUNCT
dpc-5749	614	1	pmid	pmid	NOUN
dpc-5749	614	2	:	:	PUNCT
dpc-5749	614	3	37122191	37122191	NUM
dpc-5749	614	4	.	.	PUNCT
dpc-5749	615	1	adult	adult	PROPN
dpc-5749	615	2	t	t	PROPN
dpc-5749	615	3	-	-	PUNCT
dpc-5749	615	4	cell	cell	NOUN
dpc-5749	615	5	leukaemia	leukaemia	NOUN
dpc-5749	615	6	/	/	SYM
dpc-5749	615	7	lymphoma	lymphoma	NOUN
dpc-5749	615	8	(	(	PUNCT
dpc-5749	615	9	atll	atll	NOUN
dpc-5749	615	10	)	)	PUNCT
dpc-5749	615	11	.	.	PUNCT
dpc-5749	616	1	leuk	leuk	PROPN
dpc-5749	616	2	res	re	NOUN
dpc-5749	616	3	.	.	PUNCT
dpc-5749	617	1	2012;36(7	2012;36(7	NUM
dpc-5749	617	2	):	):	PUNCT
dpc-5749	617	3	857	857	NUM
dpc-5749	617	4	-	-	SYM
dpc-5749	617	5	61	61	NUM
dpc-5749	617	6	.	.	PUNCT
dpc-5749	618	1	doi	doi	NOUN
dpc-5749	618	2	:	:	PUNCT
dpc-5749	618	3	10.1016	10.1016	NUM
dpc-5749	618	4	/	/	SYM
dpc-5749	618	5	j.leukres.2011.12.004	j.leukres.2011.12.004	PROPN
dpc-5749	618	6	.	.	PUNCT
dpc-5749	618	7	 	 	SPACE
dpc-5749	618	8	pmid	pmid	PROPN
dpc-5749	618	9	:	:	PUNCT
dpc-5749	618	10	22209076	22209076	NUM
dpc-5749	618	11	.	.	PUNCT
dpc-5749	619	1	67	67	NUM
dpc-5749	619	2	.	.	PUNCT
dpc-5749	620	1	iglesias	iglesias	PROPN
dpc-5749	620	2	-	-	PUNCT
dpc-5749	620	3	escudero	escudero	PROPN
dpc-5749	620	4	m	m	PROPN
dpc-5749	620	5	,	,	PUNCT
dpc-5749	620	6	arias	arias	PROPN
dpc-5749	620	7	-	-	PUNCT
dpc-5749	620	8	gonzález	gonzález	PROPN
dpc-5749	620	9	n	n	CCONJ
dpc-5749	620	10	,	,	PUNCT
dpc-5749	620	11	martínez	martínez	NOUN
dpc-5749	620	12	-	-	PUNCT
dpc-5749	620	13	cáceres	cáceres	PROPN
dpc-5749	620	14	e.	e.	PROPN
dpc-5749	620	15	regulatory	regulatory	ADJ
dpc-5749	620	16	cells	cell	NOUN
dpc-5749	620	17	and	and	CCONJ
dpc-5749	620	18	the	the	DET
dpc-5749	620	19	effect	effect	NOUN
dpc-5749	620	20	of	of	ADP
dpc-5749	620	21	cancer	cancer	NOUN
dpc-5749	620	22	immunotherapy	immunotherapy	NOUN
dpc-5749	620	23	.	.	PUNCT
dpc-5749	621	1	mol	mol	ADP
dpc-5749	621	2	cancer	cancer	NOUN
dpc-5749	621	3	.	.	PUNCT
dpc-5749	622	1	2023;22(1	2023;22(1	NUM
dpc-5749	622	2	)	)	PUNCT
dpc-5749	622	3	.	.	PUNCT
dpc-5749	623	1	doi	doi	NOUN
dpc-5749	623	2	:	:	PUNCT
dpc-5749	623	3	10.1186	10.1186	NUM
dpc-5749	623	4	/	/	SYM
dpc-5749	623	5	s12943	s12943	PROPN
dpc-5749	623	6	-	-	PUNCT
dpc-5749	623	7	023	023	NUM
dpc-5749	623	8	-	-	PUNCT
dpc-5749	623	9	01714	01714	NUM
dpc-5749	623	10	-	-	SYM
dpc-5749	623	11	0	0	NUM
dpc-5749	623	12	.	.	PUNCT
dpc-5749	624	1	pmid	pmid	NOUN
dpc-5749	624	2	:	:	PUNCT
dpc-5749	624	3	36739406	36739406	NUM
dpc-5749	624	4	.	.	PUNCT
dpc-5749	625	1	68	68	NUM
dpc-5749	625	2	.	.	PUNCT
dpc-5749	625	3	ali	ali	PROPN
dpc-5749	625	4	es	es	PROPN
dpc-5749	625	5	,	,	PUNCT
dpc-5749	625	6	mitra	mitra	PROPN
dpc-5749	625	7	k	k	PROPN
dpc-5749	625	8	,	,	PUNCT
dpc-5749	625	9	akter	akter	PROPN
dpc-5749	625	10	s	s	PART
dpc-5749	625	11	,	,	PUNCT
dpc-5749	625	12	et	et	PROPN
dpc-5749	625	13	al	al	PROPN
dpc-5749	625	14	.	.	PUNCT
dpc-5749	626	1	recent	recent	ADJ
dpc-5749	626	2	advances	advance	NOUN
dpc-5749	626	3	and	and	CCONJ
dpc-5749	626	4	limitations	limitation	NOUN
dpc-5749	626	5	of	of	ADP
dpc-5749	626	6	mtor	mtor	NOUN
dpc-5749	626	7	inhibitors	inhibitor	NOUN
dpc-5749	626	8	in	in	ADP
dpc-5749	626	9	the	the	DET
dpc-5749	626	10	treatment	treatment	NOUN
dpc-5749	626	11	of	of	ADP
dpc-5749	626	12	cancer	cancer	NOUN
dpc-5749	626	13	.	.	PUNCT
dpc-5749	627	1	cancer	cancer	NOUN
dpc-5749	627	2	cell	cell	NOUN
dpc-5749	627	3	int	int	NOUN
dpc-5749	627	4	.	.	PUNCT
dpc-5749	628	1	2022;22(1):284	2022;22(1):284	NUM
dpc-5749	628	2	.	.	PUNCT
dpc-5749	629	1	doi	doi	NOUN
dpc-5749	629	2	:	:	PUNCT
dpc-5749	629	3	10.1186	10.1186	NUM
dpc-5749	629	4	/	/	SYM
dpc-5749	629	5	s12935	s12935	PROPN
dpc-5749	629	6	-	-	PUNCT
dpc-5749	629	7	022	022	NUM
dpc-5749	629	8	-	-	PUNCT
dpc-5749	629	9	02706	02706	NUM
dpc-5749	629	10	-	-	SYM
dpc-5749	629	11	8	8	NUM
dpc-5749	629	12	.	.	PUNCT
dpc-5749	629	13	  	  	SPACE
dpc-5749	629	14	pmid	pmid	NOUN
dpc-5749	629	15	:	:	PUNCT
dpc-5749	629	16	36109789	36109789	NUM
dpc-5749	629	17	.	.	PUNCT
dpc-5749	630	1	69	69	NUM
dpc-5749	630	2	.	.	PUNCT
dpc-5749	631	1	rubicondo	rubicondo	PROPN
dpc-5749	631	2	m	m	PROPN
dpc-5749	631	3	,	,	PUNCT
dpc-5749	631	4	ciardelli	ciardelli	PROPN
dpc-5749	631	5	g	g	PROPN
dpc-5749	631	6	,	,	PUNCT
dpc-5749	631	7	mattu	mattu	PROPN
dpc-5749	631	8	c	c	NOUN
dpc-5749	631	9	,	,	PUNCT
dpc-5749	631	10	tuszynski	tuszynski	PROPN
dpc-5749	631	11	ja	ja	PROPN
dpc-5749	631	12	.	.	PUNCT
dpc-5749	632	1	recent	recent	ADJ
dpc-5749	632	2	advancements	advancement	NOUN
dpc-5749	632	3	in	in	ADP
dpc-5749	632	4	colchicine	colchicine	NOUN
dpc-5749	632	5	derivatives	derivative	NOUN
dpc-5749	632	6	:	:	PUNCT
dpc-5749	632	7	exploring	explore	VERB
dpc-5749	632	8	synthesis	synthesis	NOUN
dpc-5749	632	9	,	,	PUNCT
dpc-5749	632	10	activities	activity	NOUN
dpc-5749	632	11	,	,	PUNCT
dpc-5749	632	12	and	and	CCONJ
dpc-5749	632	13	nanoformulations	nanoformulation	NOUN
dpc-5749	632	14	for	for	ADP
dpc-5749	632	15	enhanced	enhanced	ADJ
dpc-5749	632	16	therapeutic	therapeutic	ADJ
dpc-5749	632	17	efficacy	efficacy	NOUN
dpc-5749	632	18	.	.	PUNCT
dpc-5749	633	1	drug	drug	NOUN
dpc-5749	633	2	discovery	discovery	PROPN
dpc-5749	633	3	today	today	NOUN
dpc-5749	633	4	.	.	PUNCT
dpc-5749	634	1	2025;30(3):104312	2025;30(3):104312	PROPN
dpc-5749	634	2	.	.	PUNCT
dpc-5749	635	1	doi	doi	PROPN
dpc-5749	635	2	:	:	PUNCT
dpc-5749	635	3	10.1016	10.1016	NUM
dpc-5749	635	4	/j.drudis.2025.104312	/j.drudis.2025.104312	PROPN
dpc-5749	635	5	.	.	PUNCT
dpc-5749	636	1	pmid	pmid	NOUN
dpc-5749	636	2	:	:	PUNCT
dpc-5749	636	3	39947582	39947582	NUM
dpc-5749	636	4	.	.	PUNCT
dpc-5749	637	1	70	70	NUM
dpc-5749	637	2	.	.	PUNCT
dpc-5749	638	1	yeh	yeh	PROPN
dpc-5749	638	2	jj	jj	PROPN
dpc-5749	638	3	,	,	PUNCT
dpc-5749	638	4	liw	liw	PROPN
dpc-5749	638	5	px	px	PROPN
dpc-5749	638	6	,	,	PUNCT
dpc-5749	638	7	wong	wong	PROPN
dpc-5749	638	8	ys	ys	PROPN
dpc-5749	638	9	,	,	PUNCT
dpc-5749	638	10	et	et	PROPN
dpc-5749	638	11	al	al	PROPN
dpc-5749	638	12	.	.	PUNCT
dpc-5749	639	1	the	the	DET
dpc-5749	639	2	effect	effect	NOUN
dpc-5749	639	3	of	of	ADP
dpc-5749	639	4	colchicine	colchicine	PROPN
dpc-5749	639	5	on	on	ADP
dpc-5749	639	6	cancer	cancer	NOUN
dpc-5749	639	7	risk	risk	NOUN
dpc-5749	639	8	in	in	ADP
dpc-5749	639	9	patients	patient	NOUN
dpc-5749	639	10	with	with	ADP
dpc-5749	639	11	immune	immune	NOUN
dpc-5749	639	12	-	-	PUNCT
dpc-5749	639	13	mediated	mediate	VERB
dpc-5749	639	14	inflammatory	inflammatory	ADJ
dpc-5749	639	15	diseases	disease	NOUN
dpc-5749	639	16	:	:	PUNCT
dpc-5749	639	17	a	a	DET
dpc-5749	639	18	time	time	NOUN
dpc-5749	639	19	-	-	PUNCT
dpc-5749	639	20	dependent	dependent	ADJ
dpc-5749	639	21	study	study	NOUN
dpc-5749	639	22	based	base	VERB
dpc-5749	639	23	on	on	ADP
dpc-5749	639	24	the	the	DET
dpc-5749	639	25	taiwan	taiwan	PROPN
dpc-5749	639	26	’s	’s	PART
dpc-5749	639	27	national	national	PROPN
dpc-5749	639	28	health	health	PROPN
dpc-5749	639	29	insurance	insurance	PROPN
dpc-5749	639	30	research	research	NOUN
dpc-5749	639	31	database	database	NOUN
dpc-5749	639	32	.	.	PUNCT
dpc-5749	640	1	eur	eur	PROPN
dpc-5749	640	2	j	j	PROPN
dpc-5749	640	3	med	med	PROPN
dpc-5749	640	4	res	re	NOUN
dpc-5749	640	5	.	.	PUNCT
dpc-5749	641	1	2024;29(1):245	2024;29(1):245	NUM
dpc-5749	641	2	.	.	PUNCT
dpc-5749	642	1	doi	doi	NOUN
dpc-5749	642	2	:	:	PUNCT
dpc-5749	642	3	10.1186	10.1186	NUM
dpc-5749	642	4	/	/	SYM
dpc-5749	642	5	s40001	s40001	NOUN
dpc-5749	642	6	-	-	PUNCT
dpc-5749	642	7	024	024	NUM
dpc-5749	642	8	-	-	PUNCT
dpc-5749	642	9	01836	01836	NUM
dpc-5749	642	10	-	-	SYM
dpc-5749	642	11	1	1	NUM
dpc-5749	642	12	.	.	PUNCT
dpc-5749	643	1	pmid	pmid	NOUN
dpc-5749	643	2	:	:	PUNCT
dpc-5749	643	3	38649928	38649928	NUM
dpc-5749	643	4	.	.	PUNCT
dpc-5749	644	1	71	71	NUM
dpc-5749	644	2	.	.	PUNCT
dpc-5749	645	1	guo	guo	PROPN
dpc-5749	645	2	s	s	PROPN
dpc-5749	645	3	,	,	PUNCT
dpc-5749	645	4	wang	wang	PROPN
dpc-5749	645	5	l	l	PROPN
dpc-5749	645	6	,	,	PUNCT
dpc-5749	645	7	bu	bu	PROPN
dpc-5749	645	8	d	d	PROPN
dpc-5749	645	9	,	,	PUNCT
dpc-5749	645	10	liu	liu	PROPN
dpc-5749	645	11	f.	f.	PROPN
dpc-5749	645	12	tumors	tumors	PROPN
dpc-5749	645	13	in	in	ADP
dpc-5749	645	14	the	the	DET
dpc-5749	645	15	setting	setting	NOUN
dpc-5749	645	16	of	of	ADP
dpc-5749	645	17	dupilumab	dupilumab	NOUN
dpc-5749	645	18	use	use	NOUN
dpc-5749	645	19	:	:	PUNCT
dpc-5749	645	20	a	a	DET
dpc-5749	645	21	review	review	NOUN
dpc-5749	645	22	of	of	ADP
dpc-5749	645	23	the	the	DET
dpc-5749	645	24	literature	literature	NOUN
dpc-5749	645	25	.	.	PUNCT
dpc-5749	646	1	world	world	PROPN
dpc-5749	646	2	allergy	allergy	PROPN
dpc-5749	646	3	organ	organ	PROPN
dpc-5749	646	4	j.	j.	PROPN
dpc-5749	646	5	2024;18(1):101006	2024;18(1):101006	PROPN
dpc-5749	646	6	.	.	PUNCT
dpc-5749	646	7	doi	doi	NOUN
dpc-5749	646	8	:	:	PUNCT
dpc-5749	646	9	10.1016	10.1016	NUM
dpc-5749	646	10	/	/	SYM
dpc-5749	646	11	j.waojou.2024.101006	j.waojou.2024.101006	ADJ
dpc-5749	646	12	.	.	PUNCT
dpc-5749	647	1	pmid	pmid	NOUN
dpc-5749	647	2	:	:	PUNCT
dpc-5749	647	3	39758935	39758935	NUM
dpc-5749	647	4	.	.	PUNCT
dpc-5749	648	1	72	72	NUM
dpc-5749	648	2	.	.	PUNCT
dpc-5749	649	1	ferreira	ferreira	PROPN
dpc-5749	649	2	c	c	PROPN
dpc-5749	649	3	,	,	PUNCT
dpc-5749	649	4	freitas	freitas	PROPN
dpc-5749	649	5	e	e	NOUN
dpc-5749	649	6	,	,	PUNCT
dpc-5749	649	7	torres	torre	VERB
dpc-5749	649	8	t.	t.	PROPN
dpc-5749	649	9	efficacy	efficacy	NOUN
dpc-5749	649	10	and	and	CCONJ
dpc-5749	649	11	safety	safety	NOUN
dpc-5749	649	12	of	of	ADP
dpc-5749	649	13	dupilumab	dupilumab	NOUN
dpc-5749	649	14	in	in	ADP
dpc-5749	649	15	a	a	DET
dpc-5749	649	16	patient	patient	NOUN
dpc-5749	649	17	with	with	ADP
dpc-5749	649	18	metastatic	metastatic	ADJ
dpc-5749	649	19	clear	clear	ADJ
dpc-5749	649	20	cell	cell	NOUN
dpc-5749	649	21	renal	renal	ADJ
dpc-5749	649	22	cell	cell	NOUN
dpc-5749	649	23	carcinoma	carcinoma	NOUN
dpc-5749	649	24	.	.	PUNCT
dpc-5749	650	1	j	j	PROPN
dpc-5749	650	2	int	int	PROPN
dpc-5749	650	3	med	med	PROPN
dpc-5749	650	4	res	re	NOUN
dpc-5749	650	5	.	.	PUNCT
dpc-5749	651	1	2024;52(11):3000605241297551	2024;52(11):3000605241297551	X
dpc-5749	651	2	.	.	PUNCT
dpc-5749	651	3	doi	doi	PROPN
dpc-5749	651	4	:	:	PUNCT
dpc-5749	651	5	10.1177/03000605241297551	10.1177/03000605241297551	NUM
dpc-5749	651	6	.	.	PUNCT
dpc-5749	652	1	pmid	pmid	NOUN
dpc-5749	652	2	:	:	PUNCT
dpc-5749	652	3	39575618	39575618	NUM
dpc-5749	652	4	.	.	PUNCT
dpc-5749	653	1	73	73	NUM
dpc-5749	653	2	.	.	PUNCT
dpc-5749	654	1	deeks	deek	VERB
dpc-5749	654	2	ed	ed	NOUN
dpc-5749	654	3	,	,	PUNCT
dpc-5749	654	4	lamb	lamb	PROPN
dpc-5749	654	5	yn	yn	PROPN
dpc-5749	654	6	.	.	PROPN
dpc-5749	654	7	cenegermin	cenegermin	PROPN
dpc-5749	654	8	:	:	PUNCT
dpc-5749	654	9	a	a	DET
dpc-5749	654	10	review	review	NOUN
dpc-5749	654	11	in	in	ADP
dpc-5749	654	12	neurotrophic	neurotrophic	ADJ
dpc-5749	654	13	keratitis	keratitis	NOUN
dpc-5749	654	14	.	.	PUNCT
dpc-5749	655	1	drugs	drug	NOUN
dpc-5749	655	2	.	.	PUNCT
dpc-5749	656	1	2020;80(5):489	2020;80(5):489	NUM
dpc-5749	656	2	-	-	SYM
dpc-5749	656	3	494	494	NUM
dpc-5749	656	4	.	.	PUNCT
dpc-5749	657	1	doi	doi	NOUN
dpc-5749	657	2	:	:	PUNCT
dpc-5749	657	3	10.1007	10.1007	NUM
dpc-5749	657	4	/	/	SYM
dpc-5749	657	5	s40265020	s40265020	NOUN
dpc-5749	657	6	-	-	PUNCT
dpc-5749	657	7	01289	01289	NUM
dpc-5749	657	8	-	-	PUNCT
dpc-5749	657	9	w.	w.	PROPN
dpc-5749	657	10	 	 	SPACE
dpc-5749	657	11	pmid	pmid	PROPN
dpc-5749	657	12	:	:	PUNCT
dpc-5749	657	13	32185680	32185680	NUM
dpc-5749	657	14	.	.	PUNCT
dpc-5749	658	1	74	74	NUM
dpc-5749	658	2	.	.	PUNCT
dpc-5749	659	1	hayes	hayes	PROPN
dpc-5749	659	2	df	df	PROPN
dpc-5749	659	3	.	.	PUNCT
dpc-5749	660	1	bevacizumab	bevacizumab	PROPN
dpc-5749	660	2	treatment	treatment	NOUN
dpc-5749	660	3	for	for	ADP
dpc-5749	660	4	solid	solid	ADJ
dpc-5749	660	5	tumors	tumor	NOUN
dpc-5749	660	6	:	:	PUNCT
dpc-5749	660	7	boon	boon	NOUN
dpc-5749	660	8	or	or	CCONJ
dpc-5749	660	9	bust	bust	NOUN
dpc-5749	660	10	?	?	PUNCT
dpc-5749	661	1	jama	jama	NOUN
dpc-5749	661	2	.	.	PUNCT
dpc-5749	662	1	2011;305(5):506	2011;305(5):506	NUM
dpc-5749	662	2	-	-	SYM
dpc-5749	662	3	8	8	NUM
dpc-5749	662	4	.	.	PUNCT
dpc-5749	662	5	doi	doi	NOUN
dpc-5749	662	6	:	:	PUNCT
dpc-5749	662	7	10.1001	10.1001	NUM
dpc-5749	662	8	/	/	SYM
dpc-5749	662	9	jama.2011.57	jama.2011.57	PROPN
dpc-5749	662	10	.	.	PUNCT
dpc-5749	663	1	pmid	pmid	NOUN
dpc-5749	663	2	:	:	PUNCT
dpc-5749	663	3	21285431	21285431	NUM
dpc-5749	663	4	.	.	PUNCT
dpc-5749	664	1	75	75	NUM
dpc-5749	664	2	.	.	PUNCT
dpc-5749	664	3	vultaggio	vultaggio	PROPN
dpc-5749	664	4	a	a	PRON
dpc-5749	664	5	,	,	PUNCT
dpc-5749	664	6	petrella	petrella	PROPN
dpc-5749	664	7	mc	mc	PROPN
dpc-5749	664	8	,	,	PUNCT
dpc-5749	664	9	tomao	tomao	ADJ
dpc-5749	664	10	f	f	X
dpc-5749	664	11	,	,	PUNCT
dpc-5749	664	12	et	et	PROPN
dpc-5749	664	13	al	al	PROPN
dpc-5749	664	14	.	.	PUNCT
dpc-5749	665	1	the	the	DET
dpc-5749	665	2	anti	anti	ADJ
dpc-5749	665	3	-	-	ADJ
dpc-5749	665	4	ige	ige	ADJ
dpc-5749	665	5	monoclonal	monoclonal	NOUN
dpc-5749	665	6	antibody	antibody	NOUN
dpc-5749	665	7	omalizumab	omalizumab	NOUN
dpc-5749	665	8	as	as	ADP
dpc-5749	665	9	adjuvant	adjuvant	ADJ
dpc-5749	665	10	treatment	treatment	NOUN
dpc-5749	665	11	in	in	ADP
dpc-5749	665	12	desensitization	desensitization	NOUN
dpc-5749	665	13	to	to	PART
dpc-5749	665	14	carboplatin	carboplatin	VERB
dpc-5749	665	15	in	in	ADP
dpc-5749	665	16	patients	patient	NOUN
dpc-5749	665	17	with	with	ADP
dpc-5749	665	18	ovarian	ovarian	ADJ
dpc-5749	665	19	cancer	cancer	NOUN
dpc-5749	665	20	.	.	PUNCT
dpc-5749	666	1	gynecol	gynecol	PROPN
dpc-5749	666	2	oncol	oncol	PROPN
dpc-5749	666	3	rep	rep	PROPN
dpc-5749	666	4	.	.	PROPN
dpc-5749	666	5	2021;38:100880	2021;38:100880	NUM
dpc-5749	666	6	.	.	PUNCT
dpc-5749	667	1	doi	doi	NOUN
dpc-5749	667	2	:	:	PUNCT
dpc-5749	667	3	10.1016	10.1016	NUM
dpc-5749	667	4	/	/	SYM
dpc-5749	667	5	j.gore.2021.100880	j.gore.2021.100880	ADJ
dpc-5749	667	6	.	.	PUNCT
dpc-5749	668	1	pmid	pmid	NOUN
dpc-5749	668	2	:	:	PUNCT
dpc-5749	668	3	34926761	34926761	NUM
dpc-5749	668	4	.	.	PUNCT
dpc-5749	669	1	76	76	NUM
dpc-5749	669	2	.	.	PUNCT
dpc-5749	670	1	neumann	neumann	PROPN
dpc-5749	670	2	r	r	PROPN
dpc-5749	670	3	,	,	PUNCT
dpc-5749	670	4	tauber	tauber	PROPN
dpc-5749	670	5	j	j	PROPN
dpc-5749	670	6	,	,	PUNCT
dpc-5749	670	7	foster	foster	PROPN
dpc-5749	670	8	cs	cs	PROPN
dpc-5749	670	9	.	.	PROPN
dpc-5749	670	10	remission	remission	NOUN
dpc-5749	670	11	and	and	CCONJ
dpc-5749	670	12	recurrence	recurrence	NOUN
dpc-5749	670	13	after	after	ADP
dpc-5749	670	14	withdrawal	withdrawal	NOUN
dpc-5749	670	15	of	of	ADP
dpc-5749	670	16	therapy	therapy	NOUN
dpc-5749	670	17	for	for	ADP
dpc-5749	670	18	ocular	ocular	ADJ
dpc-5749	670	19	cicatricial	cicatricial	ADJ
dpc-5749	670	20	pemphigoid	pemphigoid	NOUN
dpc-5749	670	21	.	.	PUNCT
dpc-5749	671	1	ophthalmology	ophthalmology	NOUN
dpc-5749	671	2	.	.	PUNCT
dpc-5749	672	1	1991;98(6):858	1991;98(6):858	NUM
dpc-5749	672	2	-	-	PUNCT
dpc-5749	672	3	62	62	NUM
dpc-5749	672	4	.	.	PUNCT
dpc-5749	673	1	doi	doi	NOUN
dpc-5749	673	2	:	:	PUNCT
dpc-5749	673	3	10.1016	10.1016	NUM
dpc-5749	673	4	/	/	SYM
dpc-5749	673	5	s01616420(91)32209	s01616420(91)32209	NOUN
dpc-5749	673	6	-	-	PUNCT
dpc-5749	673	7	7	7	NUM
dpc-5749	673	8	.	.	PUNCT
dpc-5749	674	1	pmid	pmid	NOUN
dpc-5749	674	2	:	:	PUNCT
dpc-5749	674	3	1866137	1866137	NUM
dpc-5749	674	4	.	.	PUNCT
dpc-5749	675	1	77	77	NUM
dpc-5749	675	2	.	.	PUNCT
dpc-5749	676	1	tofern	tofern	PROPN
dpc-5749	676	2	s	s	PROPN
dpc-5749	676	3	,	,	PUNCT
dpc-5749	676	4	fähnrich	fähnrich	NOUN
dpc-5749	676	5	a	a	X
dpc-5749	676	6	,	,	PUNCT
dpc-5749	676	7	künzel	künzel	PROPN
dpc-5749	676	8	s	s	PROPN
dpc-5749	676	9	,	,	PUNCT
dpc-5749	676	10	et	et	PROPN
dpc-5749	676	11	al	al	PROPN
dpc-5749	676	12	.	.	PROPN
dpc-5749	676	13	075	075	NUM
dpc-5749	676	14	inhibition	inhibition	NOUN
dpc-5749	676	15	of	of	ADP
dpc-5749	676	16	phosphodiesterase-4	phosphodiesterase-4	NOUN
dpc-5749	676	17	significantly	significantly	ADV
dpc-5749	676	18	decreases	decrease	VERB
dpc-5749	676	19	oral	oral	ADJ
dpc-5749	676	20	mucosa	mucosa	NOUN
dpc-5749	676	21	lesions	lesion	NOUN
dpc-5749	676	22	in	in	ADP
dpc-5749	676	23	experimental	experimental	ADJ
dpc-5749	676	24	anti	anti	ADJ
dpc-5749	676	25	-	-	ADJ
dpc-5749	676	26	laminin	laminin	ADJ
dpc-5749	676	27	332	332	NUM
dpc-5749	676	28	mucous	mucous	ADJ
dpc-5749	676	29	membrane	membrane	NOUN
dpc-5749	676	30	pemphigoid	pemphigoid	NOUN
dpc-5749	676	31	.	.	PUNCT
dpc-5749	677	1	journal	journal	NOUN
dpc-5749	677	2	of	of	ADP
dpc-5749	677	3	investigative	investigative	ADJ
dpc-5749	677	4	dermatology	dermatology	NOUN
dpc-5749	677	5	.	.	PUNCT
dpc-5749	678	1	2019;139(9):s227	2019;139(9):s227	NUM
dpc-5749	678	2	.	.	PUNCT
dpc-5749	678	3	doi	doi	NOUN
dpc-5749	678	4	:	:	PUNCT
dpc-5749	678	5	10.1016	10.1016	NUM
dpc-5749	678	6	/	/	SYM
dpc-5749	678	7	j.jid.2019.07.078	j.jid.2019.07.078	PROPN